European Organisation for Research and Treatment of Cancer

Coming events

Latest publications

  • Associations of a Breast Cancer Polygenic Risk Score with Tumor Characteristics and Survival (2023)

  • Patient-reported outcome measures for physical function in cancer patients: content comparison of the EORTC CAT Core, EORTC QLQ-C30, SF-36, FACT-G, and PROMIS measures using the International Classification of Functioning, Disability and Health (2023)

  • Mitotic count is prognostic in IDH-mutant astrocytoma without homozygous deletion of CDKN2A/B. Results of consensus panel review of EORTC trials 26053 and EORTC 22033-26033 (2022)

  • The EORTC QLU-C10D – development and investigation of general population utility norms for Canada, France, Germany, Italy, Poland and the U.K. (2022)

  • Relapse Patterns in early-PET negative, limited stage Hodgkin Lymphoma (HL) after ABVD with or without Radiotherapy – A joint analysis of the EORTC/FIL/LYSA H10 and NCRI RAPID Trials (2022)

  • Assessment of RANK/RANK-L prevalence and clinical significance in NSCLC European Thoracic Oncology Platform Lungscape cohort and SPLENDOUR randomized clinical trial (2022)

  • Comprehensive molecular profiling of sarcomas in adolescent and young adult patients: results of the EORTC SPECT-AYA international proof-of-concept study (2022)

  • Employment situation among long-term Hodgkin lymphoma survivors in Europe: An analysis of patients from nine consecutive EORTC-LYSA trials (2022)

  • Content validity of the EORTC quality of life questionnaire QLQ-C30 for use in cancer (2022)

  • Radiotherapy or Surgery of the Axilla after a Positive Sentinel Node in Breast Cancer: 10 year Results of the Randomised Controlled EORTC 10981-22023 AMAROS Trial (2022)

  • Thrombocytopenia limits the feasibility of salvage lomustine chemotherapy in recurrent glioblastoma: a secondary analysis of EORTC 26101 (2022)

  • Comparison of outcomes between Hodgkin's lymphoma patients treated in and outside clinical trials: A study based on the EORTC-Dutch late effects cohort-linked data (2022)

  • Tomotherapy for cranio-spinal irradiation (2022)

  • EORTC is 60 - and far from contemplating retirement (2022)

  • Meta-Analysis of the Test-Retest Repeatability of [18F]-Fluorodeoxyglucose Standardized Uptake Values: Implications for Assessment of Tumor Response (2022)

  • Socioeconomic outcomes among long-term childhood acute lymphoblastic leuke-mia survivors enrolled between 1971 and 1998 in EORTC CLG studies: results of the 58LAE study (2022)

  • A multicenter international prospective study of the validity and reliability of a COVID-19-specific health-related quality of life questionnaire (2022)

  • Quality of life of long-term childhood acute lymphoblastic leukemia survivors: Comparison with healthy controls (2022)

  • Association of antidepressant drug use with outcome of patients with glioblastoma (2022)

  • Imaging endpoints for clinical trial use: a RECIST perspective (2022)

  • Challenges related to data protection in clinical research before and during the COVID-19 pandemic: An exploratory study. Frontiers In Medicine. (2022)

  • European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus on re-irradiation: definition, reporting, and clinical decision making (2022)

  • Neural Networks for Survival Prediction in Medicine Using Prognostic Factors: A Review and Critical Appraisal (2022)

  • Radiomics in Neuro-Oncology Clinical Trials (2022)

  • Imaging standardisation in metastatic colorectal cancer: A joint EORTC-ESOI-ESGAR expert consensus recommendation (2022)

  • Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial (2022)

  • Five-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III Melanoma (2022)

  • New benchmarks to design clinical trials with advanced or metastatic liposarcoma or synovial sarcoma patients: An EORTC – Soft Tissue and Bone Sarcoma Group (STBSG) meta-analysis based on a literature review for soft-tissue sarcomas (2022)

  • Linking the European Organisation for Research and Treatment of Cancer (EORTC) Item Library to the Common Terminology Criteria for Adverse Events (CTCAE) (2022)

  • Highlights from the 2022 ASCO Gastrointestinal Cancer Symposium: an overview by the EORTC Gastrointestinal Cancer Group (2022)

  • How do cancer clinicians perceive the use of real-world evidence in oncology? Findings from an international survey of the European Organisation for Research and Treatment of Cancer (2022)

  • Activity of Cabazitaxel in metastatic or inoperable locally advanced dedifferentiated liposarcoma: a phase 2 study of EORTC Soft Tissue and Bone Sarcoma Group (STBSG) (2022)

  • Neurocognitive impairment and patient–proxy agreement on health‑related quality of life evaluations in recurrent high‑grade glioma patients (2022)

  • First-line chemotherapy in advanced well-differentiated / dedifferentiated liposarcoma: An EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis (2022)

  • Empiric versus pre-emptive antifungal strategy in high-risk neutropenic patients on fluconazole prophylaxis: a randomized trial of the European organization for Research and Treatment of cancer (EORTC 65091) (2022)

  • Preoperative radiotherapy in patients with primary retroperitoneal sarcoma: trial (STRASS) vs off-trial (STREXIT) results (2022)

  • Associations of levetiracetam use with the safety and tolerability profile of chemoradiotherapy for (patients with) newly diagnosed glioblastoma (2022)

  • Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial Tumors (2022)

  • The PROTEUS-Trials Consortium: Optimizing the use of patient-reported outcomes in clinical trials (2022)

  • High-risk stage IIB Hodgkin lymphoma treated in the H10 and AHL2011 trials: TMTV is a useful risk factor to stratify patients at baseline (2022)

  • Immunoglobulin Heavy Chain High-Throughput Sequencing in Pediatric B-Precursor Acute Lymphoblastic Leukemia: Is the Clonality of the Disease at Diagnosis Related to Its Prognosis? (2022)

  • European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022 (2022)

  • Correlation of Immunological and Molecular Profiles with Response to Crizotinib in Alveolar Soft Part Sarcoma: An Exploratory Study Related to the EORTC 90101 “CREATE” Trial (2022)

  • Exercise in lung Cancer, the healthcare providers opinion (E.C.H.O.): Results of the EORTC lung cancer Group (LCG) survey (2022)

  • Results of screening in early and advanced thoracic malignancies in the EORTC pan‑European SPECTAlung platform (2022)

  • Clustering of EORTC QLQ-C30 Health-related quality of life scales across several cancer types : validation study (2022)

  • European consensus-based interdisciplinary guideline for melanoma Part 1: Diagnostics : Update 2022 (2022)

  • The association of internal mammary and medial supraclavicular lymph node radiation technique with clinical outcomes: results from the EORTC 22922/10925 randomised trial. (2022)

  • Ethical Considerations for the Inclusion of Patient-Reported Outcomes in Clinical Research The PRO Ethics Guidelines (2022)

  • Critical impact of Radiotherapy Protocol compliance and Quality in the Treatment of Retroperitoneal sarcomas: Results from the EORTC 62092-22092 STRASS trial (2022)

  • Exploratory analysis of tumor imaging in a Phase 2 trial with cabozantinib in gastrointestinal stromal tumor: lessons learned from study EORTC STBSG 1317 ‘CaboGIST’ (2022)

  • Representativeness of trial participants: linking the EORTC boost-no boost trial to the Netherlands cancer registry (2022)

  • Factors associated with health-related quality of life (HRQoL) deterioration in glioma patients during the progression-free survival period (2022)

  • Development of ‘Core Outcome Sets’ for Meningioma in Clinical Studies (The COSMIC Project): protocol for two systematic literature reviews, eDelphi surveys and online consensus meetings (2022)

  • Another look at floor and ceiling effects in the EORTC QLQ-C30 Physical Functioning subscale and possible solutions (2022)

  • Infectious complications of targeted drugs and biotherapies in acute leukemia. Clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN) (2022)

  • Prognostic significance of bone metastasis in soft tissue sarcoma patients receiving palliative systemic therapy: an explorative, retrospective pooled analysis of the prospective EORTC - Soft Tissue and Bone Sarcoma Group (STBSG) database (2022)

  • Minimally important differences of EORTC QLQ-C30 scales in patients with lung cancer – Interpretation guidance derived from two randomized EORTC trials (2022)

  • Health-related quality of life in patients with COVID-19; international development of a patient-reported outcome measure (2022)

  • Prognostic significance of therapy-induced myelosuppression in newly diagnosed glioblastoma (2022)

  • Diagnosis and treatment of Merkel cell carcinoma: European consensus-based interdisciplinary guideline – Update 2022 (2022)

  • Prognostic significance of DNA methylation profiles at MRI enhancing tumor recurrence: a report from the EORTC 26091 TAVAREC trial (2022)

  • Temozolomide and radiotherapy versus radiotherapy alone in patients with glioblastoma, IDH-wildtype: post-hoc analysis of the EORTC randomized phase 3 CATNON trial (2022)

  • Prognostic and predictive value of β-blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab vs placebo in resected high-risk stage III melanoma (2022)

  • MGMT promoter methylation determined by the MGMT-STP27 algorithm is not predictive for outcome to temozolomide in IDH-mutant anaplastic astrocytomas (2022)

  • Health-related Quality of Life (HRQoL) in older patients with HER2+ metastatic breast cancer: Comparing pertuzumab plus trastuzumab with or without metronomic chemotherapy in a randomised open-label phase II clinical trial (2022)

  • Outcome of patients with an ultralow risk 70-gene signature in the MINDACT trial (2022)

  • Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis (2022)

  • Twenty Years On: RECIST as a Biomarker of Response in Solid Tumours an EORTC Imaging Group – ESOI Joint Paper (2022)

  • Association of selected (immune-related) adverse events and outcome in two adjuvant phase III trials, Checkmate-238 and EORTC1325/KEYNOTE-054 (2022)

  • Responding to COVID‐19: International nonprofits' stakeholder channels, resource pressures and governance responses (2022)

  • Early-Onset Colorectal Adenocarcinoma in the IDEA database: Treatment Adherence, Toxicities and Outcomes with 3 and 6 months of Adjuvant Fluoropyrimidine and Oxaliplatin (2021)

  • Sociodemographic and medical determinants of quality of life in long-term childhood acute lymphoblastic leukemia survivors enrolled in EORTC CLG studies (2021)

  • Artificial intelligence based treatment planning of radiotherapy for locally advanced breast cancer (2021)

  • Outcome without adjuvant systemic treatment in stage I ER+/HER2- breast cancer patients included in the MINDACT trial (2021)

  • A Simulation Study to Compare the Predictive Performance of Survival Neural Networks with Cox Models for Clinical Trial Data (2021)

  • Developing an e-learning course on the use of PRO measures in oncological practice: health care professionals' preferences for learning content and methods (2021)

  • Bone Metastases Are Measurable: The Role of Whole-Body MRI and Positron Emission Tomography (2021)

  • Individual patient data meta-analysis of neoadjuvant chemotherapy followed by surgery versus upfront surgery for carcinoma of the oesophagus or the gastro-oesophageal junction (2021)

  • A phase II study of monalizumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: results of the I1 cohort of the EORTC-HNCG-1559 trial (UPSTREAM) (2021)

  • Cytoreductive nephrectomy and exposure to sunitinib - a post-hoc analysis of the SURTIME trial (2021)

  • Trabectedin for recurrent WHO grade II or III meningioma: a randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG) (2022)

  • Deep-learning based synthesis of post-contrast T1-weighted magnetic resonance imaging for tumor response assessment in neuro-oncology: a multicenter, retrospective study (2021)

  • Temporal muscle thickness as a prognostic marker in newly diagnosed glioblastoma patients: translational imaging analysis of the CENTRIC EORTC 26071-22072 and CORE trials (2021)

  • Fertility status among long-term childhood acute lymphoblastic leukaemia survivors enrolled between 1971 and 1998 in EORTC CLG studies: results of the 58LAE study (2021)

  • Minimally important differences for the EORTC QLQ-C30 in prostate cancer clinical trials (2021)

  • Investigating the response scale of the EORTC QLQ-C30 in German cancer patients and a population survey (2021)

  • Phase II trial of atezolizumab (anti-PD-L1) in the treatment of stage IIb-IVB mycosis fungoides/Sézary syndrome patients relapsed/refractory after a previous systemic treatment (PARCT) (2021)

  • Prognostic factor analysis and long-term results of the TAX 323 (EORTC 24971) study in unresectable head and neck cancer patients (2021)

  • Side Effects 15 Years After Lymph Node Irradiation in Breast Cancer: Randomized EORTC Trial 22922/10925 (2021)

  • Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase 3 trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma (2021)

  • Combined, patient-level, analysis of two randomised trials evaluating the addition of denosumab to standard first-line chemotherapy in advanced NSCLC – the ETOP/EORTC SPLENDOUR and AMGEN -249 trials (2021)

  • Cancer patient satisfaction with health care professional communication: An international EORTC study (2021)

  • The Porto European Cancer Research Summit 2021 (2021)

  • Patterns of genomic change in residual disease after neo-adjuvant chemotherapy for estrogen-receptor positive and HER2 negative breast cancer (2021)

  • Assessment of a treatment’s net benefit using prioritized outcomes (2021)

  • Psychometric validation of the European Organisation for Research and Treatment of Cancer–Quality of Life Questionnaire Sexual Health (EORTC QLQ-SH22) (2021)

  • General Spanish population normative data analysis for the EORTC QLQ-C30 by sex, age, and health condition (2021)

  • CXCR4 and Hif-1α as prognostic molecular markers for stage 3 colon cancer patients: post hoc analysis of the randomized, multicenter phase 3 PETACC-2 trial dataset (2021)

  • Long term efficacy update of crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumor from EORTC trial 90101 CREATE (2021)

  • Systematic review on the use of patient-reported outcome measures in brain tumor studies: part of the Response Assessment in Neuro-Oncology Patient-Reported Outcome (RANO-PRO) initiative (2021)

  • The impact of isolated local recurrence on long-term outcome in early-breast cancer patients after breast-conserving therapy (2021)

  • Short androgen suppression and radiation dose escalation for intermediate and limited high risk localized prostate cancer. 12-year results of EORTC trial 22991. EORTC trial 22991 for intermediate and limited high risk prostate cancer (2021)

  • Evaluation of multiple transcriptomic gene risk signatures in male breast cancer (2021)

  • Niraparib for advanced breast cancer with germline BRCA1 and BRCA2 mutations: the EORTC 1307-BCG/BIG5-13/TESARO PR-30-50-10-C BRAVO study (2021)

  • Efficacy thresholds for clinical trials with advanced or metastatic leiomyosarcoma patients: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) meta-analysis based on a literature review for soft-tissue sarcomas (2021)

  • Equivalence testing of a newly developed interviewer‑led telephone script for the EORTC QLQ‑C30 (2021)

  • Methodological approach for determining the Minimal Important Diference and Minimal Important Change scores for the European Organisation for Research and Treatment of Cancer Head and Neck Cancer Module (EORTC QLQ‑HN43) exemplifed by the Swallowing scale (2021)

  • Accelerating regulatory approval of anticancer therapies: benefits, drawbacks and recommendations for a more sustainable approach (2021)

  • Development of Randomized Trials in Adults with Medulloblastoma-The Example of EORTC 1634-BTG/NOA-23 (2021)

  • Adjuvant therapy in stage IIIA melanoma - Authors' reply (2021)

  • Estimation of an EORTC QLU‑C10 Value Set for Spain Using a Discrete Choice Experiment (2021)

  • Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study (2021)

  • CNS-3 status remains an independent adverse prognosis factor in children with acute lymphoblastic leukemia (ALL) treated without cranial irradiation: Results of EORTC Children Leukemia Group study 58951 (2021)

  • Combining method of detection and 70-gene signature for enhanced prognostication of breast cancer (2021)

  • Health-related quality of life issues, including symptoms, in patients with active COVID-19 or post COVID-19; a systematic literature review (2021)

  • Gene expression signatures for tailoring adjuvant chemotherapy of luminal breast cancer: stronger evidence, greater trust (2021)

  • Randomized phase 2 study comparing the efficacy and safety of the oral tyrosine kinase inhibitor nintedanib with single agent ifosfamide in patients with advanced, inoperable, metastatic soft tissue sarcoma after failure of first-line chemotherapy. EORTC-1506-STBSG “ANITA” (2021)

  • Prognostic significance of genome-wide DNA methylation profiles within the randomised, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma (2021)

  • Design, Organization and Impact of Treatment Optimization Studies in Breast, Lung and Colorectal Cancer: the Experience of the European Organisation for Research and Treatment of Cancer (2021)

  • Association of Increased Prostate-Specific Antigen Levels After Treatment and Mortality in Men With Locally Advanced vs Localized Prostate Cancer A Secondary Analysis of 2 Randomized Clinical Trials (2021)

  • Treatment patterns in older patients with locallyadvanced head and neck squamous cellcarcinoma: Results from an EORTC led survey (2021)

  • Functional health and symptoms in Spain before and during the COVID-19 pandemic (2021)

  • Quality assurance of radiotherapy in the ongoing EORTC 1420 "Best of" trial for early stage oropharyngeal, supraglottic and hypopharyngeal carcinoma: results of the benchmark case procedure (2021)

  • Independent external validation using the EORTC HNCG-ROG 1219 DAHANCA trial data of NTCP models for acute oral mucositis (2021)

  • Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis (2021)

  • Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial (2021)

  • Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a randomised, controlled, double-blind, phase 3 trial (2021)

  • Predicting outcomes in men with metastatic non seminomatous germ cell tumors (NSGCT): Results from the IGCCCG Update Consortium (2021)

  • Early discontinuation of PD-1 blockade upon achieving a complete or partial response in patients with advanced melanoma: the multicentre prospective Safe Stop trial (2021)

  • Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations (2021)

  • Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium (2021)

  • 70-gene signature as an aid to treatment decisions in early breast cancer: updated results of the Phase 3 randomized MINDACT trial (2021)

  • The EGFRvIII Transcriptome in glioblastoma, a meta-omics analysis (2022)

  • Establishing anchor-based minimally important differences for the EORTC QLQ-C30 in glioma patients (2021)

  • Impact of depatuxizumab mafodotin on health-related quality of life and neurological functioning in the phase II EORTC 1410/INTELLANCE II trial for EGFR-amplified recurrent glioblastoma (2021)

  • Reference values for the EORTC QLQ-C30 in patients with advanced stage Hodgkin Lymphoma and in Hodgkin Lymphoma survivors (2021)

  • Development of staffing, workload and infrastructure in member departments of the European Organisation for Research and Treatment of Cancer (EORTC) radiation oncology group (2021)

  • Objective neurocognitive functioning and neurocognitive complaints in patients with high-grade glioma: Evidence of cognitive awareness from the European Organisation for Research and Treatment of Cancer brain tumour clinical trials (2021)

  • Dutch utility weights for the EORTC cancer‑specifc utility instrument: the Dutch EORTC QLU‑C10D (2021)

  • Development of an EORTC questionnaire measuring instrumental activities of daily living (IADL) in patients with brain tumours: phase I–III (2021)

  • Incorporating radiomics into clinical trials: expert consensus endorsed by the European Society of Radiology on considerations for data-driven compared to biologically driven quantitative biomarkers (2021)

  • Final analysis of the randomized trial on imatinib as an adjuvant in localized gastrointestinal stromal tumors (GIST) from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG), the Australasian Gastro-Intestinal Trials Group (AGITG), UNICANCER, French Sarcoma Group (FSG), Italian Sarcoma Group (ISG), Spanish Group for Research on Sarcomas (GEIS) (2021)

  • Molecular Characterization of Ovarian Yolk Sac Tumor (OYST) (2021)

  • The spleen as an organ at risk in paediatric radiotherapy: A SIOP-Europe Radiation Oncology Working Group report (2021)

  • Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial (2020)

  • Survival prediction models since liver transplantation - comparisons between Cox models and machine learning techniques (2020)

  • Survival Improvement over Time of 960 s-AML Patients Included in 13 EORTC-GIMEMA-HOVON Trials (2020)

  • Developing Symptom Lists for People with Cancer Treated with Targeted Therapies (2020)

  • First results of the SPECTA/Arcagen study exploring the genomics of rare cancers in collaboration with the European reference network EURACAN (2020)

  • Internal mammary and medial supraclavicular lymph node chain irradiation in stage I–III breast cancer (EORTC 22922/10925): 15-year results of a randomised, phase 3 trial (2020)

  • Memory in low-grade glioma patients treated with radiotherapy or Temozolomide. A correlative analysis of EORTC study 22033-26033 (2020)

  • iCREATE: Imaging features of primary and metastatic alveolar soft part sarcoma in the EORTC CREATE study. (2020)

  • Calculating the net clinical benefit in neuro-oncology clinical trials using two methods: quality-adjusted survival effect sizes and joint modeling (2020)

  • Cross-Border Access to Clinical Trials in the EU: Exploratory study on needs and reality (2020)

  • Pre- and Postoperative Capecitabine Without or With Oxaliplatin in Locally Advanced Rectal Cancer: PETACC 6 Trial by EORTC GITCG and ROG, AIO, AGITG, BGDO, and FFCD (2020)

  • A randomized double-blind phase II study evaluating the role of maintenance therapy with cabozantinib in high-grade uterine sarcoma after stabilization or response to doxorubicin ± ifosfamide following surgery or in metastatic first line treatment (EORTC62113) (2020)

  • Demystifying the estimand framework: a case study using patient-reported outcomes in oncology (2020)

  • Minimally important differences for interpreting European Organisation for Research and Treatment of Cancer (EORTC) Quality of life Questionnaire core 30 scores in patients with ovarian cancer (2020)

  • A new measure of treatment effect in clinical trials involving competing risks based on generalized pairwise comparisons (2020)

  • Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial (2020)

  • Survival of soft tissue sarcoma patients after completing six cycles of first-line anthracycline containing treatment: an EORTC-STBSG database study (2020)

  • SOX10 is as specific as S100 protein in detecting metastases of melanoma in lymph nodes and is recommended for sentinel lymph node assessment (2020)

  • The evolving field of Dermato‐oncology and the role of dermatologists: Position Paper of the EADO, EADV and Task Forces, EDF, IDS, EBDV–UEMS and EORTC Cutaneous Lymphoma Task Force (2020)

  • Pediatric randomized trial EORTC CLG 58951: Outcome for adolescent population with acute lymphoblastic leukemia (2020)

  • Methylome analyses of three glioblastoma cohorts reveal chemotherapy sensitivity markers within DDR genes (2020)

  • Normative data for the EORTC QLQ-C30 from the Austrian general population (2020)

  • Results from a one-day workshop on the assessment of Quality of Life in cancer patients: A joint initiative of the Japan Clinical Oncology Group and the European Organisation for Research and Treatment of Cancer (2020)

  • Updated EORTC QLQ-C30 general population norm data for Germany (2020)

  • Evaluating the potential of relapse-free survival as a surrogate for overall survival in the adjuvant therapy of melanoma with checkpoint inhibitors (2020)

  • Minimally important differences for interpreting the EORTC QLQ-C30 in patients with advanced colorectal cancer treated with chemotherapy (2020)

  • Management of Immune-Related Adverse Events Affecting Outcome in Patients Treated With Checkpoint Inhibitors-Reply (2020)

  • Prognosis of Patients With Stage III Melanoma According to American Joint Committee on Cancer Version 8: A Reassessment on the Basis of 3 Independent Stage III Melanoma Cohorts (2020)

  • Noninvasive Characterization of Tumor Angiogenesis and Oxygenation in Bevacizumab-treated Recurrent Glioblastoma by Using Dynamic Susceptibility MRI: Secondary Analysis of the European Organization for Research and Treatment of Cancer 26101 Trial (2020)

  • Controlling technical variation amongst 6693 patient microarrays of the randomized MINDACT trial (2020)

  • CODEL: phase III study of RT, RT + TMZ, or TMZ for newly diagnosed 1p/19q codeleted oligodendroglioma. Analysis from the initial study design (2020)

  • Past, current and future cancer clinical research collaborations: the case of the EORTC (2020)

  • The EORTC-DeCOG nomogram adequately predicts outcomes of patients with sentinel node–positive melanoma without the need for completion lymph node dissection (2020)

  • Event-Free Survival, a Prostate-Specific Antigen–Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation (2020)

  • A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR Trial (2020)

  • Measuring change in health-related quality of life: the impact of different analytical methods on the interpretation of treatment effects in glioma patients (2020)

  • Minimally important differences for interpreting European Organisation for Research and Treatment for Cancer (EORTC) Quality of life Questionnaire Core 30 scores in patients with head and neck cancer (2020)

  • Evaluation of the use and efficacy of (neo)adjuvant chemotherapy in angiosarcoma: a multicentre study (2020)

  • Organ at risk delineation for clinical trials: A Global Harmonization Group consensus guideline (2020)

  • EORTC pushes for the State of Science in Care (2020)

  • EORTC QLU‑C10D value sets for Austria, Italy, and Poland (2020)

  • Activity and safety of the multi-target tyrosine kinase inhibitor cabozantinib in patients with metastatic gastrointestinal stromal tumor after treatment with imatinib and sunitinib: European Organization for Research and Treatment of Cancer Phase 2 trial 1317 "CaboGIST" (2020)

  • Management of primary cutaneous lymphoma patients during COVID‐19 pandemic: EORTC CLTF guidelines (2020)

  • Validation of diffusion MRI phenotypes for predicting response to bevacizumab in recurrent glioblastoma: post-hoc analysis of the EORTC-26101 trial (2020)

  • Psychometric properties of the updated EORTC module for assessing quality of life in patients with lung cancer (QLQ-LC29): an international, observational field study (2020)

  • Differences in Patient-Reported Outcomes That Are Most Frequently Detected in Randomized Controlled Trials in Patients With Solid Tumors: A Pooled Analysis of 229 Trials (2020)

  • The European Organisation for Research and Treatment of Cancer, State of Science in radiation oncology and priorities for clinical trials meeting report (2020)

  • Generalizability Assessment of Head and Neck Cancer NTCP Models Based on the TRIPOD Criteria (2020)

  • Adjuvant therapy with Pegylated Interferon-alfa2b vs Observation in stage II B/C patients with ulcerated primary: results of the European Organisation for Research and Treatment of Cancer 18081 randomised trial (2020)

  • Impact of acute kidney injury on anticancer treatment dosage and long-term outcomes: a pooled analysis of European Organisation for Research and Treatment of Cancer trials (2020)

  • Quality of Surgery and Outcome in Localized Gastrointestinal Stromal Tumors Treated Within an International Intergroup Randomized Clinical Trial of Adjuvant Imatinib (2020)

  • Impact of the type of anthracycline and of stem cell transplantation in younger patients with acute myeloid leukaemia: long-term follow up of a phase III study (2020)

  • Clinical research for patients with cancer in palliative care: where we stand (2020)

  • Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first‐line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group (2020)

  • Standard Anthracycline Based Versus Docetaxel-Capecitabine in Early High Clinical and/or Genomic Risk Breast Cancer in the EORTC 10041/BIG 3-04 MINDACT Phase III Trial (2020)

  • Sharing of clinical trial data and samples: The cancer patient perspective (2020)

  • Views of European Drug Development Stakeholders on Treatment Optimization and Its Potential for Use in Decision-Making (2020)

  • European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment Update 2019 (2020)

  • International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: recommendations of the SISAQOL Consortium (2020)

  • An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients: EORTC QLQ-BR45 (2020)

  • Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER) (2020)

  • VESTIGE: Adjuvant Immunotherapy in Patients With Resected Esophageal, Gastroesophageal Junction and Gastric Cancer Following Preoperative Chemotherapy With High Risk for Recurrence (N+ and/or R1): An Open Label Randomized Controlled Phase-2-Study (2020)

  • International validation of the EORTC CAT Core: a new adaptive instrument for measuring core quality of life domains in cancer (2020)

  • Clinical research tools in pediatric oncology: challenges and opportunities (2020)

  • Clinical research in Europe: who do we do all that for? (2020)

  • Gender issues from the perspective of healthcare professionals in Neuro-oncology: an EANO & EORTC Brain Tumor Group survey (2020)

  • European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics – Update 2019 (2020)

  • Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo A Secondary Analysis of a Randomized Clinical Trial (2020)

  • Characterization and classification of oligometastatic disease: and ESTRO and EORTC consensus recommendation (2020)

  • EGFR-mutations are associated with response to Depatux-M in combination with temozolomide and result in a receptor that is hypersensitive to ligand. (2019)

  • Prognostic value of patient-reported outcomes from international randomised clinical trials on cancer: a systematic review (2019)

  • Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium (2019)

  • Definition of synchronous oligo-metastatic non-small cell lung cancer - a consensus report (2019)

  • INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFRamplified glioblastoma (2019)

  • Multidisciplinary management of stage II-III gastric and gastro-oesophageal junction cancer (2019)

  • Symptom clusters in newly diagnosed glioma patients: which symptom clusters are independently associated with functioning and global health status? (2019)

  • Reference Values for the EORTC QLQ-C30 in Early and Metastatic Breast Cancer (2019)

  • Organ Preservation and Late Functional Outcome in Oropharyngeal Carcinoma: Rationale of EORTC 1420, the “Best of” trial (2019)

  • Defining EGFR amplification status for clinical trial inclusion (2019)

  • Evaluation of the Hippocampal Normal Tissue Complication Model in a Prospective Cohort of Low Grade Glioma Patients-An Analysis Within the EORTC 22033 Clinical Trial. (2019)

  • Thresholds for clinical importance were defined for the European Organisation for Research and Treatment of Cancer Computer Adaptive Testing Coredan adaptive measure of core quality of life domains in oncology clinical practice and research (2019)

  • Defining oligometastatic non-small cell lung cancer: a simulated multidisciplinary expert opinion (2019)

  • U.K. utility weights for the EORTC QLU‐C10D (2019)

  • SPECTA-AYA: A unique molecular profiling platform for adolescents and young adults with cancer in Europe (2019)

  • German value sets for the EORTC QLU‑C10D, a cancer‑specific utility instrument based on the EORTC QLQ‑C30 (2019)

  • Current state of quality of life and patient-reported outcomes research (2019)

  • Current management of limited-stage SCLC and CONVERT trial impact: results of the EORTC Lung Cancer Group survey (2019)

  • Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial. (2019)

  • Evaluation of diffusion-weighted MRI and (18F) fluorothymidine-PET biomarkers for early response assessment in patients with operable non-small cell lung cancer treated with neoadjuvant chemotherapy (2019)

  • Temporal muscle thickness is an independent prognostic marker in patients with progressive glioblastoma: translational imaging analysis of the EORTC 26101 trial. (2019)

  • Access to Clinical Trials for adolescents and young adults with cancer: a meta-research analysis (2019)

  • Quality of surgery and surgical reporting for patients with primary gastrointestinal stromal tumours participating in the EORTC STBSG 62024 adjuvant imatinib study (2019)

  • Sample size computation in phase II designs combining the A'Hern design and the Sargent and Goldberg design (2019)

  • The statistical evalutation of treatment and outcomes in Head and Neck Squamous Cell Carcimona Clinical Trials (2019)

  • Bringing Europe together in building clinical evidence for proton therapy - the EPTN-ESTRO-EORTC endeavor (2019)

  • Results of a multicentre dosimetry audit using a respiratory phantom within the EORTC LungTech trial (2019)

  • Sensitivity to change of the EORTC quality of life module measuring cancer‐related fatigue (EORTC QlQ‐Fa12): Results from the international psychometric validation (2019)

  • Minimally important differences for interpreting EORTC QLQ-C30 scores in patients with advanced breast cancer (2019)

  • The added value of Health-Related Quality of Life (HRQoL) as a prognostic indicator of overall survival and progression free survival in glioma patients: a meta-analysis based on individual patient data from randomized controlled trials (2019)

  • Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma (2019)

  • Oligometastatic non-small cell lung cancer (NSCLC): Does number of metastasis matter? (2019)

  • EORTC-1203-GITCG - the “INNOVATION”-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab in the perioperative treatment of HER-2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC- GI-group, Korean Cancer Study Group and Dutch Upper GI-Cancer group. (2019)

  • International validation of the revised European Organisation for Research and Treatment of Cancer Head and Neck Cancer Module, the EORTC QLQ‐HN43: Phase IV (2019)

  • Addressing the dichotomy between individual and societal approaches to personalized medicine in oncology (2019)

  • Meta-Analysis in Metastatic Uveal Melanoma to Determine Progression-Free and Overall Survival Benchmarks: an International Rare Cancers Initiative (IRCI) Ocular Melanoma study (2019)

  • Results of successive EORTC‐CLG 58 881 and 58 951 trials in paediatric T‐cell acute lymphoblastic leukaemia (ALL) (2019)

  • Building a collaboration to improve surgical research through EORTC/ESSO 1409-CLIMB Study : a propective liver metastasis database with an integrated Quality Assurance program (2019)

  • Imaging necrosis during treatment is associated with worse survival in EORTC 26101 study (2019)

  • Impact of Radiation Target Volume on Health-Related Quality of Life in Patients With Low-Grade Glioma in the 2-Year Period Post Treatment: A Secondary Analysis of the EORTC 22033-26033 (2019)

  • Impact of deviations in target volume delineation – Time for a new RTQA approach? (2019)

  • Use of metformin and outcome of patients with newly diagnosed glioblastoma: Pooled analysis. (2019)

  • Estimation of Distant Metastasis–free Survival in Trials of Adjuvant Therapy for Melanoma (2019)

  • Automated quantitative tumour response assessment of MRI in neuro-oncology with artificial neural networks: a multicentre, retrospective study. (2019)

  • 10-day vs 5-day decitabine: equivalence cannot be concluded (2019)

  • Improving the quality of care in the molecular era for children and adolescents with medulloblastom (2019)

  • Molecular apocrine-like tumors in EORTC 10994/BIG 1-00 phase III study: pathological response after neoadjuvant chemotherapy and clinical outcomes (2019)

  • Repeatability and reproducibility of relative cerebral blood volume measurement in recurrent glioma (2019)

  • RECIST1.1 criteria for response evaluation not only applies to chemotherapy treated patients but also to targeted cancer agents: a pooled database analysis (2019)

  • Radiotherapy practice for paediatric brain tumours accross Europe and quality assurance initiatives: Current situation, international survey and future perspectives (2019)

  • Cumulative toxicity in targeted therapies: what to expect at the recommended Phase II dose (2019)

  • A multinational multi-tumour basket study in very rare cancer types: the European Organisation for Research and Treatment of Cancer phase II 90101 "CREATE" trial (2019)

  • Cancer events in Belgian nursing home residents: An EORTC prospective cohort study (2019)

  • Association of pazopanib-induced toxicities with outcome of patients with advanced soft tissue sarcoma; a retrospective study based on the European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 clinical trials (2019)

  • Study risk assessment of Japan Clinical Oncology Group (JCOG) clinical trials using the European Organisation for Research and Treatment of Cancer (EORTC) study risk calculator (2019)

  • MGMT Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical Trials (2019)

  • The 18-year-old clinical trial inclusion limit is a major barrier in the access to immunotherapies and targeted therapies for adolescents and young adults (AYAs) with cancer (2019)

  • Impact of Concomitant Administration of Gastric Acid-Suppressive Agents and Pazopanib on Outcomes in Soft-Tissue Sarcoma Patients Treated within the EORTC 62043/62072 Trials (2019)

  • The RANO Leptomeningeal Metastasis Group proposal to assess response to treatment: lack of feasibility and clinical utility and a revised proposal (2019)

  • Establishing the European Norm for the health-related quality of life domains of the computer-adaptive test EORTC CAT Core (2019)

  • The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma: revisiting the results of the EORTC-STBSG 62931 randomised trial (2019)

  • Radiotherapy quality assurance of SBRT for patients with centrally located lung tumours within the multicentre phase II EORTC Lungtech trial: Benchmark Case results (2019)

  • General population normative data for the EORTC QLQ-C30 health-related quality of life questionnaire based on 15,386 persons across 13 European countries, Canada and the Unites States (2019)

  • The EORTC CAT Core – The computer adaptive version of the EORTC QLQ-C30 questionnaire (2018)

  • 182P Real world anti-PD-L1 treatment (tx) outcomes in a multinational European non- small cell lung cancer (NSCLC) cohort with focus on toxicity (tox) and brain metastases (BM): Preliminary data from an EORTC young investigators lung cancer group collaborative analysis (2018)

  • Association of BRCA1, ERCC1, RAP80, PKM2, RRM1, RRM2, TS, TSP1, and TXR1 mRNA expression levels between primary tumors and infiltrated regional lymph nodes in patients with resectable non-small cell lung cancer. (2018)

  • Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial (2013)

  • Development of a questionnaire (EORTC module) to measure quality of life in patients with cholangiocarcinoma and gallbladder cancer, the EORTC QLQ-BIL21 (2011)

  • Impact of the COVID-19 Crisis on Imaging in Oncological Trials (2020)

  • Conducting Non-COVID-19 Clinical Trials during the Pandemic: Can Today’s Learning Impact Framework Efficiency? (2020)

  • Using both clinical research and population-based cancer registry in longterm research- a case study using EORTC trials and the Dutch national cancer registry (IKNL) (2020)

  • Gender effects on quality of life and symptom burden in patients with lung cancer: results from a prospective, cross-cultural, multi-center study (2020)

  • Evaluating the use of the EORTC patient-reported outcome measures for improving inter-rater reliability of CTCAE ratings in a mixed population of cancer patients: study protocol for a randomized controlled trial (2020)

  • Long-term follow-up of a trial comparing post-remission treatment with autologous or allogeneic bone marrow transplantation or intensive chemotherapy in younger acute myeloid leukemia patients (2019)

  • Molecular evolution of IDH-wildtype glioblastomas treated with standard of care affects survival and design of precision medicine trials: a report from the EORTC 1542 study (2019)

  • Prospective data registration and clinical trials for particle therapy in Europe (2018)

  • Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial (2018)

  • Effect of Neoadjuvant Chemotherapy Plus Regional Hyperthermia on Long-term Outcomes Among Patients With Localized High-Risk Soft Tissue Sarcoma: The EORTC 62961-ESHO 95 Randomized Clinical Trial (2018)

  • Radiotherapy Quality assurance for the RTOG 0834/EORTC 26053-22054/NCIC CTG CEC.1/CATNON Intergroup trial “concurrent and adjuvant temozolomide chemotherapy in newly diagnosed non-1p/19q deleted anaplastic glioma”: individual case review analysis (2018)

  • Statistical Analysis of Patient Reported Outcome Data in Cancer Randomized Controlled Trials on Locally Advanced and Metastatic Breast Cancer – A Systematic Review (2018)

  • Diversity of brain metastases screening and management in non-small cell lung cancer in Europe: Results of the European Organisation for Research and Treatment of Cancer Lung Cancer Group survey (2018)

  • Outcomes of Elderly Patients with Advanced Soft Tissue Sarcoma Treated with First-Line Chemotherapy: A Pooled Analysis of 12 EORTC Soft Tissue and Bone Sarcoma Group Trials (2018)

  • Impact of Induction Regimen and of Allogeneic Hematopoietic Cell Transplantation on the Outcome in Younger Adults Patients with Acute Myeloid Leukemia with a Monosomal Karyotype: Results from the EORTC/GIMEMA AML-10 and AML-12 Trials (2018)

  • Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer (2018)

  • Responding to the challenges of international collaborations between the east and the west - a perspective from young investigators of EORTC and JCOG (2018)

  • Moving forward from drug-centered to patient-centered clinical research (2018)

  • Surgical quality assurance in head and neck cancer trials: an EORTC Head and Neck Cancer Group positions paper based on the EORTC 1420 "Best-of" and 24954 "larynx-preservation" study (2018)

  • Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: a consensus recommendation from the EORTC Imaging Group (2018)

  • European Organization for Research and Treatment of Cancer (EORTC) recommendations for planning and delivery of high-dose, high precision radiotherapy for lung cancer (2017)

  • Personalized biomarker-based treatment strategy for patients with squamous cell carcinoma of the head and neck: EORTC position and approach (2018)

  • EORTC Lung Cancer Group survey on the definition of NSCLC synchronous oligometastatic disease (2019)

  • Interpreting EORTC Quality of life Questionnaire core 30 scores as minimally importantly different for patients with malignant melanoma (2018)

  • Defining Synchronous Oligometastatic Non-Small Cell Lung Cancer: A Systematic Review (2019)

  • Does GDPR implementation in health research harm or benefit research participants ? A point of view of the European Organization for Research and Treatment of Cancer (EORTC) (2018)

  • Late translational research: putting forward a new model for developing new anti-cancer treatments that address needs of patients and society (2018)

  • Call for action to end discrimination against cancer survivors (2018)

  • A unique research infrastructure from the European Organisation for Research and Treatment of Cancer (EORTC) to optimize long-term follow-up of patients-the YOU (Your Outcome Update) protocol: Rationale, scope, design and research opportunities (2018)

  • Research on cancer survivorship needs a timely frameshift, in Europe and worldwide (2018)

  • Reply to Zhang et al (2018)

  • Cytogenetic clonal heterogeneity is not an independent prognosis factor in younger AML patients: Results on 1291 patients included in the EORTC/GIMEMA AML-10 and AML-12 trials (2018)

  • Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer: results from the EORTC 75111-10114 ETF/BCG randomized phase II study (2018)

  • What do we mean by the right to be forgotten? An analysis of the French case study from a lawyer’s perspective (2018)

  • Evaluating Continuous Tumor Measurement-Based Metrics as Phase II Endpoints for Predicting Overall Survival (2015)

  • Will molecular target agents enable the multidisciplinary treatment in stage IV gastric cancer? (2017)

  • Profile of European proton and carbon ion therapy centers assessed by the EORTC facility questionnaire (2017)

  • Tumor predispostion syndromes: The challenge of the novo mutations (2017)

  • Lessons learnt from the medical and psychosocial evaluation of childhood acute lymphoblastic leukemia (ALL) survivors enrolled in EORTC Children Leukemia Group Trials between 1971 and 1998 and future perspectives for long-term outcome research (2018)

  • A prospective study to validate the Polish language version of the European Organisation for Research and Treatment of Cancer (EORTC) Colorectal Liver Metastases (QLQ-LMC21) module (2017)

  • Patient-Reported Outcomes and Quality of Life with Sunitinib Versus Placebo for Pancreatic Neuroendocrine Tumors: Results From an International Phase III Trial. (2016)

  • Clinical Utility of Metrics Based on Tumor Measurements in Phase II Trials to Predict Overall Survival Outcomes in Phase III Trials by Using Resampling Methods. (2015)

  • Infantile hemangiopericyoma leading to hypovolemic shock in a neonate: A cas report (2017)

  • Farewell to monomodality treatment in patients with WHO lower grade glioma ?. (2018)

  • Core clinical data elements for cancer genomic repositories: A multi-sakeholder Consensus. (2017)

  • Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial. (2017)

  • Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3. European Organization for Research and Treatment of Cancer (EORTC) phase 2 trial 90101 "CREATE" (2017)

  • Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial (2018)

  • The tyrosine kinase inhibitor crizotinib does not have clinically meaningful activity in heavily pre-treated patients with advanced alveolar rhabdomyosarcoma with FOXO rearrangement: European Organisation for Research and Treatment of Cancer phase 2 trial 90101 ‘CREATE’ (2018)

  • Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial (2018)

  • Steps forward for cancer precision medicine (2017)

  • Investigating the heterogeneity of alkylating agents’ efficacy and toxicity between sexes: A systematic review and meta-analysis of randomized trials comparing cyclophosphamide and ifosfamide (MAIAGE study) (2017)

  • An update on the management of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma PAtients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG) (2017)

  • Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib – Analysis of prognostic factors (EORTC-STBSG collaborative study) (2014)

  • Strategies and Technical Challenges for Imaging Oligometastatic Disease: Recommendations from the EORTC Imaging Group. (2018)

  • Trastuzumab versus observation for high-risk, HER2 non-amplified early breast cancer with Circulating Tumor Cells (EORTC 90091-10093, BIG 1-12, Treat CTC): A multicenter, randomized phase 2 trial (2018)

  • Quality of life (QoL) in male breast cancer (BC): prospective study of the EORTC10085/TBCRC029/BIG2-07/NABCG International Male BC Program. Poster presentation at the San Antonio Breast Cancer Symposium (SABCS), Texas, USA, December 5-9, 2017. (2017)

  • Identification of SNPs associated with response of breast cancer patients to neoadjuvant chemotherapy in the EORTC-10994 randomized phase III trial (2015)

  • Clinical and Biological Characterization of Male Breast Cancer (MBC) : Baseline results from the prospective registry EORTC 10085/TBCR029/BOOG2013-02/BIG2-07. Poster presentation at the San Antonio Breast Cancer Symposium (SABCS), Texas, USA, December 5-9, 2017. (2017)

  • Guidelines for time-to-event end point definitions in sarcomas and gastrointestinal stromal tumors (GIST) trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)† (2015)

  • Beam Output Audit results within the EORTC Radiation Oncology Group network (2016)

  • Mammographic screening detects low-risk tumor biology breast cancers (2014)

  • Blood classification and blood response criteria in mycosis fungoides and Se´zary syndrome using flow cytometry: recommendations from the EORTC cutaneous lymphoma task force (2018)

  • EORTC Soft Tissue and Bone Sarcoma Group (STBSG) experience with advanced/metastatic epithelioid sarcoma patients treated in prospective trials: clinical profile and response to systemic therapy (2018)

  • Prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving first-line chemotherapy An exploratory, retrospective analysis of the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG) (2018)

  • A Gleason Score-Dependent Effect of Androgen Deprivation Therapy Duration on Survival Outcomes: An Individual Patient-Level Meta-Analysis of Six Randomized Trials (2018)

  • Comparison of Local Control of Brain Metastasis with Stereotactic Radiosurgery versus Surgical Resection: A Secondary Analysis of EORTC 22952-26001 (2018)

  • Adjuvant postoperative high-dose radiotherapy for atypical and malignant meningioma: a Phase-II parallel nonrandomized and observation study (EORTC 22042-26042) (2018)

  • Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma (2018)

  • Toward a Tiered Model to Share Clinical Trial Data and Samples in Precision Oncology (2018)

  • EORTC Manifesto - Letter to Editor (2019)

  • Multidisciplinary quality assurance and control in oncological trials: Perspectives from European Organisation for Research and Treatment of Cancer (EORTC) (2017)

  • Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials (2018)

  • Perspectives on window of opportunity trials in head and neck cancer: lessons from the EORTC 90111-24111-NOCI-HNCG study (2018)

  • Quality Assurance and Improvement in Head and Neck Cancer Surgery: from Clinical Trials to National Healthcare Initiatives (2018)

  • La randomisation adaptative bayésienne (2019)

  • Novel, improved grading system(s) for IDH-mutant astrocytic gliomas. (2018)

  • Understanding the quality of life (QOL) issues in survivors of cancer: towards the development of an EORTC QOL cancer survivorship questionnaire. (2018)

  • Long-term outcome evaluation of medium/high risk acute lymphoblastic leukemia children treated with or without cranial radiotherapy in the EORTC 58832 randomized study (2019)

  • Moving forward towards standardizing analysis of quality of life data in randomized cancer clinical trials (2018)

  • Guidelines for Inclusion of Patient-Reported Outcomes in Clinical Trial Protocols: The SPIRIT-PRO Extension. (2018)

  • Establishing anchor-based minimally important differences (MID) with the EORTC quality-of-life measures: a meta-analysis protocol (2018)

  • The effect of adjuvant chemotherapy on symptom burden and quality oflife over time; a preliminary prospective observational study usingindividual data of patients aged ≥ 70 with early stage invasivebreast cancer. (2018)

  • A critical evaluation of quality of life in clinical trials of breast cancer patients treated with radiation therapy (2017)

  • An international study to revise the EORTC questionnaire for assessing quality of life in lung cancer patients (2017)

  • A systematic review of the quality of statistical methods employed for analysing quality of life data in cancer randomised controlled trials (2017)

  • Phase III study of the European Organisation for Research and Treatment of Cancer satisfaction with cancer care core questionnaire (EORTC PATSAT-C33) and specific complementary outpatient module (EORTC OUT-PATSAT7) (2018)

  • EORTC Quality of Life Group Item Library: Technical Guidelines (2018)

  • Guidance on the implementation and management of EORTC quality of life instruments in electronic applications (2018)

  • EORTC quality of life group translation procedure (2017)

  • Lapatinib with ECF/X in the first-line treatment of metastatic gastric cancer according to HER2neu and EGFR status: a randomized placebo-controlled phase II study (EORTC 40071). (2018)

  • Clinical consequences of chemotherapy dose reduction in obese patients with stage III colon cancer: A retrospective analysis from the PETACC 3 study. (2018)

  • EORTC QLQ-COMU26: a questionnaire for the assessment of communication between patients and professionals. Phase III of the module development in ten countries (2017)

  • EORTC Quality of Life Group Module Development Guidelines (2011)

  • Anal Cancer: Putting Health-Related Quality of Life at the Forefront (2018)

  • Does age matter? A comparison of health-related quality of life issues of adolescents and young adults with cancer. (2018)

  • International validation of the EORTC QLQ-PRT20 module for assessment of quality of life symptoms relating to radiation proctitis: a phase IV study (2018)

  • Differences in health care professionals' and cancer patients' views on sexual health issues. (2018)

  • Phase 1-3 of the cross-cultural development of an EORTC questionnaire for the assessment of sexual health in cancer patients: the EORTC SHQ-22 (2018)

  • Phase I-III development of the EORTC QLQ-ANL27, a health-related quality of life questionnaire for anal cancer. (2018)

  • International development of four EORTC disease-specific quality of life questionnaires for patients with Hodgkin lymphoma, highand low-grade non-Hodgkin lymphoma and chronic lymphocytic leukaemia (2018)

  • A cross-cultural convergent parallel mixed methods study of what makes a cancer-related symptom or functional health problem clinically important. (2018)

  • International phase IV validation study of an EORTC quality of life questionnaire for testicular cancer patients: the EORTC QLQ-TC26. (2018)

  • The international phase 4 validation study of the EORTC QLQ‐SWB32: A stand‐alone measure of spiritual well‐being for people receiving palliative care for cancer (2017)

  • Impact of Primary Tumor Location on Survival from the European Organization for the Research and Treatment of Cancer Advanced Urothelial Cancer Studies (2018)

  • Fetal hemoglobin induction during decitabine treatment of elderly high-risk myelodysplastic syndrome and acute myeloid leukemia patients: a potential dynamic biomarker for outcome (2018)

  • Associations of anticoagulant use with outcome in newly diagnosed glioblastoma (2018)

  • Expression-based intrinsic glioma subtypes are prognostic in low-grade gliomas of the EORTC22033-26033 clinical trial (2018)

  • Repeatability of quantitative 18F-FLT uptake measurements in solid tumors: an individual patient data multi-center meta-analysis (2018)

  • MGMT Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide. A Pooled Analysis of Four Clinical Trials (2018)

  • Anti-angiogenic treatment in breast cancer: facts, successes, failures and future perspectives (2017)

  • A systematic review examining factors influencing Health Related Quality of Life among melanoma cancer survivors (2016)

  • A population-based approach to compare patient-reported outcomes of survivors of Hodgkin lymphoma initially treated inside and outside clinical trials: a study based on the linkage of European Organisation for the Research and Treatment of Cancer (EORTC) and Patient Reported Outcomes Following Initial treatment and Long-term Evaluation of Survivorship (PROFILES) registry databases (2017)

  • Current management of liver metastases from gastric cancer - What is common practice ? New challenge of EORTC and JCOG (2017)

  • Predictive and prognostic factors associated with soft tissue sarcoma response to chemotherapy: a subgroup analysis of the European Organisation for Research and Treatment of Cancer 62012 study (2017)

  • Correlation between severe infection and breast cancer metastases in the EORTC 10994/BIG 1-00 trial: investigating innate immunity as a tumor suppressor in breast cancer (2017)

  • Lungtech, a phase II EORTC trial of SBRT for centrally located lung tumours – a clinical physics perspective (2016)

  • Identifying critical steps towards improved access to innovation in cancer care: a European CanCer Organisation position paper (2017)

  • Characterization of multifocal breast cancer using the 70-gene signature in clinical low-risk patients enrolled in the EORTC 10041/BIG 03-04 MINDACT trial. (2017)

  • iRECIST: Guidelines for response criteria for use in trials testing immunotherapeutics (2017)

  • Evaluation of response after neoadjuvant treatment in soft tissue sarcomas; the European Organization for Research and Treatment of CancereSoft Tissue and Bone Sarcoma Group (EORTCeSTBSG) recommendations for pathological examination and reporting (2016)

  • International Psychometric Validation of an EORTC Quality of Life Module Measuring Cancer Related Fatigue (EORTC QLQ-FA12) (2017)

  • Clinical Impact of Additional Cytogenetic Aberrations, cKIT and RAS Mutations, and Treatment Elements in Pediatric t(8;21)-AML: Results From an International Retrospective Study by the International Berlin-Frankfurt-Münster Study Group. (2015)

  • Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration. (2015)

  • Heterogeneous cytogenetic subgroups and outcomes in childhood acute megakaryoblastic leukemia: a retrospective international study. (2015)

  • Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia. (2015)

  • ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016 (2016)

  • Translation into Portuguese, cross-cultural adaptation and validation of "The European Organization for Research and Treatment of Cancer-Quality of Life Questionnaire-Bone Metastases-22" (2016)

  • Association of Patient Sex With Chemotherapy-Related Toxic Effects: A Retrospective Analysis of the PETACC-3 Trial (2018)

  • Immunohistochemical versus molecular (BluePrint and MammaPrint) subtyping of breast carcinoma. Outcome results from the EORTC 10041/BIG 3-04 MINDACT trial (2018)

  • Whole Brain Radiotherapy after Stereotactic Radiosurgery or Surgical Resection among Patients with 1-3 Brain Metastases and Favorable Prognoses: A Secondary Analysis of EORTC 22952-26001 (2017)

  • Evaluation of the impact of tumor HPV status on outcome in patients with locally advanced unresectable head and neck squamous cell carcinoma (HNSCC) receiving cisplatin, 5-Fluoroucacil with or without docetaxel: A subset analysis of EORTC 24971 study (2017)

  • Do patients whose tumor achieved a pathological response relapse at specific sites? A substudy of the EORTC 10994/BIG-1-00 trial (2018)

  • The European Cancer Patient's Bill of Rights, update and implementation 2016 (2017)

  • Predictors for doxorubicin-induced hematological toxicity and its association with outcome in advanced soft tissue sarcoma patients; a retrospective analysis of the EORTC-soft tissue and bone sarcoma group database (2018)

  • Identification of microRNA biomarkers for response of advanced soft tissue sarcomas to eribulin: translational results of the EORTC 62052 trial (2017)

  • Using PET for therapy monitoring in clinical trials: challenges ahead (2017)

  • Comparison of the FACT-C, EORTC QLQ-CR38, and QLQ-CR29 quality of life questionnaires for patients with colorectal cancer: a literature review (2016)

  • The use and impact of quality of life assessment tools in clinical care settings for cancer patients, with a particular emphasis on brain cancer: insights from a systematic review and stakeholder consultations (2016)

  • Comparison of the EORTC STO-22 and the FACT-Ga quality of life questionnaires for patients with gastric cancer. (2016)

  • The impact of bevacizumab on health-related quality of life in patients treated for recurrent glioblastoma: Results of the randomised controlled phase 2 BELOB trial. (2015)

  • Health-Related Quality of Life in a Randomized Phase III Study of Bevacizumab, Temozolomide, and Radiotherapy in Newly Diagnosed Glioblastoma. (2015)

  • EORTC QLQ-BR23 and FACT-B for the assessment of quality of life in patients with breast cancer: a literature review (2015)

  • Oral-health-related quality of life in patients with cancer: cultural adaptation and the psychometric testing of the Persian version of EORTC QLQ-OH17. Support Care Cancer (2015)

  • Development, characteristics and validity of the EORTC QLQ-PR25 and the FACT-P for assessment of quality of life in prostate cancer patients (2014)

  • Cross-cultural development of a quality-of-life measure for patients with melanoma: phase 3 testing of an EORTC Melanoma Module (2015)

  • Joint modeling of longitudinal health-related quality of life data and survival. (2015)

  • Comparison of the EORTC QLQ-BN20 and the FACT-Br quality of life questionnaires for patients with primary brain cancers: a literature review (2014)

  • Comparison of Three Shortened Questionnaires for Assessment of Quality of Life in Advanced Cancer (2014)

  • Validation of the Polish version of the EORTC QLQ-OV28 module for the assessment of health-related quality of life in women with ovarian cancer (2014)

  • Net Clinical Benefit Analysis of Radiation Therapy Oncology Group 0525: A Phase III Trial Comparing Conventional Adjuvant Temozolomide With Dose-Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma (2013)

  • Interim analysis of the EORTC randomized phase III CATNON trial on concurrent and adjuvant temozolomide in 1p/19q-intact anaplastic glioma. An intergroup trial. Oral Presentation at the ASCO Annual Meeting , Chicago, Illinois, USA, 3 - 7 June 2016 (2016)

  • EORTC 26101 trial phase III trial exploring the combination of bevacizumab and lomustine in patients with first progression of a glioblastoma. Oral Presentation at the ASCO Annual Meeting , Chicago, Illinois, USA, 3 - 7 June 2016 (2016)

  • TPF plus cetuximab (E) induction chemotherapy (ICT) followed by biochemoradiation (BCRT) with weekly E plus weekly cisplatin (P) or carboplatin (C) in stage III/IV Squamous Cell Carcinoma of the Head and Neck (HNSCC): a randomized phase II EORTC trial. Poster Presentation at the ASCO Annual Meeting, Chicago, Illinois, USA, 3 - 7 June 2016 (2016)

  • Activity of afatinib administered in a window pre-operative study in squamous cell carcinoma of the head and neck (SCCHN) : EORTC-90111. Poster Presentation at the ASCO Annual Meeting , Chicago, Illinois, USA, 3 - 7 June 2016 (2016)

  • EORTC-1203: Integration of trastuzumab (T), with or without pertuzumab (P), into perioperative chemotherapy (CT) of HER-2 positive stomach cancer. “INNOVATION” trial. Poster Presentation at the ASCO Annual Meeting , Chicago, Illinois, USA, 3 - 7 June 2016 (2016)

  • Factors predictive of locoregional recurrence following neoadjuvant chemotherapy in patients with large operable or locally-advanced breast cancer: an analysis of the EORTC 10994/BIG 1-00 study (2017)

  • EORTC-ETOP randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab versus placebo for patients with early stage non-small cell lung cancer (NSCLC) after resection and standard adjuvant chemotherapy: PEARLS (NCT02504372). Poster Presentation at the ASCO Annual Meeting , Chicago, Illinois, USA, 3 - 7 June 2016. (2016)

  • Disease free survival (DFS) is a surrogate for Overall Survival (OS) in Localized Prostate Cancer (CaP). Poster Presentation at the ASCO Annual Meeting , Chicago, Illinois, USA, 3 - 7 June 2016. (2016)

  • Prophylactic CNS Therapy (with or without Radiation Therapy) in Medium-High Risk Acute Lymphoblastic Leukemia (ALL) Children: Long-Term Outcome Evaluation of the Randomized BFM-oriented Trial 58832 (period 1983-1989) of the EORTC Children Leukemia. Poster Presentation at the American Society of Hematology’s 58th Annual Meeting (ASH), San Diego, USA, 3-6 December, 2016 (2016)

  • Post-Remission Treatment with Autologous or Allogeneic Bone Marrow Transplantation or Intensive Chemotherapy in Younger AML Patients: Long-Term Follow-up Results of the EORTC/Gimema AML-8A Study (2016)

  • Impact of Age and Treatment Group in Childhood High Hyperdiploid Low Risk B-Cell Acute Lymphoblastic Leukemia (ALL): Results of the CLG-EORTC 58951 Study. Poster Presentation at the American Society of Hematology’s 58th Annual Meeting (ASH), San Diego, USA, 3-6 December, 2016 (2016)

  • Ipilimumab (IPI) vs placebo (PBO) after complete resection of stage III melanoma: final overall survival results from the EORTC 18071 randomized, double-blind, phase 3 trial. Oral Presentation at the ESMO Congress , 7-11 October 2016, Copenhagen, Denmark. (2016)

  • Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group retrospective analysis. Poster Presentation at the ESMO Congress , 7-11 October 2016, Copenhagen, Denmark. (2016)

  • Occurrence of cancer events, referral and outcome in belgian nursing home residents (NHR) An EORTC prospective cohort study. International Society of Geriatric Oncology (SIOG), Milan, Italy, 17 - 19 November 2016. (2016)

  • A Systematic Review on the Choice and Implementation of Statistical Methods in Health-Related Quality of Life Data Analyses in Locally Advanced and Metastatic Breast Cancer Randomized Controlled Trials (SISAQOL Consortium) (2016)

  • Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial. (2017)

  • The association between pCR status after neoadjuvant chemotherapy and sites of first distant relapse after surgery: A substudy of the EORTC 10094/BIG-1-00 trial. Poster Presented at the San Antonio Breast Cancer Symposium, San Antonio, USA, 6 - 10 December, 2016 (2016)

  • Setting Standards for Analysis of Quality of Life Data for International Cancer Clinical Trials (SISAQOL Consortium). Oral Presentation at 23rd International Society for Quality of Life Research (ISOQOL), Copenhagen, Denmark, 19 - 22 October 2016 (2016)

  • Is there a relationship between spiritual wellbeing (SWB) and emotional and physical functioning for people receiving palliative care for cancer?. Oral Presented at 23rd International Society for Quality of Life Research (ISOQOL), Copenhagen, Denmark, 19 - 22 October 2016 (2016)

  • Development of thresholds for clinical importance for the EORTC quality of life measures. Oral Presented at 23rd International Society for Quality of Life Research (ISOQOL), Copenhagen, Denmark, 19 - 22 October 2016 (2016)

  • Empirical Evaluation of the Minimal Important Differences (MID) with the EORTC Quality of Life Group Measures: Embarking on a New Research Initiative on behalf of the EORTC Quality of Life Group and EORTC Quality of Life Department. Oral presented at 23rd International Society for Quality of Life Research (ISOQOL), Copenhagen, Denmark, 19 - 22 October 2016 (2016)

  • An item response theory based method for detecting item-level response-shift. Oral Presented 23rd International Society for Quality of Life Research (ISOQOL), Copenhagen, Denmark, 19 - 22 October 2016 (2016)

  • Evidence for the content validity of the EORTC QLQ-C30: Review of existing data. Oral Presented at 23rd International Society for Quality of Life Research (ISOQOL), Copenhagen, Denmark, 19 - 22 October 2016 (2016)

  • THE EORTC COMMUNICATION-QUESTIONNAIRE: Preliminary results of Phase III and design of the validation study for the EORTC QLQ-COMU26. Poster Presentation at 23rd International Society for Quality of Life Research (ISOQOL), Copenhagen, Denmark, 19 - 22 October 2016 (2016)

  • Update of the EORTC questionnaire for assessing quality of life in patients with lung cancer – introducing the new EORTC QLQ-Lung Cancer 29 module. Poster Presented 23rd International Society for Quality of Life Research (ISOQOL), Copenhagen, Denmark, 19 - 22 October 2016 (2016)

  • Comparison of the FACT-C, EORTC QLQ-CR38 and QLQ-CR29 quality of life: a review. Poster Presented at 23rd International Society for Quality of Life Research (ISOQOL), Copenhagen, Denmark, 19 - 22 October 2016 (2016)

  • Introducing the new EORTC Quality of Life Group Item Bank. Poster Presented at 23rd International Society for Quality of Life Research (ISOQOL), Copenhagen, Denmark, 19 - 22 October 2016 (2016)

  • Challenges of the translation of the EORTC patient satisfaction questionnaires. Poster Presented at 23rd International Society for Quality of Life Research (ISOQOL), Copenhagen, Denmark, 19 - 22 October 2016. 2016. (2016)

  • A manual for the use of EORTC measures in daily clinical practice. Poster Presented at 23rd International Society for Quality of Life Research (ISOQOL), Copenhagen, Denmark, 19 - 22 October 2016 (2016)

  • Quality of life evolution for melanoma patients: a systematic review. Poster Presented at 23rd International Society for Quality of Life Research (ISOQOL), Copenhagen, Denmark, 19 - 22 October 2016 (2016)

  • APPLE trial: Feasibility and activity of AZD9291 (osimertinib) treatment on Positive PLasma T790M in EGFR mutant NSCLC patients. EORTC 1613 (2017)

  • Comment on the “TrialsTracker: Automated ongoing monitoring of failure to share clinical trial results by all major companies and research institutions” (2017)

  • The European organization for research and treatment of cancer — satisfaction with cancer care questionnaire: revision and extended application development. (2017)

  • Systematic Review of the Side Effects Associated With Anti-HER2-Targeted Therapies Used in the Treatment of Breast Cancer, on Behalf of the EORTC Quality of Life Group. (2016)

  • Large variations in clinical and ethical aspects of genomic sequencing initiatives: A Global Alliance for Genomics and Health (GA4GH) survey . Poster Presentation at AACR Anuual Meeting 2016, New Orlean, USA, 16-20 (2016)

  • SPECTAlung Screening Patients with thoracic malignancies for Efficient Clinical Trial Access. Poster Presented at the 16TH World Conference on Lung Cancer, Denver, Colorado, USA, 6 - 9 September 2015 (2015)

  • Pan-European survey on thymic malignancies: A collaboration of the EORTC Lung Cancer Group (LCG) with the RYTHMIC network. Poster Presentation at the European Cancer Congress (ECC2015), Vienna, Austria, September 25-29, 2015. (2015)

  • SPECTAlung Screening Patients with thoracic malignancies for Efficient Clinical Trial Access. Poster Presentation the Win Symposium, Paris, France, 29 - 30 June, 2015 (2015)

  • Double Blind Randomized Phase III Study of Maintenance Pazopanib® (PZ) Versus Placebo (P) in non small cell lung cancer (NSCLC) patients (PTS) non progressive after first line chemotherapy [CT] (EORTC Lung Cancer Group, 08092): MAPPING. Poster Presentation at the 39th ESMO Congress, Madrid, Spain, 26 - 30 September 2014 (2014)

  • Making Advances in Quality of Life Studies in Head and Neck Cancer (2017)

  • Tackling brain tumours – Meet the doctors set on taming this toughest of cancers (2017)

  • Quality assurance in clinical trials (2003)

  • Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG (2017)

  • Differential impact of drugs on the outcome of ETV6-RUNX1 positive childhood B-cell precursor acute lymphoblastic leukaemia: results of the EORTC CLG 58881 and 58951 trials (2017)

  • Lomustine and Bevacizumab in Progessive Glioblastoma. (2017)

  • Characterization of male breast cancer: Results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program (2018)

  • Rituximab maintenance improves overall survival of patients with follicular lymphomadIndividual patient data meta-analysis (2017)

  • A phase III randomized controlled trial of short-course radiotherapy with or without concomitant and adjuvant temozolomide in elderly patients with glioblastoma (CCTG CE.6, EORTC 26062-22061, TROG 08.02, NCT00482677). Oral Presentation at the ASCO Annual Meeting , Chicago, Illinois, USA, 3 - 7 June 2016. J Clin Oncol 2016; 34. (2016)

  • Does Whole-Brain Radiation Therapy for Oligometastatic Brain Metastases Translate Into a Survival Benefit for Patients With a Limited Competing Risk From Extracranial Disease? A Secondary Analysis of EORTC 22952-26001. Abstract Presented at the 2016 ASTRO Annual Meeting, September 25 - 28, 2016 Boston, Massachusetts, USA (2016)

  • EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma (2012)

  • Erratum to: “EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma” (2012)

  • End Points and Trial Design in Geriatric Oncology Research: A Joint European Organisation for Research and Treatment of Cancer–Alliance for Clinical Trials in Oncology–International Society of Geriatric Oncology Position Article (2013)

  • Societal challenges of precision medicine: bringing order to chaos (2017)

  • International evaluation of the psychometrics of health-related quality of life questionnaires for use among longterm survivors of testicular and prostate cancer (2017)

  • Dose-Finding Methods: Moving Away from the 3 + 3 to Include Richer Outcomes (2017)

  • Do statins, ACE inhibitors or sartans improve outcome in primary glioblastoma? (2018)

  • Pharmacologically directed strategies in academic anticancer drug discovery based on the European NCI compounds initiative (2017)

  • Folate concentration dependent transport activity of the multidrug resistance protein 1 (ABCC1) (2004)

  • Diverging EU health regulations: the urgent need for co ordination and convergence (2017)

  • The interaction between folate homeostasis and MRPs/ABCCs and BCRP/ABCG2 expression: role in cellular drug resistance. In: Chemistry and Biology of Pteridines and Folates, 13th International Symposium, 20 - 24 June 2005, Heilbronn, Germany (2005)

  • Class of drugs and mechanisms of action. ESMO Handbook of Translational Research, (EDS: G. Tortora, C. Sessa, A Scarpa, S Banerjee (ESMO press)), Chapter 4, pp. 44-54. (2015)

  • Symptom clusters analysis in bone metastases patients. Chapter ID: 36418. Cancer: Pain and Symptom Management. 2016. Chapter 5. p. 41-74. ISBN: 978-1-63483-864-1 (2016)

  • Lung cancer and quality of life. Survival, Quality of Life and Ethical Implications. 2015. Chapter 8. ISBN: 978-1-63483-912-9 (2015)

  • Quality of Life in Radiation Treatment of Bone Metastases. In: Palliative Radiation Therapy: Utilization of Advanced Technologies. 2015. Chapter ID: 30881. Book ID: 5420. Vol 1. Chapter 11. ISBN: 978-1-63482-327-2 (2015)

  • Final results of the EORTC Brain Tumor Group randomized phase II TAVAREC trial on temozolomide with or without bevacizumab in 1st recurrence grade II/III glioma without 1p/19q co-deletion. Oral Presentation at the ASCO Annual Meeting, Chicago, Illinois, United States, June 2-6, 2017. (2017)

  • EORTC1527/JCOG1609INT: Diffusion-weighted MRI (DW-MRI) assessment of liver metastasis to improve surgical planning (DREAM). Poster Presentation at the ASCO Annual Meeting, Chicago, Illinois, United States, June 2-6, 2017. (2017)

  • Standard anthracycline-based vs. Docetaxel-Capecitabine in early breast cancer: results from the chemotherapy randomization (R-C) of EORTC 10041/ BIG 3-04 MINDACT phase III trial. Poster Presentation at the ASCO Annual Meeting, Chicago, Illinois, United States, June 2-6, 2017. (2017)

  • Validation of RECIST 1.1 for use with cytotoxic agents and targeted cancer agents (TCA): Results of a RECIST Working Group analysis of a 50 clinical trials pooled individual patient database. Poster Presentation at the ASCO Annual Meeting, Chicago, Illinois, United States, June 2-6, 2017. (2017)

  • Prognostic impact of primary tumor location in advanced urothelial carcinoma: The EORTC series. Publication at the ASCO Annual Meeting, Chicago, Illinois, United States, June 2-6, 2017. (2017)

  • Cancer events in Belgian nursing home residents (NHR): An EORTC prospective cohort study. Publication at the ASCO Annual Meeting, Chicago, Illinois, United States, June 2-6, 2017. (2017)

  • Trial in progress: EORTC Trial 1416 A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy (EORTC/ETOP 1416-PEARLS). Poster Presentation at the ELCC Meeting, Geneva, Switzerland, 5 - 8 May 2017. (2017)

  • Understanding the age-dependent cancer burden on pre-treated health-related quality of life of cancer patients using the EORTC QLQ-C30: A pooled analysis of randomized controlled trials. 21st Annual Conference of the International Society for Quality of Life Research, Berlin, Germany, October 2014. (2014)

  • Effect of completion-time windows in the analysis of health-related quality of life (HRQOL) outcomes in radiotherapy clinical trial. 21st Annual Conference of the International Society for Quality of Life Research, Berlin, Germany, October 2014. (2014)

  • Health-related quality of life and cognitive functioning in long-term anaplastic glioma survivors from eortc study 26951. 17th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology (SNO), November 15-18, 2012, Washington (2012)

  • Safeguarding the Future of Independent, Academic Clinical Cancer Research in Europe – for the Benefit of Patients (2017)

  • Reviewing Back Translation Reports of Questionnaires: The EORTC Conceptual Framework and Experience (2017)

  • The role of dosimetry audit in lung SBRT multi-centre clinical trials (2017)

  • Activity and safety of afatinib in a window pre-operative EORTC study in patients with squamous cell carcinoma of the head and neck (SCCHN) (2018)

  • Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial (2017)

  • Optimization of the antitumor activity of sequence-specific pyrrolobenzodiazepine derivatives based on their affinity for ABC transporters (2010)

  • Molecular mechanism underlying the pharmacological interactions of the Protein kinase C-ß inhibitor enzastaurin and erlotinib in non-small cell lung cancer cells (2017)

  • New tricks for old biomarkers: thymidylate synthase expression as predictor of pemetrexed activity in mesothelioma (2010)

  • Combination therapy with gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, gemcitabine and cisplatin in patients with advanced solid tumors (2004)

  • Correlation of cytidine deaminase polymorphisms and activity with clinical outcome in gemcitabine/platinum-treated advanced non-small-cell lung cancer patients (2012)

  • Sunitinib in advanced alveolar soft part sarcoma: evidence of a direct antitumor effect (2011)

  • Prevention of fluoropyrimidine toxicity: do we still have to try our patient's luck? (2016)

  • Sunitinib in Pancreatic Neuroendocrine Tumors: Updated Progression-Free Survival and Final Overall Survival From a Phase III Randomized Study (2017)

  • Guidelines for the use and interpretation of assays for monitoring autophagy (3rdedition). (2016)

  • Folate concentration dependent transport activity of the multidrug resistance protein 1 (ABCC1) (2004)

  • Gene expression profiling of leukemia T-cells resistant to methotrexate and 7-hydroxymethotrexate reveals alterations that preserve intracellular levels of folate and nucleotide biosynthesis (2009)

  • Increased levels and defective glycosylation of MRPs in ovarian carcinoma cells resistant to oxaliplatin (2010)

  • Proteasome-based mechanisms of intrinsic and acquired bortezomib resistance in non-small cell lung cancer (2012)

  • Anti-leukemic activity and mechanisms underlying resistance to the novel immunoproteasome inhibitor PR-924. (2014)

  • Fsn0503h antibody-mediated blockade of cathepsin S as a potential therapeutic strategy for the treatment of solid tumors (2015)

  • Plasminogen Activator System and Breast Cancer: Potential Role in Therapy Decision Making and Precision Medicine (2016)

  • Molecular mechanisms underlying the role of microRNAs in the chemoresistance of pancreatic cancer (2014)

  • Synthesis and antitumor activity of 2,5-bis(3'-indolyl)-furans and 3,5-bis(3'-indolyl)-isoxazoles, nortopsentin analogues (2010)

  • ). Synthesis, topoisomerase-targeting activity and growth inhibition of lycobetaine analogs (2013)

  • Disparate mechanisms of antifolate resistance provoked by methotrexate and its metabolite 7-hydroxymethotrexate in leukemia cells: implications for efficacy of methotrexate therapy (2004)

  • Molecular basis of bortezomib resistance: Proteasome subunit ß5 PSMB5) gene mutation and overexpression of PSMB5 protein (2008)

  • Prognostic relevance of ALT-associated markers in liposarcoma: a comparative analysis (2010)

  • Apollon gene silencing induces apoptosis in breast cancer cells through p53 stabilisation and caspase-3 activation (2009)

  • Beating the odds: efficacy and toxicity of dihydropyrimidine dehydrogenase-driven adaptive dosing of 5-FU in patients with digestive cancer (2016)

  • Preclinical emergence of vandetanib as a potent antitumor agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin (2011)

  • Synergistic interaction of novel lactate dehydrogenase inhibitors with gemcitabine against pancreatic cancer in hypoxia (2014)

  • EO9 (Apaziquone): From the clinic to the laboratory and back again (2013)

  • Pharmacology of the paclitaxel-cisplatin, gemcitabine-cisplatin, and paclitaxel-gemcitabine combinations in patients with advanced non-small cell lung cancer (2006)

  • Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years (2013)

  • Safety and pharmacology of gemcitabine and capecitabine in patients with advanced pancreatico-biliary cancer and hepatic dysfunction (2014)

  • Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy (2015)

  • Pharmacokinetic and pharmacodynamic study of doxorubicin in children with cancer: results of a "European Pediatric Oncology Off-patents Medicines Consortium" trial (2016)

  • Unique features of trabectedin mechanism of action (2016)

  • Validation of tumour models for use in anticancer nanomedicine evaluation: the EPR effect and cathepsin B-mediated drug release rate (2013)

  • Pharmacokinetics and pharmacogenetics of gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective (2016)

  • Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors (2014)

  • Pharmacokinetics of Selected Anticancer Drugs in Elderly Cancer Patients: Focus on Breast Cancer (2016)

  • Synthesis and antitumor activity of 3-(2-phenyl-1,3-thiazol-4-yl)-1H-indoles and 3-(2-phenyl-1,3-thiazol-4-yl)-1H-7-azaindoles (2011)

  • Oxaliplatin in the era of personalized medicine: from mechanistic studies to clinical efficacy Cancer (2016)

  • Metabolic approach to the enhancement of antitumor effect of chemotherapy: a key role of acetyl-L-carnitine (2010)

  • Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance (2011)

  • The effect of food on the pharmacokinetics of S-1 after single oral administration to patients with solid tumors (2004)

  • Gender, cytidine deaminase, and 5-aza/decitabine (2013)

  • Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082) (2016)

  • Pharmacokinetics of Irinotecan, Oxaliplatin and 5-Fluorouracil During Hepatic Artery Chronomodulated Infusion: A Translational European OPTILIV Study (2016)

  • Towards a Model-Based Dose Recommendation for Doxorubicin in Children (2017)

  • Age-Dependent Pharmacokinetics of Doxorubicin in Children with Cancer (2015)

  • Challenges, expectations and limits for nanoparticles-based therapeutics in cancer: a focus on nano-albumin-bound drugs (2013)

  • Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects (2014)

  • Folates as adjuvants to anticancer agents: chemical rationale and mechanism of action (2016)

  • Trastuzumab-induced cardiotoxicity: is it a personalized risk? (2014)

  • Synthesis and antiproliferative activity of substituted 3[2-(1H-indol-3-yl)- 1,3-thiazol-4-yl]-1H-pyrrolo[3,2-b]pyridines, marine alkaloid nortopsentin analogues (2014)

  • Impact of microRNAs in resistance to chemotherapy and novel targeted agents in non-small cell lung cancer (2014)

  • The impact of folates status on the efficacy of colorectal cancer treatment (2011)

  • The EGFR pathway regulates BCRP expression in NSCLC cells: role of Erlotinib (2014)

  • The EGFR pathway regulates BCRP expression in NSCLC cells: role of Erlotinib. (2014)

  • Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: current status and future perspective in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer (2013)

  • Intracellular trafficking of MDR transporters and relevance of SNPs (2009)

  • Molecular basis of resistance to proteasome inhibitors in hematological malignancies (2015)

  • Therapeutic drug monitoring in cancer--are we missing a trick? (2014)

  • Review of therapeutic drug monitoring of anticancer drugs part one--cytotoxics (2014)

  • Review of therapeutic drug monitoring of anticancer drugs part two--targeted therapies (2014)

  • On the use of pharmacogenetics in cancer treatment and clinical trials (2014)

  • N-Hydroxyindole-based inhibitors of lactate dehydrogenase against cancer cell proliferation (2011)

  • Water-soluble isoindolo[2,1-a]quinoxalin-6-imines: in vitro antiproliferative activity and molecular mechanism(s) of action (2015)

  • [1,2]Oxazolo[5,4-e]isoindoles as promising tubulin polymerization inhibitors (2016)

  • Overcoming bortezomib resistance in human B cells by anti-CD20/rituximab-mediated complement-dependent cytotoxicity and epoxyketone-based irreversible proteasome inhibitors (2013)

  • On the pharmacogenetics of non-small cell lung cancer treatment (2016)

  • ). Pharmacogenetics and breast cancer management: current status and perspectives (2015)

  • Role of cytidine deaminase in toxicity and efficacy of nucleosidic analogs (2015)

  • Pre-mRNA splicing in cancer: the relevance in oncogenesis, treatment and drug resistance (2015)

  • Nucleoside analogs: ready to enter the era of precision medicine? (2016)

  • Entrectinib: a potent new TRK, ROS1, and ALK inhibitor (2015)

  • The potential of neurotrophic tyrosine kinase (NTRK) inhibitors for treating lung cancer (2016)

  • Recent developments in the use of immunotherapy in non-small cell lung cancer (2016)

  • Telomere maintenance in Wilms tumors: first evidence for the presence of alternative lengthening of telomeres mechanism (2011)

  • Chromosome 7 gain and DNA hypermethylation at the HOXA10 locus are associated with expression of a stem cell related HOX-signature in glioblastoma (2015)

  • Higher ratio immune versus constitutive proteasome level as novel indicator of sensitivity of pediatric acute leukemia cells to proteasome inhibitors (2013)

  • The association of aberrant folylpolyglutamate synthetase splicing with ex vivo MTX resistance and clinical outcome in childhood acute lymphoblastic leukemia (2016)

  • Antiproliferative Effects of Novel Aliphatic Acetogenin Analogs Against Aggressive Solid Tumor Cell Lines (2011)

  • Folylpolyglutamate synthetase splicing alterations in acute lymphoblastic leukemia are provoked by methotrexate and other chemotherapeutics and mediate chemoresistance (2016)

  • Cellular pharmacology of multi- and duplex drugs consisting of ethynylcytidine and 5-fluoro-2'-deoxyuridine (2011)

  • Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models (2011)

  • A phase I schedule dependency study of the aurora kinase inhibitor MSC1992371A in combination with gemcitabine in patients with solid tumors (2013)

  • Phase I dose escalation and pharmacokinetic evaluation of two different schedules of LY2334737, an oral gemcitabine prodrug, in patients with advanced solid tumors (2015)

  • Telomerase Activity and Telomere Length in Human Tumor Cells with Acquired Resistance to Anticancer Agents (2009)

  • Alkylpurine–DNA–N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients (2012)

  • Epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy: a glimmer of hope? (2017)

  • Prognostic and predictive role of thymidylate synthase expression in lung cancer: The debate is still open (2016)

  • Interferon-?-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines (2013)

  • Methotrexate resistance in relation to treatment outcome in childhood acute lymphoblastic leukemia (2015)

  • Phospho-Akt overexpression is prognostic and can be used to tailor the synergistic interaction of AKT inhibitors with gemcitabine in pancreatic cancer (2017)

  • Structure-Activity Relationships of monomeric C2-aryl pyrrolo[2,1-c][1,4]benzodiazepine (PBD) antitumour agents (2010)

  • Discovery of N-hydroxyindole-based inhibitors of human lactate dehydrogenase isoform A (LDH-A) as starvation agents against cancer cells (2011)

  • Novel 1H-pyrrolo[2,3-b]pyridine derivative nortopsentin analogues: synthesis and antitumor activity in peritoneal mesothelioma experimental models (2013)

  • Preclinical Activity of New [1,2]Oxazolo[5,4-e]isoindole Derivatives in Diffuse Malignant Peritoneal Mesothelioma (2016)

  • Strategies to translate preclinical information to breast cancer patient benefit (2011)

  • Inactivating PSMB5 mutations and P-glycoprotein (MDR1/ ABCB1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno) proteasome inhibitors in mononuclear blood cells from rheumatoid arthritis patients (2012)

  • One marker does not fit all": additional translational and validation studies are needed to identify faithful predictors of pemetrexed activity in mesothelioma (2013)

  • cMET exon 14 skipping: from the structure to the clinic (2016)

  • Women at a Disadvantage in Fluorouracil Treatment (2016)

  • Molecular neuro-oncology in clinical practice: a new horizon (2013)

  • Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial (2014)

  • Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study (2016)

  • Pharmacogenetic study of patients with advanced non-small cell lung cancer treated with second-line pemetrexed or pemetrexed-carboplatin (2012)

  • Synthesis and antiproliferative activity of 2,5-bis(3'-indolyl)pyrroles, analogues of the marine alkaloid nortopsentin (2013)

  • Association of polymorphisms in AKT1 and EGFR with clinical outcome and toxicity in non-small-cell lung cancer patients treated with gefitinib (2010)

  • Sulphasalazine down-regulates the expression of the angiogenic factors platelet-dervied endothelial cell growth factor/thymidine phosphorylase and interleukin 8 in human monocytic-macrophage THP-1 and U937 cells (2004)

  • Antileukemic activity and mechanism of drug resistance to the marine Salinispora tropica proteasome inhibitor salinosporamide A (Marizomib) (2014)

  • Molecular mechanisms underlying the antitumor activity of 3-aminopropanamide Irreversible Inhibitors of the Epidermal Growth Factor Receptor in Non-Small Cell Lung Cancer (2013)

  • Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma (2015)

  • Antiproliferative activity and mechanism of action of fatty acid derivatives of gemcitabine in leukemia and solid tumor cell lines and in human xenografts (2004)

  • Antiproliferative activity and mechanism of action of fatty acid derivatives of arabinosylcytosine (Ara-C) in leukemia and solid tumor cell lines (2004)

  • Study of apoptosis induction and deoxycytidine kinase/cytidine deaminase modulation in the synergistic interaction of a novel ceramide analog and gemcitabine in pancreatic cancer cells (2010)

  • Selection of the best blood compartment to measure cytidine deaminase activity to stratify for optimal gemcitabine or cytarabine treatment (2014)

  • A specific inhibitor of lactate dehydrogenase overcame the resistance towards gemcitabine in hypoxic mesothelioma cells, and modulated the expression of the human equilibrative transporter-1 (2016)

  • miR-21: an oncomir on strike in prostate cancer (2010)

  • A gene expression signature classifying telomerase and ALT immortalization reveals an hTERT regulatory network and suggests a mesenchymal stem cell origin for ALT (2009)

  • Identification of LDH-A as a therapeutic target for cancer cell killing via (i) p53/NAD(H)-dependent and (ii) p53-independent pathways (2014)

  • OTX015 (MK-8628), a novel BET inhibitor, exhibits antitumor activity in non-small cell and small cell lung cancer models harboring different oncogenic mutations (2016)

  • Multifactorial resistance to aminopeptidase inhibitor prodrug CHR2863 in myeloid leukemia cells: down-regulation of carboxylesterase 1, drug sequestration in lipid droplets and pro-survival activation ERK/Akt/mTOR (2016)

  • New developments in the management of Non-Small Cell Lung Cancer, focus on rociletinib: what went wrong? (2016)

  • Impact of ABCG2 polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients (2011)

  • Personalized medicine in oncology: where have we come from and where are we going? (2013)

  • Polymorphisms in SLCO1B3 and NR1I2 as genetic determinants of hematotoxicity of carboplatin and paclitaxel combination (2015)

  • Pharmacogenetic variants associated with outcome in patients with advanced gastric cancer treated with fluoropyrimidine and platinum-based triplet combinations: a pooled analysis of three prospective studies (2016)

  • Contemporary reviews on cancer treatment. Cancer Chemother (2016)

  • Thymidylate synthase inhibitors for thoracic cancers (2013)

  • Polymorphisms Correlated with the Clinical Outcome of Locally Advanced or Metastatic Colorectal Cancer Patients Treated with ALIRI vs FOLFIRI (2013)

  • Minimization of the preanalytical error in plasma samples for pharmacokinetic analyses and therapeutic drug monitoring--using doxorubicin as an example (2011)

  • Testing of SNS-032 in a Panel of Human Neuroblastoma Cell Lines with Acquired Resistance to a Broad Range of Drugs (2013)

  • Lactate dehydrogenase acetylation adds another piece to the puzzle of metabolic reprogramming in pancreatic cancer (2014)

  • Better to be alone than in bad company: the antagonistic effect of cisplatin and crizotinib combination therapy in non-small cell lung cancer (2016)

  • A large scale prospective clinical and psychometric validation of the EORTC colorectal (QLQ-CR29) module in Polish patients with colorectal cancer (2017)

  • When a parent has cancer: challenges to patients, their families and health providers (2012)

  • Quality of Life After Palliative Radiation Therapy for Patients With Painful Bone Metastases: Results of an International Study Validating the EORTC QLQ-BM22 (2012)

  • Comparison of the EORTC QLQ-LC13 and the FACT-L for assessment of quality of life in patients with lung cancer (2015)

  • Psychometric Validation of the EORTC QLQ-PAN26 Pancreatic Cancer Module for Assessing Health Related Quality of Life after Pancreatic Resection (2017)

  • Adaptation of quality of life module EORTC QLQ-CR29 for Polish patients with rectal cancer – initial assessment of validity and reliability (2011)

  • Development of an EORTC quality of life phase III module measuring cancer-related fatigue (EORTC QLQ-FA13) (2012)

  • EORTC Quality of Life Department and Patient Reported Outcome and Behavioral Evidence (PROBE). Impact of neurocognitive deficits on patient-proxy agreement regarding health-related quality of life in low-grade glioma patients (2016)

  • An evaluation of the response category translations of the EORTC QLQ-C30 questionnaire (2013)

  • Cross-cultural development of an EORTC questionnaire to assess health-related quality of life in patients with testicular cancer: the EORTC QLQ-TC26 (2012)

  • Quality of life priorities in patients with thyroid cancer - a multi-national EORTC phase I study (2016)

  • Sharing human samples and patient data: opening Pandora's box (2017)

  • Prospective assessment of the predictive value of the BRCA1 gene status in sarcoma patients treated with trabectedin: an updated analysis of the EORTC 62091 trial (2018)

  • From bench to clinical trials. The EORTC experience in biology-based clinical cancer research (2017)

  • A transatlantic perspective on the integration of Immuno-Oncology Prognostic and Predictive Biomarkers in innovative clinical trial design (2018)

  • Metastasis free survival is a strong surrogate of overall survival in localized prostate cancer (2017)

  • Prognostic value of baseline metabolic tumor volume in early stage Hodgkin's lymphoma in the standard arm of H10 trial (2018)

  • Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study (2017)

  • Detailed statistical assessment of the characteristics of the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) (2017)

  • Multi-disciplinary quality assurance and control in oncological trials: perspectives from European Organisation for Research and Treatment of Cancer (EORTC) (2017)

  • Precision Medicine: from “Omics” to economics towards data driven health care: time for European transformation (2017)

  • Quality of life as a prognostic indicator of survival: a pooled analysis of individual patient data from canadian cancer trials group clinical trials (2018)

  • "Mind the gap" between the development of therapeutic innovations and the clinical practice in oncology: a proposal of the European Organisation for Research and Treatment of Cancer (EORTC) to optimize cancer clinical research (2017)

  • EORTC experience with advanced/metastatic epithelioid sarcoma patients treated in prospective clinical trials: clinical profile and response to systemic therapy. Poster Presentation at the ESMO Annual Meeting, Madrid, Spain, September 7 – 12, 2017. (2017)

  • Time to definitive failure to the first tyrosine kinase inhibitor in localized gastrointestinal stromal tumors (GIST) treated with imatinib as an adjuvant: final results of the EORTC STBSG, AGITG, UNICANCER, FSG, ISG, and GEIS randomized trial. Oral Presentation at the ESMO Annual Meeting, Madrid, Spain, September 7 – 12, 2017. (2017)

  • Hope for salivary gland cancer (SGC): EORTC HNCG/UKCRN 1206 randomized phase II study to evaluate the efficacy and safety of Chemotherapy (CT) vs androgen deprivation therapy (ADT) in patients with recurrent and/or metastatic androgen receptor (AR) expressing SGC. Poster Presentation at the ESMO Annual Meeting, Madrid, Spain, September 7 – 12, 2017. (2017)

  • Not all small node negative (pT1abN0) breast cancers are similar: Outcome results from the EORTC 10041/BIG 3-04 (MINDACT) trial. Oral Presentation at the ESMO Annual Meeting, Madrid, Spain, September 7 – 12, 2017. (2017)

  • Diagnostic and therapeutic strategies for elderly patients with advanced Non-Small cell lung cancer (NSCLC): results from an EORTC pan-european survey. Poster Presentation at the ESMO Annual Meeting, Madrid, Spain, September 7 – 12, 2017. (2017)

  • Diversity of brain metastasis (BM) management in non-small cell lung cancer (NSCLC) in Europe (EU): Results of the Young Investigators European Organisation for Research and Treatment of Cancer Lung Cancer Group (YI EORTC LCG) survey. Poster Presentation at the ESMO Annual Meeting, Madrid, Spain, September 7 – 12, 2017. (2017)

  • Development of a Guidance on the Implementation and use of EORTC Instruments in Electronic Applications. ISPOR 19th Annual European Congress, Vienna, Austria, November 2016. (2016)

  • A virtual dosimetry audit – towards transferability of gamma index analysis between clinical trial QA groups (2017)

  • The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033 (2018)

  • Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis (2017)

  • Comparison of two chemotherapy regimens in patients with newly diagnosed Ewing sarcoma (EE2012): an open-label, randomised, phase 3 trial (2022)

  • Module Development Guidelines ISBN 978-2-930064-48-2 (2021)

  • Long term outcome data from the EORTC 75111-10114 ETF/BCG randomized phase II study: Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer, followed by T-DM1 after progression (2022)

  • QUARTET: A SIOP Europe project for quality and excellence in radiotherapy and imaging for children and adolescents with cancer (2022)

  • Advancing academia-driven treatment optimisation in oncology: launch of the EMA Cancer Medicines Forum (2022)

  • EMA Cancer Medicines Forum: nieuw platform voor regelgevers en academici over optimaal gebruik van kankergeneesmiddelen (2022)

  • Standardised lesion segmentation for imaging biomarker quantitation: a consensus recommendation from ESR and EORTC (2022)

  • Molecular profiling and precision medicine in rare gastrointestinal cancers within EURACAN in the SPECTA Arcagen study (EORTC-1843): too few patients treated and too many inequalities across countries (2022)

  • Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: A report from EORTC study 26951 (2009)

  • MGMT promoter methylation in malignant gliomas: Ready for personalized medicine? (2010)

  • Prognostic and predictive factors for outcome to first-line ifosfamide-containing therapy (IFM) in patients (pts) with advanced soft tissue sarcomas (STS) treated in EORTC-STBSG studies. Oral presentation at the Annual Meeting of the American Society of Clinical Oncology (ASCO), Orlando, U.S.A., May 30-June 3, 2008 (2008)

  • The end of adjuvant chemotherapy (adCT) era with doxorubicin-based regimen in resected high-grade soft tissue sarcoma (STS): Pooled analysis of the two STBSG-EORTC phase III clinical trials (2008)

  • Prognostic and predictive factors analysis based on two pooled EORTC clinical trials in patients with high grade Soft Tissue Sarcoma (STS) and treated by adjuvant chemotherapy (adCT). Oral and (2008)

  • Prognostic factors in adolescents and young adults (AYA) with high risk soft tissue sarcoma (STS) treated by adjuvant chemotherapy: A study based on two pooled European Organization for Research and Treatment of Cancer (EORTC) clinical trials (2009)

  • Analyse de facteurs pronostiques et prédictifs sur des patients de haut grade (II/III) atteints d'un sarcome des tissus mous et ayant subit une chirurgie complète (R0/R1) provenant de deux études cliniques randomisées conduites par le groupe STBSG-EORTC. Oral presentation at Journées des Statisticiens des Centres de Lutte contre le Cancer, Nice, France, May 11-14, 2009 (2009)

  • Expert opinion in Melanoma group recommendations on practical methodology of the measurement of the microanatomic location of metastases and metastatic tumour burden (2009)

  • EORTC Elderly Task Force Position Paper: Approach to the older cancer patient (2010)

  • Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas. An exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG) (2010)

  • Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas. An exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG) (2009)

  • EORTC Elderly Task Force experts' opinion for the treatment of colon cancer in older patients (2010)

  • Clinical and psychometric validation of the EORTC QLQ-CR29 questionnaire module to assess health-related quality of life in patients with colorectal cancer (2009)

  • Circulating melanoma cells and distant metastasis-free survival in stage III melanoma patients with or without adjuvant interferon treatment (EORTC 18991 side study) (2009)

  • Changes of ferritin and CRP levels in melanoma interferon a (EORTC 18952) have no prognostic value on treatment outcome (2009)

  • Tissue biomarker development in a multicentre trial context: A feasibility study on the PETACC3 stage II and III colon cancer adjuvant treatment trial (2009)

  • Quality assurance for radical hysterectomy for cervical cancer: The view of the European Organization for Research and Treatment of Cancer - Gynecological Cancer Group (EORTC-GCG) (2009)

  • EORTC-GCG process quality indicators for ovarian cancer surgery (2009)

  • Clear cell carcinoma compared to serous carcinoma in early ovarian cancer: Same prognosis in a large randomized trial (2009)

  • Gynecologic Cancer Intergroup (GCIG) proposals for changes of the current FIGO staging system (2009)

  • Practice patterns of radiotherapy in endometrial cancer among member groups of the gynecologic cancer intergroup (2009)

  • Patterns of care for radiotherapy in vulvar cancer: A Gynecologic Cancer Intergroup study (2009)

  • A randomized trial in ovarian cancer (OC) of early treatment of relapse based on CA125 level alone versus delayed treatment based on conventional clinical indicators (MRC OV05/EORTC 55955 trials) (2009)

  • Randomized MRC OV05/EORTC 55955 trial in recurrent ovarian cancer: Early treatment based on increased serum CA125 alone versus delayed treatment based on conventional clinical indicators (2009)

  • Randomized MRC OV05/EORTC 55955 trial in recurrent ovarian cancer: Early treatment based on increased serum CA125 alone versus delayed treatment based on conventional clinical indicators. Communication at the joint ECCO 15 - 34th ESMO Multidisciplinary Congress, Berlin, Germany, September 20-24, 2009 (2009)

  • Upfront chemotherapy versus surgery in advanced ovarian cancer. Communication at the 7th International symposium on advanced ovarian cancer: update on optimal therapy, February 27, 2009 (2009)

  • Chemoradiation for locally advanced cervical cancer in Europe: First results of a radioatherapy quality assurance project within the EORTC 55994 trial. Communication at the 16th International meeting of the European Society of Gynaecological Oncology (ESGO), Belgrade, Serbia, October 11-14, 2009 (2009)

  • Revising pathology in ovarian cancer: Highly discrepant outcomes (2009)

  • Comparative genomic hybridisation (CGH) in early stage ovarian cancer (2009)

  • Multicentre analysis of oncological and survival outcomes following anastomotic leakage after rectal cancer surgery (2009)

  • pT3N0M0 Prostate Cancer: a plea for adjuvant radiation (2009)

  • Acute toxicity of curative radiotherapy for intermediate risk localized prostate cancer in the EORTC trial 22991 (2009)

  • Three years of adjuvant androgen deprivation with goserelin in patients with locally advanced prostate cancer treated with radiotherapy: Results at 10 years of EORTC trial 22863 (2009)

  • Adjuvant Whole Brain Radiotherapy versus Observation after Radiosurgery or Surgical Resection of 1-3 Cerebral Metastases - Results of the EORTC 22952-26001 Study (2009)

  • Oral presentation at the ECCO 15 - 34th ESMO Multidisciplinary Congress, Berlin, Germany, September 20-24, 2009 (2009)

  • Three years of adjuvant androgen deprivation with goserelin in patients with locally advanced prostate cancer treated with radiotherapy: Results at 10 years of EORTC trial 22863. Oral presentation at the ECCO 15 - 34th ESMO Multidisciplinary Congress, Berlin, Germany, September 20-24, 2009 (2009)

  • Adjuvant Whole Brain Radiotherapy versus Observation after Radiosurgery or Surgical Resection of 1-3 Cerebral Metastases - Results of the EORTC 22952-26001 Study. Oral presentation at the Joint ECCO 15 - 34th ESMO Multidisciplinary Congress, Berlin, Germany, September 20-24, 2009 (2009)

  • Adjuvant Whole Brain Radiotherapy vs. Observation after Radiosurgery or Surgical Resection of 1-3 Cerebral Metastases - Results of the EORTC 22952-26001 Study. Proceedings of the American Society for Radiation (2009)

  • Adjuvant Whole Brain Radiotherapy vs. Observation after Radiosurgery or Surgical Resection of 1-3 Cerebral Metastases - Results of the EORTC 22952-26001 Study. Oral presentation at the 51st Annual Meeting of American Society for Radiation Oncology, Chicago, Illinois, USA, November 1-5, 2009 (2009)

  • First line chemotherapy for Malignant Peripheral Nerve Sheath Tumour (MPNST) versus other histologic soft tissue sarcoma subtypes and as a prognostic factor for MPNST: An EORTC Soft Tissue and Bone Sarcoma Group (STBSG) Study (2011)

  • EORTC study 26041-22041: Phase I/II study on concomitant 3 and adjuvant temozolomide (TMZ) and radiotherapy (RT) with 4 PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma (2010)

  • Alpha-internexin expression predicts outcome in anaplastic oligodendroglial tumors and may positively impact the efficacy of chemotherapy: European organization for research and treatment of cancer trial 26951 (2011)

  • A simulation study provided sample size guidance for differential item functioning (DIF) studies using short scales (2009)

  • Differential item functioning (DIF) in the EORTC QLQ-C30: a comparison of baseline, on-treatment and off-treatment data (2009)

  • Making better use of existing cancer data: Patient Reported Outcomes and Behavioural Evidence: a new international initiative (2009)

  • Quality of Life Issues (2009)

  • Is patient self-reporting more accurate than clinician reporting of symptoms for predicting survival in patients with cancer? Meta-analysis of 30 closed EORTC randomized controlled trials (2009)

  • The predictive accuracy of survival between patient-reported versus clinician-reported pain in a cohort of 1,214 patients with metastatic cancer (2009)

  • Relationships among health-related quality of life indicators in cancer patients: A pooled study of baseline EORTC QLQ-C30 data from 6,739 patients (2009)

  • Health-related quality of life indicators and overall quality of life: Results from a cluster analysis on baseline EORTC QLQ-C30 data from 6,739 cancer patients (2009)

  • Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: An European Organisation for Research and Treatment of Cancer study (2010)

  • Sperm quality before treatment in patients with early stage Hodgkin's lymphoma enrolled in EORTC-GELA Lymphoma Group trials (2009)

  • Quality of life after successful treatment of early-stage Hodgkin's lymphoma: 10-year follow-up of the EORTC-GELA H8 randomised controlled trial (2009)

  • Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: Results of the TRanslational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial (2010)

  • An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in (2009)

  • Revised Definitions of Invasive Fungal Disease from the European Organisation for Research and Treatment of Cancer / Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Mycoses Study Group (EORTC/MSG) consensus Group (2008)

  • Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications (a study from the Lunenburg Lymphoma Biomarker Consortium) (2009)

  • Improved outcome with pulses of vincristine and corticosteroids in continuation therapy of children with average risk acute lymphoblastic leukemia (ALL) and lymphoblastic non-Hodgkin lymphoma (NHL): report of the EORTC randomized phase III trial 58951 (2010)

  • Comparison of Two Doses of Imatinib for the Treatment of Unresectable or Metastatic Gastrointestinal Stromal Tumors: A Meta-Analysis of 1,640 Patients (2010)

  • Dummy run and conformity indices in the ongoing EORTC Low Grade Glioma Trial 22033-26033: first evaluation of quality of radiotherapy planning (2010)

  • Does local treatment of the Prostate in advanced and/or lymph node metastatic disease improve efficacy of androgen-deprivation therapy? A systematic review (2010)

  • Questionnaires and instruments for a multidimensional assessment of the older cancer patients: What clinicians need to know? (2010)

  • Cancer Research UK, ALM-CAO, AGITG and FFCD. Elevated Carcinoembryonic Antigen (CEA) is the most predictive baseline factor for the benefit of perioperative FOLFOX in resectable liver metastasis from colorectal cancer (EORTC study 40983) (2010)

  • First Report On the H10 EORTC/GELA/IIL Randomized Intergroup Trial On Early FDG-PET Scan Guided Treatment Adaptation Versus Standard Combined Modality Treatment in Patients with Supra-Diaphragmatic Stage I/II Hodgkin's Lymphoma, for the Groupe d'Etude Des Lymphomes De l'Adulte (GELA), European Organisation for the Research and Treatment of Cancer (EORTC) Lymphoma Group and the Intergruppo Italiano Linfomi (IIL). Oral presentation at the 51th ASH Annual Meeting and Exposition, New Orleans, Los Angeles, USA, December 5 -8, 2009 (abs. 97) (2009)

  • Boron neutron capture therapy for newly diagnosed glioblastoma multiforme: an assessment of clinical potential (2010)

  • Dexamethasone(DEX)(6mg/sm/d) and Prednisolone(PRED)(60mg/sm/d) in Induction Therapy of Childhood ALL Are Equally Effective: Results of the 2nd Interim Analysis of EORTC Trial 58951 (2008)

  • Improved Outcome with Pulses of Vincristine and Steroids in Continuation Therapy of Children with Average Risk Acute Lymphoblastic Leukemia (ALL) and Non Hodgkin Lymphoma (NHL): Final Report of the EORTC Randomized Phase III Trial 58951 (2008)

  • Prognostic Significance of Central Nervous System (CNS) Status of Children with Acute Lymphoblastic Leukemia (ALL) Treated without Cranial Irradiation: Results of European Organization for Research and Treatment of Cancer (EORTC) Children Leukemia Group Study 58951 (2008)

  • Low Dose Decitabine Versus Best Supportive Care in Elderly Patients with Intermediate or High Risk MDS Not Eligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study (06011) of the EORTC Leukemia and German MDS Study Groups (2008)

  • Phase II-III Study of Gemtuzumab Ozogamicin Monotherapy versus Best Supportive Care in Older Patients with Newly Diagnosed AML Unfit for Intensive Chemotherapy: First Results of the EORTC-GIMEMA AML-19 Trial (2008)

  • High Dose (HD-AraC) Vs Standard Dose Cytosine Arabinoside (SDAraC) during Induction and Value of IL-2 during Maintenance in Acute Myelogenous Leukemia (AML): Impact of AraC Dose on Complete Remission Rate and Toxicity (Results on the first 1700 randomized patients of the AML-12 trial of EORTC and GIMEMA Leukemia Groups) (2008)

  • Adjuvant gemcitabine alone versus gemcitabine-based chemoradiation after curative resection for pancreatic cancer: a randomized EORTC /FFCD/ GERCOR phase II study (EORTC 40013 - 22012 - FFCD 9203) (2010)

  • An international validation study of the EORTC brain cancer module (EORTC QLQ-BN20) for assessing health-related quality of life and symptoms in brain cancer patients (2010)

  • Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses study group and european organization for research and treatment of cancer consensus criteria (2008)

  • Treatment of small-cell lung cancer in elderly patients (2010)

  • Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of Epirubicin, Bacillus Calmette-Guérin, and Bacillus Calmette-Guérin plus Isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carconima of the bladder (2010)

  • New insights in intravesical treatment for intermediate- and high-risk non-muscle-invasive urothelial bladder carcinoma (2010)

  • Reply from authors re: Marko Babjuk. New insights in intravesical treatment for intermediate- and high-risk non-muscle-invasive urothelial bladder carconima (2010)

  • Cytidine deaminase redsidual activity in serum is a predictive marker of early severe toxicities in adults after gemcitabine-based chemotherapies (2010)

  • Vascular disrupting activity of tubulin-binding 1,5-diaryl-1H-imidazoles (2009)

  • Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial (2010)

  • Sagopilone (ZK-EPO, ZK219477) for recurrent glioblastoma. A phase II multicenter trial by the European Organisation for Research and Treatment of Brain Tumor Group (2011)

  • BCG treatment of non muscle invasive bladder cancer (2010)

  • EAU Guidelines on non muscle invasive urothelial carcinoma of the bladder (2010)

  • What should a reviewer consider in terms of statistical analysis and methodology? (2010)

  • An immediate post operative instillation of chemotherapy after TURBT in non muscle invasive bladder cancer (2010)

  • Sequential chemo-immunotherapy with mitomycin C (MMC) and bacillus Calmette-Guerin (BCG) versus BCG alone in patients with carcinoma in situ (CIS) of the urinary bladder. Results of EORTC GU Group randomized phase II study 30993 (2010)

  • Sequential chemo-immunotherapy with mitomycin C (MMC) and bacillus Calmette-Guerin (BCG) versus BCG alone in patients with carcinoma in situ (CIS) of the urinary bladder. Results of EORTC GU Group randomized phase II study 30993. Communication at the 2010 annual congress of the American Urological Association, San Francisco, California, May 29-June 3, 2010 (2010)

  • Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma (2011)

  • Prognostic significance of the initial cerebro-spinal fluid (CSF) involvement of children with acute lymphoblastic leukemia (ALL) treated without cranial irradiation: Results of European Organization for Research and Treatment of Cancer (EORTC) Children Leukemia Group study 58881 (2011)

  • Multicentric parallel phase II trial of the polo-like kinase 1inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI) (2010)

  • Extended Schedule, Escalated Dose Temozolomide Versus Dacarbazine in Stage IV Melanoma: Final Results of a Randomized Phase III Study (EORTC 18032) (2011)

  • Survival after recurrent osteosarcoma: data from 3 European Osteosarcoma Intergroup (EOI) randomized controlled trials (2011)

  • Development of computerised adaptive testing (CAT) for the EORTC QLQ-C30 dimensions - General approach and initial results for physical functioning (2010)

  • The European Organisation for Research and Treatment of treatment of cancer Imaging Programme (2010)

  • BCL-2/IgH Polymerase chain reaction status at the end of induction treatment is not predictive for progression-free survival in relapsed/resistant follicular lymphoma: Results of a prospective randomized EORTC 20981 phase III intergroup study (2010)

  • Intensive consolidation therapy compared with standard consolidation and maintenance therapy for adults with acute myeloid leukaemia aged between 46 and 60 years: final results of the randomized phase III study (AML 8B) of the European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups (2012)

  • Dose intensity of chemotherapy in patients with relapsed Hodgkin Lymphoma (2010)

  • Understanding the problem of inadequately staging early ovarian cancer (2010)

  • Clear cell carcinoma compared to serous carcinoma in early ovarian cancer: same prognosis in a large randomized trial (2009)

  • Lymph node sampling and taking of blind biopsies are important elements of the surgical staging of early ovarian cancer (2010)

  • Surgical staging and treatment of early ovarian cancer: Long-term analysis from a randomized trial (2010)

  • Rituximab maintenance treatment of relapsed/resistant follicular non-hodgkin's lymphoma: Long-term outcome of the EORTC 20981 phase III randomized intergroup study (2010)

  • Robot-assisted cyctectomy: does it meet expectations? (2010)

  • Tailored follow-up for early breast cancer patients: A prognostic index that predicts locoregional recurrence (2010)

  • EORTC workshop on clinical trial methodology in older individuals with a diagnosis of solid tumors (2011)

  • A prospective randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low stage renal cell carcinoma (2011)

  • Standardized MRD quantification in European ALL trials: Proceedings of the second international symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. Leukemia, 24 (3):521-535, 2010 (2010)

  • Wilms tumor 1 (WT1) gene mutations in pediatric T-cell malignancies (2010)

  • Strategies to promote translational research within the European Organisation for Research and Treatment of Cancer (EORTC) Head and Neck Cancer Group: a report from the Translational Research Subcommittee (2010)

  • Specific Scoring Systems to predict survival of patients with high-risk Myelodysplastic Syndrome (MDS) and de novo Acute Myeloid Leukemia (AML) after intensive antileukemic treatment based on results of the EORTC-GIMEMA AML-10 and intergroup CRIANT studies (2015)

  • Sequential Intravesical Chemo-Immunotherapy with Mitomycin C and Bacillus Calmette-Guérin versus Bacillus Calmette-Guérin Alone in Patients with Carcinoma in Situ of the Urinary Bladder: Results of an EORTC Genito-Urinary Group Randomized Phase 2 trial (30993) (2011)

  • Bacillus Calmette Guérin Treatment of Non Muscle Invasive Bladder Cancer (2011)

  • Expression of the Androgen-Regulated Fusion Gene TMPRSS2-ERG Does Not Predict Response to Endocrine Treatment in Hormone-Naïve, Node-Positive Prostate Cancer (2010)

  • Prognostic factor analysis of health-related quality of life data in cancer: a statistical methodological evaluation. Expert Rev Pharmacoeconomics Outcomes Res 8 (2): 179-196, 2008 (2008)

  • Value of allogeneic stem cell transplantation versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia: a prospective randomized European intergroup trial (2010)

  • Randomized phase III trial comparing postoperative adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation in stage II (T3-T4N0M0) melanoma: Final results of study EORTC 18961 (2010)

  • NOTCH1 and FBXW7 mutations have a favorable impact on early response to treatment, but not on outcome, in children with T-cell acute lymphoblastic leukemia (T-ALL) treated on EORTC trials 58881 and 58951. Leukemia 24: 2023-2031, 2010 (2010)

  • Randomized trial of two schedules of low-dose gemtuzumab ozogamicin as induction monotherapy for newly diagnosed acute myeloid leukaemia in older patients not considered candidates for intensive chemotherapy. A phase II study of the EORTC and GIMEMA leukaemia groups (AML-19) (2010)

  • Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials (2010)

  • Current technological practice in breast radiotherapy; results of a survey in EORTC- Radiation Oncology Group affiliated institutions (2010)

  • Low grade astrocytoma, anaplastic oligodentroglioma or astrocytoma and glioblastoma: the clinical trial portfolio of the EORTC Brain Tumor and Radiation Oncology Groups for newly diagnosed patients. Proc. American Society of Clinical Oncology, Chicago, USA, June 4-8, 2010 (abs) (2010)

  • EORTC 24051: Unexpected side effects of a phase I study of TPF induction chemotherapy followed by chemoradiation with lapatinib, a dual EGFR/ErbB2 inhibitor, in patients with locally advanced resectable larynx and hypopharynx squamous cell carcinoma (2012)

  • Prognostic value of Ki-67 index in anaplastic oligodendroglial tumors - a translational study of the EORTC Brain Tumor Group (2012)

  • 5. Longitudinal quality of life data: a comparison of continuous and ordinal approaches (2014)

  • External irradiation with and without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study (2010)

  • Randomized Phase II/III Trial Assessing Gemcitabine/Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients with Advanced Urothelial Cancer "Unfit" for Cisplatin Based Chemotherapy: Phase III-Results of EORTC Study 30986 (2009)

  • Adaptive Designs in der klinischen Forschung (2011)

  • Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004) (2012)

  • What can be concluded from the ERSPC and PLCO trial data? (2010)

  • Can radical prostatectomy benefit patients despite the presence of regional metastases? (2010)

  • European Organisation for Research and Treatment of Cancer Recommendations for Planning and Delivery of High-Dose, High-Precision Radiotherapy for Lung Cancer (2010)

  • Dose Intensity of Chemotherapy in Patients With Relapsed Hodgkin's Lymphoma (2010)

  • What have we learned from EORTC GU Group trials in the treatment of superficial bladder cancer? 3 decades of research (2005)

  • Update on BCG for the treatment of stage Ta T1 bladder cancer (2005)

  • How to treat T1G3 bladder tumors: The conservative approach (2005)

  • What is new in bladder cancer? (2005)

  • What have we learned from EORTC GU Group trials in the treatment of superficial bladder cancer? 3 decades of research (2005)

  • What have we learned from EORTC GU Group trials in the treatment of superficial bladder cancer? 3 decades of research (2005)

  • Bacillus Calmette-Guerin versus Epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: Results of an European Organization for the Research and Treatment of Cancer Genito-Urinary Group phase III trial (30906) (2005)

  • Keep it simple - lymph node (LN) dissection, tumoral vessels and nervous embolism have a major prognostic impact on survival after resection of stage II and III colon cancer. Lessons from the joint adjuvant chemotherapy study EORTC 40911 and FFCD 9204 trial. Proc. World Congress on Gastrointestinal cancer, Barcelona, Spain, June 15-18, 2005 (2005)

  • Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group (GI) study 40986 (2005)

  • Adjuvant regional chemotherapy and systemic chemotherapy versus systemic chemotherapy alone in patients with stage II-III colorectal cancer: A multicentre randomised controlled phase III trial (2005)

  • Docetaxel plus gemcitabine or docetaxel plus cisplatin in advanced pancreatic carcinoma: Randomized phase II study 40984 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group (GI) (2005)

  • Capecitabine plus irinotecan versus 5-FU/FA/Irinotecan +/- celecoxib in first line treatment of metastatic colorectal cancer. Safety results of the prospective multicenter EORTC phase III study 40015 (2005)

  • Feasibility and risks of pre-operative chemotherapy (CT) with Folfox 4 and surgery for resectable colorectal cancer liver metastases (LM). Interim results of the EORTC Intergroup randomized phase III study 40983 (2005)

  • Quality control (QC) tissue array for the prospective evaluation of translational research projects. A program of the EORTC Gastrointestinal Tract Cancer Group (GI) and Receptor and Biomarker Group (RGB) (2005)

  • Randomized phase III trial comparing infused irinotecan/5-fluorouracil (5-FU)/folinic acid (IF) versus 5-FU/FA (F) in stage III colon cancer patients (pts). (PETACC 3) (2005)

  • Safety of caelyx combined with ifosfamide in previously untreated adult patients with advanced or metastatic Soft Tissues Sarcomas (STS). Final data of an EORTC Phase 1 Study. Oral presentation at ECCO 13th Annual Meeting, Paris, France, October 30-November 3, 2005 (abs. 1188) (2005)

  • Safety of caelyx combined with ifosfamide in previously untreated adult patients with advanced or metastatic Soft Tissues Sarcomas (STS). Final data of an EORTC Phase 1 Study. Oral presentation at CTOS 11th Annual Meeting, Boca Raton, November 19-21, 2005 (abs. 432) (2005)

  • Potentiation of paclitaxel-induced apoptosis by the novel cyclin-dependent kinase inhibitor NU6140: A possible role for survivin down-regulation (2005)

  • Prognostic relevance of response evaluation using [18F]-2-Fluoro-2-Deoxy-D-Glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer (2005)

  • Induction of unique structural changes in guanine-rich DNA regions by the triazoloacridone C-1305, a topoisomerase II inhibitor with antitumor activities (2005)

  • Down-regulation of DNA topoisomerase II alpha leads to prolonged cell cycle transit in G2 and early M phases and increased survival to microtubule-interacting agents (2005)

  • Cross-talk between DNA damage and cell survival checkpoints during G2 and mitosis: Pharmacologic implications (2005)

  • Pharmacodynamics of the G-quadruplex-stabilizing telomerase inhibitor 3,11-difluoro-6,8,13-trimethyl-8H-quino[4,3,2-kl]acridinium methosulfate (RHPS4) in vitro: Activity in human tumor cells correlates with telomere length and can be enhanced, or antagonized, with cytotoxic agents (2005)

  • Quinols as novel therapeutic agents. 2.(1) 4-(1-Arylsulfonylindol-2-yl)-4-hydroxycyclohexa-2,5-dien-1-ones and related agents as potent and selective antitumor agents (2005)

  • Use of cancer chemopreventive phytochemicals as antineoplastic agents (2005)

  • Patients with early stage ovarian cancer who are adequately staged do not need adjuvant chemotherapy. Communication at the 2nd European Conference Perspectives in Gynecological Oncology, Nice, France, January 2005 (2005)

  • Circulating natural killer lymphocytes are potential cytotoxic effectors against autologous malignant cells in sezary syndrome patients (2005)

  • Identification of molecular apocrine breast tumors by microarray analysis (2005)

  • Conservative local treatment versus mastectomy after induction chemotherapy in locally advanced breast cancer: A randomized phase III study (EORTC 10974/22002, LAMANOMA) - Why did this study fail? (2005)

  • Interféron alpha et lymphome cutané T épidermotrope (2005)

  • Peripheral T-cell lymphoma with secondary epithelioid granulomatous cutaneous involvement: A clinicopathologic study of four cases (2005)

  • International Society for Cutaneous Lymphoma: Defining early mycosis fungoides (2005)

  • Classification of cutaneous lymphomas 2005: Histological and molecular aspects (2005)

  • Kutane T-zell-lymphome (2003)

  • Primäre kutane B-Zell-Lymphome. Primary cutaneous B-cell lymphomas (2004)

  • Comparative genomic hybridization analysis of cutaneous large B-cell lymphomas (2005)

  • CD8(+) T lymphocytes reactive against Epstein-Barr virus antigens in skin lesions of a patient with Sezary syndrome (2005)

  • Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: Phase II study of 32 patients (2005)

  • Aberrant DNA methylation in cutaneous malignancies (2005)

  • Dystrophic xanthomatosis in primary CD30-positive cutaneous T-cell lymphoma. Report of two cases and review of the literature (2005)

  • A retrospective study of the probability of the evolution of parapsoriasis en plaques into mycosis fungoides (2005)

  • Recurrent and self-healing cutaneous monoclonal plasmablastic infiltrates in a patient with AIDS and Kaposi sarcoma (2005)

  • Primary cutaneous marginal zone B-cell lymphoma: Clinical and therapeuticfeatures in 50 cases (2005)

  • Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer (2005)

  • Final results of a EORTC phase III trial of paclitaxel versus teniposide, in combination with cisplatin, in advanced NSCLC (1997)

  • Phase II trials of etoposide in malignant pleural mesothelioma. Lung (1997)

  • Gemcitabine (G) in malignant pleural mesothelioma (MPM): A phase II study. Lung (1997)

  • A randomized trial of cisplatin plus paclitaxel versus cisplatin plus teniposide in advanced non-small cell lung cancer. Lung (1997)

  • A EORTC randomized phase III trial of three chemotherapy regimens in advanced NSCLC (NSCLC) (2001)

  • Dose-intensification of cyclophosphamide, doxorubicin and etoposide (CDE)-chemotherapy does not improve survival in small cell lung cancer (SCLC): Final results of a randomized phase III EORTC study (2001)

  • Randomized double blind placebo controlled trial of marimastat in patients with small cell lung cancer (SCLC) following response to first line chemotherapy: An NCIC-CTG and EORTC study (2001)

  • A EORTC randomized phase III trial of three chemotherapy regimens in advanced NSCLC (NSCLC) (2001)

  • Final results of a double blind placebo controlled study of adjuvant marimastat in small cell lung cancer (SCLC) patients responding to standard therapy (2001)

  • Health economic aspects of lung cancer (1999)

  • Letter to the editor regarding chemotherapy for non-small-cell lung cancer (2001)

  • Baseline quality of life measured with the EORTC QLQ-C30 helps to select a subset of good prognosis metastatic prostate cancer patients (2001)

  • Baseline quality of life measured with the EORTC QLQ-C30 helps to select a subset of good prognosis metastatic prostate cancer patients (2001)

  • Preoperative radiochemotherapy in rectal cancer: Long-term results of a phase II trial (2000)

  • Impact of a boost dose of 16 Gy on the local control and cosmesis in patients with early breast cancer: The EORTC “boost versus no boost” trial (2000)

  • Estimation of the influence of the given dose on the endpoint of EORTC trial 22922/10925 concerning Internal Mammary - Medial Supraclavicular (IM-MS) irradiation: A report on behalf of the Quality Assurance committee after 32 dummy runs (2000)

  • Estimation of the influence of the given dose on the endpoint of EORTC trial 22922/10925 concerning Internal Mammary - Medial Supraclavicular (IM-MS) irradiation: A report on behalf of the Quality Assurance committee after 32 dummy runs. Oral presentation at the 19th ESTRO Meeting, Istanbul, Turkey, September 19-23, 2000 (2000)

  • Impact of a boost dose of 16 Gy on local control in patients with early breast cancer: The EORTC “Boost versus no boost” trial (2000)

  • Impact of a boost dose of 16 Gy on local control in patients with early breast cancer: The EORTC “Boost versus no boost” trial. Oral presentation. 19th ESTRO Meeting, Istanbul, Turkey, 19-23 September, 2000 (2000)

  • The hypothetical influence of dose variation on survival in EORTC trial 22922/10925 investigating the role of internal mammary chain (IMC) irradiation: A quality assurance report (2000)

  • Impact of a boost dose of 16 Gy on the local control and cosmesis in patients with early breast cancer: The EORTC “boost versus no boost” trial (2000)

  • Postoperative pelvic radiotherapy with or without elective irradiation of para-aortic nodes and liver in rectal cancer patients. A controlled clinical trial of the EORTC Radiotherapy Group (2001)

  • A glance on quality assurance in EORTC study 22922 evaluating techniques for internal mammary and medial supraclavicular lymph node chain irradiation in breast cancer (2001)

  • EORTC trials: A bridge between two millenia (2001)

  • Chemo-radiotherapy, as compared to radiotherapy alone, significantly increases disease-free and overall survival in head and neck cancer patients after surgery: Results of EORTC phase III trial 22931 (2001)

  • Results of EORTC phase III trial 22931 comparing, postoperatively, radiotherapy (RT) to concurrent chemo-radiotherapy (RT-CT) with high dose cisplatin in loclly advanced head and neck (H&N) carcinomas (SCC) (2001)

  • Results of the dummy-run of EORTC Trial No.22961: A phase III study of long term hormonal treatment on locally advanced prostatic carcinoma treated by radiation therapy and a 6 months CAB (2001)

  • The EORTC “boost versus no boost” trial: Local control and cosmesis in patients with conservative management of early breast cancer (2001)

  • The EORTC “boost versus no boost” trial: Local control and cosmesis in patients with conservative management of early breast cancer (2001)

  • Preoperative radiochemotherapy ; experience of the FFCD-EORTC (2001)

  • Preoperative radiochemotherapy vs preoperative radiotherapy, with or without postoperative chemotherapy in rectal cancer: Progress report of EORTC 22921 phase III trial. Communication at the 2nd International Symposium “Sphincter saving treatment in rectal cancer”, Lyon, France, April 6-7, 2001 (2001)

  • Optimal conservation management in breast cancer; the EORTC “Boost vs. no Boost” trial. Innovations in Radiation Oncology. Communication at the 6th Annual Northern Israel Dov and Yossi Shapira Memorial Oncology Conference, Haifa, Israel, March 15, 2001 (2001)

  • Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: A phase I study (2001)

  • Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European organisation for research council study 22845 with the Medical Research Council (MRC) study BR04: An interim analysis (2002)

  • Gemcitabine in advanced soft tissue sarcomas. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group (2002)

  • Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas (2002)

  • In vitro and in vivo properties of novel nucleoside transport inhibitors with improved pharmacological properties that potentiate antifolate activity. Clinical Cancer Research 7 (7): 2105-2113, 2001 (2001)

  • Randomized doubleblind phase II survival study comparing immunization with the anti idiotypic monoclonal antibody 105AD7 against placebo in advanced colorectal cancer (2001)

  • ET-743 is an active drug in adult soft-tissue sarcoma (STS): A soft tissue and bone sarcoma group-EORTC Phase II Trial (2001)

  • Progression free rate as the principal end-point for phase II trial on soft tissue sarcoma: What should be the target? A retrospective study of the EORTC soft tissue and bone sarcoma (STBSG) database (2001)

  • Quality control of involved-field radiotherapy in patients with advanced stage Hodgkins lymphoma (HL) enrolled on the EORTC trial 20884 (2004)

  • Outcome of patients treated for Hodgkin lymphoma (HL) before the age of 30: An EORTC-GELA-SFCE collaborative study (2004)

  • Quality of life (QOL) in early stages Hodgkin lymphoma (HL) patients enrolled onto EORTC/GELA h8 trial (20931): A longitudinal survey in 1015 patients (2004)

  • Lymphocyte-rich classical Hodgkin lymphoma (LRCHL): Clinico-pathological characteristics and outcome of a rare entity (2004)

  • 6 cycles of EBVP followed by 36 GY involved-field irradiation versus 20 GY versus no irradiation in favourable supra-diaphragmatic clinical stages I-II Hodgkins lymphoma: The EORTC-GELA treatment strategy in 771 patients (h9-f trial 20982) (2004)

  • Chimeric anti-CD20 monoclonal antibody (Rituximab;Mabthera) in remission induction and maintenance treatment of relapsed /resistant follicular non-Hodgkins lymphoma: A phase III randomized Intergroup clinical trial. EORTC Lymphoma Group, HOVON, EORTC Data Center, NCIC CTG Hematology Group (Canada), BNLI, Australasian Leukaemia and Lymphoma Group, Nordic Lymphoma Group (2004)

  • Variation of quality of life with time at end of treatment. Oral presentation at the International Conference on Statistics in Health Sciences, Nantes, France, June 23-25, 2004 (2004)

  • Treatment of Ta G1 superficial bladder tumors. Presentation at the WHO/ICUD/SIU Consultation on Bladder Cancer, Honolulu, Hawaii, October 3-7, 2004 (2004)

  • Is maintenance bacillus calmette-guerin for Ta T1 bladder cancer associated with increased toxicity? Results from EORTC study 30911. Presentation at the Congress of the Dutch Society of Urology, Nijmegen, The Netherlands, April 8, 2004 (2004)

  • Is maintenance bacillus calmette-guerin for Ta T1 bladder cancer associated with increased toxicity? Results from EORTC study 30911. Presentation at the Congress of the Greek Society of Urology, Alexandropolis, Greece, June 25, 2004 (2004)

  • Phase II study of OSI-211 (liposomal lurtotecan) in patients with metastatic or loco-regional recurrent squamous cell carcinoma of the head and neck. An EORTC New Drug Development Group Study (2004)

  • A. KUTEN, L. COLLETTE, M. PIERART, M. BOLLA. Late toxicity following conventional radiotherapy for prostate cancer: Analysis of the EORTC trial 22863 (2004)

  • The influence of the boost technique on local control in breast conserving treatment in the EORTC “Boost versus No Boost” trial (2004)

  • Significance of margins of excision on breast cancer recurrence (on behalf of the EORTC Radiotherapy and Breast Cancer Groups) (2004)

  • EORTC 10981-22023 trial: AMAROS: After mapping of the axilla: Radiotherapy or surgery? Trial update (2004)

  • Preoperative chemoradiotherapy (preop XRT-CT) versus preoperative radiotherapy (preop XRT) in rectal cancer: Effect of adding CT on the pathological parameters. Report of the 22921 randomised trial conducted by the EORTC Radiotherapy Group. Gastrointestinal Cancers Symposium, San Francisco, California, U.S.A., January 22-24, 2004 (2004)

  • Is combination chemoradiotherapy the new gold standard for glioma? A case study in the light of the EORTC/NCIC phase III randomized trial on radiotherapy with or without temozolomide in glioblastoma multiforme. Educational Symposium on the Treatment of Brain Tumours. Communication at the 46th ASTRO Meeting, Atlanta, U.S.A., October 3-7, 2004 (2004)

  • The EORTC Radiotherapy Group: Recent accomplishments and future perspectives. Communication at the National Chinese Society of Radiation Oncology, Chen Yang, China, May 22-24, 2004 (2004)

  • Local treatment of pelvic disease. EORTC Trial 22921 T34 tumours. Communication at the 2nd Multidisciplinary Colorectal Cancer Congress, Noordwijk, The Netherlands, February 15-17, 2004 (2004)

  • Estimated effect of patient non-compliance to dose-time constraints in five randomized clinical trials of altered fractionation in radiotherapy for head and neck carcinomas. Proceedings of the International Head and Neck Cancer Conference, Washington DC, U.S.A., August 7-11, 2004. (abs. s043) (2004)

  • Chemo-radiation as adjuvant treatment in locally advanced head and neck squamous cell carcinomas (HNSCC): Comparative analysis of selection criteria, disease patterns and treatment outcomes in EORTC 22931 and RTOG 9501/intergroup trials. Proceedings of the International Head and Neck Cancer Conference, Washington DC, U.S.A., August 7-11, 2004 (abs. s324) (2004)

  • The International Bladder Cancer Bank: Proposal for a new study concept (2004)

  • Modeling of the hazard function for recurrence of a single superficial bladder cancer. Presentation at the 25th Annual Conference of the International Society for Clinical Biostatistics, Leiden, The Netherlands, August 15-19, 2004 (2004)

  • A Bayesian approach to jointly estimate center and treatment by center interaction heterogeneity in a proportional hazards model. Presentation at the 25th Annual Conference of the International Society for Clinical Biostatistics, Leiden, The Netherlands, August 15-19, 2004 (2004)

  • One immediate postoperative instillation of chemotherapy reduces the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of the published results of randomized clinical trials (2004)

  • High grade Ta urothelial carcinoma and carcinoma in situ of the bladder. Presentation at the WHO/ICUD/SIU Consultation on Bladder Cancer, Honolulu, Hawaii, October 3-7, 2004 (2004)

  • An overview of randomized trials investigating the treatment of carcinoma in situ. Presentation at the 4th Annual Perspectives in Bladder Cancer, Seville, Spain, November 12-13, 2004 (2004)

  • One immediate postoperative instillation of chemotherapy reduces the risk of recurrence in patients with stage Ta T1 bladder cancer: A meta-analysis of the published results of randomized clinical trials. Presentation at Controversies in Urology, Portuguese GU Group, Carvoeiro, Portugal, November 18-20, 2004 (2004)

  • BCG versus chemotherapy in the intravesical treatment of patients with carcinoma in situ of the bladder: A meta-analysis of the published results of randomized clinical trials. Presentation at State of the Art in Urology, Leuven, Belgium, November 26-27, 2004 (2004)

  • One immediate postoperative instillation of chemotherapy reduces the risk of recurrence in patients with stage Ta T1 bladder cancer: A meta-analysis of the published results of randomized clinical trials. Presentation at the Meeting of the North West Urological Oncology Group, Manchester, United Kingdom, December 2, 2004 (2004)

  • BCG in the treatment of superficial bladder cancer. Presentation at the Meeting of the North West Urological Oncology Group, Manchester, United Kingdom, December 2, 2004 (2004)

  • One immediate postoperative instillation of chemotherapy reduces the risk of recurrence in patients with stage Ta T1 bladder cancer: A meta-analysis of the published results of randomized clinical trials (2004)

  • BCG vs epirubicin in carcinoma in situ of the bladder: Results of an EORTC GU Group phase III trial (30906) (2004)

  • BCG vs epirubicin in carcinoma in situ of the bladder: Results of an EORTC GU Group phase III trial (30906). Presentation at the 27th Congress of the Société Internationale d’Urologie, Honolulu, Hawaii, October 3-7, 2004 (2004)

  • The European Organisation for Research and Treatment of Cancer: A unique pan-European network. Ashley Publications Ltd ISSN 1465-6566. Expert Opin Pharmacother 6 (1): 141-145, 2005 (2005)

  • Prospects for future studies in head and neck cancer (1997)

  • Phase I-II study with docetaxel (D), cisplatin © and 5-fluorouracil (5-FU) in patients with locally advanced inoperable squamous cell carcinoma of the head and neck (SCCHN) (1999)

  • Phase I-II study with docetaxel (D), cisplatin (C) and 5-fluorouracil (5-FU) in patients with locally advanced inoperable squmaous cell carcinoma of the head and neck (SCCHN). Proc. Eur. Conf. Clin. Oncol. 10: S164, 1999 (abs. 614) (1999)

  • Taxoids in head and neck cancer: The European approach. Communication at the International Conference of Head & Neck Oncology, Brussels, Belgium, December 4, 1999 (1999)

  • Subcellular localization of boron compounds by electron energy loss spectroscopy of cryosections (1999)

  • The higher local recurrence rate after breast conserving therapy in youn patients explained by larger tumour size, incomplet excision at first attempt and smaller excision volume ? Communication at the 40th Annual Meeting of ASTRO. Phoenix, U.S.A., October 25-29, 1998 (1998)

  • The higher local recurrence rate after breast conserving therapy in youn patients explained by larger tumour size, incomplet excision at first attempt and smaller excision volume ? Communication at the 40th Annual Meeting of ASTRO. Phoenix, U.S.A., October 25-29, 1998 (1998)

  • Myelodysplastic syndrome (1998)

  • High local recurrence risk after breast-conserving therapy in node-negative premenopausal breast cancer patients is greatly reduced by one course of perioperative chemotherapy: A European organisation for research and treatment of cancer breast cancer cooperative group study (2000)

  • Summary measures and statistics in the analysis of quality of life data: An example from an EORTC-NCIC-SAKK locally advanced breast cancer study (2000)

  • The role of meta-analyses in assessing cancer treatments (2000)

  • Second-line treatment of small-cell lung cancer with the camptothecin-derivative G1147211: A study of the EORTC early clinical studies group (ECSG) (2000)

  • Final results of a randomized phase III trials of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European organization for research and treatment of cancer gastrointestinal tract cancer cooperative group (2000)

  • Treatment of superficial bladder tumors: Achievements and needs (2000)

  • Quality Control in multicentric clinical trials. An experience of the EORTC gynecological cancer cooperative group (2000)

  • Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: A randomized phase II study of the European organization for research and treatment of cancer gynecology group (2000)

  • Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: Three-year results (2000)

  • Confirmation of the "old" standard of care for ovarian cancer and a challenge (2000)

  • Euroscan, a randomized trial of vitamine A and N-acetylcysteine in patients with head & neack cancer or lung cancer (2000)

  • Gemcitabine and cisplatin as induction regimen for patients with biopsy-proven stage IIIA N2 non-small-cell lung cancer: A phase II study of the European organization for research and treatment of cancer lung cancer cooperative group (EORTC 08955) (2000)

  • Toxicity of high-dose radiotherapy combined with daily cisplatin in non-small cell lung cancer: Results of the EORTC 08912 phase I/II study (2000)

  • Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European organization for research and treatment of cancer/soft tissue and bone sarcoma group (2000)

  • Epirubicin is not superior to doxorubicin in the treatment of advanced soft tissue sarcoma. The experience of the EORTC soft tissue and bone sarcoma group. Sarcoma 4: 31-35, 2000 (2000)

  • Pentostatin in T-cell malignancies - A phase II trial of the EORTC (1999)

  • Weekly 24h infusion of high-dose (HD) 5-fluorouracil (5-FU24h) with or without folinic acid (FA) vs. bolus 5-FU/FA (NCCTG/Mayo) in advanced colorectal cancer (CRC): A randomized phase III study of the EORTC Gastrointestinal Tract Cancer Cooperative Group and the AIO (2000)

  • Weekly high-dose 5-fluorouracil (5FU) and folinic acid (LV) in metastatic pancreatic carcinoma: A phase II study of the EORTC gastrointestinal tract cancer cooperative group (2000)

  • A phase III trial of flutamide (F) versus prednisone (P) in hormone resistant metastatic prostate cancer (HRMPC) (EORTC 30903) (2000)

  • Final analysis demonstrating the equivalence of 3-BEP vs. 4 cycles and the 5 day schedule vs. 3 days per cycle in good prognosis germ cell cancer. An EORTC/MRC phase III study (2000)

  • Randomized phase III trial in advanced urothelial tract tumours with high dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC (2000)

  • Randomized phase III trial in advanced urothelial tract tumours with high dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC. Communication at the Thirty-sixth Annual Meeting of the American Society of Clinical Oncology, New Orleans, LA, U.S.A., May 20-23, 2000 (2000)

  • Final analysis demonstrating the equivalence of 3-BEP vs. 4 cycles and the 5 day schedule vs. 3 days per cycle in good prognosis germ cell cancer. An EORTC/MRC phase III study. Communication at the Thirty-sixth Annual Meeting of the American Society of Clinical Oncology, New Orleans, LA, U.S.A., May 20-23, 2000 (2000)

  • A phase III trial of flutamide (F) versus prednisone (P) in hormone resistant metastatic prostate cancer (HRMPC) (EORTC 30903). Communication at the Thirty-sixth Annual Meeting of the American Society of Clinical Oncology, New Orleans, LA, U.S.A., May 20-23, 2000 (2000)

  • Tissue polypeptide specific antigen (TPS) determinations before and during intermittent hormonal therapy in metastatic prostate carcinoma (PC). Communication at the American Urological Association 95th Annual Meeting, Atlanta, Georgia, U.S.A., April 29 - May 4, 2000 (2000)

  • Tissue polypeptide specific antigen (TPS) determinations before and during intermittent hormonal therapy in metastatic prostate carcinoma (PC). J. Urol. 163 (4): 181, 2000 (abs. 803) (2000)

  • Adjuvant hormone therapy in localized and locally advanced prostate cancer: The EORTC Trials. Communication at the 5th International Symposium on Special Aspects of Radiotherapy. Controversies in Uro-Oncology. Berlin, Germany, May 11-13, 2000 (2000)

  • TA - HPV, a modified vaccinia virus carrying HPV 16 and 18 E6 and E7 proteins induces potent immunity in women with early cervical cancer. Proc. American Association for Cancer Research, San Francisco, U.S.A., April 1-5, 2000 (abs.) (2000)

  • Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors (2000)

  • A 12 country field study of the EORTC QLQ-C30 (version 3.0) and the head and neck cancer specific module (EORTC QLQ-H&N35) in head & neck patients (2000)

  • Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC soft tissue and bone sarcoma group (2000)

  • Assessing the impact of uncertainty by using bootstrap techniques when cost and outcome data are censored: A case study of chemotherapy in ovarian cancer (2000)

  • Cost-effectiveness of addition of early hormonal therapy in locally advanced prostate cancer: results decisively determined by cut-off time point chosen for the analysis (2000)

  • Clinical trials update of the European Organization for Research and Treatment of Cancer Breast Cancer Group (2004)

  • Project management platform in an academic environment: The EORTC’s promising experience (2004)

  • Health-related quality of life parameters as prognostic factors in a non metastatic breast cancer population: An international multicenter study (2004)

  • One immediate postoperative instillation of chemotherapy in low risk Ta, T1 bladder cancer patients. Is it always safe? (2004)

  • Clinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangements. Leukemia 17 (4): 700-706, 2003 (2003)

  • Intraperitoneal or intraportal 5 FU combined with systemic chemotherapy for the adjuvant treatment of colorectal cancer: An EORTC (40911) and FFCD (9204) phase III study (2004)

  • Workshop: Cytogenetics based treatment of acute leukemia: When do we need transplantation? EBMT 2003 Istanbul, Turkey, July 20-23, 2003 (2003)

  • Disease-specific prognostic factors for outcome of patients with poor-risk myelodysplastic syndrome and acute myeloid leukemia treated with intensive antileukemic therapy. The Hematology Journal 5 (2): S165, 2004 (2004)

  • The impact of post-remission therapy on outcome of patients with poor risk MDS and secondary AML (sAML) treated with intensive chemotherapy with or without stem cell transplantation in a joint study (2004)

  • Transplant algorithms in AML; The EORTC/Gimema proposal study (2004)

  • CNS-directed therapy for childhood acute lymphoblastic leukemia: Childhood ALL Collaborative Group overview of 43 randomized trials (2003)

  • Treatment of acute lymphoblastic leukemia in childhood: Survey of successive EORTC trials (2004)

  • Secondary neoplasms subsequent to the EORTC 58881 trial for ALL or NHL in childhood: Remarkable low incidence of CNS tumours. Proc. 36th Congress of the SIOP, Norway, September 16-19, 2004 (abs.) (2004)

  • The value of 6-Mercaptopurine i.v. during continuation treatment in childhood acute lymphoblastic leukemia and non-Hodgkin lymphoma: Final results of the randomized phase III trial (58881) of the EORTC CLG. Proc. 36th Congress of the SIOP, Norway, September 16-19, 2004 (abs.) (2004)

  • Bleomycin, vincristine, lomustine and dacarbazine (BOLD) in combination with recombinant interferon alpha-2b for metastatic uveal melanoma (2003)

  • The EORTC 18951 addendum trial: DTIC versus biochemotherapy for metastatic melanoma (2004)

  • Intermediate-dose IFN (stage III) / pegylated IFN (2004)

  • Analysis of prognostic factors. EORTC Course on Clinical Trials Statistics for Non Statisticians, Brussels, June 16-18, 2004 (2004)

  • Analysis of prognostic factors. EORTC Course on Clinical Trial Statistics for Non Statisticians, Brussels, June 12-13, 2003 (2003)

  • Multicentre phase II study of imatinib mesylate in patients with recurrent glioblastoma: An EORTC: NDDG/BTG Intergroup Study. Proc. 40th Annual Meeting of the American Society of Clinical Oncology, New Orleans, U.S.A., June 5-8, 2004 (abs. 1501) (2004)

  • Clinical prognostic factors affecting survival in patients with newly diagnosed glioblastoma multiforme (GBM). Proc. 40th Annual Meeting of the American Society of Clinical Oncology, New Orleans, U.S.A., June 5-8, 2004 (abs. 9599) (2004)

  • Concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) for newly diagnosed glioblastoma multiforme (GBM). Conclusive results of a randomized phase III trial by the EORTC Brain & RT Groups and NCIC Clinical Trials Group. Communication at the 40th Annual Meeting of the American Society of Clinical Oncology, New Orleans, U.S.A., June 5-8, 2004 (abs. 2) (2004)

  • Is baseline quality of life useful for predicting overall survival with hormone refractory prostate cancer? (2004)

  • The experimental antitumor agents phortress and doxorubcin are equiactive against human-derived breast carcinoma xenograft models (2004)

  • Clinical and psychometric validation of questionnaire module, the EORTC QLQ-STO 22, to assess quality of life in patients with gastric cancer (2004)

  • Weekly high-dose 5-fluorouracil and folinic acid in metastatic pancreatic carcinoma: A phase II study of the EORTC GastroIntestinal Tract Cancer Cooperative Group (2004)

  • Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: Randomised trial (2004)

  • Quality assurance of the 22961 EORTC trial. A phase III study of the optimal combination of hormonal adjuvant treatment by LHRH analogue and radiation therapy for the management of locally advanced prostate cancer: The dummy run (2004)

  • What is the effect of systematic anticancer treatment on cognitive function? (2004)

  • Short and long term health related quality of life issues following brachytherapy for prostate cancer. Expert Rev of Pharmacoeconomics Outcomes Res 4 (3): 277-286; 2004 (2004)

  • The European Organization for Research and Treatment of Cancer QLQ-C30: An examination into the cultural validity and reliability of the Turkish version of QLQ-C30 (2004)

  • What do we really know? (2004)

  • Key issues in measuring health-related quality of life in the anaemic cancer patient (2004)

  • Methodological Challenges of Conducting Quality of Life Studies with Gynaecological Cancer Patients (2004)

  • Guidelines for assessing quality of life in breast studies (2004)

  • Predicting survival with health related quality of life scores in locally advanced breast cancer: Results of an international randomised controlled trial. Proc. 40th American Society of Clinical Oncology (ASCO) Annual meeting, New Orleans, U.S.A., June, 2004 (abs. 618) (2004)

  • The status of quality of life studies in oncology (2004)

  • Quality of life methodology (2004)

  • Quality assurance of the EORTC 26981/22981; NCIC CE3 intergroup trial on radiotherapy with or without temozolomide for newly-diagnosed glioblastoma multiforme: The individual case review (2004)

  • Temozolomide (TMZ)targets only glioblastoma with a silenced MGMT-gene. Results of a translational companion study to EORTC 26981/NCIC CE.3 or radiotherapy ± TMZ (2004)

  • Randomized study comparing doxorubicin to taxoteretm in previously untreated soft tissue sarcomas. Communication at 4th Annual Scientific Meeting Vancouver, B.C., Canada, November 13-14, 1998 (1998)

  • Medical basis of the neutron capture therapy and its results obtained in HFR reactor - examples of patients treatment. Communication at the Meeting on Neutron Capture Therapy for Brain Cancer, Department of Operation Research Reactor MARIA at the Institute of Atomic Energy, Swierk, Poland, January 28 -29, 1999 (1999)

  • Boron neutron capture therapy for the treatment of glioblastoma. Communication at the 9th International Congress on Anti-Cancer Treatment, Paris, France, February 2-5, 1999 (1999)

  • Florence statement on breast cancer, 1998 forging the way ahead for more research on and better care in breast cancer (1999)

  • Prognosis after treatment for loco-regional recurrence after mastectomy or breast conserving therapy in two randomised trials (EORTC 10801 and DBCG 82TM) (1999)

  • Final results of a large phase II study of a high dose 5-fluorouracil (5-FU) and 1-folinic acid (FA) chronomodulated (chrono) combination in advanced colorectal cancer (ACC). Communication at the International Conference on Chemotherapeutic Strategies for Treatment of Colorectal Cancer. Present and Future Developments, Amsterdam, The Netherlands, February 10-12, 1999 (1999)

  • 5-fluorouracil and l-folinic acid pharmacokinetics during chronomodulated delivery. Communication at the International Conference on Chemotherapeutic Strategies for Treatment of Colorectal Cancer. Present and Future Developments, Amsterdam, The Netherlands, February 10-12, 1999 (1999)

  • Chronotherapy with 5-fluorouracil, leucovorin and oxaliplatin against metastatic colorectal cancer. Communication at the International Conference on Chemotherapeutic Strategies for Treatment of Colorectal Cancer. Present and Future Developments, Amsterdam, The Netherlands, February 10-12, 1999 (1999)

  • Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: An analysis of 2,185 patients treated with anthracycline-containing first-line regimens - A European organization for research and treatment of cancer soft tissue and bone sarcoma group study (1999)

  • A cross-validation of the european organization for research and treatment of cancer QLQ-C30 (EORTC QLQ-C30) for japanese with lung cancer (1998)

  • Health-related quality of life in the general norwegian population assessed by the european organization for research and treatment of cancer core quality-of-life questionnaire: The QLQ=C30 (+3) (1998)

  • Temozolomide in adult patients with advanced soft tissue sarcoma: A phase II study of the EORTC soft tissue and bone sarcoma group (1999)

  • Candidemia in cancer patients: A prospective, multicenter surveillance study by the invasive fungal infection group (IFIG) of the European organization for research and treatment of cancer (EORTC). Clin. Infec. Dis. 28: 1071-1079, 1999 (1999)

  • Sunscreen use and duration of sun exposure: A double-blind, randomized trial (1999)

  • Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy (1999)

  • Results of a phase II trials with second-line cystemustine at 60mg/m2 in advanced soft tissue sarcoma: A trial of the EORTC early clinical studies group (1998)

  • Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: A randomised controlled trial (1999)

  • Assessing the quality of life of patients with cancer: East meets west (1998)

  • Long term results of adjuvant hormonal therapy with goserilin in patients with locally advanced prostate cancer treated with radiotherapy (1999)

  • The three-month recurrence rate as a prognostic factor for the long term outcome of TaT1 bladder cancer (1999)

  • Randomized phase II trial of weekly methotrexate (MTX) versus two schedules of triweekly paclitaxel (Taxol®) in patients with metastatic or recurrent squamous cell carcinoma of the head & neck (SCCHN). J. Clin. Oncol. 18: 395a, 1999 (abs. 1527) (1999)

  • Is 3BEP equivalent to 3BEP-1EP in good prognosis germ cell cancer? An EORTC/MRC phase III study (1999)

  • Vinorelbine and cisplatin in metastatic epidermoid carcinoma of the esophagus (MECE). An EORTC phase II study (1999)

  • Quality-adjusted survival (Q-Twist) analysis of EORTC trial 30853 comparing goserelin acetate and flutamide with bilateral orchiectomy in patients with metastatic prostate cancer. The Prostate 38: 100-109, 1999 (1999)

  • Quality of life after radiation therapy of cerebral low-grade gliomas of the adult: Results of a randomised phase III trial on dose response (EORTC trial 22844) (1998)

  • Sample size estimation in phase III cancer clinical trials (1999)

  • Adjuvant portal-vein infusion of fluorouracil and heparin in colorectal cancer: A randomised trial (1998)

  • Reduction of chemotherapy-induced febrile leukopenia by ciprofloxacin and roxithromycin in small cell lung cancer (SCLC) patients: An EORTC phase III study (1999)

  • Taxol® and carboplatin induction chemotherapy in stage IIIA non-small cell lung cancer (NSCLC): An EORTC 08958 phase II trial (1999)

  • Combination chemotherapy with cisplatin and topotecan as second-line treatment of sensitive (S) and refractory (R) small cell lung cancer (SCLC): An EORTC LCCG phase II study (1999)

  • Analysis of longitudinal, ordinal, and categorical QL data with dropout, in session "new developments in analysis of quality of life in clinical trials". Communication at the International Biometrics Society Eastern Northern American Region (ENAR), Atlanta, GA, U.S.A., March 28-31, 1999 (1999)

  • Clinical trial data analysis. Communication at the EORTC Scientific Strategy Meeting (ESSM), Brussels, Belgium, March 25-26, 1999 (1999)

  • EORTC QLQ-C30 Scoring Manual: 2nd Edition" 1999, ISBN 2-930064-16-1, 78 pp (1999)

  • Guidelines for assessing quality of life in EORTC clinical trials. 1999, ISBN 2-930064-17-X, 41 pp (1999)

  • Analysis of longitudinal, ordinal, categorical QL data with dropout. Proceedings of the International Biometrics Society Eastern Northern American Region (ENAR), Atlanta, U.S.A., March 28-31, 1999. Biometrics, 1999 (1999)

  • Implementing proper SAE procedures in an academic research environment. Communication at the 6th Applied Clinical Trial European Conference, Paris, France, March 13, 1999 (1999)

  • Reporting of serious adverse events. Communication at the One-day Introduction to EORTC Trials, Brussels, Belgium, September 17, 1999 (1999)

  • Factorial design: pro s and con s (1999)

  • Quality of life issues. Communication at the EORTC Scientific Strategy Meeting (ESSM), Brussels, Belgium, March 25-26, 1999 (1999)

  • Quality of life assessment: The EORTC experience. Communication at the 10th European Cancer Conference, Vienna, Austria, September 12-16, 1999 (1999)

  • Is neoadjuvant chemotherapy the answer for bladder cancer? (1999)

  • Design issues in head and neck clinical trials: a statistician's perspective. Anti Cancer Drugs 22 (7): 682-687, 2011 (2011)

  • Low grade astrocytoma, anaplastic oligodentroglioma or astrocytoma and glioblastoma: the clinical trial portfolio of the EORTC Brain Tumor and Radiation Oncology Groups for newly diagnosed patients. Proc. 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago, USA, June 4-8, 2010 (abs e12551) (2010)

  • Minimal clinically meaningful differences for the EORTCQLQ-C30 and EORTC QLQ-BN20 scales in brain cancer patients (2011)

  • Integrating collection of biospecimens in clinical trials: The approach of the European Organisation for Research and Treatment of Cancer (EORTC). (2011)

  • Adjuvant Whole Brain Radiotherapy versus Observation after Radiosurgery or Surgical Resection of 1-3 Cerebral Metastases - Results of the EORTC 22952-26001 Study (2011)

  • Quality of pathology reports for advanced ovarian cancer: Are we missing essential information? An audit of 479 pathology reports from the EORTC-GCG 55971/NCIC-CTG OV13 neoadjuvant trial (2011)

  • 2010 update of EORTC guidelines for the use of granulocytecolonystimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours (2011)

  • Dexamethasone compared to prednisolone for adults with acute lymphoblastic leukemia or lymphoblastic lymphoma: final results of the ALL-4 randomized, phase III trial of the EORTC Leukemia Group (2010)

  • Les assurances pour essais cliniques en Europe: une tour de Babel? Onco Hemato 4 (7): 233-236, 2010 (2010)

  • Pattern of care in locally advanced breast cancer: Focus on local therapy. Breast 20: 145-150, 2011 (2010)

  • Definition and Function of E.O.R.T.C. (1976)

  • The Practice of Cooperative Clinical Trials (1976)

  • The Data Center of the European Organization for Research on Treatment of Cancer (1976)

  • A Decision Theory Approach to Phase II Clinical Trials. Biomedicine (26): 262-266, 1977 (1977)

  • Prognostic factors for the response to chemotherapy in advanced breast cancer. Can (1978)

  • Designs for phase III trials. Can (1979)

  • The delta and epsilon errors in the assessment of cancer clinical trials. Cancer Treat Rep (63): 1917-1921, 1979 (1979)

  • A prognostic index for thyroid carcinoma. A study of the E.O.R.T.C. thyroid cancer cooperative group (1979)

  • N-(phosphonacetyl)-L-asparate (PALA) in advanced breast cancer: A phase II trial of the EORTC breast cancer cooperative group (1982)

  • Quality of institutional participation in multicenter clinical trials (1981)

  • Guidelines for the preparation of EORTC cancer clinical trial protocols (1980)

  • Phase II study of amsacrine in refractory lymphomas. A report of the EORTC Early Clinical Trials Group (1984)

  • Phase II trial of epirubicin in advanced squamous, adeno- and large cell carcinoma of the lung (1984)

  • Pharmacokinetics of carminomycin in man: biweekly schedule vs single dose every three weeks (1984)

  • Relationship between cathepsin-D content and disease-free survival in node-negative breast cancer patients: a meta-analysis. (1992)

  • Methylated genes as new cancer biomarkers (2009)

  • Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the prostate cancer clinical trails working group (2008)

  • A REPORT OF AN EXPERT GROUP. Research in the behavioural and social sciences to improve cancer control and care: A strategy for development (2004)

  • Quality assurance in radiotherapy (2003)

  • Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. New Engl J Med 344 (14): 1031-1037, 2001 (2001)

  • The baseline quality of life of patients with advanced prostate cancer (1997)

  • Final results of a phase III clinical trial on adjuvant intraportal infusion with heparin and 5-fluorouracil (5-FU) in resectable colon cancer (EORTC GITCCG 1983-1987) (1997)

  • Phase II study of high-dose megestrol acetate in patients with advanced ovarian carconima (1994)

  • Phase II trial of flutamide in advanced ovarian cancer: An EORTC gynaecological cancer cooperative group study (1994)

  • Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. New Engl J Med 344 (14): 1038-1042, 2001 (2001)

  • Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study (2010)

  • Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer--results from two randomised studies (2010)

  • Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse (2010)

  • Gem-(R)CHOP versus (R)CHOP: a randomized phase II study of gemcitabine combined with (R)CHOP in untreated aggressive non-Hodgkin's lymphoma The EORTC lymphoma group protocol 20021 (EudraCT number 2004-004635-54) (2010)

  • Diffuse large B-cell and peripheral T-cell non-Hodgkin's lymphoma in the frail elderly: A phase II EORTC trial with a progressive and cautious treatment emphasizing geriatric assessment. J Geriatric Oncol 2 (1): 36-44, 2011 (2011)

  • The development of priority cervical cancer trials: a Gynecologic Cancer InterGroup report (2010)

  • Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer (2010)

  • Long-term quality of life and functional outcome of rectal cancer patients treated with preoperative (chemo)-radiotherapy in a randomised trial. Cancer Radio 14: 530-534, 2010 (2010)

  • Value of infliximab (Remicade®) in patients with low-risk myelodysplastic syndrome. Final results of a phase II randomized trial of the EORTC leukemia group (2012)

  • Prognostic value of serial blood S100B determinations in stage IIB-III melanoma patients: A corollary study to EORTC trial 18952 (2011)

  • Autoimmunity and treatment outcome in melanoma (2011)

  • Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954 (2010)

  • Clinical Outcome of Children with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Treated Between 1995 and 2005 (2010)

  • Improved outcome with hematopoietic stem cell transplantation in a poor prognostic subgroup of infants with mixed-lineage-leukemia (MLL)? Rearranged acute lymphoblastic leukemia: results from the Interfant-99 Study (2010)

  • A meta-analysis of six europena trials to develop validated nomograms for the prediction of local control, distant metastases and survival for locally advanced rectal cancer patients after long course chemoradiotherapy. Radioth Oncol 96 (suppl 1):15, 2010 (Abs 32) (2010)

  • The impact of radiation dose, histology and age in breast conserving therapy: long term results form the EORTC boost versus no boost trial. Radioth Oncol 96 (suppl 1):S36-37, 2010 (Abs 96.) (2010)

  • Long term results of immediate post-operative radiotherapy after radical prostatectomy in pT3N0 prostate cancer (EORTC 22911). Radioth Oncol 96 (suppl 1):S113, 2010 (Abs 298.) (2010)

  • A meta-analysis of six europena trials to develop validated nomograms for the prediction of local control, distant metastases and survival for locally advanced rectal cancer patients after long course chemoradiotherapy. Oral Presentation at the ESTRO 29, Barcelona, Spain, September 12-16, 2010 (2010)

  • The impact of radiation dose, histology and age in breast conserving therapy: long term results form the EORTC boost versus no boost trial. Oral Presentation at the ESTRO 29 Barcelona, Spain, September 12-16, 2010 (2010)

  • Long term results of immediate post-operative radiotherapy after radical prostatectomy in pT3N0 prostate cancer (EORTC 22911). Oral Presentation at the ESTRO 29 Barcelona, Spain, September 12-16, 2010 (2010)

  • A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, ifosfamide (VIP) plus stem cell support in males with poor prognosis germ cell cancer (GCC): An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974). Oral Presentation at the ASCO 2010, Chicago, IL, June 4-8, 2010 (2010)

  • Irradiation of the internal mammary and medial supraclavicular lymph node chain in stage I to III breast cancer: state of the day of EORTC phase III trial 22922/10925 with 4004 patients. Oral Presentation at the 7th European Breast Cancer Conference (EBCC), Barcelona, Spain, March 24-27, 2010 (2010)

  • Quality of Life results of an EORTC phase III randomized trial of adjuvant Whole Brain Radiotherapy versus Observation after Radio surgery or Surgical Resection of 1-3 Cerebral Metastases of solid tumors. Oral Presentation at the ASCO 2010, Chicago, IL, June 4-8, 2010 (2010)

  • Quality of Life results of an EORTC phase III randomized trial of adjuvant Whole Brain Radiotherapy versus Observation after Radio surgery or Surgical Resection of 1-3 Cerebral Metastases of solid tumors (2010)

  • Combination chemotherapy of bleomycin, vindesine, mitomycin and cisplatin versus single agent cisplatin in disseminated squamous cell carcinoma of the uterine cervix: A phase II study (1992)

  • Phase II study of high-dose epirubicin in ovarian cancer patients previously treated with cisplatin. Annals of (1992)

  • A phase II trial of 10-ethyl-10-deaza-aminopterin, a novel antifolate, in patients with advanced and/or recurrent squamous cell carcinoma of head and neck (1992)

  • EORTC program for quality control of chemotherapy in multicenter trials (1992)

  • Fungal infections in cancer patients (1992)

  • New perspectives for the management of fungal infections in cancer patients (1992)

  • Prophylaxis of systemic fungal infections (1992)

  • Prevention and treatment of infections (1992)

  • An overview of mycoses in cancer patients (1992)

  • The Challenge of Invasive Fungal Infection (1992)

  • (1992)

  • Infections mycotiques chez le patient cancéreux: Données actuelles et perspectives futures (1992)

  • Fungal infections in cancer patients (1992)

  • Antifungal prophylaxis during neutropenia: State of the art (1992)

  • Liposomal amphotericin B. Clinical experiences (1992)

  • Invasive fungal infections: Incidence, diagnosis, risk factors and treatment (1992)

  • Management of fungal infections (1992)

  • Antifungal prophylaxis. Overview (1992)

  • Treatment of myelodysplastic syndromes (MDS) and high leukaemic risk with low-dose cytosine arabinoside (LD-AraC) plus granulocyte-macrophage colony-stimulating factor (rh GM-CSF). The EORTC Leukaemia Group. Infection. 20 (Suppl 2): S116-S123, 1992 (1992)

  • Modulation of multidrug-resistant multiple myeloma by cyclosporin (1992)

  • Therapy of adult ALL: overview of 2 successive EORTC studies: ALL-2 & ALL-3 (1992)

  • A randomized phase I/II study of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) therapy for patients with myelodysplastic syndromes and a relatively low risk of acute leukemia. Annals of Hematology 64 (4): 173-180, 1992 (1992)

  • Intensive consolidation chemotherapy versus standard consolidation maintenance in acute myelogenous leukemia (AML) in first remission. An EORTC/GIMEMA phase III trial (AML8 B). Leukemia 6 (Suppl. 2): 76-77, 1992 (1992)

  • Allogeneic versus autologous bone marrow transplantation (BMT) versus intensive consolidation in acute myelogenous leukemia (AML) in first remission. An EORTC/GIMEMA phase III trial (AML8 A). Leukemia 6(Suppl. 2): 114-115, 1992 (1992)

  • A pilot study of intensive remission induction chemotherapy for bad prognosis myelodisplastic syndromes (MDS) and acute myelogenous leukemia secondary (sAML) to MDS of more than 6 months duration (1992)

  • Pentostatin induces long lasting remissions in patients with hairy cell leukemia resistant or intolerant to interferon-alpha. The European Organization for Research and Treatment of Cancer Leukemia Cooperative Group (1992)

  • Pentostatin in prolymphocytic leukemia. A phase II study of the EORTC Leukemia Cooperative Group (1992)

  • A pilot study of intensive remission induction chemotherapy for bad prognosis myelodisplasia (MDS) and secondary acute myelogenous leukemia (sAML) following MDS of more than 6 months duration. An EORTC Leukemia Cooperative Group Study. Communication at the 24th Congress of the International Society of Hematology, London, United Kingdom, August 23-27, 1992. Backwell Scient. Publ., 1992 (abs. 133) (1992)

  • Modulation of multidrug resistance in refractory myeloma by cyclosporin and its non-immunosuppressive analogue PSC 833 (1992)

  • A randomized phase I/II multicenter study (EORTC 06891) of rh-IL-3 in patients with myelodysplastic syndromes at relatively low risk of developing leukemia (MDS-LR). Communication at the American Society of Hematology 34th Annual Meeting, Anaheim, California, USA, December 4-8, 1992 (1992)

  • Evaluation methodology in the EORTC trials including bone marrow transplantation (BMT) in acute leukemia (AL) patients in first remission (Abs 25). Communication at the Meeting of the International Society for Clinical Biostatistics, Copenhagen, Denmark, August 17-21, 1992 (1992)

  • Relative value of autologous bone marrow transplantation (ABMT), allogeneic BMT (allo-BMT) and intensive chemotherapy (IC) consolidation in acute myelogenous leukemia (AML). Proc. 18th Annual Meeting Eur. Coop. Group Bone Marrow Transplant. (EBMT), Stockholm, Sweden, June 1-2, 1992 (1992)

  • Autologous versus allogeneic BMT versus intensive chemotherapy (CT) in first complete remission of acute myelogenous leukemia (AML): the AML 8-A protocol of EORTC-GIMEMA. Communication at the 6th International Symposium on Autologous Bone Marrow Transplantation, Houston, Texas, USA, December 1-3, 1992 (1992)

  • Chemoprevention in the management of oral cancer: Euroscan and other studies (1992)

  • Views and news from Melbourne, the Sixth World Conference on Lung Cancer. Eur. Resp. J. 5: 1023-1026, 1992 (1992)

  • Epirubicin in malignant mesothelioma: A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J. Clin. Oncol. 10: 824-828, 1992 (1992)

  • Phase II study of ACNU as second-line treatment in small-cell lung cancer (1992)

  • Comparison of two carboplatin-containing regimens with standard chemotherapy for small cell lung cancer in a randomised phase II study (1992)

  • Epirubicin in previously untreated patients with small cell lung cancer: A phase II study by the EORTC Lung Cancer Cooperative Group (1992)

  • Les infections fongiques chez le sujet immuno-déprimé (non SIDA) (1993)

  • Epidemiology of invasive aspergillosis in European cancer centers. Proc. 6th European Congress of Clinical Microbiology and Infectious Diseases. Seville, Spain, March 28-31, 1993 (abs. 768) (1993)

  • Epidemiology of invasive aspergillosis in European cancer centres. EORTC Invasive Fungal Infections Cooperative Group [letter] (1993)

  • Piperacillin/ tazobactam plus amikacin versus ceftazidime plus amikacin as empirical therapy for fever in patients with granulocytopenia: A prospective, randomized, multicenter study (efficacy, safety and tolerance). Proc. 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, Louisiana, USA, October 17-20, 1993 (abs. 645) (1993)

  • In-vitro activity of Piperacillin-tazobactam against 365 aerobic bacteria isolated from blood in granulocytopenic cancer patients. Proc. 18the International Congress of Chemotherapy, Stockholm, Sweden, June 1994 (abs. 380) (1993)

  • Efficacy and toxicity of single daily doses of Amikacin and Ceftriaxone versus multiple daily doses of Amikacin and Ceftazidime for infection in patients with cancer and granulocytopenia. Annals Int. Med. 119: 584-593, 1993 (1993)

  • Head and neck cancer: the EORTC experience (1993)

  • Research in head and neck oncology in Europe. Invited Lecture, Indore, India, October 1993 (1993)

  • Results of the allo-BMT in the randomized trial AML 8A (Chemo vs ABMT): an EORTC-GIMEMA study in AML patients. Communication at the EBMT Meeting, Garmisch-Partenkirchen, Germany, January 17-21, 1993 (abs 908) (1993)

  • Candidiasis in cancer patients: Current concepts and future perspectives. Pathogenesis, diagnosis, and treatment of candida infections (1993)

  • Radiothérapie et chimiothérapie dan les cancer rectaux: bilan et perspectives. 4e Congrès de la SFRO, Paris, France, November 25-26, 1993 (1993)

  • Cell cycle modifications of breast cancers during neoadjuvant chemotherapy: A flow cytometry study of fine needle aspirates (1993)

  • Plasma insulin-like growth factor 1 (IGF1) concentration in human breast cancer (1993)

  • Progesterone receptors in routinely paraffin-embedded primary breast carcinomas and lymph node metastases (1993)

  • Epidermal growth factor receptor and prognosis in human breast cancer: A prospective study (1993)

  • Prognostic factors and response to therapy in breast cancer. Cancer Surv. 18: 165-198, 1993 (1993)

  • Cell biological factors associated with the response of breast cancer to systemic treatment. Cancer Treat. Rev. 19 (Suppl. B): 45-63, 1993 (1993)

  • TGF alpha and TGF beta expression in mammary carcinoma. J. Pathol. 170: 15-22, 1993 (1993)

  • The necessity to analyze the patient population entered in clinical studies: Presentation of breast cancer in EORTC trial 22881/10882 on the role of a booster dose in breast conserving therapy. Communication at the EORTC Radiotherapy Cooperative Group Meeting, Tours, France, April 1-3, 1993 (1993)

  • The necessity to analyze the patient population entered in clinical studies: Presentation of breast cancer in EORTC trial 22881/10882 on the role of a booster dose in breast conserving therapy (1993)

  • Plenary Session: Radiothérapie et Chimiothérapie Concomitante des Cancers. 4ème Congrès National de la SFRO, Paris, France November 25-26, 1993 (1993)

  • Radiotherapy data entered in EORTC trial 22881/10882 on the role of a booster dose in breast conserving therapy: Analysis of the reporting of data from 1909 patients and comparison with the previous sample analysis. Communication at the EORTC Radiotherapy Cooperative Group Meeting, Pavia, Italy, October 8-10, 1993 (1993)

  • Results of EORTC trial 22831 in resectable rectal cancer using postoperative pelvic radiotherapy with and without irradiation of para-aortic nodes and liver. ESTRO 12/ECCO 7, Jerusalem, Israel, November 17, 1993 (1993)

  • DNA content and cell cycle analysis by flow-cytometry in clinical samples: Application in breast cancer. Biol. Cell. 78: 69-72, 1993 (1993)

  • Quality assurance programme of the EORTC Cooperative Group for Radiotherapy. A 10-year experience: historical overview and future directions. EORTC Radiotherapy Group Consensus Meeting on High Dose/High Precision in Radiotherapy, Geneva, Switzerland, January 15-16, 1993 (1993)

  • Hyperfractionated and accelerated fractionation regimes: protocols and results of the EORTC Cooperative Group for Radiotherapy. International and 3rd Panhellenic Congress of Radiation Oncology, Athens, Greece, September 23-26, 1993 (1993)

  • Present status and updated results of the trials on hyperfractionation and/or accelerated fractionation. ESTRO 12/ECCO 7, Jerusalem, Israel, November 17, 1993 (1993)

  • Present status and updated results of the trials on hyperfractionation and/or accelerated fractionation. International Congress of Radiation Oncology (ICRO), Kyoto, Japan, June 21-26, 1993 (1993)

  • Quality assurance in Radiotherapy. First consensus meeting of the ESTRO/ECC committee of Experts on Quality Assurance in Radiation Oncology, Leuven, Belgium, September 9-10, 1993 (1993)

  • Update of EORTC fractionation studies in head and neck carcinoma. 8th annual CERRO (Clinical and Experimental Research in Radiation Oncology) meeting, St. Martin de Belleville, France, January 16-23, 1993 (1993)

  • The polace of adjuvant irradiation in the management of rectal cancer. A critical analysis of the results of clinical randomized trials with possible new ways for the clinical research in the next future (1993)

  • La radiothérapie préopératoire dans les cancers du rectum. Euromédicine 93, Montpellier, France, November 10-13, 1993 (1993)

  • Radiochimiothérapies pré et post-opératoires des cancers du rectum. Réunion de la Fondation Française de Cancérologie Digestive, Nantes, France, June 3-5, 1993 (1993)

  • Quel traitement pré-opératoire pour les cancers du rectum à haut risque de récidive? Fondation Française de Cancérologie Digestive, Montauban, France, April 16, 1993 (1993)

  • Conduite de l'irradiation dans les cancers inopérables. Cours Supérieur Fondation Française de Cancérologie Digestive, Marseille, France, February 21-23, 1993 (1993)

  • The EORTC QA Programme in Radiotherapy: a 10-year experience. Meeting on Quality Assurance, Royal College of Radiologists, London, U.K. February 26, 1993 (1993)

  • Ifosfamide plus doxorubicin in previously untreated patients with advanced soft tissue sarcomas. Cancer Chemother. Pharmacol. 31S: 204-209, 1993 (1993)

  • Randomized phase II study of neoadjuvant chemotherapy in soft tissue sarcomas in adults. Protocol 62874 (1993)

  • European experience in metastatic bladder cancer : Genitourinary cancer update. Communication at the Roswell Park Cancer Institute, Buffalo, October 2, 1993 (1993)

  • Genetic effects of radioiodine: Preliminary results of a survey on women treated for differentiated thyroid cancer (1993)

  • International IMRT credentialing by physical phantom irradiation: The EORTC ROG experience (2011)

  • The value of early decrease in CA125 levels as a prognostic or surrogate marker for disease progression in patients with recurrent ovarian cancer: Results from the CALYPSO study (2010)

  • Can elderly patients with recurrent ovarian cancer (ROC) be treated with a platinum-based doublet? Results from the CALYPSO trial (2010)

  • Development of a nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer based on the CALYPSO trial (2010)

  • Health-related quality of life (HRQL) and progression-free survival (PFS) in patients with recurrent ovarian cancer: Results from the CALYPSO trial (2010)

  • A randomized trial in ovarian cancer (OC) of early treatment of relapse based on CA125 level alone versus delayed treatment based on conventional clinical indicators (MRC OV05/EORTC 55955 trials) (2009)

  • A randomized, phase III study of carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in relapsed platinum-sensitive ovarian cancer (OC): CALYPSO study of the Gynecologic Cancer Intergroup (GCIG) (2009)

  • Randomized MRC OV05/EORTC trial in recurrent ovarian cancer: Early treatment based on increased serum CA125 alone versus delayed treatment based on conventional clinical indicators (2009)

  • Quality of surgery in advanced ovarian cancer: Validation of the EORTC-GCG quality indicators (2010)

  • The value of early decrease in CA125 levels as a prognostic or surrogate marker for disease progression in patients with recurrent ovarian cancer: Results from the CALYPSO study (2010)

  • Development of a nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer based on the CALYPSO trial (2010)

  • Can elderly patients with recurrent ovarian cancer (ROC) be treated with a platinum-based doublet? Results from the CALYPSO trial (2010)

  • Health-related quality of life (HRQL) and progression-free survival (PFS) in patients with recurrent ovarian cancer: Results from the CALYPSO trial (2010)

  • Adjuvant platin-based chemotherapy improves survival in medium risk stage I ovarian carcinoma. Long-term follow-up results of the EORTC-ACTION trial. Plenary presentation at the 12th Biennial meeting International Gynecologic Cancer Society IGCS, Bangkok, Thailand, October 25-28, 2008 (abs) (2008)

  • Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987 (2012)

  • What is the clinical benefit of preoperative chemoradiotherapy with 5FU/leucovorin for T3-4 rectal cancer in a pooled analysis of EORTC 22921 and FFCD 9203 trials: Surrogacy in question? (2011)

  • European guidelines for the diagnosis and management of upper urinary tract urothelial cell carcinomas: 2011 update (2011)

  • Low-Dose Decitabine Versus Best Supportive Care in Elderly Patients With Intermediate- or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group (2011)

  • The malicious host: A minimax solution of the monty hall problem (2012)

  • TP53 status for prediction of sensitivity to taxane versus non- taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG1-00): a randomized phase 3 trial (2011)

  • Randomized Trial of Carboplatin Versus Radiotherapy for Stage I Seminoma: Mature Results on Relapse and Contralateral Testis Cancer Rates in MRC TE19/EORTC 30982 Study (ISRCTN27163214) (2011)

  • A randomized phase III study comparing standard dose BEP with sequential high-dose Cisplatin, Etoposide, Ifosfamide (VIP) plus stem cell support in males with poor prognosis germ cell cancer. An intergroup study of EORTC, GTCSG and Grupo Germinal (EORTC 30974) (2011)

  • Trends in translation requests and arising issues regarding cultural adaptation. Expert Rev Pharmacoeconomics Outcomes Res 11 (3): 307-314, 2011 (2011)

  • Response to chemotherapy is prognostic in relation to longer overall survival in an individual patient combined-analysis with pleural mesothelioma (2012)

  • International Phase III Trial Assessing Neoadjuvant Cisplatin, Methotrexate, and Vinblastine Chemotherapy for Muscle-Invasive Bladder Cancer: Long-Term Results of the BA06 30894 Trial (2011)

  • International investigator-driven clinical trials: challenges and opportunities for US-Europe cooperation through the US cooperative group networks. Clin Invest 1 (4): 493 - 500, 2011 (2011)

  • A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (2011)

  • Quality Assurance for Prospective EORTC Radiation Oncology Trials: The Challenges of Advanced Technology in a Multicentre International Setting (2011)

  • Frailty modelling for survival data from multi-centre clinical trials. Statist Med 30: 2144-2159, 2011 (2011)

  • Testing new regimens in patients with advanced soft tissue sarcoma: Analysis of publications from the last 10 years (2011)

  • Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: A multivariate analysis of 704 patients. Annals of (1997)

  • Autologous stem cell transplantation in myelodysplastic syndromes. Semin Hematol 44: 274-277, 2007 (2007)

  • Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: A multivariate analysis of 704 patients (1997)

  • Treatment of neutropenic infection: trends towards monotherapy? Support Care (1997)

  • Clinical trials and ethical issues in cancer research. Advances in Hadrontherapy: 1997 (1997)

  • Evaluation of new bone resorption markers in a randomized comparison of pamidronate or clodronate for hypercalcemia of malignancy (1997)

  • EORTC classification for primary cutaneous lymphomas: a proposal from the cutaneous lymphoma study group of the European Organisation for Research and Treatment of Cancer (1997)

  • Chemotherapy for gastric cancer. Libri Oncol 22 (3): 161-170, 1993 (1993)

  • Combined modality adjuvant treatment of high-risk rectal cancer: A treatment of choice or a choice of treatment? Annals Oncol 3: 197-199, 1992 (1992)

  • Superficial bladder disease: case studies and therapeutic advances. Supplement to Urology 40 (6): 1992 (1992)

  • The relation between radiotherapist, surgeon, pathologist and physicist in the treatment of early breast cancer (1991)

  • Rationale for a quality assurance programme in clinical trials of conservative management of breast carcinoma (1991)

  • Three-dimensional dose distribution of tangential breast treatment: a national dosimetry intercomparison (1991)

  • Biopsy Diagnosis of Intraductal Carcinoma is Prognostic in Intermediate and High Risk Prostate Cancer Patients Treated by Radiation and Androgen Deprivation (2012)

  • Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial (2011)

  • Carboplatin paclitaxel induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer (2011)

  • Disease control rate at 9 and 18 weeks as primary endpoints for phase II clinical trials in patients with malignant pleural mesothelioma: an individual patient data combined analysis of 10 European Organisation for Research and Treatment of Cancer (EORTC) Lung Cancer Group studies. Oral Presentation at the 14th World Conference on Lung Cancer, Amsterdam, The Netherlands, July 3-7, 2011 (abs. 1871) (2011)

  • Where should we be investing our money in the fight against colorectal cancer: screening, adjuvant therapy or specialised units ? (1993)

  • Phase III trials in oesophageal cancer. Communication at the 1st International Symposium on Conservative Treatment in Oncology, Lyon, France, June 17-19, 1993 (1993)

  • Controverses sur le traitement des cancers de l'oesophage T3-T4. Communication at the Journées de la FFCD, Nantes, France, June 4, 1993 (1993)

  • New aspects in surgery of the oesophagus. Communication at the EORTC Symposium on Research, Diagnosis and Treatment of Gastrointestinal Cancer, Porto, Portugal, April 21-23, 1993 (1993)

  • Place des traitements adjuvants dans les cancers de l'oesophage. Cours Intensif de Cancérologie Digestive, Marseille, France, January 21-23, 1993 (1993)

  • Faut-il surveiller les cancers colo-rectaux opérés ? Cours Intensif de Cancérologie Digestive, Marseille, France, January 21-23, 1993 (1993)

  • Panel discussion, EORTC Symposium on Research, Diagnosis and Treatment of Gastrointestinal Cancer, Porto, Portugal, April 21-23, 1993 (1993)

  • Chemotherapy of metastatic gastric cancer: a review. Revista Oncologia 3: 65-66, 1993 (1993)

  • Quality of life in patients with prostatic cancer. A feasibility study. The Members of Quality of Life Committee of the EORTC Genitourinary Group. Cancer. 71: 1138-1142, 1993 (1993)

  • Carboplatin-based chemotherapy in good prognosis metastatic non seminoma of the testis (NSGCT): an interim report of an MRC/EORTC randomized trial (1993)

  • Biologic response modifiers in penal cancer : Genitourinary cancer update. Communication at the Roswell Park Cancer Institute, Buffalo, September 30, 1993 (1993)

  • European trials in invasive bladder cancer : Genitourinary cancer update. Communication at the Roswell Park Cancer Institute, Buffalo, October 1, 1993 (1993)

  • Proceedings International Consensus Conference on Intensive Chemotherapy plus Hematopoietic Stem-Cell Transplantation in Malignancies: Lyon, France, June 4-6, 1993 (1993)

  • The need for improved methods of assessing antitumor acitivity of new anticancer agents in advanced ovarIan cancer. Proc. Clinical Trials in Oncology: Improving their design and analysis, Toronto, Ontario, October 28-30, 1993 (1993)

  • Chemotherapy in advanced transitional cell carcinoma of the urothelial tract, present status and future perspectives. Communication at the 4th International Symposium on Advances in Urologic Oncology, San Remo, March 20, 1993 (1993)

  • Optimal hormonal treatment in stage D prostate cancer. Communication at the 48th Annual Meeting of the Canadian Urological Association, Montreal, Canada, June 20-24, 1993 (1993)

  • Experiences of the EORTC in bladder cancer. Communication at the 48th Annual Meeting of the Canadian Urological Association, Montreal, Canada, June 20-24, 1993 (1993)

  • Superficial bladder cancer. Proc. 107th Annual Meeting of the American Association of Genitourinary Surgeons, Phoenix, Arizona, April 16-18, 1993 (abs.) (1993)

  • An EORTC GU Group phase II study of neoadjuvant chemotherapy in T3-4N0-XM0 bladder cancer: multivariate analysis of prognostic factors. Proc. AACR, 1993 (abs. 1354) (1993)

  • A plea for cold biopsy, fulguration and immediate bladder instillation with epirubicin in small superficial bladder tumors. Proc. 88th Annual Meeting of the American Urological Association, San Antonio, Texas, USA, May 16-20, 1993 (abs. 470) (1993)

  • Comparison of high dose Estracyt and Mitomycin C in the treatment of hormone relapsed prostate cancer. The final results of EORTC study 30865 (1993)

  • Current views on intravesical treatment and chemoprophylaxis of superficial bladder cancer. The present role of epirubicin and doxorubicin. J. Chemother. 5: 207-211, 1993 (1993)

  • Maximal androgen blockade - EORTC 30853 trial. Proc. 3rd International Symposium on GnRH Analogues in Cancer and Human Reproduction, Geneva, February 25-28, 1993. Gynecological Endocrinology 7: 103, 1993 (1993)

  • A further analysis of European Organization for Research and Treatment of Cancer-protocol 30805 : Orchidectomy versus orchidectomy plus Cyproterone Acetate versus low-dose Diethylstilbestrol (1993)

  • Liarozole-hydrochlorided (R 75251), a novel treatment in hormone-resistant prostatic cancer : response on PSA (1993)

  • Prognostic factors for randomization, stratification and endpoints for the evaluation of bladder trials (1993)

  • Response criteria and end points employed in phase III studies of superficial bladder cancer (1993)

  • Study design, specific aims, quality assurance, minimum data to be collected, evaluation decision points, statistical statements, hypothesis to be tested (1993)

  • Hormonal therapy for advanced carcinoma of the prostate. The European experience (1993)

  • Study performance, administration, quality assurance, and publication rules in clinical trials for bladder cancer (1993)

  • Statistical analysis/sample size determination for clinical trials of treatments of bladder cancer (1993)

  • Minimal guidelines for the organization of data collection and quality control in multicenter clinical trials (1993)

  • Deoxyribonucleic acid ploidy of core biopsies and metastatic lymph nodes of prostate cancer patients : Impact on time to progression. J. Urol. 150: 400-406, 1993 (1993)

  • Comparability of prostate trials (1993)

  • Prognostic factors in metastatic non-seminomatous germ cell tumours: An interim analysis of the EORTC GU Group experience (1993)

  • Orchiectomy versus Goserelin and Flutamide in the treatment of newly diagnosed metastatic prostate cancer: Analysis of the criteria of evaluation used in the European Organization for Research and Treatment of Cancer-Genitourinary Group Study 30853 (1993)

  • Prognostic importance of various markers of response and progression in patients treated by Zoladex and Flutamide or Orchidectomy for newly diagnosed metastatic prostate cancer. Further evaluation of the criteria of response used in EORTC GU Group study 30853 (1993)

  • Phase I study on EO9 given every 3 weeks (1993)

  • Docetaxel (taxotere) in advanced breast cancer: a phase II trial of the EORTC Early Clinical Trials Group. EORTC Early Drug Development Meeting, Rotterdam, The Netherlands, September 24, 1993 (1993)

  • Taxotere is active in advanced gastric carcinoma: results of a phase II clinical trial. 7th European Conference on Clinical Oncology, Jerusalem, Israel, November 16, 1993 (1993)

  • Oxaliplatin. Pharmacokinetics and chronopharmacological aspects. Clinical Pharmacokinetics 36 (1): 1-21, 2000 (2000)

  • Circadian variation of cell proliferation and cell cycle protein expression in man: Clinical implications (1999)

  • Therapeutic implications of circadian rhythms in cancer patients (2000)

  • A new prognostic of response and toxicities in metastatic colorectal cancer treated by chronomodulated infusion of high-dose 5-fluorouracil and folinic acid (1999)

  • Chronomodulated CPT-11. A pilot study (1999)

  • Chronotherapy against metastatic colorectal cancer (MCC). Chronobiol. Int. 16 (1): 67, 1999 (abs.) (1999)

  • Invasive vs non-invasive rhythm assessment in cancer patients. Chronobiol. Int. 16 (1): 77, 1999 (abs.) (1999)

  • Circadian rhythms alterations in patients with metastatic colorectal cancer and good performance status (1999)

  • Most important achievements of the group. Communication at the EORTC Scientific Strategy Meeting, Brussels, Belgium, March 25-26, 1999 (1999)

  • Projects/strategies for the next 5 years. Communication at the EORTC Scientific Strategy Meeting, Brussels, Belgium, March 25-26, 1999 (1999)

  • Gemcitabines and taxanes. Communication at the Symposium of the EORTC Chronotherapy Study Group. Cancer of the exocrine pancreas. Communication at the Hôpital Paul Brousse, Villejuif, France, September 30, 1999 (1999)

  • Avantages cliniques de la chronomodulation en cancérologie. Communication aux Journées d Oncologie, Université Libre de Bruxelles - Institut Jules Bordet: Nouveaux agents anticancéreux cytotoxiques et biologiques (présent et perspectives) et apport de la pharmacocinétique/dynamique à l administration des médicaments anticancéreux, Brussel, Belgium, February 19, 2000 (2000)

  • Pilot experience of chronotherapy. Communication at the Symposium of the EORTC Chronotherapy Study Group. Cancer of the exocrine Pancreas, Hôpital Paul Brousse, Villejuif, France, September 30, 1999 (1999)

  • Chronotherapy vs flat infusion: Status of ongoing EORTC trial. Communication at the Symposium of the EORTC Chronotherapy Study Group. Cancer of the exocrine Pancreas, Hôpital Paul Brousse, Villejuif, France, September 30, 1999 (1999)

  • Chronotherapy with 5-fluorouracil, leucovorin and oxaliplatin against metastatic colorectal cancer. Communication at the Sixth International Conference on Gastrointestinal Cancer: Pancreas, biliary tract and hepatic metastasis, Williamsburg, VA, U.S.A., October 20-22, 1999 (1999)

  • Chronopharmacologic approach to the chemotherapy delivery. Communication at the Symposium of the EORTC Chronotherapy Study Group. Cancer of the exocrine Pancreas. Hôpital Paul Brousse, Villejuif, France, September 30, 1999 (1999)

  • Intérêt de l approche chronobiologique dans le traitement des tumeurs de l Homme. Communication at the Conférence Post-Universitaire CHU Sart-Tilman, Liège, Belgium, March 17, 2000 (2000)

  • Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: Results of a phase III randomized trial of the European organization for research and treatment of cancer, radiotherapy and gastrointestinal cooperative groups (1999)

  • Radiation dose homogeneity in an EORTC multicentre trial on breast irradiation (1999)

  • Adjuvant hormonal therapy with radiotherapy for locally advanced prostate cancer (1999)

  • The value of pretreatment cell kinetic parameters as predictors for radiotherapy outcome in head and neck cancer: A multicenter analysis (1999)

  • Position paper. EORTC Scientific Strategy Meeting, 25-26 March 1999 (1999)

  • Preoperative radiochemotherapy and total mesorectal excision (TME) surgery of rectal cancer: Towards the eradication of pelvic failures? Aust. N. Z. J. Surg. 69: 622-624, 1999 (1999)

  • Long term results of immediate adjuvant hormonal therapy with goserelin in patients with locally advanced prostate cancer treated with radiotherapy. A phase III EORTC study. Proc. 41st Annual Meeting of the American Society For Therapeutic Radiology & Oncology, San Antonio, U.S.A., October 31 to November 4, 1999 (abs. 5) (1999)

  • A 30-year trek through the arcanes of clinical research. FECS Pezcoller award lecture (1999)

  • Boost versus no boost trial for breast conserving therapy: Status and cosmetic outcome. Proc. Annual meeting of the Austrian Society for Radiation Oncology, 0GRO 16 meeting, Salzburg, Austria, December 9-10, 1999 (1999)

  • L association radiothérapie hormonothérapie dans les cancers de la prostate localement avancés. Communication at the Dixième Congrès National de la Société Française de Radiothérapie Oncologique, Paris, France, November 25-26, 1999 (1999)

  • Combination of hormonotherapy and radiotherapy in localized and locally advanced prostate cancer. The EORTC experience. Communication at the Western Genito-urinary Radiation Oncology Forum, Vancouver, Canada, May 1-2, 1999 (1999)

  • Fractionation schemes, trial results and practices: A critical look. Communication at the Annual Meeting of the Belgian Association for Radiotherapy and Oncology, Brussels, Belgium, March 19, 1999 (1999)

  • Combined preoperative radiochemotherapy versus preoperative radiotherapy, with or without postoperative chemotherapy in patients with locally advanced resectable non-metastatic rectal cancers: EORTC 22921 phase III trial, progress report. Communication at the EORTC-FFCD Meeting, Paris, France, June 23-26, 1999 (1999)

  • Radiochemotherapy in locally advanced anal carcinoma. First results of the EORTC 22953 phase II trial. Communication at the EORTC-FFCD Meeting, Paris, France, June 23-26, 1999 (1999)

  • The EORTC 22921 trial. Communication at the Third International Conference on Colorectal Cancer, Congrès AERO, Cannes, France, June 1999 (1999)

  • Shortened irradiation scheme, continuous 5FU and fractionation of mitomycin C in locally advanced anal carcinoma - Early results of an EORTC phase II study. Communication at the Combined Chemotherapy and Radiotherapy in GI Tumours, London, United Kingdom, October 8, 1999 (1999)

  • Analysis of definitions used in clinical research on invasive fungal infections (IFI): Consensus proposal fot new standardized definitions. Proc. 39th Intersc. Conf. Antimicrob. Agents Chemother. 1999 (abs. J-1639) (1999)

  • EORTC - Fungal studies. Communication at the 21st Annual Meeting NIAID Mycoses Study Group, Bethesda, Maryland, U.S.A., April 1999 (1999)

  • EORTC guidelines development - Research challenges. Communication at the 24th Federal Conference Society of Hospital Pharmacists of Australia, Perth, Australia, November 1999 (1999)

  • New guidelines to evaluate the response to treatment in solid tumors (2000)

  • Vinorelbine: Mechanism of action and activity in gastrointestinal (GI) tumors. Communication at the International Congress on Anti-Cancer Treatment - New Drug in Malignacies: A Look to the Next Century, Paris, France, January 31 to February 3, 2000 (abs. 24) (2000)

  • La recherche clinique en cancérologie en Europe: Un réel défi pour le XXe siècle. Med. Hyg. 57: 1353-1358, 1999 (1999)

  • Quality of life assessment. Communication at the EORTC Scientific Strategy Meeting, Brussels, Belgium, March 25-26, 1999 (1999)

  • Quality of life assessment in cancer clinical trials - A European perspective. Journal of Pain and Symptom Management 18 (5): S16, 1999 (abs. 53) (1999)

  • Maintenance chemotherapy in small-cell lung cancer: Long-term results of a randomized trial (1993)

  • High dose-intensity chemotherapy, with accelerated cyclophosphamide-doxorubicin-etoposide and granulocyte-macrophage colony stimulating factor, in the treatment of small cell lung cancer (1993)

  • EORTC-GIMEMA AML 8 protocol. A phase II study on autologous bone marrow transplantation in acute myelogenous leukemia (AML). Communication at the International Consensus Conference on Intensive Chemotherapy plus Hematopoietic Stem Cell Transplantation in Malignancies. Lyon, France, June 4-6, 1993 (1993)

  • Therapeutic approach of acute myeloid leukaemia on the basis of cytological classification. Communication at the 12th Meeting of the International Society of Hematology, Vienna, Austria, August 28-Sptember 3, 1993 (1993)

  • On the influence of human recombinant alpha 2 Interferon (Roferon-A) on remission duration in patients with stages III and IV low grade malignant Non-Hodgkin's lymphoma; results from a prospective randomised phase II clinical trial in 346 patients. Proc. Fifth International Conference on Malignant Lymphoma, Lugano, Switzerland, 1993 (abs. 66) (1993)

  • Entry of elderly patients in EORTC new drug development studies. Proc. 29th Annual Meeting of the American Society of Clinical Oncology, Orlando, Florida, U.S.A., May 16-18, 1993 (abs. 329) (1993)

  • Treatment of patients (pts) with acute promyelocytic leukemia, the EORTC experience. Acute Promyelocytic Leukemia. A curable disease, Rome, Italy, November 11-12, 1993 (1993)

  • Evaluation methodology in the EORTC trials including bone marrow transplantation (BMT) in acute myelogenous leukemia (AML) patients in first remission. Communication at the EBMT Meeting, Garmisch-Partenkirchen, Germany, January 17-21, 1993 (abs 911) (1993)

  • Modulation of multidrug resistance in refractory myeloma by ciclosporin and its non-immunosuppressive analogue PSC 833. Proc 22nd International Society for Experimental Hematology Meeting, Rotterdam, The Netherlands, August 22-26, 1993 (abs. 392) (1993)

  • Autologous BMT versus chemotherapy for ALL. Communication at the Seminar on New Trends in the Treatment of Acute Leukemia, Zagreb, Croatia, June 7-10, 1993 (abs L-12) (1993)

  • Phase II study of vinorelbine (Navelbine) in previously treated small cell lung cancer patients (1993)

  • Conference Report of European Organization for Research and Treatment of Cancer (EORTC)-Melanoma Cooperative Group (MCG) meeting. Lyon, France, 6-7 November 1992. Melanoma. Res. 3: 79-80, 1993 (1993)

  • Pharmacodynamic-pharmacokinetic relationships and therapeutic drug monitoring (1993)

  • Pharmacokinetics of alkylating agents (1993)

  • Pharmacokinetic principles of locoregional chemotherapy (1993)

  • Pharmacokinetics and early clinical studies of selected new drugs (1993)

  • Scientific report EORTC (Genito-Urinary Group) GU 1993. European Urology Today 3: 2, 1993 (1993)

  • A pilot study of interleukin-3 plus low-dose cytosine arabinoside in myelodysplastic syndromes with high risk of developing acute leukemia. Communication at the Meeting of the American Association for Cancer Research, Orlando, Florida, USA, May 19-22, 1993 (abs. 1293) (1993)

  • New approaches in preclinical and clinical pharmacokinetics (1993)

  • New techniques in the pharmacokinetic analysis of cancer drugs. I. Mass spectrometry: recent technical developments and applications in cancer chemotherapy (1993)

  • Pharmacokinetics of high molecular weight agents (1993)

  • Platinum complexes in cancer medicine: pharmacokinetics and pharmacodynamics in relation to toxicity and therapeutic activity (1993)

  • Biochemical consequences of 5-fluorouracil gastrointestinal toxicity in rats; effect of high dose uridine. Cancer Chemother. Pharmacol. 32: 243-248, 1993 (1993)

  • Influence of uridine treatment in mice on the protection of gastrointestinal toxicity caused by 5-fluorouracil (1993)

  • Commission of the European Communities - "Europe against Cancer" Programme - European School of Oncology Advisory Report. Cancer treatment in the elderly (1993)

  • Cancer in the elderly: Meeting the challenge of an aging population (1993)

  • Clinical and biological relationships with pathology in Hodgkin's disease: the EORTC Lymphoma Cooperative Group and Groupe Pierre-et Marie Curie experience. Proc. Fifth International Conference on Malignant Lymphoma, Lugano, Switzerland, 1993 (abs. P 68) (1993)

  • A randomized trial on prophylactic isolation perfusion for stage 1 high risk (i.e. > 1.5 mm thickness) malignant melanoma of the limbs. An interim report (1993)

  • Effects of systemic interferon-alpha (IFN-alpha) on the antigenic phenotype of melanoma metastases. EORTC melanoma group cooperative study No. 18852. Melanoma. Res. 3: 173-180, 1993 (1993)

  • Effect of Toremifene in patients with metastatic melanoma: a phase II study of the EORTC Melanoma Cooperative Group. Melanoma. Res. 3: 123-126, 1993 (1993)

  • Validity of the histopathological criteria used for diagnosing dysplastic naevi. An interobserver study by the pathology subgroup of the EORTC Malignant Melanoma Cooperative Group (1993)

  • Long-term adjuvant immunotherapy in stage I high risk malignant melanoma, comaring two BCG preparations versus non-treatment in a randomized multicentre study (EORTC protocol 18781) (1993)

  • EORTC study Non-Hodgkin-Lymphoma. Phase III study comparing CHVmP/VCR-BLEO vs PROMACE-MOPP in patients with stage II, III and IV intermediate and high grade (1993)

  • EORTC study Non-Hodgkin Lymphoma. Phase III study comparing CHVmP/VCR-Bleo vs ProMACE-MOPP in patients with stage II, III and IV intermediate and high grade lymphomas. Proc. Fifth International Conference on Malignant Lymphoma, Lugano, Switzerland, 1993 (abs. P 115) (1993)

  • Response to MOPP/ABV chemotherapy in advanced stages Hodgkin's Disease: The EORTC Lymphoma Cooperative Group and Groupe Pierre-et-Marie Curie experience. Proc. Fifth International Conference on Malignant Lymphoma, Lugano, Switzerland, 1993 (abs. P-76) (1993)

  • Preliminary results of an EORTC-GPMC controlled trial in early stage Hodgkin's Disease. Proc. Fifth International Conference on Malignant Lymphoma, Lugano, Switzerland, 1993 (abs. 56) (1993)

  • On the influence of alpha-2 Interferon (Roferon-A) on remission duration in patients with stages III and IV low grade malignant Non-Hodgkin's Lymphoma. Proc. Hongarian Haematology meeting, May 28,1993 (abs.) (1993)

  • On the influence of alpha-2 Interferon (Roferon-A) on remission duration in patients with stages III and IV low grade malignant Non-Hodgkin's Lymphoma. Proc. ECCO 7, Jerusalem, Israel, 1993 (abs. 962) (1993)

  • Heart and lung function in patients with pulmonary metastases of osteosarcoma treatment with metastatectomy and 20 Gy postoperative irradiation. 7th European Conference on Clinical Oncology and Cancer Nursing, Jerusalem, Israel, November 1993 (1993)

  • Fourth International Consensus Meeting on Bladder Cancer, Antwerp, Belgium, March 24-26, 1993 (1993)

  • Epirubicin in patients with advanced or recurrent adenoid cystic carcinoma of the head and neck: A phase II study of the EORTC Head and Neck Cancer Cooperative Group (1993)

  • Intervention debulking surgery does improve survival in advanced epithelial ovarian cancer: An EORTC Gynecological Cancer Cooperative Group study (1993)

  • Studying spreading pattern in Hodgkin’s disease: Is it relevant to modern cancer treatment? Radioth. Oncol. 47 : 3-5, 1998 (1998)

  • Phase II trial of Fludarabine monophosphate in patients with Mantle cell lymphomas (1998)

  • Quality of life assessment in Hodgkin’s disease: A new comprehensive approach. First Experiences from the EORTC/GELA and GHSG Trials (1998)

  • Maintenance of remission with human recombinant interferon alfa-2a in patients with stages III and IV low-grade malignant non-Hodgkin's lymphoma (1998)

  • Time to relapse has prognostic value in aggressive lymphoma enrolled in the Parma trial at first relapse (1998)

  • International Prognostic Factors Project on advanced Hodgkin’s disease. New Engl J Med 339 (21): 1506-1514, 1998 (1998)

  • Long-term outcome of relapsed non-Hodgkin's lymphoma (NHL) patients included in the Parma trial: Incidence of late relapses, long-term toxicity and impact of the international prognostic index (IPI) at relapse (1998)

  • CHOP is the standard regimen in patients of 70 years of age or more with intermediate and high grade Non-Hodgkin’s lymphoma: Result of a randomized study of the EORTC Lymphoma Cooperative Group (1998)

  • Facteurs pronostiques et traitements des formes localisées de la maladie de Hodgkin (1998)

  • EBV infection is predictive for a higher probability of treatment failure after irradiation in early stages Hodgkin’s disease (HD). IVth International Symposium on Hodgkin’s Lymphoma, Köln, Germany, March 28-April 1, 1998 (abstr.) (1998)

  • L’EBVP en association à une irradiation localisée dans les maladies de Hodgkin stades I-II- Résultats de l’essai H7 «groupe Favorable». Congrès de la Société Française d’Hématologie (SFH), Paris, 2-3 Février 1998; Hématologie (hors série) 4 : 54, 1998 (abstr. 89) (1998)

  • EBVP chemotherapy in combination with irradiation provides Event-Free Survival superior to subtotal nodal irradiation in favorable clinical stage I-II Hodgkin's Disease but inferior to MOPP-ABV in combination with irradiation in unfavorable cases: The EORTC-GPMC H7 randomized trials. IVth International Symposium on Hodgkin’s Lymphoma, Köln, Germany, March 28-April 1, 1998. Leukaemia Lymphoma 29(S1): 0-6, 1998 (1998)

  • Quality of life in Hodgkin’s disease: Longitudinal results from the EORTC/GELA multicentre trial (protocol 20931). Leukaemia Lymphoma, 29 (Suppl. 1):P-140, 1998 (1998)

  • Results from the EORTC and GHSG trials. Leukaemia Lymphoma, 29 (Suppl. 1): I-7, 1998 (1998)

  • Fludarabine versus conventional CVP chemotherapy in newly diagnozed patients with stages III and IV low grade non-Hodgkin’s lymphoma. Preliminary results from a prospective, randomized phase III clinical trial in 381 patients. On behalf of the EORTC Lymphoma Cooperative Group and the British National Lymphoma Investigation (BNLI) (1998)

  • The first intergroup study on early stage Hodgkin’s disease (H8) between the EORTC Lymphoma Cooperative Group and the Groupe d’Etude des Lymphomes de l’Adulte (GELA). Leukaemia Lymphoma, 29 (Suppl. 1):P-56 (Poster) 1998 (1998)

  • Radiotherapy in early stage Hodgkin’s disease : Principles and results of recent clinical trials. Leukaemia Lymphoma, 29 (Suppl. 1):I-4 1998 (1998)

  • Very favourable Hodgkin’s disease: Does it really exist ? Leukaemia Lymphoma, 29 (Suppl. 1): P-49 1998 (1998)

  • A meta-analysis of randomised trials evaluating the role of interferon as treatment for follicular lymphoma (1998)

  • A meta-analysis (MA) of interferon (IFN) studies in follicular lymphoma (FL) - Annals of (1998)

  • Intermediate and high grade non Hodgkin's Lymphomas in the elderly. Prospective registration study in a regional lymphoma network. Annals of (1998)

  • Mantle cell lymphoma cases in the EORTC Lymphoma Cooperative Group trials. Three more years of follow-up. Annals of (1998)

  • Fourth International Symposium Hodgkin's Lymphoma. Cologne, Germany, March 28-April 1, 1998 (1998)

  • Chemotherapy of Non Hodgkin Lymphoma. St Petersburg Lymphoma Group (SPLG) third meeting, 29 April- 1 May 1998 (1998)

  • Chemotherapy of Hodgkin Lymphoma. St Petersburg Lymphoma Group (SPLG) third meeting, 29 April- 1 May 1998 (1998)

  • Workshop & protocol discussion on Non Hodgkin and Hodgkin Lymphoma, St Petersburg Lymphoma Group (SPLG) third meeting, 29 April- 1 May 1998 (1998)

  • EBVP chemotherapy in combination with irradiation provides Event-Free Survival (EFS) superior to subtotal nodal irradiation (STNI), in favorable clinical stage (CS) I-II Hodgkin's Disease but inferior to MOPP-ABV in combination with irradiation in unfavorable cases: the EORTC-GPMC H7 randomized trials. IVth International Symposium on Hodgkin’s Lymphoma. Köln, March 28-April 1, 1998 (1998)

  • Late effects of the treatment of Hodgkin’s disease with emphasis on second malignancies. Workshop on Hodgkin’s Disease, Swiss Society for Medical and Mediatric Oncology (SSOM), Zürich, March 26, 1998 (1998)

  • A meta-analysis of randomised trials evaluating the role of interferon as treatment for follicular lymphoma. ASCO 34th Annual Meeting, May 16-19, 1998, Los Angeles, U.S.A (1998)

  • Sorting the hype from the facts in melanoma (1998)

  • Influence of sun exposures during childhood and during adulthood on melanoma risk. EPIMEL and EORTC Melanoma Cooperative Group. European Organization for Research and Treatment of Cancer (1998)

  • The case for sunscreens revisited. Arch. Dermatol. 134: 509-11,1998 (1998)

  • Circulating Melan-A/Mart-1 specific cytolytic T lymphocyte precursors in HLA-A2+ melanoma patients have a memory phenotype (1998)

  • Strategy of the EORTC-MCG trial programme for adjuvant treatment of moderate-risk and high-risk melanoma (1998)

  • New prognostic factors in melanoma: mRNA tumour markers (1998)

  • Results of interleukin-2-based treatment in advanced melanoma: A case record-based analysis of 631 patients (1998)

  • Reliability of reverse transcription-polymerase chain reaction- based assays for the detection of circulating tumour cells: A quality- assurance initiative of the EORTC Melanoma Cooperative Group (1998)

  • Isolated limb perfusion in primary and recurrent melanoma: Indications and results. Semin. Surg. Oncol. 14 : 202-9, 1998 (1998)

  • Complete response of melanoma-in-transit metastasis after isolated limb perfusion with tumor necrosis factor alpha and melphalan without massive tumor necrosis: A clinical and histopathological study of the delayed-type reaction pattern (1998)

  • Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial (1998)

  • Neuroendocrine carcinoma mimicking adeno- and basal cell carcinoma. Ophthalmic Research 30 (S1):114, 1998 (abs. 1243) (1998)

  • Isolation of native collagenase-3 (matrix metalloproteinase-13) from ascites of ovarian carcinoma patients and determination of MMP-13-levels utilizing a newly developed ELISA. Communication at the DFG Symposium, Bielefeld, Germany, March 7-9, 2001 (2001)

  • Phenotyping of disseminated tumor cells in bone marrow aspirates of breast cancer patients. Communication at the 3rd International Symposium on Minimal Residual Cancer. Hamburg, Germany, February 16-18, 2001 (2001)

  • Occult metastatic cells in bone marrow as criterion for adjuvant treatment decisions: Evaluation of node-negative breast cancer patients without adjuvant systemic therapy. Communication at the 3rd International Symposium on Minimal Residual Cancer. Hamburg, Germany, February 16-18, 2001 (2001)

  • Multivariated analyses of flow cytometric s-phase and ploidy as node-negative breast cancer prognostic factors – An international and multi-center study. Communication at the 24th Breast Cancer Symposium, San Antonio, U.S.A., December 10-13, 2001 (2001)

  • Sparing adjuvant chemotherapy in node-negative breast cancer patients with low risk of relapse identified by tumor-biological factors: Interim analysis of a randomized trial. The Breast 10 (Supp. 1): P90, 2001 (abs.) (2001)

  • HER-2/neu Expression und Amplifikation beim fortgeschrittenen Ovarialkarzinom FIGO III. Gynäkol Geburtshilfliche Rundschau 41: 88, 2001 (abs. 4.002) (2001)

  • Small molecule approach to inhibit the urokinase-type plasminogen activator system. Proc. 92nd Annual Meeting of the American Association for Cancer Research, New Orleans, U.S.A., March 24-28, 2001 (abs. 370) (2001)

  • Development of active site urokinase-type plasminogen actvator (uPA) inhibitors for the treatment of solid malignant tumors. Communication at the IPS-meeting, Freiburg, Germany, November 2001 (2001)

  • New aspects of designing anti-protease-compounds. Communication at the Congress on “Molecular staging of cancer”, Munich, Germany, December 6-9, 2001 (2001)

  • Generalization of competing-risk neural networks in breast cancer (2001)

  • Occult metastatic cells in bone marrow as a criterion for treatment decisions: Evaluation of node-negative breast cancer patients without adjuvant therapy. The Breast 10 (Supp. 1): P29, 2001 (abs.) (2001)

  • Cytokeratin-positive tumorzellen im knochenmark vs. HER2 status und tumorangiogenese als prognosefaktoren des primären mammakarzinoms. Gynäkol Geburtshilfliche Rundschau 41: 117, 2001 (abs. 7.033) (2001)

  • Using occult metastatic cells in bone marrow (OMC-BM) and HER2 status for prognostic evaluation of patients with stage I-III breast cancer (BC). Proc. American Society for Clinical Oncology, San Francisco, California, U.S.A., May 12-15, 2001 (2001)

  • Inhibition of collagenolytic activity of soluble uPA receptor (suPAR)-overexpressing breast carcinoma cells is TIMP-1-independent. Proc. 92nd Annual Meeting of the American Association for Cancer Research, New Orleans, U.S.A., March 24-28, 2001 (abs. 274) (2001)

  • Differential expression of tyrosine kinase c-Met, its ligand HGF/SF, and HER2 in primary breast carcinomas and corresponding lymph node metastases has clinical implications. Proc. 92nd Annual Meeting of the American Association for Cancer Research, New Orleans, U.S.A., March 24-28, 2001 (abs. 38) (2001)

  • High tumour levels of vascular endothelial growth factor (VEGF) predict poor response to systemic therapy in advanced breast cancer. Proc. 92nd Annual Meeting of the American Association for Cancer Research, New Orleans, New Jersey, U.S.A., March 24-28, 2001 (abs. 638) (2001)

  • Tumor-biological factors uPA and PAI-1 enable clinically relevant risk-group assessment for adjuvant therapy decisions in node-negative breast cancer. The Breast 10 (1): P22, 2001 (abs.) (2001)

  • Klinische Relevanz der tumorassoziierten Proteolysefaktoren uPA und PAI-1 beim primären Mammakarzinom – bestätigt durch zwei Level-1 Evidenz Studien. Gynäkol Geburtshilfliche Rundschau 41: 117, 2001 (abs. 7.034) (2001)

  • Transcription Factor YB-1 Predicts Drug Resistance and Patient Prognosis in Breast Cancer Independent of Clinically Relevant Tumor-Biological Factors HER2, uPA, and PAI-1. Proc. 92nd Meeting of the American Association for Cancer Research, New Orleans, New Jersey, U.S.A., March 24-28, 2001 (abs. 639) (2001)

  • Usefulness of Quality of Life (QOL) Information in a trial of a matrix metaolloproteinase inhibitor (MMPI) Marimastat. Quality of Life Research 10 (3): 270, 2001 (abs. 310) (2001)

  • No adverse impact on serum lipids of the irreversible aromatase inactivator AromasinR (Exemestane (E)) in 1st line treatment of metastatic breast cancer (MBC): Companion study to a European Organisation of Research and Treatment of Cancer (Breast Group) Trial with Pharmacias Upjohn. Proc. Thirty-seventh Annual Meeting of the American Society of Clinical Oncology, San Francisco, U.S.A., 2001 (abs. 43a) (2001)

  • Efficacy of and tolerance to Exemestane (E) versus Tamoxifen (T) in 1st line hormone therapy (HT) of postmenopausal metastatic breast cancer (MBC) patients (pts): A European Organisation for the Research and Treatment of Cancer (EORTC Breast Group) phase II trial with Pharmacia and Upjohn. Proc. Thirty-seventh annual meeting of the American Society of Clinical Oncology, San Francisco, U.S.A., 2001 (abs. 29a) (2001)

  • An EORTC-IDBBC phase I study of Cyclophoshamide (C) and Epirubicin (E) in combination with Capecitabine (X) (CEX) as primary treatment of locally advanced/inflammatory (LA/I) of large operable (LO) breast cancer (BC). Proc. Thirty-Seventh Annual Meeting of the American Society of Clinical Oncology, San Francisco, U.S.A. 2001 (abs. 13b) (2001)

  • uPA and PAI-1 ready for routine testing in primary breast cancer: Pooled analysis (n=8,377) provides level-1 evidence for clinical relevance (2001)

  • Editorial - Response evaluation criteria in solid tumors (RECIST): New guidelines. Medical and Pediatric (2001)

  • Quality management for BNCT at the high flux reactor HFR Petten (2001)

  • EORTC clinical trials for boron neutron capture therapy BNCT (2001)

  • Status report of the European clinical trial of BNCT at Petten (EORTC Protocol 11961) (2001)

  • Report on the first patient group of the European phase I trial (EORTC protocol 11961) at the High Flux Reactor Petten (2001)

  • Quality control of Na2B12SH, a drug for boron neutron capture therapy in EORTC trial 11961 (2001)

  • Boron Neutron Capture Therapy: Principles and recent developments. Hungarian Oncology (Magyar Onkológia) 45: 298, 2001 (abs.) (2001)

  • The approach of the EORTC to investigate BNCT. Communication at the NCI/DOE Meeting on BNCT, National Cancer Institute, Rockville, MD, U.S.A., June 29-30, 2000 (2000)

  • EORTC clinical trials for BNCT. An International Physical and Clinical Workshop “Boron Neutron Capture Therapy: State t of the art”. Communication at the Istituto per la Ricerca e la Cura del Cancro, Candiola, Torino, Italy, February 17, 2001 (2001)

  • Coordination and quality management for BNCT - The experience from EORTC trials at HFR Petten. Communication at the Comision Nacional de Energia Atomica. Buenos Aires, Argentina, March 27, 2001 (2001)

  • Development of a European Organization for Research and Treatment of Cancer questionnaire module to assess the quality of life of ovarian cancer patients in clinical trials: A progress report (2001)

  • The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: First results from a three-country field study Classic Papers and current Comments, (2001)

  • Guidelines for developing Quality of Life Questionnaires (Second Edition). EORTC Quality of Life Group, Brussels, 2001, 34 pp (2001)

  • EORTC QLQ-C30 Scoring Manual (Third edition). Brussels, EORTC Quality of Life Group, 2001, 86 pp (2001)

  • EORTC Quality of Life Group Brussels, 2001, 20 pp (2001)

  • Research and quality control in surgical oncology (2001)

  • The importance of quality assurance in surgical oncology in the treatment of colorectal cancer (2001)

  • Boron neutron capture therapy: An interdisciplinary cooperation (2001)

  • Quantification of antigen-reactive T cells in peripheral blood by IFN g-ELISPOT assay and chromium release assay: A four center comparative study. J. Immunol. Methods 244: 81-89, 2000 (2000)

  • High tPA-expression in primary melanoma of the limb correlates with good prognosis (2000)

  • Dacarbazine, cisplatin and IFNa with or without IL-2 in advanced melanoma (EORTC 18951). Ann. of (2000)

  • Quality of life evaluation in oncological clinical trials - The EORTC model. The EORTC quality of life study group (2000)

  • Monte Carlo simulation of fast neutron spectra: Mean lineal energy estimation with an effectiveness function and correlation to RBE (2001)

  • Controversies in establishment of dose limiting qualitative and quantitative toxicity for radiation modality. Radiat. Oncol. 57 (Suppl. 1): S7-S9, 2000 (2000)

  • Clinical trial end points in malignant glioma: Need for effective trial design strategy. Semin. Oncol. 27: 11-19, 2000 (2000)

  • Parenchymal pineal tumors: A clinicopathological study of 76 cases (2000)

  • Chemotherapy of malignant inoperable gliomas. The association of fotemustine-cisplatine-etoposide as neoadjuvants. Rev. Neurol. 156: 53-58, 2000 (2000)

  • Irradiations des gliomes de haut grade par neutrons rapides, thérapie par captures de neutrons et potentialisation par captures de neutrons. Neurochirurgie 46: 23-33, 2000 (2000)

  • Beam collimation and patient contentious material optimizations for 10 boron neutron capture enhancement of fast neutron (BNCEFN): Definition of the optimum irradiation technique (1999)

  • Preliminary clinical results from the EORTC 11961 trial at the Petten irradiation facility. Proc. 9th International Symposium on Neutron Capture Therapy for Cancer, Osaka, Japan, October 2-6, 2000 (abs.) (2000)

  • New EORTC clinical trials for boron neutron capture therapy. Proc. 9th International Symposium on Neutron Capture Therapy for Cancer, Osaka, Japan, October 2-6, 2000 (abs.) (2000)

  • In-vivo measurements with TLD detectors for boron neutron capture therapy of glioblastoma patients at the high flux research reactor Petten/NL. Proc. 9th International Symposium on Neutron Capture Therapy for Cancer, Osaka, Japan, October 2-6, 2000 (abs.) (2000)

  • Boron neutron capture therapy enhanced fast neutron therapy: In vitro studies for preparing a clinical trial at the Essen cyclotron. Proc. 9th International Symposium on Neutron Capture Therapy for Cancer, Osaka, Japan, October 2-6, 2000 (abs.) (2000)

  • Quality assurance for boron neutron capture therapy at nuclear facilities - A necessary burden or the unavoidable seal of approval. Proc. 9th International Symposium on Neutron Capture Therapy for Cancer, Osaka, Japan, October 2-6, 2000 (abs.) (2000)

  • Patient positioning and ist influence on dose distrtibution. Proc. 9th International Symposium on Neutron Capture Therapy for Cancer, Osaka, Japan, October 2-6, 2000 (abs.) (2000)

  • Validation of epithermal neutron beam at LVR-15. Proc. 9th International Symposium on Neutron Capture Therapy for Cancer, Osaka, Japan, October 2-6, 2000 (abs.) (2000)

  • The boron neutron capture therapy project in Czech Republic. Proc. 9th International Symposium on Neutron Capture Therapy for Cancer, Osaka, Japan, October 2-6, 2000 (abs.) (2000)

  • Boron neutron capture therapy (BNCT) at the high flux reactor in Petten (2000)

  • Boron neutron capture therapy: Translational research in medicine, nuclear technology and politics (2000)

  • Past, present and future developments of boron neutron capture therapy (BNCT) (2000)

  • Clinical testing of a new radiation quality produced by a binary system (2000)

  • Boron neutron capture reaction enhanced fast neutron therapy at the medical cyclotron Essen (2000)

  • Psychological consideration of clinical trial execution in non-medical environment in interdisciplinary, cross-cultural, trans-european set up (2000)

  • Indikationsstellung zur protonentherapie des aderhautmelanoms (1999)

  • Comparing the results of cost-effectiveness analyses conducted in germany (d) and the Netherlands (Nl) for antibiotic prophylaxis in small cell lung cancer patients (SCLC) (2000)

  • Cost-utility analysis of the adjuvant interferon alpha 2-B treatment in melanoma (2000)

  • Economic evaluation of reducing the intensity of chemotherapy in good prognosis testis cancer patients in the Netherlands (2000)

  • Chemotherapy as primary treatment in advanced colorectal cancer: Economic evaluation of three different 5-fu schedules (2000)

  • Comparing the results of cost-effectiveness analyses conducted in germany (D) and the Netherlands (NL) for antibiotic prophylaxis in small cell lung cancer patients (SCLC) (2000)

  • Cost-utility analysis of the adjuvant interferon alpha 2-B treatment in melanoma (2000)

  • Assessing the impact of uncertainty by using bootstrap techniques when cost and outcome data are censored: A case study of chemotherapy in ovarian cancer (2000)

  • Cost-effectiveness of addition of early hormonal therapy in locally advanced prostate cancer: Results decisively determined by cut-off time point chosen for the analysis (2000)

  • Economic evaluation of reducing the intensity of chemotherapy in good prognosis testis cancer patients in the Netherlands (2000)

  • Chemotherapy as primary treatment in advanced colorectal cancer: Economic evaluation of three different 5-fu schedules (2000)

  • Received dose and dose-intensity of chemotherapy and outcome in nonmetastatic extremity osteosarcoma (2000)

  • Localised extremity osteosarcoma: Mature survival data from two European osteosarcoma intergroup randomised clinical trials (2000)

  • Long-term survival in localised extremity osteosarcoma: Mature follow up from two randomised trials of the European osteosarcoma intergroup (2000)

  • Does the histologic subtype of high-grade central osteosarcoma influence the response to treatment with chemotherapy and does it affect overall survival? A study based on the material of two consecutive trials of the European osteosarcoma intergroup (EOI) consisting of 570 patients. Communication at the Connective Tissue Oncology Society, 6th Annual scientific Meeting, Amsterdam, The Netherlands, November 2-4, 2000 (2000)

  • Three cycles of MOPP/ABV hybrid and involved-field irradiation is more effective than subtotal nodal irradiation in favorable supradiaphragmatic clinical stages I-II Hodgkin s disease: Preliminary results of the EORTC-GELA H8-F randomized trial in 543 patients (2000)

  • MOPP/ABV hybrid and irradiation in unfavorable supradiaphragmatic clinical stages I-II Hodgkin s disease: Comparison of three treatment modalities. Preliminary results of the EORTC-GELA H8-U randomized trial in 995 patients (2000)

  • Quality control in the EORTC-AMAROS (=after mapping of the axilla: Radiotherapy or surgery) trial no. 10981 (2000)

  • Doxorubicin (A)/taxol (T) versus doxorubicin (C) as first chemotherapy in metastatic breast cancer (MBC): A phase III study (2000)

  • Doxorubicin (A)/taxol (T) versus doxorubicin /cyclophosphamide (C) as first line chemotherapy in metastatic breast cancer (MBC): A phase III study. Communication a the 36th Meeting of the American Society for Clinical Oncology, New Orleans, New Jersey, U.S.A., May 20-23, 2000 (2000)

  • An EORTC-BG-IDBCC trial with Pharmacia & Upjohn. Promising activity and safety of exemestane (E) as first-line hormonal therapy (HT) in metastatic breast cancer (MBC) patients (pts): Final results of an EORTC randomised phase II trial. Communication at the 23rd Annual San Antonio Breast Cancer Symposium, San Antonio, U.S.A., December 6-9, 2000 (2000)

  • Baseline anemia (BA) as a predictor of response to first line chemotherapy (CT) in metastatic breast cancer (MBC) patients (pts). Communication at the 2nd European Breast Cancer Conference, Brussels, Belgium, September 26-30, 2000 (2000)

  • Analysis of two EORTC trials in metastatic breast cancer (MBC) support the recommendation for external response review (ERR) in trials with response rate (RR) as primary endpoint. Communication at the 2nd European Breast Cancer Conference, Brussels, Belgium, September 26-30, 2000 (2000)

  • Doxorubicin (A)/taxol (T): A safe regimen in terms of cardiac toxicity in the context of an EORTC multicenter trial. Communication at the 2nd European Breast Cancer Conference, Brussels, Belgium, September 26-30, 2000 (2000)

  • A phase I study of continuous infusion 5-fluorouracil (5-infu) in combination with gemcitabine (GEM) in patients (pts) with anthracycline - (A) refractory or a- and taxane- (T) pretreated metastatic breast cancer (MBC). Communication at the 2nd European Breast Cancer Conference, Brussels, Belgium, September 26-30, 2000 (2000)

  • Pre-operative chemotherapy in primary operable breast cancer. Results of EORTC trial 10902. Communication at the 2nd European Breast Cancer Conference, Brussels, Belgium, September 26-30, 2000 (2000)

  • Peri-operative chemotherapy in early breast cancer. Results of EORTC trial 10854 after 9 of follow-up. Communication at the 2nd European Breast Cancer Conference, Brussels, Belgium, September 26-30, 2000 (2000)

  • Quality control in the EORTC-AMAROS (=after mapping of the axilla: Radiotherapy or surgery) trial no. 10981. Communication at the 2nd European Breast Cancer Conference, Brussels, Belgium, September 26-30, 2000 (2000)

  • Treatment of brain metastases of small-cell lung cancer: Comparing teniposide and teniposide with whole-brain radiotherapy - A phase III study of the European organization for the research and treatment of cancer lung cancer cooperative group (2000)

  • Activity and toxicity of GI147211 in breast, colorectal and non-small-cell lung cancer patients: An EORTC-ECSG phase II clinical study (2000)

  • Twenty years of experience with the steroid receptor external quality assessment program - The paradigm for tumour biomarker EQA studies (2000)

  • Clinical impact of dosimetry quality assurance programmes assessed by radiobiological modelling of data from the thermoluminescent dosimetry study of the European Organisation for Research and Treatment of Cancer (2000)

  • A survey on staging and treatment in uterine cervical carcinoma in the radiotherapy cooperative group of the European organization for research and treatment of cancer (2000)

  • Exemestane (aromasin) is active and well tolerated as first-line hormonal therapy (HT) of metastatic breast cancer (MBC) patients (pts): Results of a randomized phase II trial (2000)

  • Cost effectiveness of paclitaxel / cisplatin compared to cyclophosphamide / cisplatin in the treatment of advanced ovarian cancer in Belgium (2000)

  • Phase I/II study of vaccination with a MAGE-3 protein plus immunological adjuvant SB AS-2 in HLA class I selected patients with MAGE-3 positive tumors (2000)

  • Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: A meta-analysis of four randomized trials (2001)

  • An EORTC-BG-IDBCC trial with pharmacia. Tamoxifen vs. exemetane as first-line endocrine therapy in advanced breast cancer: An EORTC randomized phase II-III trial. Communication at the Aromatase 2000 and the Third Generation, Port Douglas, Australia, November 3-7, 2000 (2000)

  • EORTC IFICG phase II study on liposomal nystatin in patients with invasive aspergillus infections, refractory or intolerant to conventional/lipid amphotericin B. Communication at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Toronto, Canada, September,17-20, 2000 (abs. 112j) (2000)

  • Phase II study of raltitrexed (Tomudex) for patients with advanced soft tissue sarcomas refractory to doxorubicin-containing regimens. Anticancer Drugs 10 (10): 873-877, 1999 (1999)

  • How should treatment costs impact on physician's decisions? (1999)

  • Quality of life of patients with newly diagnosed poor prognosis M1 prostate cancer undergoing orchiectomy without or with mitomycin C. Results from the EORTC Phase-III trial 30893 (2000)

  • Studies on health-related quality of life in childhood cancer in the European setting: An overview (1999)

  • Treatment of disseminated non-seminomatous testicular cancer: The European experience. Semin. Surg. Oncol. 17 (4): 250-256, 1999 (1999)

  • In vivo potentiation of radiation response by topotecan in human rhabdomyosarcoma xenografted into nude mice. Clin (2000)

  • BCL2/BAX protein ratio predicts 5-fluorouracil sensitivity independently of p53 status (2000)

  • Population pharmacokinetics of topotecan: Intraindividual pharmacokinetics variability of topotecan. Cancer Chemoth. Pharmacol. 46: 375-381, 2000 (2000)

  • Dose and time dependencies of 5-fluorouracil pharmacokinetics: Relationships between patient characteristics and pharmacokinetic parameters. Clin. Pharmacol. Ther. 68: 270-279, 2000 (2000)

  • A limited sampling strategy for determining carboplatin AUC and monitoring drug dosage (2000)

  • Ifosfamide DNA damage measured by the COMET assay in clinical and in vitro studies. Cancer Chemother. Pharmacol. 46: 433-441, 2000 (2000)

  • Pulmonary availability of isotretinoin in rats after inhalation of a powder aerosol. Brit. J (2000)

  • Interrater and intrarater reliability of histologic criteria in early cutaneous T-cell lymphoma. Dermatol. Clin. 12: 323-326, 1994 (1994)

  • EORTC receptor and biomarker study group report: A sandwich enzyme-linked immunosorbent assay for vascular endothelial growth factor in blood and tumor tissue extracts (2000)

  • Cyclophosphamide or ifosfamide in patients with advanced and/or recurrent endometrial carcinoma: A randomized phase II study of EORTC gynaecological cancer cooperative group (1999)

  • A phase II study of high-dose epirubicin in ovarian cancer patients previously treated with cisplatin (2000)

  • New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer) (2000)

  • Cancer clinical trials in Europe: Issues and challenges, the academic point of view of the EORTC. Good Clinical Practice Journal (GCP Journal), 7 (3): 15-18, 2000 (2000)

  • Die qualitätssicherungsseinheit der EORTC, schulungsplan für study nurses/ lokale studien organisatoren. Communication at the Deutsche Krebsgesellschaft e.V., Frankfurt, Germany, March 13 and August 21, 2000 (2000)

  • Anforderungen an dokumentationsbögen, das studienprotokoll - therapieoptimierungsprüfung I-II. Communication at the Deutsche Krebsgesellschaft e.V., Frankfurt, Germany, December 2, 2000 (2000)

  • Immediate hormonal therapy improves locoregional control and survival in patients with locally advanced prostate cancer. Results of a randomized phase III clinical trial of the EORTC Radiotherapy and Genitourinary Tract Cancer Cooperative Groups. Oral Presentation at 15th ESTRO Annual Meeting, Vienna, September 23-26, 1996 (1996)

  • Controlled clinical trial in high risk metastatic carcinoma of the prostate comparing pelvic radiotherapy alone to pelvic radiotherapy plus LHRH analogue. Oral Presentation at the 38th Annual ASTRO Meeting. Los Angeles, October 27-30, 1996 (1996)

  • Including literature data in individual patient data meta-analyses for time-to-event endpoints (1997)

  • Liposomal amphothericin B (AMBISOME) and invasive aspergillosis (IA) - Randomised multicentre trial of 1mg/kg vs 4mg/kg. Oral presentation at the 9th International MASCC Symposium, St. Gallen, Switzerland, February 26 - March 1, 1997 (1997)

  • Strontium chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: A phase III study of the European Organisation for Research and Treatment of Cancer Genitourinary Group (2003)

  • Impact of locoregional treatment on the early-stage breast cancer patients: A retrospective analysis (2003)

  • Construction and validation of a prognostic model across several studies, with an application in superficial bladder cancer. Statistics in Medicine (2003)

  • A meta-analysis of randomized trials investigating transurethral resection plus one immediate instillation of chemotherapy. Presentation at Perspectives in Bladder Cancer, Padova, Italy, November 14-15, 2003 (2003)

  • Non mortal outcomes in oncology. Presentation at Second International Sepsis Forum Colloquium, Cambridge, United Kingdom, June 29 -July 1, 2003 (2003)

  • From the study concept to the publication of results. Presentation at One Day Introduction to EORTC Trials, Brussels, Belgium, October 3, 2003 (2003)

  • Interim analyses, early stopping rules and data monitoring committees. Presentation at EORTC course on Clinical Trial Statistics for Non Statisticians, Brussels, Belgium, June 12-13, 2003 (2003)

  • Statistical analysis of phase III trials, time to event endpoints. Presentation at EORTC course on Clinical Trial Statistics for Non Statisticians, Brussels, Belgium, June 12 - 13, 2003 (2003)

  • The side effects of bacillus calmette-guerin in the treatment of TaT1 bladder cancer do not predict its efficacy: Results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group phase III trial (2003)

  • BCG immunotherapy for superficial bladder cancer: An overview of the past, the present and the future. EAU Update Series 1 (2): 80-86, 2003 (2003)

  • Non muscle invasive bladder cancer: Recommendations from the EAU Working Party on Superficial Bladder Cancer. EAU Guidelines, Pocket Edition 2: 4-9, 2003 (2003)

  • The side effects of bacillus calmette-guerin in the treatment of TaT1 bladder cancer do not predict its efficacy: Results from an EORTC Genito-Urinary Group phase III trial (2003)

  • The side effects of bacillus calmette-guerin in the treatment of TaT1 bladder cancer do not predict its efficacy: Results from an EORTC Genito-Urinary Group phase III trial. European Urology Supplements 2 (1): 191, 2003 (abs. 753) (2003)

  • Maintenance bacillus calmette-guerin for TaT1 bladder cancer is not associated with increased toxicity: Results from an EORTC Genito-Urinary Group phase III trial (2003)

  • Maintenance bacillus calmette-guerin for TaT1 bladder cancer is not associated with increased toxicity: Results from an EORTC Genito-Urinary Group phase III trial. European Urology Supplements 2 (1): 190, 2003 (abs. 751) (2003)

  • The side effects of Bacillus Calmette-Guerin in the treatment of TaT1 bladder cancer do not predict its efficacy: Results from an EORTC Genito-Urinary Group phase III trial (2003)

  • The side effects of Bacillus Calmette-Guerin in the treatment of TaT1 bladder cancer do not predict its efficacy: Results from an EORTC Genito-Urinary Group phase III trial (2003)

  • Maintenance bacillus calmette-guerin for TaT1 bladder cancer is not associated with increased toxicity: Results from an EORTC Genito-Urinary Group phase III trial (2003)

  • Maintenance bacillus calmette-guerin for TaT1 bladder cancer is not associated with increased toxicity: Results from an EORTC Genito-Urinary Group phase III trial (2003)

  • Which patients treated with BCG do better: those with or those without side effects? Presentation at Perspectives in Bladder Cancer, Padova, Italy, November 14-15, 2003 (2003)

  • Allogenic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): An intention-to-treat analysis of the EORTC/GIMEMA AML-10 trial (2003)

  • Human tissue research: EORTC recommendations on its practical consequences (2003)

  • European Organization for Research and Treatment of Cancer (EORTC) open label phase II study on glufosfamide administered as a 60-minute infusion every 3 weeks in recurrent glioblastoma multiforme (2003)

  • A phase II multicentre study of SCH66336 in combination with gemcitabine as second line treatment in patients with advanced/metastatic urothelial tract tumor (2003)

  • Phase II study of OSI-211 (formerly NX-211, liposomal lurtotecan) in patients with metastatic or loco-regional recurrent squamous cell carcinoma of the head and neck (2003)

  • EORTC 62011: Phase II trial of brostallicin for soft tissue sarcoma (2003)

  • Chemoresction of superficial bladder tumors. Presentation at Perspectives in Bladder Cancer, Padova, Italy, November 14-15, 2003 (2003)

  • Developments in Cancer Care – New anticancer agents : an embattled future! Hospital Decisions International Spring, 149-151, 2003 (2003)

  • European Organisation for Research and Treatment of Cancer’s point of view (2003)

  • Reflection & Reaction: Throwing a wrench in the works? (2003)

  • Experts question impact of EU Directive on Research (2003)

  • Overview of bladder cancer trials in the European Organization for Research and Treatment of Cancer. Cancer 97: 2120-2126, 2003 (2003)

  • A prospective survey of surgical approaches in clinically localized renal cell carcinoma: A preliminary attempt at surgical quality control. Uro (2003)

  • Clinical significance of HOX11L2 expression linked to t(5;14)(q35;q32), of HOX11 expression, and of SIL-TAL fusion in childhood T-cell malignancies: Results of EORTC studies 58881 and 58951 (2004)

  • Beyond the development of Health-Related Quality of Life (HRQOL) Measures: A Checklist for evaluation HRQOL Outcomes in Cancer Clinical Trials- Does HRQOL evaluation in prostate cancer research inform clinical decision making (2003)

  • Radiotherapy in conjunction with intravenous infusion of 180mg disodium pamidronate in the management of osteolytic metastases from breast cancer: Clinical evaluation, biochemical markers, quality of life and monitoring of recalcification using assessments of gray level histogram in plain radiographs (2003)

  • External beam radiotherapy in prostate cancer patients: Long and short term health related quality of life issues. Expert Review of Pharmacoeconomics and Outcomes Research 3: 487-495, 2003 (2003)

  • From Laboratory to Hospital: Translation of Boronated Compounds to Clinical Applications for BNCT. Communication at the Centre for Cancer Therapeutics, Ottawa Regional Cencer Cantre, Ottawa, Canada, July 30, 2002 (2002)

  • Imaging of BSH by 10B MRI. Communication at the 10th International Congress on Neutron Capture Therapy, Essen, Germany, September 8-13, 2002 (2002)

  • Advantage and limitations of weighting factors and equivalent dose quantities and units in BNCT. Communication at the 10th International Congress on Neutron Capture Therapy, Essen, Germany, September 8-13, 2002 (2002)

  • Determination of in vivo boron distribution in patients during boron neutron capture therapy by means of gamma–ray telescope measurements. Communication at the 10th International Congress on Neutron Capture Therapy, Essen, Germany, September 8-13, 2002 (2002)

  • Imaging of atomic and molecular species in cancer cell cultures and tissue materials with TOF-SIMS and Laser SNMS. Communication at the 10th International Congress on Neutron Capture Therapy, Essen, Germany, September 8-13, 2002 (2002)

  • Boron localistation in cells by electron energy loss spectroscopy. Communication at the 10th International Congress on Neutron Capture Therapy, Essen, Germany, September 8-13, 2002 (2002)

  • Tissue uptake of BSH in patients with gliblastoma in the EORTC 11961 phase I BNCT trial. Communication at the 10th International Congress on Neutron Capture Therapy, Essen, Germany, September 8-13, 2002 (2002)

  • Neutron spectrometry measurements at the fast neutron therapy facility of the Universitätklinikum Essen, Germany. Communication at the 10th International Congress on Neutron Capture Therapy, Essen, Germany, September 8-13, 2002 (2002)

  • New analytical method to determine boron derivates using capillary electrophoresis. Communication at the 10th International Congress on Neutron Capture Therapy, Essen, Germany, September 8-13, 2002 (2002)

  • A dose-escalation study design considering late toxicities in radiotherapeutic trials. Communication at the 10th International Congress on Neutron Capture Therapy, Essen, Germany, September 8-13, 2002 (2002)

  • A system for the assessment of normal tissue injury in the EORTC 11961 phase I study. Communication at the 10th International Congress on Neutron Capture Therapy, Essen, Germany, September 8-13, 2002 (2002)

  • Current clinical results of the EORTC Study 11961. Communication at the 10th International Congress on Neutron Capture Therapy, Essen, Germany, September 8-13, 2002 (2002)

  • Role and results of neuroradiologic reference imaging in EORTC/BNCT studies. Communication at the 10th International Congress on Neutron Capture Therapy, Essen, Germany, September 8-13, 2002 (2002)

  • Verification of treatment planning using the new water phantom at the HFR Petten (2002)

  • Towards in vivo monitoring of neutron distributions for quality contol of BNCT. Communication at the 10th International Congress on Neutron Capture Therapy, Essen, Germany, September 8-13, 2002 (2002)

  • New patient positioning system for the treatment of patients suffering from brain metastases from malignant melanoma (2002)

  • Tools to improve commmunication flow between multiple centre programmes (2002)

  • New treatment positioning system for the treatment of patients suffering from brain metastases of malignant melanoma (2002)

  • The economics of using rHuEPO in cancer therapy (2002)

  • Economic assessment of the use of paclitaxel in advanced ovarian cancer (2002)

  • Economic Evaluation of New Poly-Chemotherapy regimens as alternatives to cisplatin plus paclitaxel in advanced non-small cell lung cancer. Value in Health 5 (6): 443, 2002 (abs.) (2002)

  • A Monte Carlo simulation of comparison of methods for estimating right-censored mean treatment costs. Medical Decision Making 22 (6): 558, 2002 (abs.) (2002)

  • Conduite des études pharmaco-économiques internationales multicentriques en oncologie. Oral presentation at the 3ème Rencontre Annuelle des Pharmaco-économistes / Institute for International Research, Paris, France, March 26-27, 2002 (2002)

  • Economic evaluation of new poly-chemotherapy regimens as alternatives to cisplatin plus paclitaxel in advanced non-small cell lung cancer. Oral presentation at the European International Society for Pharmaco-economics and Outcomes Research Meeting, Rotterdam, The Netherlands, November 3-5, 2002 (2002)

  • Estimating mean survival time as an outcome measure in medical economic evaluations. Oral presentation at the 2nd Development of Economic Evaluation Methods Meeting, York, United Kingdom, September 23-24, 2002 (2002)

  • Methods for estimating average treatment cost in the presence of right-censoring (2002)

  • Correction Methods for Censored Cost Data: Should we distrust them? (2002)

  • Meta-analysis of the performance of hpv triage versus repeat cytology in women with an atypical pap-smear (2002)

  • Phase II study of XR5000 (DACA) administered as a 120-h infusion in patients with recurrent glioblastoma multiforme (2002)

  • Phase II study on glufosfamide administered as a 60 minute infusion every 3 weeks in recurrent glioblastoma multiforme. Proc. 93rd Annual Meeting American Association for Cancer Research (AACR), San Francisco, California, U.S.A., April 6-10, 2002 (abs. 3710) (2002)

  • Assessment of the chromosomal lesions of oligodendroglial tumors included in EORTC study 26951 with fluorescence in situ hybridization using locus specific probes. Communication at the EORTC Translational Research Meeting, Brussels, Belgium, June 7-8, 2001 (2001)

  • EORTC Brain Tumor Group study 26971: First line chemotherapy with temozolomide in recurrent oligodendroglial tumors. A phase II study. Proc. 38th annual American Society of Clinical Oncology (ASCO) Meeting Orlando, Florida, May 18-21, 2002 (abs. 285). Proc. 5th congress of the European Association for NeuroOncology, Florence, Italy, September 2002 (abs. S99) (2002)

  • The development of a survey questionnaire assessing the attitude of young breast cancer patients towards the risk of sterility induced by adjuvant chemotherapy. A qualitative pilot study for EORTC protocol 10002. Quality of Life Research 11 (7): 677, 2002 (abs. 223) (2002)

  • Health related quality of life of metastatic breast cancer (MBC) patients undergoing doxorubicin (A)/taxol (T) versus doxorubicin/cyclophosphamide (c) as first line chemotherapy: A phase three RCT of treatment related influences. Quality of Life Research 11 (7): 659, 2002 (abs. 150) (2002)

  • The impact of the CT Directive on non industry sponsored research (2003)

  • Phase I and pharmacokinetic study of E7070, a novel chloroindolyl sulfonamide cell-cycle inhibitor, administered as a one-hour infusion every three weeks in patients with advanced cancer (2002)

  • Development and validation of limited sampling strategies for prediction of the systemic exposure to the novel anti-cancer agent E7070. Br. J. Clin. Pharmacol. 54: 463-471, 2002 (2002)

  • Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil – leucovorin as first line treatment of metastatic colorectal cancer. Update (2002)

  • Rhythms in human gastrointestinal mucosa and skin. Chronobiology International 19 (1): 129-140, 2002 (2002)

  • Tumor-based rhythms of anticancer efficacy in experimental models. Chronobiology International 19 (1): 21-42, 2002 (2002)

  • Rhythms in human bone marrow and blood cells. Chronobiology International 19 (1): 101-128, 2002 (2002)

  • Three cycles of MOPP/ABV hybrid (m/a) and involved-field irradiation is more effective than subtotal nodal irradiation (STNI) in favourable supradiaphragmatic clinical stages I/II Hodgkin’s lymphoma: preliminary results of the EORTC-GELA H8-F randomized trial (# 20931) in 543 patients. Proc. 5th International Symposium on Hodgkin’s lymphoma, Cologne, Germany, September 22-25, 2001 (2001)

  • EORTC strategy in the treatment of Hodgkin’s disease. Communication at the St Petersburg Lymphoma Group (SPLG) fifth meeting, St Petersburg, Russia, September 13-14, 2001 (2001)

  • Involved field irradiation (IFRT) versus no further treatment in patients with stage III/IV Hodgkin’s lymphoma in CR after MOPP/ABV: First results of the randomised EORTC trial # 20884 (2001)

  • Three cycles of MOPP/ABV hybrid (m/a) and involved-field irradiation is more effective than subtotal nodal irradiation (STNI) in favourable supradiaphragmatic clinical stages I/II Hodgkin s lymphoma: Preliminary results of the EORTC-GELA H8-F randomized trial (# 20931) in 543 patients (2001)

  • EORTC/GELA H8 Unfavorable trial (2001)

  • Early response as a surrogate for final outcome in advanced stages Hodgkin’s disease (2001)

  • Quality of life in EORTC-GELA Hodgkin’s disease trials (2001)

  • Treatment of elderly patients (2001)

  • Treatment of Hodgkin s disease: The EORTC studies. Communication at the Gemeinsame Jahrestagung des Deutsche und Osterreichische Gesellschaften für Hämatologie und Onkologie, Mannheim, Germany, September 30, 2001 (2001)

  • Overview on EORTC lymphoma trials. Communication at the Nordic Lymphoma Group, Copenhagen, Denmark, October 25, 2001 (2001)

  • Antifungal prophylaxis and the rate of bacteremia among neutropenic patients (2001)

  • Piperacillin/tazobactam (p/t) monotherapy in high-risk febrile neutropenic cancer patients (FNCP). Proc. 22nd International Congress of Chemotherapy, Amsterdam, The Netherlands, June 30-July 3, 2001 (abs. p22008) (2001)

  • Incidence of single agent gram-negative bacteremias (SAGNB) in neutropenic cancer patients (NCP) in EORTC-IATG trials of empirical therapy for febrile neutropenia. Proc. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, U.S.A., December 16-19, 2001 (abs. 773) (2001)

  • An EORTC-IATG double-blind trial of vancomycin (Van) vs placebo (Pla) for persistent fever in neutropenic cancer patients (NCP) given piperacillin/tazobactam (PT) monotherapy. Proc. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, U.S.A., December 16-19, 2001 (abs. 774) (2001)

  • STI571: A magic bullet? (2001)

  • Glivec for GIST (2001)

  • Consistent evidence of activity of ecteinascidin (ET-743) in pretreated, advanced soft tissue sarcoma (ASTS): Results from a pooled analysis of three pivotal phase II clinical trials (p2ct) and safety profile of a 24 h infusion schedule (2001)

  • Glivec for GIST (2001)

  • ET743, a new active drug in sarcoma (2001)

  • STI 571: The EORTC phase II study (2001)

  • Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus (2002)

  • Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer: Classic Papers and Current Comments from ( (2001)

  • A randomized trial of alternating versus sequential radio/chemotherapy in limited disease patients with small cell lung cancer (SCLC): A EORTC lung cancer cooperative group study: Classic Papers and Current Comments form ( (2001)

  • An EORTC Randomized Phase III of three chemotherapy regimens in advanced NCSLC. Communication at the IV International Congress on Lung Cancer, Barcelona, Spain, November 2001 (2001)

  • Optimizing flow cytometric DNA ploidy and S-phase fraction as independent prognostic markers for node-negative breast cancer specimens. Clinical Cytometry 46: 121-135, 2001 (2001)

  • Histological and thermodynamical features of cathepsin B-positive tumor cells of non-small cell lung tumors obtained by syntactic structure analysis. Electronic J. Pathol. Histol. 7.1: 011-06, 2001 (2001)

  • Molecular profiles of BRCA1-mutated and matched sporadic breast tumours: Relation with clinico- pathological features (2001)

  • Vascular endothelial growth factor in ovarian cyst fluid (2001)

  • Is immunohistochemical analysis an appropriate diagnostic technique for bone marrow micrometastases? (2001)

  • Thymidine kinase as a proliferative marker: Clinical relevance in 1692 primary breast cancer patients (2001)

  • S-phase fraction and DNA ploidy in 633 T1T2, N0N1 breast cancers: A standardized flow-cytometric study. Clin (2001)

  • In vitro activity of a trinuclear platinum complex in human ovarian cancer cell lines sensitive and resistant to cisplat (2001)

  • Tamoxifen resistance in breast cancer: Elucidating mechanisms. Drugs 61: 1721-1733, 2001 (2001)

  • Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for erbB-1- and/or erbB-2-positive, estrogen receptor positive primary breast cancer: Evidence from a phase III randomized trial (2001)

  • Prognostic importance of the soluble plasminogen activator receptor, suPAR, in plasma from rectal cancer patients (2001)

  • Frequency and genome load of Epstein-Barr virus in 509 breast cancers from different geographical areas (2001)

  • High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer (2001)

  • Thymidine kinase and thymidylate synthase in advanced breast cancer. Response to tamoxifen and chemotherapy (2001)

  • Urokinase plasminogen activator and its inhibitor, PAI-1, in association with progression-free survival in early stage endometrial cancer (2001)

  • Clinical relevance of the plasminogen activator inhibitor type 1 (PAI-1) - a multifaceted proteolytic factor. Onkologie 24: 238-244, 2001 (2001)

  • Prognostic impact of proteolytic factors (urokinase-type plasminogen activator, plasminogen activator inhibitor 1, and cathepsins B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapy. Clin (2001)

  • EORTC: A unique European network to screen new anti cancer agents for high-grade gliomas. Communication at the Third International from Gene to Cure Congress, Amsterdam, The Netherlands, April 26-28, 2001 (2001)

  • Toxicity of Irinotecan in patients with colorectal cancer (2001)

  • Surgery and liver surgery in Europe. The European Organization for Research and Treatment of Cancer Gastrointestinal Group Trials (2001)

  • Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer (2001)

  • Randomised phase II study of weekly 24h infusion of high dose 5-FU +/-fonilic acid (HD-FU+/-FA) versus HD-FU/FA/biweekly cisplatin in advanced gastric cancer. EORTC-trial 40953. Proc. ECCO 11 The European Cancer Conference, Lisbon, Portugal, October 21-25, 2001 (abs. 88) (2001)

  • Radiochemotherapy in locally advanced anal carcinoma (LAAC). Results of the 22953 EORTC phase III trial. Proc. ECCO 11 The European Cancer Conference, Lisbon, Portugal, October 21-25, 2001 (abs. 84) (2001)

  • Phase II study of XR5000, an inhibitor of topoisomerases I and II, in advanced colorectal cancer (2002)

  • V. DIERAS, M. BORNER, J.F. SMYTH, R. MORANT, M.J. DE VRIES, M. ROELVINK, P. FUMOLEAU. Phase II trial with ISIS 5132 in patients with small-cell (SCLC) and non-small cell (NSCLC) lung cancer. A European Organisation for Research and Treatment of Cancer (EORTC) Early Clinical Studies Group report (2001)

  • Phase I and Pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patienst with advanced solid tumors (2001)

  • Population pharmacokinetics and dynamics in phase II studies of the novel bioreductive alkylating cytotoxic indoloquinone EO9. Anticancer Drugs 12 (7): 583-590, 2001 (2001)

  • Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin. A randomised crossover trial in advanced colorectal cancer (2002)

  • Pharmacokinetics of MEN-10755, a novel anthracycline disaccharide analogue, in two phase I studies in adults with advanced solid tumours. Cancer Chemother. Pharmacol. 48: 361-9, 2001 (2001)

  • Activity of the dolastatin analogue, LU103793, in malignant melanoma (2001)

  • Limited 5-fluorouracil 85-FU pharmacokinetics (PK) in EORTC ECSG phase II clinical trials of S-1; disease-dependent relation with toxicity. Communication at the 92nd Meeting of the American Association for Cancer Research, New Orleans, New Jersey, U.S.A., March 24-28, 2001 (2001)

  • Phase II study of XR5000 administrered as a 120-hour intravenous infusion in advanced colorectal cancer. EORTC study 16991C. Proc. 92nd Meeting of the American Association for Cancer Research, New Orleans, New Jersey, U.S.A., March 24-28, 2001 (abs. 3335) (2001)

  • Phase II study of XR5000 administered as a 120-hour intravenous infusion in recurrent glioblastoma multiforme. EORTC study 16991G. Proc. 92nd Meeting of the American Association for Cancer Research, New Orleans, New Jersey, U.S.A., March 24-28, 2001 (abs. 3508) (2001)

  • Phase II study of XR5000 administered as a 120-hour intravenous infusion in advanced ovarian cancer. EORTC study 16991O. Proc. 92nd Meeting of the American Association for Cancer Research, New Orleans, New Jersey, U.S.A., March 24-28, 2001 (abs. 253) (2001)

  • An EORTC/ECSG phase I and pharmacokinetics (PK) study of MS209 in combination with docetaxel in patients with progressive solid tumors. EORTC study 16992. Proc. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, 2001 (abs. 437) (2001)

  • Limited pharmacokinetics (PK) in EORTC ECSG phase II clinical trials of S-1; disease-dependent relation with toxicity. Proc. Amer. Assoc (2001)

  • Phase II study on glufosfamide administered as a 60 minute infusion every 3 weeks in non small cell lung cancer. EORTC study 16994N. 2001 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (abs. 203) (2001)

  • First results of a phase III study comparing BCG and epirubicin in TIS of the bladder: An EORTC Genito-Urinary Group study (2001)

  • Does the surgeon have an impact in the outcome of patients with Ta T1 TCC of the bladder? Results of an EORTC quality control study on TURBT (2001)

  • First results of a phase III study comparing BCG and epirubicin in TIS of the bladder: An EORTC Genito-Urinary Group study. Communication at the XVIth Congress of the European Association of Urology, Geneva, Switzerland, April 7–10, 2001 (2001)

  • Does the surgeon have an impact in the outcome of patients with Ta T1 TCC of the bladder? Results of an EORTC quality control study on TURBT. Communication at the XVIth Congress of the European Association of Urology, Geneva, Switzerland, April 7–10, 2001 (2001)

  • How to do and interpret meta-analyses. Communication at the Institute of Tropical Medicine, Antwerp, Belgium, May 9, 2001 (2001)

  • A meta-analysis of bladder screening tests. Communication at the International Consultation on the Diagnosis of Non Invasive Urothelial Neoplasms, Ancona, Italy, May 11–12, 2001 (2001)

  • Proposed monitoring schedules based on risk. Communication at the International Consultation on the Diagnosis of Non Invasive Urothelial Neoplasms, Ancona, Italy, May 11–12, 2001 (2001)

  • Interim analyses, early stopping rules and data monitoring committees. Communication at the EORTC course Clinical Trial Statistics for Non Statisticians, Brussels, Belgium, June 14–15, 2001 (2001)

  • Sample size determination in phase III trials. Communication at the EORTC course Clinical Trial Statistics for Non Statisticians, Brussels, Belgium, June 14–15, 2001 (2001)

  • The concept of meta-analysis of clinical trials. Communication at the workshop Methods in Clinical Cancer Research, Flims, Switzerland, June 23–28, 2001 (2001)

  • Diagnostic tests. Presentation at meeting Multicenter Urothelial Neoplasia Detection Study, Lund, Sweden, August 31 – September 1, 2001 (2001)

  • Common pitfalls in assessing and reporting results. Communication at the EORTC course Cancer Clinical Trials: Methods and Practice, Brussels, Belgium, November 5–9, 2001 (2001)

  • Prognostic factors in superficial bladder cancer. Communication at Perspectives in Bladder Cancer, Monte Carlo, Monaco, November 16–17, 2001 (2001)

  • Tamoxifen vs exemestane as first-line endocrine therapy in advanced breast cancer: An EORTC randomized phase II-III trial. J. Steroid Biochem. Mol. Biol. 79:1-5, 2001 (2001)

  • Cyclophosphamide (C) - Epirubicine (E) – Capecitabine (X) combination. CEX: A safe and active regimen in the treatment of locally advanced/inflammatory (LA/I) or large operable (LO) breast cancer (BC). An EORTC-IDBBC study (2001)

  • Cyclophosphamide (C) - Epirubicine (E) – Capecitabine (X) combination. CEX: A safe and active regimen in the treatment of locally advanced/inflammatory (LA/I) or large operable (LO) breast cancer (BC). An EORTC-IDBBC study (2001)

  • Pharmacokinetic phase I study of caelyx in metastatic breast cancer patients. Communication at the 22nd Meeting of EORTC-PAMM Group, January 31-February 3, 2001 (2001)

  • Assessment of the economic value of epoetin use in anemic cancer patients. Expert Reviews of Pharmacoeconomics and Outcomes Research 1: 167-175, 2001 (2001)

  • The cost-effectiveness of colorectal cancer screening. Reviews of Pharmacoeconomics and Outcomes Research 1: 157-166, 2001 (2001)

  • Pharmaco-economic analyses of the use of EPO in chemotherapy-induced anemia of cancer patients (2001)

  • Economic evaluation: In cancer clinical trials (2001)

  • Interferon-a as adjuvant therapy for melanoma: An individual patient data meta-analysis of randomised trials (2007)

  • LDH is a prognostic factor in stage IV melanoma patients (pts) but is a predictive factor only for bcl2 antisense treatment efficacy: Re-analysis of GM301 and EORTC 18951 randomized trials (2007)

  • Long-term protective effect of mature DC-LAMP+ dendritic cell accumulation in sentinel lymph nodes containing micrometastatic melanoma. An EORTC Melanoma group study (2007)

  • Prognostic value of autoantibodies (auto-AB) in melanoma patients (pts) in the EORTC 18952 trial of adjuvant interferon (IFN) compared to observation (obs) (2007)

  • Serum S-100B protein is a strong independent prognostic marker for distant-metastasis free survival (DMFS) in stage III melanoma patients: An evaluation of the EORTC randomized trial 18952 comparing IFNa versus observation (2007)

  • Prognostic value of autoantibodies in melanoma stage III patients in the EORTC 18991 phase III randomized trial comparing adjuvant pegylated interferon [alpha]2b vs observation (2007)

  • Quality assurance in the EORTC low grade glioma trial 22033-26033: The dummy run (2007)

  • The impact of boost dose and margins on the local recurrence rate in breast conserving therapy: Results from the EORTC boost-no boost trial. Int. J Radiat Oncol Biol Phys 69 (Suppl. 3): S2, 2007 (abs. 4) (2007)

  • Is long-term survival in glioblastoma possible? Updated results of the EORTC/NCIC phase III randomized trial on radiotherapy (RT) and concomitant and adjuvant temozolomide (TMZ) versus RT alone (2007)

  • PACS 01 trial: Questions about patients' characteristics and reported results. J Clin Onco author reply 25 (15): 2143-2144, 2007 (2007)

  • 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomized controlled trial (2007)

  • Pathological analysis of hepatic injury after oxaliplatin-based neoadjuvant chemotherapy of colorectal cancer liver metastases: Results of the EORTC intergroup phase III study 40983 (2007)

  • Uptake of two 10B-compounds in liver metastases of colorectal adenocarcinoma for extracorporeal irradiation with BNCT (EORTC trial 11001). International Journal of (2008)

  • Prognostic value of health-related quality-of-life data in predicting survival in patients with anaplastic oligodendrogliomas, from a phase III EORTC Brain Cancer Group Study (2007)

  • Monosomy 7 and deletion 7q in children and adolescents with acute myeloid leukemia: an international retrospective study (2007)

  • Overt testicular disease (OTD) at diagnosis is not associated with a poor prognosis in childhood acute lymphoblastic leukemia: Results of the EORTC CLG study 58881. Pediatr Blood (2007)

  • Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia (2007)

  • Autologous stem cell transplantation after complete remission and first consolidation in acute myeloid leukemia patients aged 61-70 years: results of the prospective EORTC-GIMEMA AML-13 study (2007)

  • High Dose (HD-AraC) vs Standard Dose Cytosine Arabinoside (SD-AraC) during Induction in Acute Myelogenous Leukemia (AML): Impact on Stem Cell Mobilization after Consolidation and on Autologous Transplantation (Second Report of the EORTC-Leukemia Group (LG) GIMEMA AML-12 Trial. American Society of Hematology Meeting, Orlando, December, 2007 (2007)

  • Allogeneic SCT planned in CR-1 after intensive chemotherapy in patients with bad prognosis MDS results in better outcome in the intermediate/high-risk cytogenetic group: a study by the EORTC, EBMT, SAKK, HOVON and GIMEMA Leukemia Group. EBMT meeting, Hamburg, Germany, March 2006. Received the van Bekkum award for the best abstract (2006)

  • Assessment of Two Doses of Infliximab in Patients with Low / Intermediate Risk IPSS Myelodysplastic Syndrome (MDS): An EORTC Leukemia Group (LG) Randomized Phase II trial (06023) (2007)

  • Leukemia and Lymphoma: East and West Together. Dubrovnik, Croatia, September 15-19, 2007. Leukemia Research 31 (Suppl. 2): S15, 2007 (2007)

  • High-dose (HD-AraC) vs standard dose cytosine arabinoside (SD-Ara-C) during induction in acute myelogeneous leukemia (AML): impact on stem cell mobilization after consolidation and on autologous transplantation (AML-12 trial). Leukemia and Lymphoma: East and West Together. Dubrovnik, Croatia, September 15-19, 2007. Leukemia Research 31 (Suppl. 2): S34, 2007 (2007)

  • AML in older patients: the EORTC/GIMEMA experience. Leukemia and Lymphoma: East and West Together. Dubrovnik, Croatia, September 15-19, 2007. Leukemia Research 31 (Suppl. 2): S36, 2007 (2007)

  • Design and analysis of clinical trials in acute leukemia: review of a 25-year experience. Leukemia and Lymphoma: East and West Together. Dubrovnik, Croatia, September 15-19, 2007. Leukemia Research 31 (Suppl. 2): S39, 2007 (2007)

  • Stem cell transplantation (SCT) in MDS. Leukemia and Lymphoma: East and West Together. Dubrovnik, Croatia, September 15-19, 2007. Leukemia Research 31 (Suppl. 2): S43, 2007 (2007)

  • Christine McKillop: Interview with Dr Richard Sylvester: Transitional Cell Carcinoma of the Bladder (2007)

  • Baseline and treatment effect heterogeneity for survival times between centers using a random effects accelerated failure time model with flexible error distribution. Statist Med 26: 5457–5472, 2007 (2007)

  • Interim analyses and early stopping rules (2007)

  • Health-Related Quality of Life in Patients Treated for Anaplastic of a European Organisation for Research and Treatment of Cancer Randomizaed Clinical trial (2007)

  • Elucidating the role of chest wall irradiation in "intermediate-risk" breast cancer: the MRC/EORTC SUPREMO trial (2008)

  • Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC) - gastrointestinal cancer group (2008)

  • The Prognostic Significance of Patient-Reported Outcomes in Cancer Clinical Trials (2008)

  • Understanding the reliability and validity of the EORTC QLQ-C30 in Turkish cancer patients (2008)

  • Prostate-specific antigen (PSA) as a surrogate end point for survival in prostate cancer clinical trials (2008)

  • Nomograms for predicting survival of patients with newly diagnosed glioblastoma: Prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3 (2008)

  • Early versus delayed endocrine treatment of pN1-3M0 prostate cancer without local treatment of the primary tumor: results of European Organisation for Research and Treatment of Cancer protocol 30846 at 15 years of follow-up. A phase III study. Oral presentation at the 2008 ASCO Genitourinary Cancers Symposium 2008, February 14-16, 2008, San Francisco, California (abs. 5) (2008)

  • Early versus delayed endocrine treatment of pN1-3M0 prostate cancer without local treatment of the primary tumor: results of European Organisation for Research and Treatment of Cancer protocol 30846 at 15 years of follow-up. A phase III study. Oral presentation at the 2008 ASCO Genitourinary Cancers Symposium 2008, February 14-16, 2008, San Francisco, California (abs. 5) (2008)

  • Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-OG25, to assess health-related quality of life in patients with cancer of the esophagus, the esophago-gastric junction and the stomach (2007)

  • Six-month concomitant and adjuvant hormonal treatment with external beam irradiation is inferior to 3-years hormonal treatment for locally advanced prostate cancer: results of the EORTC randomized phase III trial 22961 (2008)

  • Six-month concomitant and adjuvant hormonal treatment with external beam irradiation is inferior to 3-years hormonal treatment for locally advanced prostate cancer: results of the EORTC randomized phase III trial 22961 (2008)

  • Palliative-care trials: how best to publish findings? (2008)

  • Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials (2006)

  • Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines (2006)

  • Risk of second cancer after treatment of aggressive non-Hodgkin's lymphoma; an EORTC cohort study (2006)

  • Impact of involved field radiotherapy in partial response after doxorubicin-based chemotherapy for advanced aggressive non-Hodgkin's lymphoma (2006)

  • Involved-field radiotherapy for patients in partial remission after chemotherapy for advanced Hodgkin's lymphoma (2007)

  • High-dose chemotherapy with autologous stem cell support in first-line treatment of aggressive non-Hodgkin lymphoma - results of a comprehensive meta-analysis (2007)

  • Gonadal function in males after chemotherapy for early-stage Hodgkin's lymphoma treated in four subsequent trials by the European Organisation for Research and Treatment of Cancer: EORTC Lymphoma Group and the Groupe d'Etude des Lymphomes de l'Adulte (2007)

  • Implications of prostate-specific antigen doubling time as indicator of failure after surgery or radiation therapy for prostate cancer (2007)

  • Long-Term protective effect of mature DC-LAMP+ Dendritic cell accumulation in sentinel lymph nodes containing micrometastatic melanoma (2007)

  • Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with american joint committee on cancer stage IV melanoma: Results of the EORTC 18951 biochemotherapy trial (2007)

  • Effect of age and radiation dose on local control after breast conserving treatment: EORTC trial 22881-10882. Radioth and Oncol 82 (3): 265-271, 2007 (2007)

  • Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy (EORTC trial 22911) (2007)

  • Patients With Curative Resection of cT3-4 Rectal Cancer After Preoperative Radiotherapy or Radiochemotherapy: Does Anybody Benefit From Adjuvant Fluorouracil-Based Chemotherapy? A Trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group (2007)

  • Guidelines for target volume definition in post-operative radiotherapy for prostate cancer, on behalf of the EORTC Radiation Oncology Group (2007)

  • Intravesical chemotherapy in non-muscle-invasive bladder cancer: What schedule and Duration of treatment ? (2007)

  • Prognostic factors in non-muscle-invasive-bladder tumors. I. Clinical prognostic factors: A review of the experience of the EORTC Genito-Urinary Group. II. Biologic prognostic markers (2007)

  • Multicenter randomized EORTC trial 30021 of Docetaxel + Oblimersen and Docetaxel in patients (pts) with hormone refractory prostate cancer (HRPC). Oral presentation at the ASCO Prostate Cancer Symposium, Orlando, Florida, 22-24 February 2007 (2007)

  • Abdominoperineal Resection and not Distance, Gender or Age Associated with Circumferential Resection Margin Involvement in a Pooled analysis of five large European randomised clinical trials on rectal cancer (n=5187) (2007)

  • Predictors of increased risk of breast fibrosis at 10 years with higher radiation dose in the early breast cancer (EORTC ``Boost versus no Boost'' trial 22881-10882) (2007)

  • VAN DEN BERGH, J. ODDENS, P.M.P. POORTMANS, E. GEZ, P. KIL, E. MUSAT, L. COLLETTE. Six months versus three years concomitant and adjuvant hormonal treatment with external beam irradiation for locally advanced prostate cancer: Results of the EORTC randomized Phase III trial 22961 (2007)

  • Abdominoperineal Resection and not Distance, Gender or Age Associated with Circumferential Resection Margin Involvement in a Pooled analysis of five large European randomised clinical trials on rectal cancer (n=5187). Oral presentation at the 14th European Cancer Conference, Barcelona, Spain, September 23-27, 2007 (2007)

  • Predictors of increased risk of breast fibrosis at 10 years with higher radiation dose in the early breast cancer ( EORTC ``Boost versus no Boost'' trial 22881-10882). Oral presentation at the 14th European Cancer Conference, Barcelona, Spain, September 23-27, 2007 (2007)

  • VAN DEN BERGH, J. ODDENS, P.M.P. POORTMANS, E. GEZ, P. KIL, E. MUSAT, L. COLLETTE. Six months versus three years concomitant and adjuvant hormonal treatment with external beam irradiation for locally advanced prostate cancer: Results of the EORTC randomized Phase III trial 22961. Oral presentation at the 14th European Cancer Conference, Barcelona, Spain, September 23-27, 2007 (2007)

  • Phase 2 study of irinotecan and cisplatin in epidermoid carcinoma of the penis (EORTC 30992). Oral presentation at the 14th European Cancer Conference, Barcelona, Spain, September 23-27, 2007 (2007)

  • Chemotherapy plus involved-field radiation in early-stage hodgkin's disease (2007)

  • Causes of death and excess mortality after Hodgkin lymphoma (HL) The EORTC-Gela exprerience (2007)

  • Dose and field size. The EORTC Experience (2007)

  • EORTC lymphoma group; groupe d'études des lymphomes adultes (GELA). Results of the EORTC-GELA H9 randomized trials: The H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage hodgkin's lymphoma (HL) : (2007)

  • Sperm quality before treatment in patients with early stage hodgkin's lymphoma (HL) in EORTC trials (2007)

  • In reply to Raltitrexed and Pemetrexed studies in Mesothelioma have not shown improved quality of life nor prolonged survival compared with effective Pleurodesis with thoracoscopic talc poudrage? (2006)

  • A prospective randomized EORTC intergroup phase 3 study comparing the complications of elective Nephron-Sparing surgery and radical Nephrectomy for low-stage renal cell carcinoma (2007)

  • Surgery does matter to the outcome of T3-T4 rectal cancer patients: Surgical quality assurance in EORTC trial 22921 (2006)

  • Pooled analysis of five large European randomised clinical trials (n=5158) on rectal cancer to identify surgery related parameters affecting outcome (2006)

  • Resultats preliminairs de l'essai EORTC 22911: prostatectomie radicale suivie ou non de radiotherapie dans les cancers de la prostate a haut-risque de recidive. Presentation orale au 28th congres de la Societe Française de Radiotherapie Oncologique (SFRO), Paris, France, November 28-30, 2007 (2007)

  • Gender as a predictor for optimal dynamic scheduling of oxaliplatin, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer. Results form EORTC randomized phase III trial 05963. Proc. American Society of Clinical Oncology, 41th Annual Meeting, Orlando, USA, May 13-17th, 2005 (abs. 3587) (2005)

  • Pulses of vincristine and dexamethasone in addition to intensive chemotherapy for children with intermediate-risk acute lymphoblastic leukaemia: a multicentre randomised trial (2007)

  • GEERTS, K.M. HEBEDA, P.M. KLUIN, K.H. LAM, C.J.L.M. MEIJER, and R. WILLEMZE. Reclassification of 300 primary cutaneous B-cell lumphoma according to the new WHO-EORTC classification for cutaneous lymphoma: Comparison with previous classification and identification of prognostic markers (2007)

  • Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: Validation of tissue miccroarray as a prerequisite for broad clinical applications - a study from the Lunenburg Lymphoma Biomarker Consortium (2007)

  • 10B-uptake in different tumors using the boron compounds BSH and BPA (EORTC 11001) (2006)

  • Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: Analysis of EORTC-ISG-AGITG study 62005 (2007)

  • Exatecan in pretreated adult patients with advanced soft tissue sarcoma: Results of phase II - Study of the EORTC Soft Tissue and Bone Sarcoma Group (2007)

  • EORTC 10981-22023 AMAROS trial: After mapping of the axilla: Radiotherapy or surgery? Current Status (2005)

  • Assessment of molecular determinants of development and treatment efficacy in radiation induced sarcoma (RIS). EORTC STBSG Translational Research Project 01/01 (2005)

  • Exatecan (DX-8951f), a new topoisomerase I - inhibitor, is inactive in heavily pretreated patients (pts.) with advanced soft tissue sarcoma (STS): A phase II - study of the EORTC Soft Tissue and Bone Sarcoma Group (2005)

  • Risk assessment of early progression among 213 pts with high-risk soft tissue sarcomas (HR-STS) treated with neoadjuvant chemotherapy ± regional hyperthermia: EORTC 62961/ESHO-RHT 95 intergroup phase III study (2005)

  • First interim report on the randomized EORTC 62961/ESHO-RHT 95 intergroup study (phase III) combined with regional hyperthermia (RHT) versus chemotherapy alone in the treatment of high-risk soft tissue sarcomas (HR-STS) in adults (2004)

  • First interim report on the randomized EORTC 62961/ESHO-RHT 95 intergroup study (phase III) combined with regional hyperthermia (RHT) versus chemotherapy alone in the treatment of high-risk soft tissue sarcomas (HR-STS) in adults (2004)

  • Outcome of patients with advanced gastro-intestinal stromal tumors (GIST) crossing over to a daily imatinib dose of 800mg (HD) after progression on 400mg (LD) - an international, intergroup study of the EORTC, ISG and AGITG (2004)

  • Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO (2005)

  • Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: A retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group (2005)

  • Phase II study of ET-743 in advanced soft tissue sarcomas: A European Organisation for the Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group trial (2005)

  • Gene expression profiling of primary cutaneous melanoma and clinical outcome (2006)

  • Development of a disease-specific quality of life questionnaire module for patients with gastrointestinal neuroendocrine tumours (2006)

  • Lymphocyte-rich classical Hodgkin lymphoma (LRCHL): Clinico-pathological characteristics and outcome of a rare entity. Ann Onc 17 (1): 141-145, 2006 (2006)

  • Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin's lymphoma (2006)

  • Quality of life and symptom end points in palliative bone metastases trials (2006)

  • Radiotherapy in breast-conserving treatment for ductal carcinoma in situ (DCIS): Ten-year results of European Organisation for Research and Treatment of Cancer (EORTC) randomized trial 10853 (2005)

  • Is there a regimen-specific gene signature predicting for pathological complete response after neoadjuvant chemotherapy in hormone-negative breast cancer patients? A microarray substudy of 101 patients included in EORTC 10994/BIG 00- 01 trial (2005)

  • Multi-center independent validation of a gene prognostic signature for patients with node-negative breast cancer (BC)- final results (2005)

  • A quantitative study of tumor response and progression-free survival as surrogate endpoints for overall survival in first-line treatment of metastatic breast cancer (2005)

  • Effects of taxanes alone or in combination with anthracyclines on tumor response, progression-free survival and overall survival in first-line chemotherapy of patients with metastatic breast cancer: An analysis of 4,256 patients randomized in 12 trials (2005)

  • Establishing baseline quality of life reference data for the EORTC QLQ-C30 in locally advanced breast cancer patients (2005)

  • Challenges in the design of the mindact ( (MICROARRAY IN NODE NEGATIVE DISEASE MAY AVOID CHEMOTHERAPY) trial (EORTC 10041 - BIG/TRANSBIG 3-04) (2005)

  • Radiotherapy in breast-conserving treatment for ductal carcinoma in situ (DCIS): Ten-year results of European organisation for research and treatment of cancer (EORTC) randomized trial 10853 (2005)

  • Is there a regimen-specific gene signature predicting for pathological complete response after neoadjuvant chemotherapy in hormone-negative breast cancer patients? A microarray substudy of 101 patients included in EORTC 10994/BIG 00-01 trial (2005)

  • Multi-center independent validation of a gene prognostic signature for patients with node-negative breast cancer (BC) -final results (2005)

  • EORTC 10981-22023 AMAROS trial: After mapping of the axilla: Radiotherapy or surgery? Current Status (2005)

  • A quantitative study of tumor response and progression-free survival as surrogate endpoints for overall survival in first-line treatment of metastatic breast cancer (2005)

  • Effects of taxanes alone or in combination with anthracyclines on tumor response, progression-free survival and overall survival in first-line chemotherapy of patients with metastatic breast cancer: An analysis of 4,256 patients randomized in 12 trials (2005)

  • Analysis of breast cancer survival by clinical response to neoadjuvant chemoendocrine therapy. Letters to the editor (2006)

  • Short-term treatment-related symptoms and quality of life: Results from an international randomized Phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: An EORTC Lung-Cancer Group and National Cancer Institute, Canada, Intergroup Study. Journal of Clinical (2006)

  • Neutron activation of patients following boron neutron capture therapy of brain tumors at the high flux reactor (HFR) Petten (EORTC tirals 11961 and 11011) (2005)

  • Phase I combining a P-glycoprotein inhibitor, MS209, in combination with docetaxel in patients with advanced malignancies (2005)

  • PSA as a surrogate marker (2006)

  • PSA: A surrogate endpoint in clinical trials? (2006)

  • Is PSA a surrogate marker? (2006)

  • Surrogate endpoints in prostate cancer clinical trials (2005)

  • Prostate specific antigen (PSA) as a surrogate endpoint in metastatic hormone naïve prostate cancer (2004)

  • Reporting recommendations for tumor marker prognostic studies (2005)

  • Resultaten van de fase II EORTC 22971 trial. Gamma 4: 6-10, 2006 (2006)

  • Survivin is an independent prognostic marker for risk stratification of breast cancer patients (2004)

  • Molecular analysis integrating different pathways associated with the androgen-independent progression in LuCaP 23.1 xenograft (2004)

  • Evidence of a new human CYP1A1 regulation pathway involving PPAR-a and 2 PPRE sites. Gastroenterology 127 (5): 1436-1445, 2004 (2004)

  • The use of cell line standards to reduce HER-2/neu assay variation in multiple european cancer centers and the potential of automated image analysis to provide for more accurate cut points for predicting clinical response to Trastuzumab. Am (2004)

  • In vitro, in vivo, and in silico analyses of the antitumor activity of 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazoles (2004)

  • The level of reporting of health-related quality of life in cancer research. Evidence from 123 randomised controlled trials enrolling 36220 cancer patients. Communication at the European Cancer Conference, Copenhagen, Denmark, September 2003 (2003)

  • Health related quality of life (HRQOL) in randomised controlled trials for non small-cell lung (NSCLC) cancer patients - what is the added clinical value. Communication at the European Cancer Conference, Copenhagen, Denmark, September 2003 (2003)

  • What is the added clinical value of health related quality of life (HRQOL) studies in randomized controlled trials (RCTs)? Results from more than 100 trials. Communication at the 10th Annual Conference of the International Society for Quality of Life Research, Prague, Czech Republic, November 2003 (2003)

  • The impact on clinical decision-making of randomized controlled trials including health-related quality of life in colorectal cancer. Communication at the 10th Annual Conference of the International Society for Quality of Life Research, Prague, Czech Republic, November 2003 (2003)

  • Research in the behavioural and social sciences to improve cancer control and care: A strategy for development. A report of an Expert Group (2004)

  • The development of a European Organisation for Research and Treatment of Cancer (EORTC) quality of life fatigue module. Quality of Life Research 11 (7): 677, 2002 (abs. 222) (2002)

  • A database review of quality of life studies in EORTC cancer clinical trials. Quality of Life Research 11 (7): 676, 2002 (abs. 218) (2002)

  • Assessing cancer related fatigue, a critical review of existing instruments. Quality of Life Research 11 (7): 676, 2002 (abs. 220) (2002)

  • The clinical impact of HRQOL studies from RCTS in advanced breast cancer patients undergoing systemic therapy. Quality of Life Research 11 (7): 650, 2002 (abs. 117) (2002)

  • EORTC Brain Tumor Group study 26972: Second line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV-chemotherapy. A Phase II study (2003)

  • EORTC Brain Tumor Group study 26971: First line chemotherapy with temozolomide in recurrent oligodendroglioma. A phase II study (2003)

  • Cost-effectiveness of HPV DNA detection in addition to or as alternative for cytological screening for cervical cancer (2003)

  • Cost-effectiveness of HPV DNA detection in addition to or as alternative for cytological screening for cervical cancer. Oral presentation at the Third European Conference on the Economics of Cancer, Brussels, Belgium, September 7-9, 2003 (2003)

  • Country and centre-specific resource use and cost analysis in a multinational clinical trial using multilevel modelling (2003)

  • Country and centre-specific resource use and cost analysis in a multinational clinical trial using multilevel modelling. Oral presentation at the Third European Conference on the Economics of Cancer, Brussels, Belgium, September 7-9, 2003 (2003)

  • Individual net benefit regression analysis of chemotherapy in advanced non-small cell lung cancer (NSCLC) (2003)

  • Individual net benefit regression analysis of chemotherapy in advanced non-small cell lung cancer (NSCLC). Oral presentation at the Third European Conference on the Economics of Cancer, Brussels, Belgium, September 7-9, 2003 (2003)

  • Management of melanoma patients: Benefit of intense follow-up schedule is not demonstrated (2003)

  • Number and size of nevi are influenced by different sun exposure components: Implications for the etiology of cutaneous melanoma (Belgium, Germany, France, Italy). Cancer Causes Control 14 (5): 453-459, 2003 (2003)

  • Analysis of the EORTC Melanoma Group 18952 randomized trial on 2 intermediate dose schedules of IFN-alpha2b compared with observation in 1388 patients with high risk melanoma stage IIb-III (2003)

  • Guidelines for the use of epoet (2003)

  • Assessing HRQOL: A neglected issue for high-grade glioma (2003)

  • Randomized clinical trial comparing quality of life after straight and pouch coloanal reconstruction. Brit. J. Surg. 90:594-595, 2003 (2003)

  • Quality of life of breast cancer patients: Results of the EORTC trials. Onkologie (2003)

  • Health related quality of life (HRQOL) in randomised controlled trials for non small-cell lung (NSCLC) cancer patients – what is the added clinical value (2003)

  • Fatigue and cancer: Quality of life and the multidisciplinary approach to cancer care (2003)

  • Quality of life in cancer care: Achievements through trials (2003)

  • Health related quality of life (HRQOL) in gynaecological cancer patients undergoing surgery, chemotherapy or radiotherapy (2003)

  • Fatigue in the anaemic cancer patient (2003)

  • What is the added clinical value of health related quality of life in randomized controlled trials? Results from more than 100 trials. Proc. 10th International Society for Quality of Life Research, Prague, Czech Republic, November, 2003 [Quality of Life Research 12 (7), p. 766 (abs. 1234)] (2003)

  • Health related quality of life of metastatic breast cancer (MBC) patients undergoing doxorubicin (A)/taxol (T) versus doxorubicin/cyclophosphamide (c) as first line chemotherapy: A phase three RCT of treatment related influences. Proc. American Society of Clinical Oncology (ASCO) Annual meeting, Chicago, U.S.A., May, 2003, Proceedings 22, p. 186 (abs. 189) (2003)

  • The European Organisation for Research and Treatment of Cancer strategy for new drug development in brain tumors (2003)

  • Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapy (2003)

  • Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis (2004)

  • Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials (2003)

  • The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: A companion study to EORTC Trial 10951, "Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients" (2004)

  • Prognostic value of facilitative glucose transporter Glut-1 in oral squamous cell carcinoma treated by surgical resection: Results of EORTC Translational Research Fund Studies (2004)

  • First-line treatment of ovarian cancer FIGO stages Iib-IV with paclitaxel/epirubicin/carboplatin versus paclitaxel/carboplatin (2003)

  • Early efficacy comparison of two doses of imatinib for the treatment of advanced gastro-intestinal stromal tumors (GIST): Interim results of a randomized phase III trial from the EORTC-STBSG, ISG and AGITG (2003)

  • Prognostic factors of toxicity and efficacy in patients with gastro-intestinal stromal tumors (GIST) treated with imatinib: A study of the EORTC-STBSG, ISG and AGITG (2003)

  • Chemotherapy at standard or increased dose intensity in patients with operable osteosarcoma of the extremity: A randomised controlled trial conducted by the European Osteo Sarcoma Intergroup (ISRCTN 86294690) (2003)

  • Quality of life in good prognosis patients with metastatic germ cell cancer: A prospective study of the European Organization for Research and Treatment of Cancer Genitourinary Group/Medical Research Council Testicular Cancer Study Group (30941/TE20) (2003)

  • Randomized trial of surgery versus radiotherapy in patients with stage IIIA (N2) non small cell lung cancer after a response to induction chemotherapy. EORTC 08941. Clinical Lung Cancer 2 (1): 69-72, 2000 (2000)

  • Cisplatin, adriamycin, and etoposide (CAV) for remission induction of small-cell bronchogenic carcinoma. Evaluation of efficacy and toxicity and pilot study of a “late intensification” with autologous bone-marrow rescue (1982)

  • Combination chemotherapy with cisplatin, etoposide and vindesine in non-small cell lung carcinoma: A clinical trial of the EORTC Lung Cancer Working Party. Cancer Treat Rep 67: 7-8, 1983 (1983)

  • Combination chemotherapy with cisplatin and etoposide in bronchogenic squamous cell carcinoma and adenocarcinoma. A study by the EORTC Lung Cancer Working Party. Cancer 50: 2751-2756, 1982 (1982)

  • Randomized trial of surgery versus radiotherapy in patients with stage IIIA non-small cell lung cancer after response to induction-chemotherapy. Intergroup study 08941. Proc. 8th World Conference on Lung Cancer, Dublin, Ireland, August 10-15, 1997 (1997)

  • The biological bases and prognostic factors for a classification of small cell lung cancer. Advances in the Biosciences 72: 51-61, 1988 (1988)

  • EORTC Lung Cancer Cooperative Group. Phase II trial with pepleomycin in squamous cell carcinoma of the lung (1981)

  • Badania kliniczne w raku pluca w EORTC. Pneum Pol 53 (6): 286-288, 1985 (1985)

  • Neo-adjuvante chemotherapie in de behandeling van het niet-kleincellig longcarcinoom. Tijdschrift voor Geneeskunde 53 (2): 83-93, 1997 (1997)

  • Prophylactic cranial irradiation is indicated following complete response to induction therapy in small cell lung cancer: Results of a multicentre randomised trial (1997)

  • A prospective randomized trial to determine the benefit of surgical resection of residual disease following response of small cell lung cancer to combination chemotherapy. Chest 106 (6): 320S-323S, 1994 (1994)

  • Treatment of small cell lung cancer. Recent experience of the EORTC Lung Cancer Cooperative Group (1994)

  • Locally advanced/inflammatory breast cancers treated with intensive epirubicin-based neoadjuvant chemotherapy: Are there molecular markers in the primary tumor that predict for 5-year clinical outcome? (2003)

  • Doxorubicin-paclitaxel: A safe regimen in terms of cardiac toxicity in metastatic breast carcinoma patients. Results from a European Organization for Reasearch and Treatment of Cancer Multicenter Trial. Cancer 97: 40-45, 2003 (2003)

  • A prospective survey of surgical approaches in clinically localized renal cell carcinoma: A preliminary attempt at surgical quality control. Uro (2002)

  • The stem cell mobilizing capacity of patients with acute myeloid leukaemia in complete remission correlates with relapse risk: Results of the EORTC-GIMEMA AML-10 trial (2003)

  • The Quality Assurance programme of the Radiotherapy Group of the European Organization for Research and Treatment of Cancer (EORTC): A critical appraisal of 20 years of continuous efforts (2003)

  • Role of pegylated liposomal doxorubicin (Caelyx) in the treatment of elderly patients with metastatic breast cancer: Safety and activity data from two EORTC studies. Proc. American Association for Cancer Research 44: 210, 2003 (abs. 919) (2003)

  • Can patient-, treatment- and pathology-related characteristics explain the high local recurrence rate following breast-conserving therapy in young patients? (2003)

  • Shortened irradiation scheme, continuous infusion of 5-fluorouracil and fractionation of mitomycin C in locally advanced anal carcinomas. Results of a phase II study of the European Organization for Research and Treatment of Cancer. Radiotherapy and Gastrointestinal Groups (2003)

  • An EORTC-ECSG phase I study of LU 79553 administered every 21 or 42 days in patients with solid tumours (2003)

  • Phase II study of XR 5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with non-small cell lung cancer (2003)

  • Quality of Life in breast cancer patients aged over 70 years, participating in the EORTC 10850 randomised clinical trial (2003)

  • Temozolomide in patients with advanced non-small cell lung cancer with and without brain metastases - a phase II study of the EORTC Lung Cancer Group (08965) (2003)

  • Early versus delayed endocrine treatment in pN1-3M0 prostate cancer without local treatment of the primary tumor. Results of EORTC 30846 – a phase III study (2003)

  • Early versus delayed endocrine treatment in pN1-3M0 prostate cancer without local treatment of the primary tumor. Results of EORTC 30846 – a phase III study (2003)

  • Is immediate post-operative radiation of pT3N0 prostate cancer a safe treatment? Results of EORTC trial 22911. Oral presentation of the 98th meeting of the American Urological Association, Chicago, U.S.A., April 26-May 1, 2003 (2003)

  • Is immediate post-operative radiation of pT3N0 prostate cancer a safe treatment? Results of EORTC trial 22911 (2003)

  • Phase II study of fotemustine in patients with advanced ovarian carcinoma. A trial of the EORTC Gynecological Cancer Group (2003)

  • Phase I clinical and pharmacokinetic study of E7070, a novel sulfonamide given as a 5-day continuous infusion repeated every 3 weeks in patients with solid tumours. A study by the EORTC Early Clinical Study Group (ECSG) (2003)

  • Irinotecan improves the activity of the AIO regimen in metastatic colrectal cancer: Results of EORTC GI Group study 40986 (2003)

  • Development of an EORTC disease-specific quality of life questionnaire for use in patients with liver metastates from colorectal cancer (2003)

  • Phase II trial with S-1 in chemotherapy-naïve patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECSG) (2003)

  • An EORTC phase I study of capecitabine (Xeloda®) in combination with fixed doses of cyclophosphamide and epirubicin (cex) as primary treatment for large operable or locally advanced/inflammatory breast cancer (2003)

  • Advanced bladder cancer (ABC) meta-analysis collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: A systematic review and meta-analysis (2003)

  • Leukemia Cooperative Group and the European Organisation for Research and Treatment of Cancer. Semin. Oncol (United States) 27(2 Suppl. 5): 52-57, 2000 (2000)

  • for the EORTC-LCG, EBMT, SAKK, GIMEMA. Chemotherapy only versus chemotherapy followed by transplantation in high risk MDS and sAML: two parallel studies adjusted for various prognostic factors (2000)

  • on behalf of EORTC, EBMT, SAKK, HOVON, GIMEMA and Scandinavian Leukemia Groups. Intensive chemotherapy versus autologous stem cell transplantation for the treatment of patients with poor risk MDS and secondary AML (2000)

  • The presence of an HLA-identical sibling donor has no impact on outcome of patients with high-risk MDS or secondary AML (sAML) treated with intensive chemotherapy followed by transplantation: Results of a prospective study of the EORTC, EBMT, SAKK and GIMEMA Leukemia Groups (EORTC study 06921). Leukemia 17 (5): 859-868, 2003 (2003)

  • Clinical and psychometric validation of an EORTC questionnaire module, the EORTC QLQ-OES18, to assess quality of life in patients with oesophageal cancer (2003)

  • No benefit from involved field radiotherapy on involved areas in stage III/IV Hodgkin’s lymphoma in complete remission after MOPP/ABV: The EORTC # 20884 randomized trial. Communication at the 7th Meeting of the European Hematology Association (EHA), Florence, Italy, June 6-9, 2002 (2002)

  • First results of EORTC trial 20962 evaluating the toxicity and efficacy of two cycles of the MBVP chemotherapy schedule followed by consolidating radiotherapy in primary central nervous system lymphoma (PCNSL). Communication at the 16th Conference on Clinical and Experimental Research in Radiation Oncology (CERRO), Les Menuires, France, January 19-26, 2002 (2002)

  • Treatment of primary CNS lymphoma in immuno-competent patients (NAPCL). Communication at the Update on Lymphomas Symposium, Antwerp, Belgium, April 11, 2002 (2002)

  • High-dose MTX-based chemotherapy followed by consolidating radiotherapy in non -AIDS related primary central nervous system lymphoma: First results of the phase II EORTC trial 20962. Communication at the 8th International Conference on Malignant Lymphoma, Lugano, Switzerland, June 12-15, 2002 (2002)

  • First results of the phase II EORTC trial 20962 evaluating high-dose MTX-based chemotherapy followed by consolidating radiotherapy in non -AIDS related Primary Central Nervous System Lymphoma (NAPCL). Communication at the 21st ESTRO Meeting, Praha, Czech Republic, September 17-21, 2002 (2002)

  • Primary central nervous system lymphoma: A multidisciplinary challenge! Proc. Russian-Dutch conference “Diagnosis and treatment of lymphomas”, Sint-Petersburg, Russia, September 27, 2002 (2002)

  • Population pharmacokinetics of the novel anti-cancer agent E7070 during four phase I studies: Model building and validation (2002)

  • E7070: a novel synthetic sulfonamide targeting the cell cycle progression for the treatment of cancer. A review (2002)

  • Phase II study of carboplatin in patients with advanced or recurrent endometrial carcinoma. A trial of the EORTC Gynaecological Cancer Group (2003)

  • Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-adjuvant chemotherapy in ovarian neoplasm trial (2003)

  • International collaborative ovarian neoplasm trial 1 and adjuvant chemotherapy in ovarian neoplasm trial: Two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma (2003)

  • Cisplatin, doxorubicin, and ifosfamide in carcinosarcoma of the female genital tract. A phase II study of the European Organization for Research and Treatment of Cancer Gynaecological Cancer Group (EORTC 55923) (2003)

  • Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: Definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group (2003)

  • First line treatment of ovarian cancer FIGO stages IIb-IV with paclitaxel-epirubicin-carboplatin (TEC) vs paclitaxel-carboplatin (TC). Interim results of an NSGO - EORTC GCG - NCIC CTG intergroup phase III study (2002)

  • Long-term follow-up confirims a survival advantage of the paclitaxel-cisplatin (TP) regimen over the cyclophosphamide-cisplatin (CP) combination in advanced ovarian cancer (AOC) (2002)

  • Long-term follow-up confirms a survioval advantage of paclitaxel-cisplatin (CP) regimen over the cyclophosphamide-cisplatin (CP) combination in advanced ovarian cancer. Proc. European Society for Medical Oncology (ESMO), Nice, France, 2002 (abs. 395) (2002)

  • The aryl hydrocarbon receptor mediates sensitivity of MCF-7 breast cancer cells to the antitumor agent 2-(4-aminophenyl)benzothiazole. Molecular Pharmacol. 61: 13-19, 2002 (2002)

  • Preclinical evaluation of amino acid prodrugs of novel antitumor 2-(4-amino-3-methylphenyl)benzothiazoles. Molecular Cancer Therapeutics 1: 239-246, 2002 (2002)

  • In vitro evaluation of amino acid prodrugs of novel antitumour 2-(4-amino-3-methylphenyl)benzothiazoles. Brit. J (2002)

  • 4-Substituted 4-hydroxycyclohexa-2,5-dien-1-ones with selective activities against colon and renal cancer cell lines (2003)

  • Evaluation of pharmacodynamic endpoints of antitumour benzothiazoles. Brit. J (2002)

  • Cancer Chronotherapy (2001)

  • From circadian rhythms to cancer chronotherapeutics. Chronobiology International 19 (1): 1-19, 2002 (2002)

  • Circadian concepts in normal and neoplastic breast. Chronobiology International 19 (1): 221-236, 2002 (2002)

  • Chronobiological concepts underlying the chronotherapy of human. Chronobiology International 19 (1): 253-274, 2002 (2002)

  • Pharmaco-economic comparative evaluation of combination chronotherapy vs standard chemotherapy for colorectal cancer. Chronobiology International 19 (1): 289-298, 2002 (2002)

  • Chronotherapy of colorectal cancer. Chronobiology International 19 (1): 207-220, 2002 (2002)

  • Contribution of the rest-activity circadian rhythm to quality of life in cancer patients. Chronobiology International 19 (1): 313-323, 2002 (2002)

  • Quality of life and chronotherapy. Chronobiology International 19 (1): 299-312, 2002 (2002)

  • Phase II trial of chronomodulated infusion of high-dose fluorouracil and l-folinic acid. In replyLetter (2002)

  • Chronomodulation of chemotherapy against metastatic colorectal cancer (2002)

  • Chronotherapy of colorectal liver metastases (2002)

  • The cost of Gastrointestinal Endoscopy: An activity-based approach. Can J. Gastroenterology 16 (7): 473-482, 2002 (2002)

  • Management of the N0 neck: Radiation therapy options. Proc. 2nd International Conference on Head and Neck Cancer, Abano Terme, Italy, November 11, 2002, (pp 35-40) (2002)

  • Surgical treatment of extensive cervical metastases in head and neck cancer. Proc. 2nd International Conference on Head and Neck Cancer, Abano Terme, Italy, November 11, 2002, (pp 66-71) (2002)

  • Surgical treatment of advanced laryngeal cancer. Proc. 2nd International Conference on Head and Neck Cancer, Abano Terme, Italy, November 11, 2002, (pp 87-89) (2002)

  • Treatment in advanced laryngeal cancers: radiation therapy options. Proc. 2nd International Conference on Head and Neck Cancer, Abano Terme, Italy, November 11, 2002, (pp 94-95) (2002)

  • Chemotherapy in laryngeal tumors. Review of the literature. Proc. 2nd International Conference on Head and Neck Cancer, Abano Terme, Italy, November 11, 2002, (pp 96-98) (2002)

  • Organ preservation for hypopharyngeal tumors. Proc. 2nd International Conference on Head and Neck Cancer, Abano Terme, Italy, November 11, 2002, (pp 99-103) (2002)

  • Chemotherapy in head and neck cancer: State of the art. Proc. 2nd International Conference on Head and Neck Cancer, Abano Terme, Italy, November 11, 2002, (pp 157-164) (2002)

  • Measurement of perfusion in stage IIIA-N2 non-small cell lung cancer using H215O and positron emission tomography (2002)

  • Methods to monitor response to chemotherapy in non-small cell lung cancer with 18F-FDG PET (2002)

  • Prognostic factors for survival and factors associated with long-term remission in patients with advanced melanoma receiving cytokine-based treatments: Second analysis of a randomized EORTC Melanoma Group trial comparing interferon-alfa2a (IFNalfa) and interleukin-2 (IL-2) with or without cisplatin (2002)

  • Effects of patient selection on the applicability of results from a randomized clinical trial (EORTC 10853) investigating breast-conserving therapy for DCIS. Brit. J (2002)

  • High-dose 5-fluorouracil plus low dose methotrexate plus or minus low dose PALA in advanced colorectal cancer: A randomised phase II-III trial of the EORTC Gastrointestinal Group (2003)

  • The development and utilisation of the European Organisation for Research and Treatment of Cancer - Quality-of-Life Group item bank (2002)

  • The shared frailty model and the power for heterogeneity tests in multicenter trials. Computational Statistics and Data Analysis 40: 603-620, 2002 (2002)

  • Multicollinearity in prognostic factor analyses using the EORTC QLQ-C30: Identification and impact on model selection. Statist. Med. 21: 3865–3884, 2002 (2002)

  • The European Organisation for Research and Treatment of Cancer (EORTC): Linking clinical trials to basic research. Communication at the 3rd International Bladder Cancer Network meeting, Trento, Italy, October 23–24, 2002 (2002)

  • Common pitfalls in assessing and reporting results. Communication at the course Cancer Clinical Trials: Methods and Practice, Brussels, Belgium, November 25–29, 2002 (2002)

  • BCG in superficial bladder cancer (2002)

  • The effect of BCG on progression in superficial bladder cancer: results of a meta-analysis. Communication at the symposium State of the Art in the Management of Urological Malignancies, Barcelona, Spain, November 10, 2002 (2002)

  • Can BCG delay or prevent progression to invasive bladder cancer ? Communication at the symposium Perspectives in Bladder Cancer, Lisbon, Portugal, November 22-23, 2002 (2002)

  • Can BCG delay or prevent progression in superficial bladder cancer? Communication at the Norwegian Society of Urology, Kristiansand, Norway, May 3, 2002 (2002)

  • Can BCG delay or prevent progression in superficial bladder cancer? Communication at the Austrian Society of Uro-Oncology, Graz, Austria, June 8, 2002 (2002)

  • Can BCG delay or prevent progression in superficial bladder cancer? Communication at the Greek Society of Urology, Kalamata, Greece, September 27, 2002 (2002)

  • Can BCG delay or prevent progression in superficial bladder cancer? Communication at a local meeting of the Dutch Society of Urology, Amsterdam, The Netherlands, September 24, 2002 (2002)

  • Can BCG delay or prevent progression in superficial bladder cancer? Communication at a local meeting of the Dutch Society of Urology, ‘s Hertogenbosch, The Netherlands, October 1, 2002 (2002)

  • Can BCG delay or prevent progression in superficial bladder cancer? Communication at a local meeting of the Dutch Society of Urology, Groningen, The Netherlands, October 7, 2002 (2002)

  • Is maintenance BCG for Ta T1 bladder cancer associated with increased toxicity? Results from EORTC study 30911. Communication at the symposium Perspectives in Bladder Cancer, Lisbon, Portugal, November 22-23, 2002 (2002)

  • Sensitivity analysis of longitudinal binary quality of life data with drop-out: An example using the EORTC QLQ-C30. Stat. Med. 20 (24): 3901-3920, 2001 (2001)

  • Assessing the reliability of the EORTC QLQ-C30 in a sample of older African American and Caucasian adults (2001)

  • Breast-conserving therapy for Paget disease of the nipple: A prospective European Organization for Research and Treatment of Cancer study of 61 patients. Cancer 94 (6): 1904-1905, 2002 (2002)

  • Chemotherapy in Stage I/II NSCLC and projects of the EORTC-Lung Cancer Group for Early Stage Lung Cancer. Lung Cancer 34 (Suppl. 3): S53-S58, 2001 (2001)

  • European Organization for Research and Treatment of Cancer and Groupe d' Etude des Lymphomes de l' Adulte very favorable and favorable, lymphocyte-predominant Hodgkin disease. Cancer 94 (6): 1731-1738, 2002 (2002)

  • Identification of histological features associated with metastatic potential in thin (<1.0 mm) cutaneous melanoma with metastases. A study on behalf of the EORTC Melanoma Group. J. Patho. 197 (2): 188-193, 2002 (2002)

  • The EORTC QLQ-C30 (version 3.0) Quality of Life questionnaire: Validation study for Spain with head and neck cancer patients. Psycho- (2002)

  • Cost of de novo acute myeloid leukemia induction therapy in adults: Analysis of EORTC-GIMEMA AML10 and FLANG regimens. J. Exp. Clin (2001)

  • Gemcitabine and cisplatin as induction therapy for patients with histologically proven stage IIIA-N2 non-small-cell bronchial cancer: A phase-II study of the EORTC Cooperative Group (EORTC 08955). Strahlenther. Onkol. 177 (4): 223-224, 2001 (2001)

  • Total skin electron radiation in the management of mycosis fungoides: Consensus of the European Organization for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Project Group (2002)

  • Quality assurance of the EORTC trial 22911. A phase III study of post-operative external radiotherapy in pathological stage T3N0 prostatic carcinoma: The dummy run (2002)

  • Spiritual issues and quality of life assessment in cancer care (2002)

  • Standards are needed for quality of life clinical trials. BMJ 324 (7346): 1156, 2002 (2002)

  • Quality of life in patients undergoing systemic therapy for advanced breast cancer (2002)

  • Metastatic colorectal cancer: Treatment challenges and quality of life [Commentary] (2002)

  • Erythropoietin improves quality of life-a response. Correspondance (2002)

  • The activity of raltitrexed (Tomudex(R)) in malignant pleural mesothelioma. An EORTC phase II study (08992) (2003)

  • Economic evaluation of antibiotic prophylaxis in small-cell lung cancer patients receiving chemotherapy: An EORTC double-blind placebo-controlled phase III study (08923) (2003)

  • Docetaxel and cisplat (1999)

  • European Organization for Research and Treatment of Cancer (EORTC) Laboratory Research Division workshop on the role of in vivo pre-clinical models in the development of contemporary cancer therapeutics, Verona, Italy, 3 February 2001 (2001)

  • CSF drug levels for children with acute lymphoblastic leukemia treated by 5 g/m2 methotrexate. A study from the EORTC Children s Leukemia Cooperative Group (1990)

  • The prognostic impact of quality of life assessed with the EORTC QLQ-C30 in inoperable non-small cell lung carcinoma treated with radiotherapy (2000)

  • A comparison of outcome from febrile neutropenic episodes in children compared with adults: Results from four EORTC studies. International Antimicrobial Therapy Cooperative Group (IATCG) of the European Organization for Research and Treatment of Cancer (EORTC) (1997)

  • Concomitant cisplatin and radiotherapy in a conventional and modified fractionation schedule in locally advanced head and neck cancer: A randomized phase II EORTC trial (2002)

  • Non-randomised phase II trials of drug combinations: Often meaningless, sometimes misleading. Are there alternative strategies? [Editorial comment] (2002)

  • EORTC is most active group (2002)

  • Comparison of escherichia coli-asparaginase with erwinia-asparaginase in the treatment of childhood lymphoid malignancies: Results of a randomized European Organisation for Research and Treatment of Cancer - Children s Leukemia Group phase 3 trials (2002)

  • A. VAN OOSTEROM, President of the EORTC (Interviewed by Jeroen van der Boon) (2002)

  • Symptom reporting in cancer patients, the role of negative affect and experienced social stigma. Cancer 77: 983-995, 1996 (1996)

  • The use of the Hospital Anxiety and Depression Scale (HADS) and the EORTC QLQ-C30 questionnaires to screen for treatable unmet needs in patients attending routinely for radiotherapy. Cancer Treatment Reviews 22 (Suppl. A): 123-129, 1996 (1996)

  • The development and psychometric validation of a brain cancer quality of life questionnaire for use in combination with general cancer specific questionnaires. Quality of Life Research 5: 1, 139-150, 1996 (1996)

  • A new quality of life questionnaire for head and neck cancers. Rev. Epidim. & Sant Publ. 44: 346-357, 1996 (1996)

  • Criterion based validation of the EORTC QLQ-C36 in advanced melanoma: The CIPS Questionnaire and proxy raters. Quality of Life Research 5: 375-386, 1996 (1996)

  • Quality of life evaluation by the EORTC questionnaire technique in patients with generalised malignant melanoma on chemotherapy (1996)

  • The effects of medroxyprogesterone acetate on appetite, weight and quality of life in advanced stage non-hormone-sensitive cancer: A placebo-controlled multicenter study (1996)

  • The European Organisation for Research and Treatment of Cancer: Breast Cancer Specific Quality of Life Questionnaire Module: First results from a three-country field study (1996)

  • A modular questionnaire for the assessment of long term quality of life in leukaemia patients: The MRC/EORTC QLQ-LEU. Quality of Life Research 5: 15-19, 1996 (1996)

  • Reply to the article "The AJCC staging proposal for cutaneous melanoma: Comments by the EORTC melanoma group", by D.J. Ruiter et al. ( (2002)

  • Chemotherapy in adult high-grade glioma: A systematic review and meta-analysis of individual patient data from 12 randomised trials (2002)

  • La recherche clinique en cancérologie en Europe: Rôle et perspectives de l EORTC. Médecine et Hygiène 2392, 1000-1007, 2002 (2002)

  • The EORTC: A model for clinical research operations and quality management. Research Practitioner 1 (n°3): 87-93, 2000 (2000)

  • Voriconazole versus amphotericin b for primary therapy of invasive aspergillosis (2002)

  • Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: A combined analysis of seven EORTC studies (2002)

  • Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomized trial (2002)

  • Recommended structure for reporting economic evaluations on pharmaceuticals in Belgium, Pharm. World Sci. 24 (1): 5-7, 2002 (2002)

  • Cost effectiveness of paclitaxel / cisplatin compared to cyclophosphamide / cisplatin in the treatment of advanced ovarian cancer in Belgium. PharmacoEconomics 20: 485-497, 2002 (2002)

  • Cost-minimization analysis of treatment options for T1N0 glottic squamous cell carcinoma: Comparison between external radiotherapy, laser microsurgery and partial laryngectomy (1999)

  • Cost assessment in colorectal cancer (2002)

  • Estimating differences in mean survival in studies where survival time is the principal outcome: A systematic assessment of the relative performance of extrapolation and restricted means methods. Medical Decision Making 20: 500, 2000 (2000)

  • Economic evaluation of induction chemotherapy versus immediate surgery in hypopharyngeal cancer. Communication at the European Association for Cancer Research 15th meeting, Stockholm, Sweden, August 15-19, 1998 (1998)

  • Health Economic Evaluation: From Data Collection to Final Analysis. Scientific presentation. Communication at the EORTC Data Center, September 23, 1998 (1998)

  • Health Economics" EORTC-ESO Residential Course on Cancer Clinical Trials: Methods and Practice, Brussels, Belgium, November 19, 1998 (1998)

  • The cost-effectiveness of alternative strategies in the management of patients with uninvestigated dyspepsia: The candys approach using ranitidine versus omeprazole as anti-secretory medication (2002)

  • The cost-effectiveness of alternative strategies in the short term management of patients with uninvestigated dyspepsia: The candys approach versus empiric anti-secretory therapy using omeprazole (2002)

  • Economic evaluations of the use of epoetin against chemotherapy induced anemia in cancer patients. Communication at the ESO course on Anemia and cancer therapy, Milan, Italy, November 10-11, 2000 (2000)

  • Methods for estimating average treatment cost in the presence of right-censoring: Should we distrust them? Oral presentation at the 8th Biennal Conference of the European Society for Decision Making, Taormina, Sicily, June 3-5, 2002 (2002)

  • Assessing the impact of uncertainty by using bootstrap techniques when cost and outcomes data are censored: A case study of chemotherapy in advanced ovarian cancer. Oral presentation at the 8th Biennal Conference of the European Society for Decision Making, Taormina, Sicily, June 3-5, 2002 (2002)

  • ICTR 2000: Individualizing cancer treatment. Editorial in the framework of the Conference organised under the auspices of the EORTC (2001)

  • It is appropriate that only randomised trials are accorded level I status in evidence based medicine (2001)

  • Optimal radiotherapy in Head and Neck tumours: From biology to physics (2001)

  • Survival analysis of induction therapy with docetaxel (taxotere) (T) containing regimens in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN). Proceedings ASCO, 20: 203b, 2001 (abs. 2564) (2001)

  • New perspectives in the treatment of advanced head and neck cancer. 5th Congress of the Polish Society of Clinical Oncology, December 13-15, 2001 (abs. A14) (2001)

  • Estimating survival gain for economic evaluations with survival time as principal endpoint: A cost-effectiveness analysis of adding early hormonal therapy to radiotherapy in patients with locally advanced prostate cancer. Health Econ 11 (3): 233-248, 2002 (2002)

  • Adjuvant hormone therapy in locally advanced and localized prostate cancer: three EORTC trials (2002)

  • Cost-effectiveness of the addition of early hormonal therapy in locally advanced prostate cancer: Results decisively determined by the cut-off time-point chosen for the analysis (2001)

  • Boron Neutron Capture Therapy Group: Background treatment, strategy. Communication at the EORTC New Treatment Committee Meeting. Bussels, October 2, 2001 (2001)

  • TOF-SIMS and Laser-SNMS characterization of cell cultures and tissue material. Communication at the 48th International Symposium of the American Vacuum Society, San Francisco, California, U.S.A., October/November 2001 (2001)

  • Characterization of cell cultures and tissue material. Communication at the 13th International Conference on Secondary Ion Mass Spectrometry and Related Topics, Nara, Japan, November 2001 (2001)

  • Positron emission tomography and treatment planning for BNCT. Communication at the Open Workshop on Treatment Planning for BNCT - EU/US Treatment Planning Meeting, Petten, The Netherlands, November 5, 2001 (2001)

  • Patient irradiation at HFR Petten for boron neutron capture therapy. Communication at the Symposium on the occasion of the 40th anniversary of the High Flux Reactor “HFR: Essential for Energy and Health”. European Commission Joint Research Centre, Petten, The Netherlands, November 9, 2001 (2001)

  • Boron Neutron Capture Therapy (BNCT). Communication at the Third International From Gene to Cure Congress, Amsterdam, The Netherlands, April 26-28, 2001 (2001)

  • Abbildung von Spurenelementen in gefriergebrochenen und gefriergetrockneten Zellkulturen mit TOF-SIMS und Laser-SNMS. Communication at the Diskussionstagung der Deutschen Gesellschaft für Massenspektrometrie, München, Germany, 2001 (2001)

  • BNCT in malignant brain tumours. The Quarterly Journal of Nuclear Medicine 45: 2, 2001 (abs. S13) (2001)

  • Boron distribution in malignant brain tumour for BNCT (2001)

  • Ein neues Paradigma für Symptomkontrolle bei Krebspatienten-der Pyramidenansatz. Tumordiagn. u Ther. 22: 36-39, 2001 (2001)

  • Chronomodulation: Optimal time finding design. Controlled dlinical trials 22: 59S-60S, 2001 (2001)

  • Role of CYP1A1 in modulation of antitumor properties of the novel agent 2-(4-amino-3-methylphenyl)benzothiazole (DF 203, NSC 674495) in human breast cancer cells (2000)

  • Antitumor benzothiazoles. 14. Synthesis and in vitro biological properties of fluorinated 2-(4-aminophenyl)benzothiazoles. J. Med. Chem. 44: 1446-1455, 2001 (2001)

  • Phase II study of a combination of cyclophosphamide, adriamycin and cisplatin in advanced fallopian tube carcinoma. An EORTC gynecological cancer group study. European Organization for Research and Treatment of Cancer (2001)

  • Expression of gp100, MART-1, tyrosinase and S100 in paraffin-embedded primary melanomas and loco-regional lymph node and visceral metastases: implications for diagnosis and immunotherapy. A study conducted by the EORTC Melanoma Group. J. Path. 193: 13-20, 2001 (2001)

  • The EORTC melanoma group translational research program on prognostic factors and ultrastaging in association with the adjuvant therapy trials in stage II and stage III melanoma. European Organization for Research and treatment of cancer. Ann. Surg. Oncol. 8 (Suppl. 9): 38S-40S, 2001 (2001)

  • Role of interferon-alpha in malignant melanoma remains to be determined (2001)

  • Adjuvant interferon-alpha for melanoma revisited: News from old and new studies (2001)

  • Microstaging in cutaneous melanoma. J. Pathol. 195: 525-529, 2001 (2001)

  • The AJCC staging proposal for cutaneous melanoma: Comments by the EORTC Melanoma Group (2001)

  • European Organization for Research and Treatment of Cancer Melanoma Group trial experience with more than 2,000 patients, evaluating adjuvant treatment with low or intermediate doses of interferon alpha-2b (2001)

  • Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: Review and 1999 EORTC recommendations (1999)

  • Symposium: Pathologists in clinical trials. Communication at the XVIII European Congress of Pathology, Berlin, Germany, October 2001 (2001)

  • Symposium: Pathologists, translational by nature. Communication at the XVIII European Congress of Pathology, Berlin, Germany, October 2001 (2001)

  • Telepathology experiment management using dynamic web technology. Communication at the 7th European Society of Cytological and Analytical Pathology, Caen, France, May 2001 (2001)

  • Developing protocols to improve static image telepathology reliability. Communication at the 7th European Society of Cytological and Analytical Pathology, Caen, France, May 2001 (2001)

  • An EORTC-IDBBC phase I study of gemcitabine and continuous infusion 5-fluorouracil in patients with metastatic (2002)

  • A phase II EORTC study of temozolomide in patients with malignant pleural mesothelioma (2002)

  • Sun exposure and sun protection in young European children: An EORTC multicentric study (2002)

  • Phase I study of MEN-10755, a new anthracycline in patients with solid tumours: A report from the European Organisation for Research and Treatment of Cancer, Early Clinical Studies Group (2002)

  • Editorial comments on "Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: An EORTC double-blind placebo-controlled phase III study" (2001)

  • EORTC honored at ASCO and Dr Drucker at AACR: The saga of STI-571 news (2001)

  • Reply to the article "Editorial comments on "Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: An EORTC double-blind placebo-controlled phase III study"", by P.A. BUNN ( (2002)

  • Reply to "Letter to the Editor on "Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: An EORTC double-blind placebo-controlled phase III study"", by V.C.G. Tjan-Heijnen, P.E. Postmus, A. Ardizzoni, ( (2002)

  • The EORTC chronotherapy study group (2002)

  • EORTC, grupo Europeo para el tratamiento del cancer (2001)

  • SAE Report handling in a multinational academic research environment. Applied Clin. Trials 9 (Supp. 4): 38-44, 2000 (2000)

  • 40 years of the EORTC: The evolution towards a unique network to develop new standards of cancer care (2002)

  • The EORTC and drug development (2002)

  • Scientific review of EORTC trials: The functioning of the new treatment committee and protocol review committee (2002)

  • The EORTC boron neutron capture therapy (BNCT) group: Achievements and future projects (2002)

  • High yield direct 76-Br bromination of monoclonal antibodies using chloramine-T. Nuclear Medicine and Biology 26: 923-929, 1999 (1999)

  • Comparison of cell survival models for mixed LET radiation (1999)

  • Closo-dodecacarborate(2-)as a linker for iodination of macromolecules. Aspects on conjugation chemistry and biodistribution. Bioconjugate Chemistry 10: 338-345, 1999 (1999)

  • An experimental approach. Strahlenther. Onkol. 175 (2): 118-120, 1999 (1999)

  • Mechanisms of transport of p-borono-phenylalanine through the cell membrane in vitro. Radiation Research 153: 173-180, 2000 (2000)

  • Effects of dextranation on the pharmacokinetics of short peptides. A PET study on mEGF. Bioconjugate Chemistry 10: 938-946, 1999 (1999)

  • Boron neutron capture enhancement of fast neutron for nonremoved glioblastomas: Rationale of a clinical trial. Front. Radiat. Ther. Oncol. 33: 43-50, 1999 (1999)

  • Status und perspektiven der therapie maligner gliome (1999)

  • Plans for the German national neutron therapy centre with a hospitla based 70 MeV proton cyclotron at the University Hospital Essen/Germany (1999)

  • Indirekte strahelnexposition von risikoorganen in der BNCT bei glioblastomen (1999)

  • Boron neutron capture therapy for glioblastoma (BNCT). Report on the first patient group (EORTC-protocol 11961). Zentralbl. Neurochir. (16): 17, 1999 (1999)

  • Re-evaluation of the study design of the phase I clinical trial with BNCT for patients with glioblastoma at the high flux reactor Petten (EORTC protocol 11961) (1999)

  • Procedures of BNCT in the European phase I clinical trial (EORTC protocol 11961) (1999)

  • Case report on a serious neurological adverse event of BNCT in the EORTC 11961 trial (1999)

  • Procedures of radiotherapy with boron neutron capture reaction at the Petten irradiation facility (1999)

  • Organisation of quality assurance, respecting medical conventions, for the treatment of glioblastoma patients by BNCT at the high flux reactor Petten (1999)

  • Comparison of clinical dosimetry in conventional radiotherapy and boron neutron capture therapy (BNCT) focusing on quality assurance (1999)

  • Boron neutron capture therapy (BNCT) for the treatment of glioblastoma (EORTC protocol 11961): First results (1999)

  • Past, present and future trends of boron neutron capture therapy (BNCT) (1999)

  • Phase I clinical trial with BNCT for patients with glioblastoma (EORTC protocol 11961) (1999)

  • Zellulare transportmechanismen von BPA (1999)

  • Subcellular localization of boron compounds by electron energy loss spectroscopy of cryosections (1999)

  • Clinical trials of boron neutron capture therapy for glioblastoma in the USA and in Europe (1999)

  • Boron neutron capture reaction enhanced fast neutron therapy for treatment of inoperable glioblastoma (1999)

  • Facility at the figh flux reactor Petten (1999)

  • Quality assurance in clinical dosimetry of BNCT compared to conventional radiotherapy (1999)

  • Phase I clinical trial with BNCT for patients with glioblastoma at the European high flux reactor Petten (EORTC 11961) (1999)

  • Procedures for BNCT treatment planning (1999)

  • Evaluation of irradiation effects: A comparison of sulforhodamine-B assay and a colony assay (1999)

  • Cellular transport mechanisms of BPA in vitro (1999)

  • Glioblastoma boron neutron capture enhancement of fast neutron (BNCEFN) irradiation: Rationale of a clinical trial. Communication at the Combined Meeting on Hadron Therapy PTCOG XXX / EHTG / ECHED, Capetown, CA, U.S.A., April 12-15, 1999 (1999)

  • The experience from the construction of BNCT facility at the LVR-15 reactor. Communication at the IAEA TCM meeting, Vienna, Austria, June 1999 (1999)

  • Postoeratív bór neutron-befogás terápia (BNCT) glioblastoma kezelésére a petteni reaktornál kiépített neutronforrással, fázis I. klinikai vizsgálat (EORTC 11961). Communication at the A Magyr Sugárterápiás Társaság IV. Kongresszusa (IV. Congress of the Hurgarian Radiotherapy Society), Szombathely, Hungary, május 15-16, 1999. Elöadások kivonata (Abstract Book) pp. 18 (1999)

  • Evaluation of the first results of the phase I clinical trial with BNCT at the High Flux Reactor in Petten (EORTC protocol 11961). Communication at the Symposium "Trends of Radiobiology in Radioonology - 25 Years Radiobiology in Essen", Essen, Germany, July 15-17, 1999 (1999)

  • Study design of boron neutropn capture enhanced fast neutron therapy for treatment of inoperable glioblastoma. Communication at the EORTC BNCT Study Group Meeting, Catholic University of Louvain-la Neuve, Brussels, Belgium, March 24, 1999. Minutes pp. 12-14 (1999)

  • Trans-nacionális struktúra Európában egy új sugárterápiás módszer, a Boron Neutron Capture Therapy (BNCT) klinikai vizsgálata kapcsán. Communication at the A Magyr Sugárterápiás Társaság IV. Kongresszusa (IV. Congress of the Hurgarian Radiotherapy Society), Szombathely, Hungary, május 15-16, 1999. Elöadások kivonata (abs. ) (1999)

  • A dose escalation study approach with lagged serious adverse events. ISCB - GMDS 99. Communication at the 20th Annual Conference of the International Society for Clinical Biostatistics and 44. Jahrestagung der Deutschen Gesellschaft für Medizinische informatik, Biometrie und Epidemiologie, Heidelberg, Germany, September 13-17, 1999 (abs.) (1999)

  • TLD 600 and TLD 700: A possible way to measure the thermal component in a fast neutron beam. Communication at the Combined Meeting on Hadron Therapy PTCOG XXX / EHTG / ECHED, Capetown, CA, U.S.A., April 12-15, 1999 (1999)

  • Optimization of the BNCT filter. Communication at the Ninth International Conference on Radiation Shielding, Tsukuba, Japan, October 1999 (1999)

  • Boron neutron capture therapy for the treatment of brain tumours in Europe. Communication at the Conference to launch the European Union s Fifth Framework Programme for research, Essen, Germany, February 25-26, 1999. Exhibition Guide p 42-43 (1999)

  • How to enhance thermal neutron flux in boron neutron capture enhancement of fast neutron irradiations? Communication at the Combined Meeting on Hadron Therapy PTCOG XXX / EHTG / ECHED, Capetown, CA, U.S.A., April 12-15, 1999 (1999)

  • Can intravesical chemotherapy prevent progression to invasive bladder cancer? Why is it so difficult to prove? (1999)

  • Statistics in clinical trials: What is necessary for a non statistician? (1999)

  • Interim analyses, early stopping rules and data monitoring committees (1999)

  • Integrating phase II and phase III clinical trials for single agent cytotoxics (1999)

  • Statistical problems and the concept of meta-analysis (1999)

  • The impact of including survival information from literature on the overall Chi-square statistic in an IPD meta-analysis (1999)

  • A phase II study of the ablative effect of quarter dose BCG on a papillary marker lesion of the bladder (1999)

  • Relationship between efficacy and side effects of BCG instillations in Ta - T1 bladder cancer: Results of EORTC trial 30911 (1999)

  • Randomized phase II trial assessing estramustine and vinblastine combination chemotherapy versus estramustine alone in patients with hormone escaped progressive metastatic prostate cancer (1999)

  • Ways of combining summary and individual patient data for survival type endpoints (1999)

  • LHRH-agonist (LHRH-A) + Tamoxifen LHRH-A alone in premenopausal women with advanced breast cancer (ABC): Results of a meta-analysis of four randomized trials. Presentation at American Society of Clinical Oncology, Atlanta, Georgia, U.S.A., May 15-18, 1999 (1999)

  • Individual patient and literature based meta-analyses of chemotherapy in head and neck cancer: Reasons for differing results. Communication at the VIIth Annual Cochrane Colloquium, Rome, Italy, October 6-9, 1999 (1999)

  • Prostate cancer treated by anti-androgen: Is sexual function perserved? (2000)

  • Patient management strategies and techniques used in Europe for high-dose chemotherapy with peripheral blood stem cell transplantation. Med Decision Making 19: 538, 1999 (1999)

  • Economic evaluation of paclitaxel/cisplatin versus cyclophosphamide/cisplatin in the treatment of advanced ovarian cancer in Belgium. Med Decision Making 19: 538, 1999 (1999)

  • Systematic reviews of evidence from economic evaluations of health care (1999)

  • Economic Analysis (1999)

  • Determining and comparing the costs of treatments (1999)

  • Determining and comparing the costs of treatments (1999)

  • Patient management strategies and techniques used in Europe for high-dose chemotherapy with peripheral blood stem cell transplantation (1999)

  • Economic evaluation of paclitaxel/cisplatin versus cyclophosphamide/cisplatin in the treatment of advanced ovarian cancer in Belgium (1999)

  • Economic evaluation in clinical trials: Yes or no? (1999)

  • Retrospective economic evaluation of adding the LHRH analogue goserelin to radiotherapy for patients with locally advanced prostate cancer (1999)

  • Cost comparison between hospitals in diffent countries by means of a resource use index. Value in Health 2: 360, 1999 (abs. CA2) (1999)

  • Estimating survival gain for cost-effectiveness analysis: The example of early hormonal treatment in locally advanced prostate cancer. Value in Health 2: 360, 1999 (abs. CA3) (1999)

  • Cost comparisons between hospitals in different countries by means of a resource use index (1999)

  • Estimating survival gain for cost-effectiveness analysis: The example of early hormonal treatment in locally advanced prostate cancer (1999)

  • How should treatment costs impact on physicians decisions? (1999)

  • Systematic reviews of evidence from economic evaluations of health care. Proc. Second Symposium on Systematic Reviews: Beyond the Basics, Oxford, United Kingdom, January 5-7, 1999, pp. 55 (1999)

  • Caring about woman and cancer (CAWAC): A European survey of the prespectives and experiences of women with female cancers (1999)

  • Economic evaluation of taxol® plus cisplatin versus teniposide plus cisplatin in non-small lung cancer (NSCLC): A multicountry analysis (1999)

  • Editorial (for special issue on health economics) (1999)

  • How should treatment costs impact on physicians decisions? (1999)

  • EORTC Study Group on Data Management, achievements and projects (1999)

  • Documentationsbögen, entwicklung und konzept, seminar (1999)

  • Data management groups in Europe (1999)

  • Development of the CRF (1999)

  • General approach to GCP (1999)

  • A phase II study of gemcitabine in patients with malignant pleural mesothelioma (1999)

  • Second-line chemotherapy and its evaluation in small cell lung cancer. Cancer Treat. Rev. 25: 199-206, 1999 (1999)

  • Gemcitabine plus taxane combinations in non-small cell lung cancer. Semin. Oncol. 26 (4): 19-24, 1999 (1999)

  • Dacarbazine, cisplatin and interferon alpha with or without interleukin-e in advanced melanoma: Interim analysis of EORTC trial 18951 (1999)

  • Received dose and dose intensity of chemotherapy has little impact on outcome in non-metastatic extremity osterosarcoma (1999)

  • Response to anthracycline based chemotherapy (ABC) and overall survival in patients (PTS) with lung metastases from soft tissues sarcoma (STS): A retrospective study of the EORTC soft tissue and bone sarcoma group (STBSG) (1999)

  • A randomised phase II trial of caelyx®/doxil® versus doxorubicin in advanced or metatastic soft tissue sarcoma (STS) - An EORTC soft tissue and bone sarcoma group (STBSG) trial (1999)

  • Pentostatin in T cell malignancies, an EORTC phase II trial (1999)

  • Received dose and dose intensity of chemotherapy has little impact on outcome in non-metastatic extremity osterosarcoma (1999)

  • A randomised phase II trial of caelyx®/doxil® versus doxorubicin in advanced or metatastic soft tissue sarcoma (STS) - An EORTC soft tissue and bone sarcoma group (STBSG) trial (1999)

  • Response to anthracycline based chemotherapy (ABC) and overall survival in patients (PTS) with lung metastases from soft tissues sarcoma (STS): A retrospective study of the EORTC soft tissue and bone sarcoma group (STBSG) (1999)

  • Vinorelbine and cisplatin in metastatic epidermoid carcinoma of the esophagus (MECE). An EORTC phase II study (1999)

  • Combination chemotherapy with cisplatin and topotecan as second-line treatment of sensitive (S) and refractory (R) small cell lung cancer (SCLC): An EORTC LCCG phase II study (1999)

  • Reduction of chemotherapy-induced febrile leukopenia by ciprofloxacin and roxithromycin in small cell lung cancer (SCLC) patients: An EORTC phase III study (1999)

  • Randomized trial of chemoprevention with vitamin a and N-acetylcysteine in patients with cancer of the upper and lower airways: The euroscan study (1999)

  • Randomized trial of chemoprevention with vitamin a and N-acetylcysteine in patients with cancer of the upper and lower airways: The euroscan study. Communication at the Thirty-Fifth Meeting of the American Society for Clinical Oncology, Atlanta, Georgia, U.S.A., May 15-18, 1999 (1999)

  • Peripheral blood stem cell transplantation for breast carcinoma in Europe 1998 - A joint EBMT and EORTC report (1999)

  • Pentostatin in T cell malignancies, an EORTC phase II trial (1999)

  • Retrospective economic evaluation of adding the LHRH analogue goserelin to radiotherapy for patients with locally advanced prostate cancer (1999)

  • Consolidation ABMT after standard chemotherapy vs CHVmP/BV alone for primary intermediate and high grade NHL. A randomized phase III EORTC study (1999)

  • Dacarbazine, cisplatin and interferon alpha with or without interleukin-e in advanced melanoma: Interim analysis of EORTC trial 18951 (1999)

  • Phase I and pharmacologic study of continuous daily oral SCH 66336, a novel farnesyl transferase inhibitor (1999)

  • Doxil®/caelyx® has antitumour activity in advanced soft tissue sarcoma with reduced toxicity compared to doxorubicin. Results of a randomised phase II trial by the EORTC soft tissue and bone sarcoma group (STBSG). Communication at the Annual Meeting of the Connective Tissue Oncology Society, Arlington, Virginia, Maryland, U.S.A., October 21-23, 1999 (1999)

  • Phase II study on gemicitabine in advanced tissue sarcomas of the adult. Communication at the Annual Meeting of the Connective Tissue Oncology Society, Arlington, Virginia, Maryland, U.S.A., October 21-23, 1999 (1999)

  • Selection bias in the treatment evaluation of acute myelogenous leukemia. PhD Thesis, Katholieke Universiteit Nijmegen, The Netherlands, October 22, 1999 (1999)

  • Regulation of apoptosis in breast cancer: Implications for tumor progression and treatment. PhD Thesis, Universiteit Leiden, Leiden, The Netherlands, February 3, 2000 (2000)

  • ELISA for complexes of urokinase-type and tissue-type plasminogen activators with their type-1 inhibitor (uPA~PAI-1 and tPA~PAI-1) (1999)

  • Prognostic impact of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) in cytosols and pellet extracts derived from 892 breast cancer patients (1999)

  • Cathepsin D in primary breast cancer: Prognostic evaluation involving 2810 patients (1999)

  • Invasion marker PAI-1 remains a strong prognostic factor after long-term follow-up both for primary breast cancer and following first relapse (1999)

  • Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers: Six-year median follow-up (1999)

  • Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc (1999)

  • A guide for reviewing submitted manuscripts (and indications for the design of translational research studies on biomarkers) (1999)

  • Differential regulation of specific genes in MCF-7 and the ICI 182780 resistant cell line MCF-7/182R-6 (1999)

  • Growth response of breast epithelial cells to estrogen is influenced by EGF. Mol. Endocrinol. 153: 1-9, 1999 (1999)

  • Acquired antiestrogen resistance in MCF-7 human breast cancer sublines is not accomplished by altered expression of receptors in the ErbB-family (1999)

  • Expression of nuclear receptor interacting proteins TIF-1, SUG-1, RIP140 and corepressor SMRT in tamoxifen-resistant breast cancer. Clin (1999)

  • Retinoic acid modulates prolactin receptor expression and prolactin induced STAT-5 activation in breast cancer cells in vitro (1999)

  • Prognostic impact of tumor biological factors on survival in node-negative breast cancer (1998)

  • Identification of low-risk node- negative breast cancer patients by tumor biological factors PAI-1 and Cathepsin L (1998)

  • Increased use of immunohistochemistry for oestrogen receptor measurement in mammary carcinoma: The need for quality assurance (1998)

  • P53 Protein accumulation predicts poor response to tamoxifen therapy of patients with recurrent breast cancer (1998)

  • Complexes between urokinase-type plasminogen activator and its receptor in blood as determined by enzyme-linked immunosorbent assay (1998)

  • Combined LHRH-agonist plus Tamoxifen treatment is superior to medical castration alone in premenopausal metastatic breast cancer: A subgroup and meta-analysis of the combined hormonal agents trialists group (CHAT). Proc. 21st Annual San Antonio Breast Cancer Symposium, San Antonio, USA, December 1998 (1998)

  • EORTC 10941: Final results of a phase II study of Liarozole fumarate in patients with metastatic breast cancer (1998)

  • Neo-adjuvant dose intensive chemotherapy in locally advanced breast cancer: An EORTC-NCIC-SAKK randomized phase III study comparing FEC (5FU, epirubicin, cyclophosphamide) vs high dose intensity EC + G-CSF (filgrastim) (1998)

  • An EORTC - NCIC - SAKK neoadjuvant randomized phase III study comparing CEF (5FU, epirubicin, cyclophosphamide) vs dose intensified EC+G-CSF (filgrastim) in locally advanced breast cancer (LABC). Updated results including quality of life (1998)

  • The influence of the boost on the cosmetic outcome after breast conserving therapy (1998)

  • Culture and communication: Approach to patients in clinical research (1998)

  • Combined treatment with the LHRH-agonist Buserelin (LHRH-A) and Tamoxifen (TAM) vs single treatment with each drug alone in premenopausal metastatic breast cancer: Final results of EORTC study 10881. Proc. 23rd ESMO Congress, Athens, Greece, November 6-10, 1998 (1998)

  • Neo-adjuvant chemotherapy for breast cancer: The EORTC experience (1998)

  • Neo-adjuvant dose intensive chemotherapy in locally advanced breast cancer: An EORTC-NCIC-SAKK randomized phase III study comparing FEC (5fu, epirubicin, cyclophosphamide) vs high dose intensity ec + g-csf (filgrastim). ASCO 34th Annual Meeting, Los Angeles, U.S.A., May 16-19, 1998 (1998)

  • An EORTC - NCIC - SAKK neo-adjuvant randomized phase III study comparing CEF (5FU, Epirubicin, Cyclophosphamide) vs dose intensified EC+G-CSF (Filgrastim) in locally advanced breast cancer (LABC). Updated results including Quality of Life (1998)

  • Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia (1998)

  • Maladie résiduelle. Invited speaker at the “XXIIIème Journées d’Hématologie de l’Hôtel-Dieu”, Paris, France, December 14, 1998 (1998)

  • Importance des groupes coopératifs dans le traitement du cancer pédiatrique. Congress of Pediatry, Lisbon, Portugal, June, 1998 (1998)

  • Treatment of acute myeloid leukemia in children. Invited speaker at the Seminar “New Trends in the Treatment of Acute Leukemia”, Dubrovnik, Croatia, September 7-9, 1998 (1998)

  • Les stratégies thérapeutiques des LAL de l’enfant sont-elles utiles aux traitements des LAL de l’adulte. Invited speaker at the “XXIIIème Journées d’Hématologie de l’Hôtel-Dieu”, Paris, December 14, 1998 (1998)

  • Circadian rhythm in docetaxel tolerability and efficacy in mice (1998)

  • Phase II trial of chronomodulated (cm) high dose 5-fluorouracil (5-FU) and l-folinic acid (l-FA) in patients with metastatic colorectal cancer (MCC) (1998)

  • Contribution of second line oxaliplatin (oxa)-chronomodulated 5-fluorouracil - folinic acid (CM-5-FU-FA) and surgery to survival in metastatic colorectal cancer patients (MCC pts) (1998)

  • for the I.O.C.C. : First line chemotherapy with 5-fluorouracil (5-FU), leucovorin, and oxaliplatin (l-OHP) (FLO) against metastatic colorectal cancer (MCC) : relationship between chronotherapy, dose intensity (DI), response and survival (1998)

  • Activity circadian rhythm as an independent prognostic factor of survival in patients (pts) with metastatic colorectal cancer (MCC). J Clin Oncol 17: 269, 1998 (abs 1032) (1998)

  • Chronotherapy of colorectal cancer metastases. Communication at the Conference on Liver Cancer : Multi Treatment Modalities, Imperial College School of Medicine, London, U.K. November 25th 1998 (1998)

  • Differences in EBV expression between primary and secondary cutaneous angiocentric lymphomas. Arch. Dermatol. 134:479-484, 1998 (1998)

  • Classification of primary cutaneous lymp-ho-mas. Cross-talk between pathologist and clinician. Curr. Diagn. Pathol. 5:23-33-, 1998 (1998)

  • The new structure of the EORTC SGDM. Communication at the EORTC Lung Cancer Cooperative Group meeting, Brussels, Belgium, November 20, 1998 (1998)

  • The new structure of the EORTC SGDM. Communication at the EORTC Radiotherapy Group meeting, Offenbach, F.R. Germany, September 17, 1998 (1998)

  • Available training on data management skills. Communication at the First National Congress of Data Managers, Brussels, Belgium, June 6, 1998 (1998)

  • Data management associations in Europe. Communication at the First National Congress of Data Managers, Brussels, Belgium, June 6, 1998 (1998)

  • Chairperson, Scoring Scales session, One-Day Introduction to EORTC Trials, Brussels, Belgium, September 27, 1998 (1998)

  • The new structure of the EORTC SGDM. Communication at the EORTC GI Tract Cancer Cooperative Group meeting, Roermond, The Netherlands, October 23, 1998 (1998)

  • The new structure of the EORTC SGDM. Communication at the EORTC Leukemia Cooperative Group meeting, Paris, France, October 24, 1998 (1998)

  • The new structure of the EORTC SGDM. Communication at the EORTC Gynecological Cancer Cooperative Group, Milan, Italy, October 31, 1998 (1998)

  • An EORTC-ECSG phase II study of vinorelbine in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Annals of (1998)

  • A phase I clinical and pharmacokinetic study of LU 79553 administered every 21 days in patients with solid tumors: An EORTC-ECSG study. Annals of (1998)

  • R. WALKER and A.R. HANAUSKE. Phase I trial and pharmacokinetics of beta-D-glucosylisophosphoramide mustard (D-19575) administered as a 6-hour infusion every three weeks: An EORTC/ECSG study. Annals of (1998)

  • Single agent taxol versus doxorubicin as first-line chemotherapy in advanced breast cancer: Final results of an EORTC randomized study with crossover (1998)

  • Phase I and pharmacokinetic study of CGP 48664, a SAMDC inhibitor, given once weekly x 4 in patients with solid tumors (1998)

  • Phase I tolerability-pharmacologic study of CGP48664, a novel polyamine biosynthesis inhibitor, given i.v. once weekly x 4 (q 6 wks) to patients with solid tumors. Annals of (1998)

  • A phase I study of LU 79553 administered every 21 days in patients with solid tumors: An EORTC/ECSG study (1998)

  • Phase II with UFT + folinic acid in patients with metastatic gastric cancer. Annals of (1998)

  • Results of the EORTC Early Clinical Studies Group phase II evaluation of carzelesin in patients with solid tumors. On behalf of the EORTC Early Clinical Studies Group (ECSG) and New Drug Development Office (NDDO) (1998)

  • A phase II study with G1147211 (GW211) in small cell lung cancer. Annals of (1998)

  • on behalf of the EORTC 22922/10925 Quality Assurance Committee. EORTC randomized phase III trials 22922/10925 investigating the role of internal mammary chain (IMC) irradiation in stage I-III breast cancer: a quality assurance report on the dummy run (1998)

  • Quality assurance in EORTC trial 22922 concerning Internal Mammary Chain (IMC) irradiation: the dummy run (1998)

  • Palliative endobronchial brachytherapy in patients with lung cancer:evaluation using the EORTC quality of life instrument. Radiotherapy & Oncology. 48 (suppl 1): S72, 1998 ( abst 281) (1998)

  • The higher local recurrence rate after breast conserving therapy in young patients explained by larger tumour size, incomplete excision at first attempt and smaller excision volume? (1998)

  • The influence of the boost on the cosmetic outcome after breast conserving therapy (1998)

  • on behalf of the EORTC Radiotherapy and Breast Cancer Cooperative Groups. The higher local recurrence rate after breast conserving therapy in young patients explained by larger tumour size, incomplete excision at first attempt and smaller excision volume? (1998)

  • Conservative treatment for laryngeal cancer. Panel: 2nd International Symposium on Head and Neck Surgery and Oncology, Jerusalem, Israel, November 1-5, 1998 (1998)

  • Radiotherapy and chemotherapy. Panel: 2nd International Symposium on Head and Neck Surgery and Oncology, Jerusalem, Israel, November 1-5, 1998 (1998)

  • Alternation of fractionation in patients with head and neck cancers: beyond the EORTC experience. 2nd International Symposium on Head and Neck Surgery and Oncology, Jerusalem, Israel, November 1-5, 1998 (1998)

  • Radiobiological analysis of beam output checks: Impact of under- and over-dosages on local disease outcome, following high dose radiation therapy. 2nd Annual meting of the Scientific Association of Swiss Radio-Oncology, Lausanne, Switzerland, March 20-21, 1998 (1998)

  • Assicurazione di qualità in radioterapia: esperienze dell’EORTC. Giornata di studio nazionale: Assicurazione di qualità in radioterapia, Istituto Superiore di Sanità, Rome, Italy, December 2, 1998 (1998)

  • Radiochimiothérapie concomitante comme traitement adjuvnt des cancers du rectum. 4th International Course in Controversies in Oncology, Murcia, Spain, May 1998 (1998)

  • Advanced and recurrent rectal carcinoma. Salvage for recurrence. Chemotherapy. Annual Meeting of the Association of Coloproctology of Great Britain and Ireland, Jersey, CI, June 29 - July 1, 1998 (1998)

  • Combined treatment modalities in the conservative approach of GI cancer. 8th World Congress of the International GastroSurgical Club (IGSC), Strasbourg, France, April 15-18, 1998 (1998)

  • Quality of life after radiation therapy of cerebral low-grade gliomas of the adult: Results of a randomised phase III trial on dose response (EORTC trial 22844). c. 34th annual meeting of the American Society of Clinical Oncology (ASCO), May 16-19, 1998, Los Angeles, U.S.A (1998)

  • Joint 1998 meeting of the British Oncological Association/Association of Cancer Physicians/Royal College of Radiologists, Nottingham, UK. July 5-7, 1998 (1998)

  • The Aneurin Bevan Health Services Research Lecture: EORTC International clinical trials: achievements and challenges. Joint 1998 meeting of the British Oncological Association/Association of Cancer Physicians/Royal College of Radiologists, Nottingham, UK. July 5-7, 1998 (1998)

  • EORTC Radiotherapy Group: a critical look at the history of prognostic factors and treatment strategies of cancer of the rectum. Proceedings 8th European Inter-university symposium on colorectal cancers, Naoussa, Greece, 26-30 August, 1998 (abs. p 18) (1998)

  • EORTC Radiotherapy Group: Combined strategies. Proceedings 8th European Inter-university symposium on colorectal cancers, Naoussa, Greece, 26-30 August, 1998, (abs. p 33) (1998)

  • EORTC Brain Tumor Group, EORTC Radiotherapy Group, MRC Brain Tumour Working Party. Immediate postoperative radiotherapy in low grade glioma improves progression free survival, but nor overall survival: Preliminary results of an EORTC/MRC randomized phase III study. ASCO 34th Annual Meeting, May 16-19, 1998, Los Angeles, U.S.A (1998)

  • On behalf of the EORTC 22922/10925 Quality Assurance Committee. Quality Assurance (QA) in EORTC randomized phase III trial 22922/10925 investigating the role of Internal Mammary Chain (IMC) irradiation in stage I - III breast cancer. Symposium Dutch Society of Radiation Oncology, Dr. B. Verbeeten Institute, Tilburg, The Netherlands, April 24, 1998 (1998)

  • Pharmacokinetics and tissue distribution of the imidazoacridinone C1311 in tumour-bearing mice. Cancer Chemotherapy Pharmacology 42: 379-385, 1998 (1998)

  • High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC Soft Tissue and Bone Sarcoma Group (1998)

  • A phase II study of raltitrexed (Tomudex) as second or third line treatment for patients with advanced soft tissue sarcomas refractory to doxorubicin containing regimens. Annals of (1998)

  • Five-year survivors in patients with advanced soft tissue sarcoma treated with doxorubic (1998)

  • Phase II randomized study comparing docetaxel (T) to doxorubicin (D) in previously untreated soft tissue sarcomas. Annals of (1998)

  • Is obtention of partial response (PR) in front line chemotherapy critical to improve outcome of metastatic soft tissue sarcoma (MSTS) patients (pts). Annals of (1998)

  • Effect of high dose ifosfamide in advanced soft tissue sarcomas: A multicenter phase II study. Proc ASCO (1998)

  • Prognostic factors for 1st line high dose chemotherapy outcome in advanced soft tissue sarcoma : An overview of 759 patients included in studies of the EORTC Soft Tissue and Bone Sarcoma Group (1998)

  • Final results of a randomized phase II study of the EORTC Soft Tissue and Bone Sarcoma Group comparing two different ifosfamide regimens in chemotherapy untreated advanced soft tissue sarcoma patients. Annals of (1998)

  • A phase II study of raltitrexed (Tomudex) as second or third line treatment for patients with advanced soft tissue sarcomas refractory to doxorubicin containing regimens. Communication at 4th Annual Scientific Meeting Vancouver, B.C., Canada, November 13-14,1998 (1998)

  • Five-year survivors in patients with advanced soft tissue sarcoma treated with doxorubic (1998)

  • Five-year survivors in patients with advanced soft tissue sarcoma treated with doxorubic (1998)

  • Malignant fibrous histiocytoma of bone (MFH-B) - 41 patients treated with doxorubicin/cisplatin (DOX/DDP) neoadjuvant chemotherapy. Communication at 4th Annual Scientific Meeting Vancouver, B.C., Canada, November 13-14, 1998 (1998)

  • Phase II randomized study comparing docetaxel (T) to doxorubicin (D) in previously untreated soft tissue sarcomas. Communication at 23rd Congress of ESMO, Athens, Greece, November 6-10, 1998 (1998)

  • Metastasectomy and chemotherapy for lung metastases from soft tissue sarcoma. Communication at 4th Annual Scientific Meeting, Vancouver, B.C., Canada, November 13-14, 1998 (1998)

  • H. MOURIDSEN, S. DAUGAARD, M. VAN GLABBEKE, A. KIRKPATRICK, J. VERWEIJ. Epirubicin is not a substitute for doxorubicin in advanced soft tissue sarcomas. Final data from the EORTC Soft Tissue and Bone Sarcoma Group. Communication at 4th Annual Scientific Meeting Vancouver, B.C., Canada, November 13-14, 1998 (1998)

  • Effect of high dose ifosfamide in advanced soft tissue sarcomas: A multicenter phase II study. ASCO 34th Annual Meeting, May 16-19, Los Angeles, U.S.A (1998)

  • Can we explain the different prognostic factors for response and survival in the various histological subtypes of advanced soft tissue sarcoma? An analysis of 2185 patients from the EORTC Soft Tissue and Bone Sarcoma Group database. Communication at 4th Annual Scientific Meeting Vancouver, B.C., Canada, November 13-14, 1998 (1998)

  • EORTC Data Center and STBSG. We need to confirm the results of small chemotherapy trials in advanced soft tissue sarcoma with randomized studies: The experience of the EORTC Soft Tissue and Bone Sarcoma Group. Communication at 4th Annual Scientific Meeting Vancouver, B.C., Canada, November 13-14,1998 (1998)

  • Prognostic factors for 1st line high dose chemotherapy outcome in advanced soft tissue sarcoma : An overview of 759 patients included in studies of the EORTC Soft Tissue and Bone Sarcoma Group. ASCO 34th Annual Meeting, May 16-19, 1998, Los Angeles, U.S.A (1998)

  • Association of docetaxel/ paclitaxel with irradiation in ovarian carcinoma cell lines in bidimensional (sulforhodamine B assay) and tridimensional (spheroids) cultures (1996)

  • In vitro evaluation of taxol® combined with radiations in human squamous cell carcinoma spheroids (1996)

  • Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. New Engl J Med 337: 295-300, 1997 (1997)

  • Randomized trial of alternating versus sequential radiotherapy/chemotherapy in limited-disease patients with small-cell lung cancer: A European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group (1997)

  • Randomized phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer (1997)

  • Linearity of pharmacokinetics and tissue distribution of C1311 (1997)

  • Assessment of murine metabolism of the imidazoacridinone C1311 (1997)

  • Antitumour activity and pharmacokinetics following oral administration of C1311. Proc. AACR 38: 306, 1997 (1997)

  • Low level multidrug resistance expression to C1311, a potential clinical candidate (1997)

  • Preclinical evaluation of novel imidazoacridinone derivatives with potent activity against experimental colorectal cancer (1996)

  • Pharmacokinetics and anti-tumour activity of V.4152, a reactive molecular combination of 5-fluorouracil and N-(2-chloroethyl)-N-nitrosourea, and its uracil analogue. Anti-Cancer Drug Design 11: 117-128, 1996 (1996)

  • Antitumor benzothiazoles. 3. Synthesis of 2-(4-aminophenyl)benzothiazoles and evaluation of their activities against breast cancer cell lines in vitro and in vivo. J. Med. Chem. 39: 3375-3384, 1996 (1996)

  • Of mice and men: things are much more difficult in men (1994)

  • Quality of life in patients with acute myelogenous leukemia in prolonged first complete remission after bone marrow transplantation (allogeneic or autologous) or chemotherapy: A cross-sectional study of the EORTC-GIMEMA AML 8A trial. Bone Marrow Transplantation 20: 307-315, 1997 (1997)

  • Measurement of workload in clinical trials (1997)

  • The implementation of nursing summaries (1997)

  • Non-surgical treatment in primarily resectable T3T4 larynx and hypopharynx SCC (1997)

  • Quality control program of radiation therapy in EORTC H8 protocol: The French centers experience (1997)

  • Phase I and pharmacokinetic study of ecteinascidin-743 (ET-743) given as a one hour infusion every 21 days (1997)

  • Clinical and pharmacokinetic evaluation of the new bisnaphtalamide LU 79553 administered every 21 days in patients with solid tumors: An EORTC/ECSG study (1997)

  • A phase I study with S-1, an oral 5-FU formulation, in patients with solid tumors (1997)

  • Pooled analysis of topotecan (T) in the second-line treatment of patients (pts) with sensitive small cell lung cancer (SCLC) (1997)

  • Phase II study of vinorelbine (NVB) in patients with metastatic and/or recurrent squamous cell carcinoma of the head and neck (SCCHN) (1997)

  • The identification of high risk patients with metastatic colorectal cancer (1997)

  • Cost-effectiveness in T1N0 glottic squamous cell carcinomas (SCC): Comparison between radiotherapy (RT), laser microsurgery (L) and partial laryngectomy (PL) (1997)

  • Achievements in the treatment of acute myelogenous leukemia (AML) (1997)

  • Neo-adjuvant chemotherapy in adult soft tissue sarcoma. EORTC PROTOCOL 62847 (1997)

  • New radiotherapy fractionation schemes in head and neck cancer. The EORTC trials: A benchmark (1997)

  • On behalf of the EORTC Early Clinical Studies Group (ECSG) and EORTC New Drug Development Office (NDDO). A phase II study with GI147211 in ovarian cancer (1997)

  • Design and regulations of clinical trials (1997)

  • Adjuvant hormonal therapy in locally advanced prostate cancer treated by external irradiation (1997)

  • PCR based detection of melanoma cells: Molecular staging? (1997)

  • An EORTC phase III study comparing orchidectomy (Ctr) and orchidectomy plus mitomycin C (Exp: 15 mg/m2 intravenously q6 wks until progression) with respect to quality of life in patients with poor prognosis M1 prostate cancer (1997)

  • Immediate hormonotherapy with an LHRH analogue improves local control and survival in patients with locally advanced prostate cancer treated by radiotherapy. A randomized phase III clinical trial of the EORTC (1997)

  • Quality of life as an outcome measure in cancer care (1997)

  • Phase II studies with GI147211 (GI) in breast (B), colorectal (C) and non small cell lung cancer (N) (1997)

  • Comparative study of intravesical instillation of epirubicin, BCG, or BCG + INH in intermediate and high risk pTa - pT1 papillary carcinoma of the urinary bladder. First results of EORTC 30911 (1997)

  • Docetaxel (D) in combination with amifostine (A) in metastatic breast cancer (MBC): A feasibility and pharmacokinetic study of the EORTC-investigational drug branch for breast cancer (IDBBC) (1997)

  • Taxol (T) versus doxorubicin (D) as first-line chemotherapy (CT) in advanced breast cancer (ABC): An EORTC randomized study with crossover (1997)

  • The development of a manual on research nursing: The ECSG research nurses group (1997)

  • Design of equivalence studies: Facts and fantasies (1998)

  • Response evaluation criteria in solid tumors; Better and simpler (1998)

  • Quality assurance in cancer services (1998)

  • Organization of preclinical and clinical research on anticancer therapy with biological response modifiers (BRMs) (1998)

  • Transfert d’énergie linéïque et radiosensibilité cellulaire. J. Chim. Phys. 95: 708-717, 1998 (1998)

  • Epidermal growth factor receptor and labelling index are independent prognostic factors in glial tumor outcome. Clinical Cancer Research 4: 2383-90, 1998 (1998)

  • The compound factor of the 10B(n,a)7Li reaction from Borocaptate Sodium and the relative biological effectiveness of recoil protons for induction of brain damage in boron neutron capture therapy. Radiation Research 149: 378-386, 1998 (1998)

  • Bór neutronbefogás terápia mint új kezelési mód (Boron neutron capture therapy as a new radiotherapy modality). Orvosi Hetilap 139 (12): 675-679, 1998 (1998)

  • Interaction of mercaptoundecahydrododeca- borate (BSH) with phosphatidylcholine: relevance to boron neutron capture therapy. Biochimica Et Biophysica Acta - Lipids and Lipid Metabolism 1391: 377-383, 1998 (1998)

  • Utilisation des codes Monte Carlo en neutronthérapie. J. Chim. Phys. 95: 851-6, 1998 (1998)

  • Combined use of FLUKA and MCNP-4A for the Monte Carlo simulation of the dosimetry of 10Boron Neutron Capture Enhancement of fast Neutron. Medical Physics 25: 885-91, 1998 (1998)

  • Selective delivery of 10B to soft tissue sarcoma using 10B-L-borophenylalanine for boron neutron capture therapy. The British Journal of Radiology 71: 320-323, 1998 (1998)

  • Calculation of boron neutron capture cell inactivation in vitro based on particle track structure and x-ray sensitivity. Radiat. Environ. Biophys. 37 : 117-123, 1998 (1998)

  • European clinical trials of boron neutron capture therapy for glioblastoma. Nuclear News 41: 54-56, 1998 (1998)

  • Evaluation of boron neutron capture effects in cell culture using suforhodamin-B assay and a colony assay (1998)

  • BNCT: Beyond glioma treatment? (1998)

  • Boron neutron capture therapy: principles and potential (1998)

  • Study preparation and patient treatment experience in the first European clinical trial on BNCT. Proc. of the first EU - US Workshop on Human BNCT Trials. Lund University, Lund, Sweden, 1998, pp 24 –29 (1998)

  • Quality control of Na2B12H11SH, a drug for Boron Neutron Capture Therapy in EORTC Trial 11961 (1998)

  • Post-operative treatment of Glioblastoma with Boron Neutron Capture Therapy at the European High Flux Reactor Petten (EORTC Protocol 11961) (1998)

  • Proton beam irradiation of high risk parapapillary, paramaculary uveal melanomas (1998)

  • Boron Neutron Capture Enhancement of fast neutrons for glioblastomas. J. Neuro. Oncol. 9:148, 1998 (1998)

  • Boron Neutron Capture Enhancement of Fast Neutron (BNCEFN) may open a therapeutic window for unresectable glioblastomas : Rationale of a clinical trial based on the Orleans Facility. Onkologie 20: 524, 1998 (1998)

  • and the EORTC BNCT Study Group. Boron Neutron Capture Therapy (BNCT) for the treatment of glioblastoma (EORTC Protocol 11961).Oncol. 48 (suppl 1) :S157, 1998 (1998)

  • Conducting phase I clinical trial in binary treatment modality: Methodical questions for the evaluation of Boron Neutron Capture Therapy (1998)

  • für die EORTC-BNCT-Studiengruppe. Bor-Neutroneneinfangtherapie: Eine neue Behandlungsmodalität auf dem europäischen Prüfstand. 4. Strahlenther. Onkol. 174 (Sondernr 1): 8, 1998 (1998)

  • Radiation treatment of follicle centre lymphoma (1998)

  • Quality control of Na2B12H11SH, a drug for boron neutron capture therapy in EORTC trial 11961. Proc. 8th International Symposium on Neutron Capture Therapy for Cancer, La Jolla, California, USA, September 13-18, 1998 (p.40) (1998)

  • The pharmacokinetics of BSH following single and multiple administrations. Proc. 8th International Symposium on Neutron Capture Therapy for Cancer, La Jolla, California USA, September 13-18, 1998 (p.176) (1998)

  • Reporting of BNCT irradiation:Application of the ICRU recommendations to the specific situation in BNCT. Proc. 8th International Symposium on Neutron Capture Therapy for Cancer, La Jolla, California, USA, September 13-18, 1998 (p.102-103) (1998)

  • Radioprotection dosimetry in the European trial on BNCT studied by an anthropomorphic phantom.Proc. 8th International Symposium on Neutron Capture Therapy for Cancer, La Jolla, California, USA, September 13-18, 1998.(p.173) (1998)

  • Intercomparison of the epithermal neutron-based clinical trials of BNCT. Proc. 8th International Symposium on Neutron Capture Therapy for Cancer, La Jolla, California, USA, September 13-18, 1998 (p.135) (1998)

  • Report on the first patient group of the European phase I trial (EORTC protocol 11961) at the High Flux Reactor Petten. Proc. 8th International Symposium on Neutron Capture Therapy for Cancer, La Jolla, California, USA, September 13-18, 1998( p.167) (1998)

  • Psychological aspects of the patient treatment by BNCT at Petten.Proc. 8th International Symposium on Neutron Capture Therapy for Cancer, La Jolla, California, USA, September 13-18, 1998 (p.153) (1998)

  • Study design of boron neutron capture reaction enhanced fast neutron therapy for treatment of inoperable glioblastoma. Proc. 8th International Symposium on Neutron Capture Therapy for Cancer, La Jolla, California, USA, September 13-18, 1998 (p.92) (1998)

  • Application of thermoluminscence dosimeters to mixed neutron-gamma dosimetry for BNCT. Proc. 8th International Symposium on Neutron Capture Therapy for Cancer, La Jolla, California, USA, September 13-18, 1998 (p.172) (1998)

  • Standard Operating Procedures Followed by the Petten BNC-Team during patient treatment.Proc. 8th International Symposium on Neutron Capture Therapy for Cancer, La Jolla, California, USA, September 13-18, 1998 (1998)

  • Radioprotection for patients and staff during BNCT at the HFR Petten. Proc. 8th International Symposium on Neutron Capture Therapy for Cancer, La Jolla, California, USA, September 13-18, 1998 ( p.154) (1998)

  • Use of Monte Carlo Simulation Techniques (FLUKA and MCNP) in the treatment of brain tumors. Séminaire au Fermi National Laboratory, Batavia, Ill., September 22, 1998 (1998)

  • Boron Neutron Capture Enhancement of Fast Neutron (BNCEFN clinical trial based for the Orleans Facility). Proc. 3rd International Symposium on Special Aspects of Radiotherapy : Controversies in Neuro-Oncology. Berlin, April 30 - May 2, 1998 (1998)

  • DIOP, A. HACHEM, R. SABATTIER, N. BRETEAU. Combined FLUKA and MCNP simulations of the BNCEFN dosimetry : enhancement of the thermal neutron flux through beam collimation and patient contention optimizations.Proc. 8th International Symposium on Neutron capture Therapy, San Diego, California USA, September 13-18, 1998 (1998)

  • Neutronen-Einfangreaktionen als Quelllen von Hoch-LET-Strahlung. Proc. 2. Jahrestagung der Gesellschaft für Biologische Strahlenforschung, Frankfurt/ Niederursel, Germany, September 23-25, 1998 (32) (1998)

  • Intratumoral microvessel density has prognostic value in soft tissue sarcomas (1997)

  • Is cisplatin-paclitaxel the standard in first-line treatment of advanced ovarian cancer? The EORTC GCCG, NOCOVA, NCI-C and Scottish intergroup experience (1997)

  • Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: Results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups (1997)

  • Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: A multiinstitutional Medical Research Council / European Organization for Research and Treatment of Cancer Trial (1997)

  • Systemic effect of intrathecal methotrexate during the initial phase of treatment of childhood acute lymphoblastic leukemia (1997)

  • Age is not a limiting factor for radical radiotherapy in pelvic malignancies (1997)

  • About the EORTC (1997)

  • Liposomal amphotericin B (Ambisome) and invasive aspergillosis. A randomized trial of 1mg/kg v 4 mg/kg. EORTC protocol 19923. Supportive Care in (1997)

  • An introduction to the statistical design of phase III cancer clinical trials (1997)

  • Quality of life as an outcome measure in cancer clinical trials (1997)

  • Economics of urinary tract cancers: State of the art (1997)

  • Evaluation and follow-up of patients with N1-3 M0 or NXM1 prostate cancer in phase III trials. Urology 49 (4A): 39-53, 1997 (1997)

  • Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than marker half-life: A study in patients with disseminated non-seminomatous testicular cancer (1997)

  • Hormonal therapy prolongs survival in irradiated locally advanced breast cancer: A European Organization for Research and Treatment of Cancer randomized phase III trial (1997)

  • Does isoniazid reduce side effects of intravesical bacillus calmette-guerin therapy in superficial bladder cancer? Interim results of European Organization for Research and Treatment of Cancer protocol 30911 (1997)

  • Radical surgery and post operative radiotherapy as combined treatment in rectal cancer. Final results of a phase III study of the European Organization for Research and Treatment of Cancer (1997)

  • Improving cancer survival in the next century (1997)

  • New trends in the treatment of adult acute myeloid leukaemia (1997)

  • The challenges and opportunities of cancer clinical research: EORTC perspectives (1997)

  • Quality of life as an outcome in EORTC clinical trials (1997)

  • Economic evaluation of cancer treatment strategies (1997)

  • Antimicrobial therapy in cancer patients: Studies from the EORTC International Antimicrobial Therapy Cooperative Group (1997)

  • Cancer Research and Treatment Towards the 21st Century (Proceedings of a Symposium held 27-26 April 1996, Heidelberg, Germany) (1997)

  • Biological therapy of cancer - From basic research to clinical application. Fourth International Symposium, 11-14 June 1997 (1997)

  • The use of a systemic therapy checklist improves the quality of data acquisition and recording in multicentre trials. A study of the EORTC Soft Tissue and Bone Sarcoma Group (1997)

  • Chemo-radiotherapy followed by surgery compared with surgery alone in squamous cell cancer of the esophagus. New Engl J Med 337: 161-167, 1997 (1997)

  • Ethical issues in cancer clinical trials: A European perspective (1997)

  • Book Review: Data Collection Forms in Clinical Trials (B. Spilker and J. Schoenfelder). Controlled Clin. Trials 13: 351-352, 1992 (1992)

  • European Organization for Research and Treatment of Cancer (EORTC): objectives, realizations and future perspectives. Bull. Mem. Acad. R. Med. Belg. 147: 334-342, 1992 (1992)

  • Book Review: Methodological Errors in Medical Research (B. Andersen). Controlled Clin. Trials 13: 91, 1992 (1992)

  • Book Review: Advanced Research Methodology: An Annotated Guide to Sources (R. Barker Bausell). Controlled Clin. Trials 13: 178-179, 1992 (1992)

  • EORTC Data Center Procedures Manual. Brussels, 1992, 143 pp (1992)

  • Implementation of eligibility checks at patient entry in phase II trials: The EORTC experience (1992)

  • Statistical Workshop: Practical Problems in Trial Analyses. Société Internationale d'Oncologie Pédiatrique, Hannover, Germany, October 12-16, 1992 (1992)

  • Leukemia: Chemotherapy or Bone Marrow Transplantation ? (Abs 52). Communication at the Meeting of the International Society for Clinical Biostatistics, Copenhagen, Denmark, August 17-21, 1992 (1992)

  • EuroCODE: A computerized network for communication. Communication at the 8th Annual Meeting of the EORTC Study Group on Data Management, Lyon, France, November 6-7, 1992 (1992)

  • EORTC, aims, achievements and future perspectives including collaboration with Czechoslovakia (1992)

  • Cancérologie: Recherche et traitement en cancérologie, implications nationales et internationales (1992)

  • L'Organisation Européenne pour la Recherche et le Traitement du Cancer (EORTC): Objectifs, réalisations et futures perspectives (1992)

  • Collaboration between EORTC and Egypt (1992)

  • Prospective patient registration in phase II trials. An asset for quality control. Proc. 7th NCI-EORTC Symposium on New Drugs in Cancer Therapy, Amsterdam, The Netherlands, March 17-20, 1992 (abs. 379) (1992)

  • Quality of life in clinical stage I-II Hodgkin's disease after the end of active oncological treatment. Experience from the EORTC/GPMC/GELA multicentre trial 20931 (1996)

  • Assessment of thyroid, pulmonary, cardiac and gonadal toxicity in stages I-II Hodgkin's disease (1996)

  • Usefulness of pathological diagnosis in the design of Hodgkin's disease trials (1996)

  • Prognostic factors for the partial remission after MOPP/ABV chemotherapy in stage III/IV Hodgkin's disease: results from the EORTC Lymphoma Cooperative Group and the Groupe Pierre-et-Marie-Curie phase III trial (1996)

  • Involved field radiotherapy for patients in partial remission after MOPP/ABV chemotherapy in stages III/IV Hodgkin's disease: results from the EORTC Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie (1996)

  • Melanoma in childhood: an EORTC-MCG multicenter study on the clinico-pathological aspects (1996)

  • A randomized trial of Inf alpha/IL-2 with or without CDDP in advanced melanoma: An EORTC Melanoma Cooperative Group Trial (1996)

  • The role of the nurse in clinical trials. Residential course Cancer Clinical Trials: Methods and Practice. Brussels, Belgium, November 12-15, 1996 (1996)

  • Metastatic osteosarcoma: the addition of HDMTX to DOX/DPP appears to improve outcome. Communication at CTOS Meeting, Toronto, Canada, October 10-13, 1996 (abs.) (1996)

  • Radiotherapy with concomitant chemotherapy superior to radiotherapy alone in the treatment of locally advanced anal cancer: Results of a phase III randomized trial of the EORTC Radiotherapy and Gastrointestinal Tract Cooperative Groups. Proc Am Soc Ther Radiol 36 (Suppl.): 210, 1996 (abs. P103) (1996)

  • Controlled clinical trial in high risk metastatic carcinoma of the prostate comparing pelvic radiotherapy alone to pelvic radiotherapy plus LHRG analogue. American Society for Therapeutic Radiology and Oncology. 38th Annual Meeting. Los Angeles October 27-30, 1996. Proc Am Soc Ther Radiol 36: 227, 1996 (abs. 138) (1996)

  • An overview of the EORTC accelerated and hyperfractionated radiotherapy trials in head and neck cancers (1996)

  • Non-surgical treatment of anal cancer. Communication at the VIth EORTC GITCCG Symposium 1996, Nijmegen, The Netherlands, June 20-21, 1996 (1996)

  • EORTC Radiotherapy Group Experience. Meeting on Rectal Cancer, Como, Italy, September 21, 1996 (1996)

  • Report of the EORTC in anal canal treatment. International Symposium on Advances in Radical Cancer Treatment, Madrid, Spain, November 14-15, 1996 (1996)

  • Concomitant chemoirradiation - EORTC experience. International Symposium on Advances in Radical Cancer Treatment, Madrid, Spain, November 14-15, 1996 (1996)

  • Metastatic osteosarcoma. The addition of HDMTX to DOX/DDP appears to improve outcome. Communication at the 2nd Annual Meeting of CTOS, October 1996 (1996)

  • Correlation between cisplatin mediated inhibition of telomerase activity and cell growth in human testicular cancer cell lines. Annals of (1996)

  • Preclinical evaluation of C1310 and C1311, novel imidazoacridinones with potential activity against colon cancer. Annals of (1996)

  • Pharmacokinetic analysis of the imidazoacridinone C1311 in tumour bearing mice. Ninth NCI-EORTC. Annals of (1996)

  • A pharmacological approach for the selection of potential anticancer agents. Annals of (1996)

  • Optimisation of EO9 activity in human tumour xenografts. Annals of (1996)

  • Structure-activity relationships in antitumour 2-(4-aminophenyl)benzothiazoles. Annals of (1996)

  • Paclitaxel versus Doxorubicin as first line chemotheapy in advanced breast cancer: A randomized trial with crossover of the EORTC-IDBBC in collaboration with EORTC-ECSG (1996)

  • Phase II study of navelbine in patients with metastatic and/or local recurrent squamous cell carcinoma of the head and neck (SCHNC) untreated by chemotherapy and with lesions within previously irradiated fields. Ann.Oncol. 7 (Suppl. 5):78, 1996 (abs.) (1996)

  • Phase II trial of cystemustine, a new nitrosourea, as second line treatment of malignant gliomas. Ann.Oncol. 7 (Suppl.5): 130, 1996 (abs.) (1996)

  • A promising regimen for treatment of squamous cell carcinoma of the head and neck: Docetaxel and cisplatin. Ann.Oncol. 7 (Suppl. 5):79, 1996 (abs.) (1996)

  • Results of a phase II trial with cystemustine in advanced malignant melanoma. A trial of the EORTC Clinical Screening Group [letter] (1996)

  • New promising anticancer agents in development: what comes next ? (1996)

  • Steroid hormone binding and hormone receptors (1996)

  • Organization, complexity and adaptative response of biological structures. Proc. Third European Congress on System Science, 1996 (1996)

  • Empirical treatment of fever in neutropenic children: the role of the carbapenems. The Pediatric Infectious Disease Journal 15: 744-748, 1996 (1996)

  • Molecular epidemiology of fluoroquinolone-resistant Escherischia coli bloodstream isolates from patients admitted to European cancer centers. Antimicrobial Agents and Chemotherapy, 40: 387-392, 1996 (1996)

  • Phase I trial of ZD1694, a new folate-based thymidylate synthase inhibitor, in patients with solid tumors (1996)

  • Reductase enzyme expression across the National Cancer Institute cell line panel: Correlation with sensitivity to mitomycin C and EO9 (1996)

  • Multicentre phase II pharmacological evaluation of rhizoxin (1996)

  • Development, pharmacology, role of DT-diaphorase and prospects of the indoloquinone EO9. Gen Pharmac 27: 421-429, 1996 (1996)

  • New roles for bisphosphonates in cancer therapy. Progress in Palliative Care 4 : 39-43, 1996 (1996)

  • The future of bisphophonates in cancer (1996)

  • Effects of bone metastases on bone metabolism : implications for diagnosis, imaging and assessment of response to cancer treatment. Cancer Treatment Reviews 22 : 289-331, 1996 (1996)

  • Imaging of metastatic bone disease. Imaging 8 : 256-273, 1996 (1996)

  • Phase II study of Navelbine in patients with metastatic and/or local recurrent Squamous Cell Carcinoma of the Head and Neck (SCHNC) untreated by chemotherapy and with lesions within previously irradiated fields. Proc. ESMO, 21, Vienna, Austria, November 1996 (abs. 371 O) (1996)

  • L'EORTC: Un centre d'excellence de la recherche clinique installé à... Bruxelles ! (1996)

  • Mitoxantrone-containing regimen of treatment of childhood acute leukemia (AML) and analysis of prognostic factors: Results of the EORTC Children Leukemia Cooperative Study 58872. Medical and Pediatric (1996)

  • A combined analysis of European Organization for Research and Treatment of Cancer and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. J. Urol. 156: 1934-1941, 1996 (1996)

  • A meta-analysis of prognostic factors of randomized trials of adjuvant chemotherapy in localized resectable soft tissue sarcoma using individual patient data (1995)

  • An overview of randomized perioperative polychemotherapy trials in early breast cancer (1995)

  • Results of the overview of randomized perioperative poly- and mono-chemotherapy trials in women with early breast cancer (1995)

  • Generalised estimating equations for repeated ordinal data analysis in SAS. Proc. PSI Annual Conference, Bristol, United Kingdom, 1994 (1994)

  • Protocole thérapeutique pour l'étude de la qualité de vie. Exemple de l'EORTC (1996)

  • Prostate cancer. An insight into screening and local treatment. Letter to the Editor (1996)

  • Radiothérapie hyperfractionnée et accélérée dans les cancers de la tête et du cou: résultats des essais de l'EORTC et impact sur la pratique clinique. Bulletin du Cancer / Radiothérapie 83: 314-320, 1996 (1996)

  • Is a boost dose essential in breast conserving therapy? An EORTC phase III study (22881/10882) (1996)

  • Radiotherapy with concomitant chemotherapy superior to radiotherapy alone in the treatment of locally advanced anal cancer: Results of a phase III randomized trial of the EORTC Radiotherapy and Gastrointestinal Tract Cooperative Groups. Proc Am Soc Ther Radiol 36, 1996 (1996)

  • Proc. Third International Workshop on ARCON, Umeå, Sweden, August 14-17, 1996 (abst.) (1996)

  • Tumor response, mucosal reactions and late effects after conventional and hyperfractionated radiotherapy (1996)

  • Immediate hormonal therapy improves locoregional control and survival in patients with locally advanced prostate cancer. Results of a randomized phase III clinical trial of the EORTC Radiotherapy and Genitourinary Tract Cancer Cooperative Groups. European Society For Therapeutic Radiology and Oncology. Radiat Oncol 40 (suppl. 1): S35, 1996 (abs. 127) (1996)

  • ARCON for glioblastoma: interim toxicity analysis. Proc. Third International Workshop on ARCON, Umeå, Sweden, August 14-17, 1996 (abs.) (1996)

  • A combined analysis of EORTC/MRC randomized clinical trials for the prophylactic treatment of TaT1 bladder cancer. EORTC Genito-Urinary Tract Cancer Cooperative Group and the Medical Research Council Working Party on Superficial Bladder Cancer. Acta Urol. Belg. 64: 27, 1996 (abs.) (1996)

  • Meta-analysis of EORTC/MRC randomized clinical trials for the prophylactic treatment of Ta, T1 bladder cancer. J. Urol. 155 (5 Suppl.): 493A, 1996 (abs. 727) (1996)

  • The EORTC Data Center Meta-Analysis Unit: Role and activities. Eur. Cancer News 9: 6-7; 1996 (1996)

  • Modulation of high-dose infusional 5-fluorouracil by low-dose methotrexate in patients with advanced or metastatic colorectal cancer: final results of a randomized EORTC trial (1996)

  • Adjuvant portal vein infusion of 5-FU and heparin in colorectal cancer. An EORTC-GIVIO intergroup phase III trial. Annal Oncol. 7 (suppl 5): 33 (A 1510), 1996 (1996)

  • Radiotherapy with concomitant chemotherapy superior to radiotherapy alone in the treatment of advanced anal carcinoma. VIth EORTC GITCCG Symposium 1996 (abs. p. 82) (1996)

  • Toxicity of FAMTX after curative resection of gastric cancer: A randomized phase III trial of the EORTC Gastrointestinal Tract Cancer Cooperative Group (GITCCG). VIth EORTC GITCCG Symposium 1996 (abs. p.83) (1996)

  • An EORTC-GIVIO intergroup phase III trial of adjuvant portal vein perfusion of 5-FU and heparin in colorectal cancer. VIth EORTC GITCCG Symposium 1996 (abs. p. 84) (1996)

  • The value of adjuvant portal vein infusion of 5-FU and heparin (PVI) in colorectal cancer: An EORTC - GIVIO inter-group phase III trial. Proc. EORTC-NCI Cairo joint meeting, November 1996, (abs. p 9) (1996)

  • Prognostic value of tuberculin and BCG in stage I high-risk malignant melanoma (EORTC protocol 18781) (1996)

  • Expression of MAGE genes in primary and metastatic cutaneous melanoma (1995)

  • Etude de la maladie résiduelle dans les leucémies aiguës de l'enfant. Arch. Pédiatr. 3 (Suppl. 1): 204s-205-s, 1996 (1996)

  • Quantification des blastes résiduels par PCR dans les LAL de l’enfant : une étude prospective multicentrique de l’EORTC. Société Française d’Hématologie, Paris, France, 9-10 February, 1996 (1996)

  • Devenir au long cours des enfants guéris de LAL. Communication at the XXXIe Congrès de l'Association des Pédiatres de Langue Française, Paris, France, May 1-4, 1996 (1996)

  • Indications et résultats des greffes de moelle. Communication at the XXXIe Congrès de l'Association des Pédiatres de Langue Française, Paris, France, May 1-4, 1996 (1996)

  • Etude de la maladie résiduelle dans les LAL. Communication at the XXXIe Congrès de l'Association des Pédiatres de Langue Française, Paris, France, May 1-4, 1996 (1996)

  • Interleukin-3 plus low-dose cytosine arabinoside for advanced myelodysplasia: a pilot study of the EORTC Leukemia Group. Cancer Invest. 14(4): 299-306, 1996 (1996)

  • Intensive antileukemic therapy including stem cell transplantation for high risk MDS and AML secondary to MDS in patients < 60 y. A joint study of the EORTC and the EBMT leukemia groups. Bone Marrorw Transplantation 17 (Suppl 1), 1996 (abs 60) (1996)

  • Evaluation of the influence of donor availability on treatment outcome for patients with AML: an analysis of the AML 8A study of the LCG of the EORTC and GIMEMA. Bone Marrorw Transplantation 17 (Suppl 1), 1996 (abs 443) (1996)

  • No age limit for radical radiotherapy in head and neck tumours (1996)

  • Chemoprevention of lung cancer (1996)

  • Docetaxel in advanced ovarian cancer: Preliminary results from three phase II trials. EORTC Early Clinical Trials Group and Clinical Screening Group, and the MD Anderson Cancer Center (1995)

  • A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) study 22844 (1996)

  • Continuing medical education in oncology (1996)

  • Surgical treatment of lung metastases: The EORTC-Soft Tissue and Bone Sarcoma Group study of 254 patients (1996)

  • Quality of life of patients with cancer. Communication at the Symposium on Cancer Research and Treatment towards the 21st Century, Heidelberg, Germany, April 26-27, 1996 (1996)

  • Kwaliteit van leven in de oncologie. Communication at the Symposium 'Oncologie voor de huisarts', Wetenschappelijke Vereniging van Vlaamse Huisartsen, Leuven, Belgium, May 11, 1996 (1996)

  • Quality of life as an endpoint in EORTC clinical trials. Communication at the Workshop 'Missing data in quality of life research on clnical cancer trials: practical and methodological issues', Swiss Group for Clinical Cancer Research, Horn, Switzerland, July 2-3, 1996 (1996)

  • Invited expert at the WHO Consensus Conference on Study Design and Evaluation of Clinical Trials on Prostate Cancer. Wallenberg Symposium. How is Quality of Life Influenced by Modern Treatment ? Stockholm, Sweden, September 12-13, 1996 (1996)

  • Adjuvant portal vein infusion of 5-FU and heparin in colorectal cancer. An EORTC-GIVIO intergroup phase III trial. Communication at the 21st Congress of the European Society for Medical Oncology (ESMO), Vienna, Austria, November 1-5, 1996 (1996)

  • The EORTC structure and activities (1996)

  • Quality of Life of women in EORTC trials (1996)

  • EORTC-Kernfragebogen QLQ-C30. Communication at the Conference: Gründungsverantstaltung der Arbeitsgruppe Lebensqualität, Arbeitsgemeeinschaft Urologische Onkologie, Deutsche Krebsgesellschaft, Frankfurt, Germany, September 13, 1996 (1996)

  • Endpoints in cancer clinical trials (1996)

  • Modular approach to Quality of Life assessment in oncology: An update (1996)

  • Clinical analysis of 670 cases in two trials of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group subtyped according to the revised European-American classification of lymphoid neoplasms: A comparison with the working formulation. Blood 87: 4358-4367, 1996 (1996)

  • Long term results versus 6-year results of a pioneer therapy tailored to prognostic factors: the H5 EORTC trial for clinical stage I-II Hodgkin's disease (CS I-II HD) (1996)

  • I. TEODOROVIC on behalf of the EORTC LYMPHOMA COOPERATIVE GROUP. Low dose total body irradiation versus combination chemotherapy for follicular lymphomas, long term results. Ann. Oncol 7 (Suppl. 3), 1996 (abs. 536) (1996)

  • Improved results of the adding Vincristine and Bleomycin to CHVmP in stage III-IV intermediate and high grade non Hodgkin's lymphoma (I/H gr NHL), a randomized study (1996)

  • Patients with stage III/IV Hodgkin's disease in partial remission after MOPP/ABV chemotherapy have excellent prognosis after additional involved field radiotherapy: Interim results from the ongoing EORTC LCG and GMPC phase III trial (1996)

  • EORTC LYMPHOMA COOPERATIVE GROUP. Treatment results in 67 patients with early-relapsed Hodgkin's disease (1996)

  • Subtyping of NHL according to the Revised European-American Classification of Lymphoid neoplasms (REAL) of 670 cases from two trials of the European Organisation for Research and Treatment of Cancer Lymphoma Cooperative Group (EORTC): Clinical analysis and comparison with the Working Formulation. Communication at the 6th International Conference on Malignant Lymphoma, Lugano, Switzerland, June 5-8, 1996 (1996)

  • Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. Pharmacology and Molecular Mechanisms Group of the European Organization for Research and Treatment of Cancer (1996)

  • Population pharmacokinetics of carboplatin in children. Clin. Pharmacol. Ther. 59 (4): 436-443, 1996 (1996)

  • Reductase enzyme expression across the National Cancer Institute cell line panel: Correlation with sensitivity to mitomycin C and EO9 (1996)

  • Introduction to statistical methods (1996)

  • Quality of life in clinical cancer trials: Experience and perspective of the European Organization for Research and Treatment of Cancer (1996)

  • Profile of radiotherapy departments contributing to the Cooperative Group of Radiotherapy of the European Organization for Research and Treatment of Cancer (1996)

  • Immediate hormonal therapy improves locoregional control and survival in patients with locally advanced prostate cancer. Results of a randomized phase III clinical trial of the EORTC Radiotherapy and Genito-Urinary Tract Cancer Cooperative Groups (1996)

  • EORTC trials on hyperfractionation and accelerated radiotherapy: results and impact on standard practice in head and neck cancers. Communication at the Balkan Congress of Oncology, Athens, Greece, July 3-7, 1996 (1996)

  • EORTC trials on hyperfractionation and accelerated radiotherapy: results and impact on standard practice in head and neck cancers (1996)

  • Immunoassays (ELISA) of urokinase-type plasminogen activator (uPA): Report of an EORTC/BIOMED-1 Workshop (1996)

  • EORTC SOFT TISSUE AND BONE SARCOMA GROUP (STBSG). Is high-dose chemotherapy of interest in advanced soft tissue sarcomas ? An EORTC randomized phase III trial (1996)

  • A model to assess cost-effectiveness of prophylaxis of febrile neutropenia. Proc. Second Educational Convention of the European School of Oncology, Vienna, Austria, June 27-29, 1996 (1996)

  • Quality of life of women in EORTC trials (1996)

  • A model to assess cost-effectiveness of prophylaxis of febrile neutropenia. (Proc. 2nd Educational Convention of the European School of Oncology) (1996)

  • The quality of life of patients with newly diagnosed M1 prostate cancer: Experience with EORTC clinical trial 30853 (1996)

  • Trial methodology. Presentation at the EORTC Workshop "One Day Introduction to EORTC Studies", Brussels, Belgium, 27 September 1996 (1996)

  • Statistical design of phase III clinical trials (1996)

  • Sample size calculations in phase III cancer clinical trials and examples of trial design (1996)

  • Analysis of prognostic factors (1996)

  • Introduction to the activities of the European Organization for Research and Treatment of Cancer (EORTC) and its meta-analysis unit. Invited presentation at the Faculté de Medecine, Université Catholique de Louvain, Brussels, Belgium, 18 March 1996 (1996)

  • Introduction to statistical principles and methodology of meta-analyses. Chairman and invited presentation at the European Symposium on Meta-Analysis: Methods and Practice, 26-27 April 1996, Brussels, Belgium (1996)

  • Basic statistics for non-statisticians and introduction to meta-analysis (1996)

  • Interim analyses and early stopping rules. Chairman and (1996)

  • Phase II study of Rhizoxin in squamous cell head and neck cancer (1996)

  • Data management of EORTC clinical trials (1996)

  • Phase II study of Liarozole in advanced breast cancer patients: Preliminary results (1996)

  • Phase II study of Liarozole in advanced breast cancer patients (1996)

  • Assessment of response in bone within an EORTC randomised trial of biphosphonate treatment (10924). Proc. 7th EORTC Breast Cancer Working Conference, Bordeaux, France, September 10-13, 1996 (abs. PP-8-7) (1996)

  • EORTC Investigational Drug Branch for Breast Cancer. A fruitful European collaboration in new drug development for breast cancer. Eur. Cancer News, 1996 (1996)

  • Résultats des protocoles de traitement des leucémies de l'enfant: à propos des études du groupe EORTC-CLCG. Arch. Pédiatr. 3 (Suppl. 1): 197s-200-s, 1996 (1996)

  • Résultats des protocoles de traitement des leucémies de l'enfant: à propos des études du groupe EORTC-CLCG. Communication at the XXXIe Congrès de l'Association des Pédiatres de Langue Française, Paris, France, May 1-4, 1996 (1996)

  • A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: Report of the Clinical Screening Group of the EORTC (1996)

  • Phase II clinical trials with rhizoxin in breast cancer and melanoma (1996)

  • Combined treatment with buserelin (LHRH-A) and tamoxifen vs single treatment with each drug alone in premenopausal metastatic breast cancer: Preliminary results of EORTC study 10881 (1996)

  • Pentostatin (2'-deoxycoformycin, dcf) in patients with low-grade (B-T-cell) and intermediate- and high-grade (T-cell) malignant lymphomas: Phase II study of the EORTC Early Clinical Trials Group (1996)

  • Improved local control and disease-free survival after perioperative chemotherapy in early breast cancer: A European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group Study (1996)

  • Docetaxel and cisplat (1996)

  • Phase II trial of vinorelbine in metastatic squamous cell esophageal carcinoma (1996)

  • Fotemustine in patients with advanced gastric cancer, a phase II trial from the EORTC-GITCCG (European Organization for Research and Treatment of Cancer, Gastrointestinal Tract Cancer Cooperative Group (1996)

  • Results of a phase II trial of epirubicin and cisplatin before and after irradiation and 5-fluorouracil in locally advanced pancreatic cancer: An EORTC GITCCG study (1996)

  • The "utility" of the visual analog scale in medical decision making and technology assessment. Is it an alternative to the time trade-off ? Intl. J. Technol. Assessment in Health Care 12: 291-298, 1996 (1996)

  • Prognostic factors in metastatic prostate cancer. Urology International 3: 17 - 18, 1996 (1996)

  • Cancers gastriques avancés - essai de phase III multicentrique comparant trois protocoles de chimiothérapie (ELF vs PFU vs FAMTX) (1996)

  • Therapie fortgeschrittener Analkarzinome: Kombinierte Radiochemotherapie der alleinigen Strahlentherapie überlegen. Communication at the 22. Deutscher Krebskongress, Berlin, Germany, February 20-24, 1996 (1996)

  • Cancers gastriques avancés. Essai de phase III multicentrique comparant trois protocoles de chimiothérapie (ELF vs PFU vs FAMTX). Communication at the Journées Francophones de Pathologie Digestive, Lille, France, March 23-27, 1996 (1996)

  • Toxicity of FAMTX after curative resection of gastric cancer: A randomized phase III trial of the EORTC Gastrointestinal Tract Cancer Cooperative Group (GITCCG). Communication at the VIth EORTC GITCCG Symposium 1996 - An Update after 25 Years Experience, Nijmegen, The Netherlands, June 20-21, 1996 (abs. p.53) (1996)

  • Single agent activity of Rhizoxin in non-small cell lung cancer: A phase II trial of the EORTC Early Clinical Trials Group (1996)

  • Economic evaluation of treatments of gastrointestinal cancer. Communication at the VIth EORTC GITCCG Symposium 1996 - An Update after 25 Years Experience, Nijmegen, The Netherlands, June 20-21, 1996 (abs.) (1996)

  • An EORTC-GIVIO intergroup phase III trial of adjuvant portal vein perfusion of 5-FU and heparin in colorectal cancer. Communication at the VIth EORTC GITCCG Symposium 1996 - An Update after 25 Years Experience, Nijmegen, The Netherlands, June 20-21, 1996 (abs. p. 54) (1996)

  • What oncologists need to know about health economic aspects of cancer treatment. Invited lecture. Seminars in Clinical and Experimental Oncology, Institut Jules Bordet, Brussels, Belgium, February 16, 1996 (1996)

  • Economic and quality of life aspects of the use of diphosphonates in the treatment of metastatic cancer patients. Invited lecture. Symposium on Diphosphonates in Bone Disease in Malignancy and Treatment Effects. Université Libre de Bruxelles, Belgium, March 27, 1996 (1996)

  • Health economics applied to the management of cancer. Invited lecture. Cancer Research and Treatment towards the 21st Century, Heidelberg, Germany, April 27, 1996 (1996)

  • Cost-effectiveness in cancer clinical trials (1996)

  • Evaluating the key alternative methodologies to ensure the optimal match between tools, products and outcomes. Invited lecture. Pharmecon Europe, Paris, France, June 12-13, 1996 (1996)

  • Evaluation economique en oncologie. Invited lecture. Séminaire Groupe d'Oncologie Clinique, Université Catholique de Louvain, Brussels, Belgium, June 15, 1996 (1996)

  • Economic evaluation of treatments of gastrointestinal cancer. Invited lecture. Communication at the VIth EORTC GITCCG Symposium 1996 - An Update after 25 Years Experience, Nijmegen, The Netherlands, June 20-21, 1996 (1996)

  • Invasive mycoses : a socio-economic and medical problem. Invited lecture. First Balkan Congress of Oncology, Athens, Greece, 3-7 July, 1996 (1996)

  • Economic issues in relation to cancer research, prevention, diagnosis and treatment. Invited lecture. First Balkan Congress of Oncology, Athens, Greece, 3-7 July, 1996 (1996)

  • Combined estrogen suppression and receptor (ER) blockade by Buserelin (LHRH-A) and Tamoxifen (TAM) in premenopausal metastatic breast cancer: preliminary results of a 3-arm randomized study (EORTC 10881) (1996)

  • Introduction to health economics (1996)

  • Current customs of usage of chemotherapy within Europe. Results of an EORTC survey. Communication at the 21st Meeting of the European Society for Medical Oncology (ESMO), Vienna, Austria, November 2-5, 1996 (1996)

  • Is economic evaluation of interest for oncologists ? Proc. 20th Congress of the European Society for Medical Oncology (ESMO), Vienna, Austria, November 2-5, 1996 (1996)

  • Randomization of the first patients: Examples from lymphoma trials (1996)

  • Trial methodology. Phase II, pilot and feasibility studies (1996)

  • Invited expert at the WHO Consensus Conference on Study Design and Evaluation of Clinical Trials on Prostate Cancer, Stockholm, Sweden, September 12-13, 1996 (1996)

  • Phase II study of cisplatin, vinblastine, and bleomycin in recurrent or advanced dysgerminoma (1995)

  • The final analysis of the EORTC Genito-Urinary Tract Cancer Cooperative Group phase III clinical trial (protocol 30805) comparing orchidectomy, orchidectomy plus cyproterone acetate and low dose stilboestrol in the management of metastatic carcinoma of the prostate (1995)

  • Phase I/II dose escalation study of cisplatin with or without amifostine in patients with advanced head and neck cancer (1995)

  • Opportunistic fungal infections in neutropenic patients (1995)

  • Neural networks and prognostic factors in ovarian cancer (1995)

  • A review of the safety of amphotericin B colloidal dispersion ('Amphocil'). Communication at the Third Biannual Symposium "Trends in Invasive Fungal Infections", Brussels, Belgium, September 7-9, 1995 (abs. 08) (1995)

  • Second line chemotherapy with bleomycin/vindesine (eldesine)/mitomycin-C (BEM) in cervical cancer patients, (1995)

  • Larynx preservation in hypopharynx SCC: Preliminary results of a randomized study (EORTC 24891). Proc. Annual Meeting SHNS, 1995 (abs. p. 71) (1995)

  • Tryptophan metabolites, pyridoxine (Vitamin B6) and their influence on the recurrence rate of superficial bladder cancer (1995)

  • Autologous bone marrow transplantation in the treatment of leukemia. Invited speaker at the 2nd International Congress on Leukemia "New Directions in Diagnosis and Treatment". Porto, Portugal, 22-25 February 1995 (1995)

  • Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. New Engl J Med 332: 217-223, 1995 (1995)

  • Repopulation after autologous bone marrow versus peripheral blood progenitor cell transplantation in younger patients with high risk myelodysplastic syndromes in complete remission after intensified induction therapy. A joint study of the EORTC LCG and the EBMT. Blood 86 (Suppl 1), Nov. 1995 (Abs 392) (1995)

  • Postremission therapy: the role of bone marrow transplantation in acute myelogenous leukemia (AML). International Symposium Acute Leukemia VI, Prognostic factors and Treatment Strategies, Munster, Germany, 25 February - 1 March 1995. Blut 70 (Suppl. 11), 1995 (abs 71) (1995)

  • Intensive remission-induction chemotherapy followed by autologous or allogeneic stem cell transplantation (SCT) for high risk MDS and AML secondary to MDS (sAML) in patients < 60 years. A joint study of the EORTC LCG and the EBMT. Blood 86 (Suppl 1), Nov. 1995 (Abs 2458) (1995)

  • GM-CSF during as well as after induction chemotherapy (CT) in elderly patients with acute myeloid leukemia (AML). The EORTC-HOVON phase Ill trial (AML 11). Blood 86 (Suppl 1) , Nov. 1995 (Abs 1719) (1995)

  • What agents would be used for treatment of candidemia in non-neutropenic patients? (1995)

  • Comparison of quality of life (QOL) of patients with acute myelogenous leukemias (AML) in long-term complete remission (CR) after bone marrow transplantation (BMT) - allogeneic or autologous - or intensive chemotherapy consolidation (ICC): EORTC AML 8A study (1995)

  • Diagnosis and treatment of acute myelgenous leukemia. Invited speaker at the 2nd International Congress on Leukemia "New Directions in Diagnosis and Treatment". Porto, Portugal, 22-25 February 1995 (1995)

  • Intensive chemotherapy for bad prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration. A pilot study by the EORTC Leukemia Cooperative Group of the European Organisation for Treatment and Research in Cancer (EORTC-LCG). Oral presentation by D. Selleslag at the Belgian Haematology Society, January 28, 1995 (1995)

  • Role of hematopoietic growth factors in the treatment of leukemia and related disorders. Invited speaker at the 2nd International Congress on Leukemia "New Directions in Diagnosis and Treatment". Porto, Portugal, 22-25 February 1995 (1995)

  • New developments in the diagnosis and treatment of adult lymphoblastic leukemia. Invited speaker at the 2nd International Congress on Leukemia "New Directions in Diagnosis and Treatment". Porto, Portugal, 22-25 February 1995 (1995)

  • Main questions in the treatment strategy of CML. Invited speaker at the 2nd International Congress on Leukemia "New Directions in Diagnosis and Treatment". Porto, Portugal, 22-25 February 1995 (1995)

  • High dose epirubicin is effective in measurable metastatic prostate cancer: a phase II study of the EORTC Genitourinary Group (1995)

  • Evaluation of the quality of peripheral blood progenitors (PBP) for autologous transplantation in adult philadelphia positive (Ph+) acute lymphoblastic leukemia (ALL): a pilot study. Blood 86 (Suppl 1), Nov. 1995 (Abs 3118) (1995)

  • Targeting Fungi: A Challenge, Plenary Lecture. 19th International Congress on Chemotherapy, Montréal, Canada, July 20, 1995. (abs. 0544) (1995)

  • New antifungals (1995)

  • Overview of therapy for invasive fungal infections (1995)

  • Increasing incidence and severity of invasive fungal infections (1995)

  • Fungemia in cancer patients in Europe (1995)

  • Antifungal strategies. Invited lecture, Session VII: Supportive Care, International Symposium Acute Leukemias VI - Prognostic Factors and Treatment Strategies, Münster, Germany, February 26 - March 1, 1995 (1995)

  • How should candidemia be managed in neutropenic patients? Invited lecture, International Advisory Board Conference for the Management of Invasive Candidiasis. Torrance, California, USA, April 20-23, 1995 (1995)

  • Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of the European Organization for Research and Treatment of Cancer (EORTC-LCG). Leukemia 9: 1805-1811, 1995 (1995)

  • State-of-the-art-lecture: Invasive fungal infections are a challenge for the patient, the practitioner and the researcher. 2nd Congress of the European Confederation of Medical Mycology (ECMM), Brussels, Belgium, April 27, 1995 (1995)

  • Meeting highlight 3rd Biannual Meeting "Trends in Invasive Fungal Infections" (1995)

  • Management of Invasive Fungal Infections in Cancer Patients (1995)

  • Management of Fungemia in Cancer Patients (1995)

  • Current Issues in the Management of Fungal Infections (1995)

  • The Management of Fungal Infections. State-of-the-art lecture at the 25th Anniversary Symposium, AZ Middelheim, Antwerp, Belgium, October 20, 1995 (1995)

  • A surveillance study of fungemia in cancer patients in Europe. Communication at 7th ECCMID, Vienna, Austria, March 26-30, 1995 (abs. 44) (1995)

  • Prophylaxie de l'aspergillose en onco-hématologie (1995)

  • A surveillance study of fungemia in cancer patients. Communication at the Third Biannual Symposium on Trends in Invasive Fungal Infections, Brussels, Belgium, September 7-9, 1995 (abs. O-2) (1995)

  • Non-surgical treatment of hepatocarcinoma. In : International Course on Digestive Oncology (E. van Cutsem, Ed), Leuven, Belgium, 1995, pp 255-274 (1995)

  • Preliminary analysis of a randomized phase III trial of FAMTX versus ELF versus Cisplatin/FU in advanced gastric cancer. A trial of the EORTC Gastrointestinal Tract Cancer Cooperative Group and the AIO (Arbeitsgemeinschaft Internistische Onkologie) (1995)

  • Chemotherapy of metastatic squamous cell esophageal carcinoma: the EORTC experience. Second International Conference on Gastrointestinal Oncology, Washington, USA, September 15-17 1995 (1995)

  • Prognostic factors in resectable gastric cancer: Results of EORTC Study n° 40813 on FAM adjuvant chemotherapy (1995)

  • Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: Results of two European Organization for Research and Treatment of Cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment. European Organization for Research and Treatment of Cancer Genitourinary Group. J. Urol. 153: 934-941, 1995 (1995)

  • Pharmacokinetics of EO9 in phase II trials (interim analysis). Proc. 2nd EORTC Early Drug Development Meeting, Corfu, Greece, June 22, 1995 (abs. p. 52 - ISBN 960-233-022-8) (1995)

  • Moving frontiers of cancer chemotherapy (opening address) (1995)

  • Integration of population pharmacokinetics into early clinical trials (1995)

  • New topoisomerase I inhibitors, from lab to clinic. Proc. 2nd EORTC Early Drug Development Meeting, Corfu, Greece, June 22, 1995 (abs. p. 15 - ISBN 960-233-022-8) (1995)

  • New drugs for the turn of the century. Communication at the 8th European Conference on Clinical Oncology (ECCO8), Paris, France, November 2, 1995 (1995)

  • Regional therapy for liver metastases from colorectal cancer.. In : International Course on Digestive Oncology (E. van Cutsem, Ed), Leuven, Belgium, 1995, pp 181-194 (1995)

  • Phase II studies with EO9 in breast, colorectal, gastric, pancreatic and non-small cell lung cancer. Proc. 2nd EORTC Early Drug Development Meeting, Corfu, Greece, June 22, 1995 (abs. p. 51 - ISBN 960-233-022-8) (1995)

  • Update on clinical studies with GI 147211, a new topoisomerase I inhibitor. Proc. 2nd EORTC Early Drug Development Meeting, Corfu, Greece, June 22, 1995 (abs. p. 18 - ISBN 960-233-022-8) (1995)

  • Final results of phase III clinical trial of adjuvant chemotherapy with the modified fluorouracil, doxorubicin and mitomycin regimen in resectable gastric cancer (1995)

  • Mitoxantrone in metastatic apudomas: a phase II study of the EORTC Gastro-Intestinal Tract Cancer Cooperative Group (1995)

  • Pancreatic cancer: a plea for more trials (1995)

  • Progress in the treatment of colorectal cancer : how to improve our results? In : International Course on Digestive Oncology (E. van Cutsem, Ed), Leuven, Belgium, 1995, pp 127-142 (1995)

  • Is there a treatment for the locally advanced and metastatic pancreatic cancer ? In : International Course on Digestive Oncology (E. van Cutsem, Ed), Leuven, Belgium, 1995, pp 299-312 (1995)

  • New promising agents in development: Who comes next (Kimura Memorial Lecture). Proc. 11th Nagoya International Cancer Treatment Symposium, Nagoya, Japan, November 24, 1995 (abs. p. 9) (1995)

  • Combined radiochemotherapy as adjuvant treatment of rectal cancer. Rationale, results and possible future directions (1995)

  • Improvement of radiotherapy in the management of rectal cancers. Proc. "Colorectal Cancer: from gene to cure", Amsterdam, February 9-11, 1995 (abstr.S03) (1995)

  • EORTC Late Effects Working Group. Late effects toxicity scoring: the SOMA scale. Radiother.Oncol. 35: 11-15, 1995 (1995)

  • Radiotherapy with concomitant chemotherapy proven to be superior to radiotherapy alone in the treatment of advanced anal carcinoma (1995)

  • Late effects consensus conference: RTOG/EORTC. Radiother.Oncol. 35: 5-7, 1995 (1995)

  • Introduction: Joint statement of mission by the RTOG/EORTC working groups (1995)

  • The EORTC randomized trial on three fractions per day and mizonidazole (trial n°22811) in advanced head and neck cancer; long term results and side effects (1995)

  • Improvement of curative management of rectal cancers by a better use of radiotherapy (1995)

  • The role of external irradiation in early prostate cancer (1995)

  • Quality assurance of the EORTC radiotherapy trial 22863 for prostatic cancer: the dummy run. Radiother.Oncol. 36: 229-234, 1995 (1995)

  • Correlation and prognostic value of pathological features, biological and clinical date before treatment, in high metastatic risk carcinoma of the prostate (1995)

  • Rationale for quality assurance. Proceedings "IAEA/ISRO Quality Assurance in Radiotherapy", Vienna, May 7-9, 1995 (abs p.1) (1995)

  • Complemenarity of independent reviews and institutional quality assurance programmes. Proc. "IAEA/ISRO Quality Assurance in Radiotherapy", Vienna, May 7-9, 1995 (abs p.13) (1995)

  • Quality assurance of radiotheray in breast conserving treatment: the experience of the EORTC Cooperative Group of Radiotherapy. Proc. 5th European Interuniversity Symposium of the Aristoteles Institute, Nauoussa, Greece, September 22-25, 1995, pp 72-73 (abs.) (1995)

  • ATP-based luminiscence assay of primary tumour cell cultures and cell lines. Communication at the Annual Scientific Meeting of the PTMG, Nice, France, December 16, 1995 (1995)

  • The EORTC randomized trial on three fractions per day and misonidazole (trial 22881) in advanced head and neck cancer: prognostic factors. Radiother.Oncol. 35: 100-106, 1995 (1995)

  • No improvement in survival by an increased radiation dose given postoperatively to patients (PTS) with low grade brain tumors: An EORTC randomized phase III study (1995)

  • Verbesserte kontinenz nach radiochemotherapie fortgeschrittener analkarzinome. Ergebnisse einer randomisierten EORTC studie. Funktionalität statt radikatitat in der onkologie, Rothemburg, Germany, 1995 (1995)

  • Altered fractionation in head and neck radiotherapy: where do we stand? European School of Oncology, "Radiotherapy 2000", Lugano, Switzerland, July 10-14, 1995 (1995)

  • Modulation of cisplatin (CDDP) cytotoxicity by all-trans retinoic acid (ATRA) on human ovarian carcinoma cell lines. Communication at the Annual Scientific Meeting of the PTMG, Nice, France, December 16, 1995 (1995)

  • EORTC cooperative trials of hyperfractionation and accelerated radiotherapy in head and neck cancers. Annual Meeting of the Canadian Association of Radiation Oncologists, Montreal, Canada, September 16, 1995 (1995)

  • New approaches in radiotherapy treatment. FECS Official Press conference, ECCO 8, Paris, October 30, 1995 (1995)

  • The need for development of quality assurance programmes in cancer treatment. Offical Press Conference during ECCO 8, Paris, November 2, 1995 (1995)

  • 77th Annual Meeting of the American Radium Society, Paris, France, April 29 - May 3, 1995 (1995)

  • Analysis of the results of the EORTC trial 22851. Celebration of the radiobiology achievements in clinical radiotherapy, Cancer Research Campaign, Mount Vernon Hospital, Gray Laboratory, London U.K., October 17, 1995 (1995)

  • EORTC trials on hyperfractionated and accelerated radiotehrapy in head and neck cancers. 5th International Meeting on Progress in Radio-Oncology, Salzburg, May 10-14, 1995 (1995)

  • Quality assurance programme in radiotherapy: physical and clinical aspects - the EORTC experience. European School of Oncology, "Radiotherapy 2000", Lugano, Switzerland, July 10-14, 1995 (1995)

  • Prognostic factors for the partial remission after MOPP/ABV chemotherapy in stage III/IV Hodgkin's disease: results from the EORTC Lymphoma Cooperative Group and the Groupe Pierre-et-Marie-Curie phase III trial. Third International Symposium on Hodgkin's Lymphoma, Köln, Germany, 1995 (abs. 134) (1995)

  • Steroids do reduce the severity and delay the onset of docetaxel (DXT) induced fluid retention: final results of a randomized trial of the EORTC Investigational Drug Branch for Breast Cancer (IDBBC) (1995)

  • Relationships between EBV infection, clinical, biological and histologic characteristics and response to therapy in patients with Hodgkin's disease. Third International Symposium on Hodgkin's Lymphoma, Köln, Germany, 1995 (abs. 9) (1995)

  • Third International Symposium on Hodgkin's Lymphoma, abstr. 127. Köln, Germany, 1995 (abs. 127) (1995)

  • Third International Symposium on Hodgkin's Lymphoma, Köln, Germany, 1995 (abs. 106) (1995)

  • Interferon-Alfa 2a vs control as maintenance therapy for low grade Non-Hodgkin's lymphoma: results from a prospective randomized clinical trial. Abstract BHS - Genval, Belgium, February 9, 1995 (1995)

  • Assessment of thyroid, pulmonary, cardiac and gonadal toxicity in stages I-II Hodgkin's disease. Third International Symposium on Hodgkin's Lymphoma, Köln, Germany, 1995 (abs. 72) (1995)

  • Mantle cell lymphoma (MCL) a clinico-pathological entity based on retrospective analysis of 557 cases of non Hodgkin's lymphoma (NHL) and 58 cases of mantle cell lymphoma in two EORTC studies. EORTC Lymphoma Group (1995)

  • Involved field radiotherapy for patients in partial remission after MOPP/ABV chemotherapy in stage III/IV Hodgkin's disease: results from the EORTC Lymphoma Cooperative Group and the Groupe Pierre-et-Marie-Curie phase III trial. Third International Symposium on Hodgkin's Lymphoma, Köln, Germany, 1995 (abs. 78) (1995)

  • Clinical analysis of 777 NHL cases subtyped according to the Revised European-American Classification of Lymphoid Neoplasms: an EORTC Lymphoma Group Study (1995)

  • for the EORTC MELANOMA COOPERATIVE GROUP. Melanoma and the use of sunscreens an EORTC case-control study in Germany, Belgium and France (1995)

  • Expression of MAGE genes in primary and metastatic cutaneous melanoma (1995)

  • Chemo-Immunotherapy of melanoma: is it time for phase III trials? (1995)

  • Prognostic factors response and survival in patients with metastatic melanoma receiving immunotherapy (1996)

  • Role of tumoral folylpolyglutamate synthetase and thymidylate synthase for predicting response to fluorouracil chemotherapy for hepatic metastases of colorectal carcinoma. Communication at the Annual Scientific Meeting of the PTMG, Nice, France, December 16, 1995 (1995)

  • Third International Symposium on Hodgkin's Lymphoma, abstr. 131. Köln, Germany 1995 (abs. 131) (1995)

  • EORTC phase III trial of standard versus alternating chemotherapy in extensive disease small cell lung cancer (1995)

  • Acute toxicity of alternating schedule of chemotherapy and irradiation in limited small-cell lung cancer in a pilot study (08877) of the EORTC Lung Cancer Cooperative Group. Annals Oncol 6: 403-405, 1995 (1995)

  • Teniposide for brain metastases of small cell lung cancer. A phase II study (1995)

  • Randomized phase III trial of edatrexate versus methotrexate in patients with metastatic and/or recurrent squamous cell carcinoma of the head and neck: A European Organization for Research and Treatment of Cancer Head and Neck Cancer Cooperative Group study (1995)

  • N-acetylcysteine for lung cancer prevention. Chest 107: 1437-1441, 1995 (1995)

  • New drugs in the treament of lung cancer. Proc. 3rd Central European Lung Cancer Conference, Prague, Czech Republic, May 28-31, 1995 (abs. L46, p.74) (1995)

  • A randomized comparison of chop vs. a new combination of VP16, mitoxantrone and prednimustine (VMP) in patients (PTS) > 70 years of age with intermediate high grade NHL: An EORTC Lymphoma Group study (1995)

  • Randomized comparison of alternating or sequential schedules of chemoradiotherapy in limited small cell lung cancer. Trial of the EORTC Lung Cancer Cooperative Group (08877) (1995)

  • A randomized trial of the INFa and IL-2 +/- cisplatinum in advanced melanoma: a preliminary analysis. Third Intl. Symp. Biological Therapy of Cancer, Munich, Germany, April 19-22, 1995 (1995)

  • Phase II study of Topotecan in refractory and sensitive small cell lung cancer. Proc. AACR 36: 237, 1995 (1995)

  • Overview of EORTC mesothelioma trials (1995)

  • Overview of current EORTC Lung Cancer Cooperative Group trials (1995)

  • Maladie de Hodgk (1995)

  • Efficacy of four different regimens in 64 mantle-cell lymphoma cases: Clinicopathologic comparison with 498 other non-Hodgkin's lymphoma subtypes (1995)

  • Contingency tables and Mosaic display of log-linear models. Communication at the EORTC Data Center Seminar, Brussels, Belgium, May 16, 1995 (1995)

  • The principle of maximum likelihood and partial likelihood. Communication at the EORTC Data Center Seminar, Brussels, Belgium, September 20, 1995 (1995)

  • A clinical database management system: results of a research project and a demonstration of a prototype. Communication at the EORTC Data Center, Brussels, Belgium, February 3, 1995 (1995)

  • Evaluation of toxicity. Communication at the Consensus Meeting on the Methodology of Combined Chemo- Radiotherapy Trials, Genoa, Italy, March 24-25, 1995 (1995)

  • The Anderson and Gill model, a 'generalized' Cox model for event history analysis. Communicationn at the EORTC Data Center, Brussels, Belgium, September 6, 1995 (1995)

  • Stability of risk groups: A bootstrap investigation. Communication at the Annual Meeting of the Belgian Statistical Society, Houthalen, Belgium, October 13-14, 1995 (1995)

  • Overview of EORTC activities (1995)

  • Outcome measurements (1995)

  • Quality assurance in cancer management: the EORTC perspective. Communication at the EORTC-ESO Course "One-Day Introduction to EORTC Studies", Brussels, Belgium, September 29, 1995 (1995)

  • Quality of life and utility measurement (1995)

  • The EORTC approach to assessment of quality of life (1995)

  • Improving the standard of quality of life data collection within EORTC trials (1995)

  • Quality of life (1995)

  • Quality of life studies (1995)

  • Mesurer la qualité de vie des patients cancéreux (1995)

  • Data management procedures and case report forms. Different steps of clinical research (1995)

  • Ethics in Cancer Clinical Trials: A European Perspective: Communication at the European Cancer Conference (ECCO 8) Paris, November 1-2, 1995 (1995)

  • Design of the protocol and design of the CRF (1995)

  • Methodology of cancer clinical trials in elderly patients (1995)

  • Overview of EORTC activities including the importance of conducting pivotal clinical trials (1995)

  • Quality of life in clinical cancer trials: The experience and perspectives of the EORTC (1995)

  • Cost evaluation of treatment modalities in cancer patients (1995)

  • The economics of urinary tract cancer. Invited lecture, EORTC Seminar on Urinary Tract Cancer : State of the Art. Brussels, Belgium, November 8-9, 1995 (1995)

  • Taxoid compounds in breast cancer: current status and future prospects (1995)

  • Quality of life around the globe (1995)

  • Eine Einführung in die statistischen Aspekte der Planung von klinischen onkologischen Studien der Phase III. Urologe [A] 34: 367-373, 1995 (1995)

  • A proposal for a new approach to intergroup cancer trials (1995)

  • Identifying patients with a high risk of relapse in quiescent Crohn's disease. Gut 37: 811-818, 1995 (1995)

  • GCP: A European way forward for professionals (1995)

  • European Forum for GCP: Training clinical investigators and their staffs on GCP standards (1995)

  • European Forum for GCP: The protocol (1995)

  • European Forum for GCP: GCP and computer use at investigator sites (1995)

  • Introduction to statistical methods (1995)

  • Coordination of a centralized facility for clinical trials in oncology (1995)

  • Prospects, priorities and recommendations for clinical cancer research (1995)

  • The monitoring and reporting of clinical trials (1995)

  • Prisen P. ( Medicin. FADLs Debatbrøger Nr 5. Foreniger af Dankse Laegestuderendes Forlag, København, (rhus, Odense, 1995, 133 pp (1995)

  • An integrated system for the meta-analysis of individual patient data: MAIS-PC. Controlled (1995)

  • Tumor bulk, histology, and baseline hemoglobin may influence response (RR) in platinum pretreated ovarian cancer (OVCA) (1995)

  • Elaboration, gestion, exploitation d'un essai randomisé. Bull (1995)

  • Challenges of clinical research (1995)

  • Statistical design of phase III clinical trials (1995)

  • Data collection and data bases (1995)

  • Cost-effectiveness analysis of treating acute myeloid leukemia. Communication at the EORTC Leukemia Cooperative Group meeting, Rome, Italy, March 30-April 1, 1995 (1995)

  • Cancer clinical research in Europe: The EORTC perspective (1995)

  • Economic evaluation, a practical issue. Communication at the IBES Seminar for the Ministère des Affaires Economiques, Brussels, Belgium, February 22, 1995 (1995)

  • Results and discussion : Autologous BMT overview. Communication at the First Main Meeting of the AML Collaborative Group. Oxford, UK, January 29-30, 1995 (1995)

  • User requirements for the meta-analysis of individual patient data. Communication at the Sixteenth Annual Meeting of the Society for Clinical Trials, Seattle, USA, April 30-May 3, 1995 (1995)

  • An introduction to the statistical design of phase III cancer clinical trials (1995)

  • Role of the EORTC Data Center. Invited lecture, A One-Day Introduction to EORTC Studies, Brussels, Belgium, September 29, 1995 (1995)

  • Meta-analysis in fungal infections. The role of Cochrane Collaboration (1995)

  • Interim analyses and early stopping rules (1995)

  • Analysis of prognostic factors (1995)

  • Methodology and analysis of leukemia trials (1995)

  • Prognostic factors of patients with acute myeloid leukemia (AML) allografted in first complete remission: an analysis of the EORTC-GIMEMA AML 8A trial (1996)

  • Results and discussion: Autologous BMT overview. Second Main Meeting of the AML Collaborative Group. Oxford, United Kingdom, September 6-7, 1996 (1996)

  • Randomized phase III study of induction (ICE vs MICE vs DCE) and intensive consolidation (IDIA vs NOVIA vs DIA) followed by stem cell transplantation in AML : EORTC/GIMEMA AML10 study. Eight International Symposium on autologous marrow and blood transplantation, Arlington, USA, August 18-21, 1996 (1996)

  • An approach for evaluating the cost-effectiveness and impact on quality of life of inpatient treatment versus outpatient treatment during consolidation chemotherapy in elderly patients with acute myeloid leukemia (1996)

  • Evaluation of the influence of center size on treatment outcome for patients (15-45 years old) with AML: an analysis of the AML 8A study of the Leukemia Cooperative Groups of the EORTC and GIMEMA. British Journal of Haematology, 39 (Suppl 2), 1996 (abs 837) (1996)

  • Auto or allotransplantation for bcr-abl+ adult acute lymplhoblastic leukemia (ALL). A pilot study by French LALA, GIMEMA and EORTC Cooperative Groups. British Journal of Haematology, 39 (Suppl 2), 1996 (abs 977) (1996)

  • Salvage treatment for primary resistant acute myelogenous leukemia consisting of intermediate-dose cytosine arabinoside and interspaced continuous infusions of idarubic (1996)

  • The EORTC trials for acute myelogenous leukemia. Hematol. Cell Ther. 38: 247-252, 1996 (1996)

  • Can the forest plot be simplified without loosing relevant information in meta-analyses? Controlled (1996)

  • Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: A randomized trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative Group (1996)

  • Evaluation of allogeneic BMT. Second Main Meeting of the AML Collaborative Group. Oxford, United Kingdom, September 6-7, 1996 (1996)

  • Methodology of the comparison BMT vs Chemotherapy. Seventh Annual Meeting of the International BFM Study Group. Gent, Belgium, May 3-5, 1996 (1996)

  • Cisplatin and etoposide combination for locally advanced or metastatic thymoma: A phase II study of the EORTC Lung Cancer Cooperative Group (1996)

  • A randomized study of high-dose split course radiotherapy preceded by high-dose chemotherapy versus high-dose radiotherapy only in locally advanced non-small-cell lung cancer. An EORTC Lung Cancer Cooperative Group trial (1996)

  • Standard versus alternating non-cross resistant chemotherapy in extensive disease small cell lung cancer. An EORTC phase III trial (1996)

  • Two schedules of teniposide with or without cisplatin in advanced non-small-cell lung cancer: A randomized study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group (1996)

  • A model to assess cost-effectiveness of prophylaxis of febrile neutropenia (1996)

  • Paclitaxel-cisplatin versus teniposide-cisplatin in advanced non-small cell lung cancer (1996)

  • Effects of prophylactic cranial irradiation in small cell lung cancer. Results of UKCCCR/EORTC randomised trial (1996)

  • Prognostic factors in patients with pleural mesothelioma. The EORTC phase II experience (1996)

  • Cervical cancer: Chemotherapy with different combinations and modalities. European experience utilizing new drugs and different approaches. Communication at the Educational Session on Cervical Cancer, ASCO, Philadelphia, USA, May 18, 1996 (1996)

  • Identifying poor prognosis patients with malignant mesothelioma: The EORTC experience. Communication at the 4th Central European Lung Cancer Conference, Gdansk, Poland, September 26-29, 1996 (1996)

  • The role of radiotherapy in the treament of brain metastases of small cell lung cancer. An EORTC phase II and III study (1996)

  • The importance of prognostic factors in the interpretation of metastatic prostate cancer trials (1996)

  • Genitourinary group phase II study of chemotherapy in stage T3-4 N0-X M0 transitional cell cancer of the bladder: Prognostic factor analysis (1996)

  • New anticancer drugs with therapeutic future. V Congreso Asociacion Espanola de Investigacion Sobre el cancer, Las Palmas de Gran Canaria, Spain, September 29, 1993 (1993)

  • Toxicity overview in phase II studies with docetaxel (taxotere). EORTC Early Drug Development Meeting, Rotterdam, The Netherlands, September 24, 1993 (1993)

  • New antimitotics, where are we now and where are we going? EORTC Early Drug Development Meeting, Rotterdam, The Netherlands, June 25, 1993 (1993)

  • Phase I clinical trials. Postgraduate course on Anticancer Drug Development, Amsterdam, The Netherlands, September 10, 1993 (1993)

  • Topotecan: phase I and phase II studies. European School of Oncology Seminar "New Drugs in Cancer Therapy", Corfu, Greece, September 18, 1993 (1993)

  • Phase II study with Topotecan in colorectal cancer. EORTC Early Drug Development Meeting, Rotterdam, The Netherlands, June 24, 1993 (1993)

  • New anticancer drug development in Europe. NCIC Clinical Trials Group Meeting - Investigational New Drug Committee, Ottawa, Canada, October 17, 1993 (1993)

  • Overview of docetaxel activity in a broad range of solid tumors. Symposium: Docetaxel, a new generation taxoid compound, Jerusalem, Israel, November 14, 1993 (1993)

  • Phase I study on EO9 given every 3 weeks. European Conference on Clinical Oncology, Jerusalem, Israel, November 18, 1993 (1993)

  • Phase I study on EO9 given every 3 weeks. 7th European Conference on Clinical Oncology, Jerusalem, Israel, November 16, 1993 (1993)

  • Phase II study with Topotecan in colorectal cancer. EORTC Early Drug Development Meeting, Rotterdam, The Netherlands, September 24, 1993 (1993)

  • Phase II clinical trials. Postgraduate course on Anticancer Drug Development, Amsterdam, The Netherlands September 10, 1993 (1993)

  • Comparison of CA 125 kinetics and WHO criteria to evaluate chemotherapy response (R): An EORTC ovarian cancer (O.C.) study with Taxotere (T). Proc ASCO 13: 269 (859), 1994 (1994)

  • EORTC: Phase I study of the bioreductive indoloquinone EO9 (1994)

  • A phase II trial of the Early Clinical Trials Group (ECTG) (1994)

  • EORTC Early Clinical Trials Group, Amsterdam, NDDO, Amsterdam: Final Results of a Large Phase II Clinical Trial of Docetaxel (TaxotereTM, RP56976) in Advanced Ovarian Cancer (OV CA) Patients (pts) Failing Platinum (PT) (1994)

  • Phase I clinical trial of Carzelesin (U80244) administered on a 4-weekly i.v. bolus schedule (1994)

  • Chimiothérapie de première ligne des cancers du sein avancés avec métastases cutanées: résultats de deux essais Phase II avec la Navelbine et le Docétaxel. Congrès de Cancérologie Cutanée, Nantes, France, June 11, 1994 (1994)

  • Comparison of CA 125 kinetics and WHO criteria to evaluate chemotherapy response (R): An EORTC ovarian cancer (O.C.) study with Taxotere (T) (1994)

  • Limited sampling model for EO9, a novel indoloquinone cytotoxic drug (1994)

  • Should there be size restricitions on indicator lesions for phase II trials? Proc 8th EORTC-NCI, (1994)

  • Proc Int Conf Biored Drug Activation, page 17, 1994 (1994)

  • Activity of Docetaxel (Taxotere) in small cell lung cancer (1994)

  • Phase II trial of CPT-11 in patients with advanced pancreatic cancer (1994)

  • Phase II study of Topotecan (TC) in patients (pts) with pretreated small cell lung cancer (SCLC). Proc Journal of the international association for the study of lung (1994)

  • Topotecan in colorectal cancer, a phase II study of the EORTC Early Clinical Trials Group. Proc 8th NCI-EORTC, (1994)

  • Essai de phase II du CPT-11 (irinotécan) dans le cancer avancé du pancréas. L'experience de l'Early Clinical Trials Group (ECTG) (1994)

  • Phase Ii study of Topotecan in pretreated small cell lung cancer (SCLC). Proc ASCO 336 (1116), 1994 (1994)

  • Phase II studies of Elsamitrucin in breast cancer, colorectal cancer, non-small cell lung cancer, and ovarian cancer (1994)

  • Docetaxel (TaxotereTM), an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck (1994)

  • Docetaxel (TaxotereTM) in advanced gastric cancer: results of a phase II clinical trial (1994)

  • Gemcitabine in patients with advanced malignant melanoma or gastric cancer: phase II studies of the EORTC Early Clinical Trials Group (1994)

  • Phase I and pharmacologic study of the novel indoloquinone bioreductive alkylating cytotoxic drug EO9 (1994)

  • Docetaxel (TaxotereTM) is active in non-small cell lung cancer: a phase II trial of the EORTC early clinical trials group (ECTG) (1994)

  • Docetaxel (Taxotere) in advanced malignant melanoma: a phase II study of the EORTC Early Clinical Trials Group (1994)

  • Docetaxel (Taxotere) in advanced renal cell cancer. A phase II trial of the EORTC Early Clinical Trials Group (1994)

  • A phase II study of Gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck (1994)

  • Phase II studies with Rhizoxin in breast cancer, head & neck cancer, and melanoma. Proc ESMO (1994)

  • A phase II trial with Docetaxel (TaxotereTM) in second line treatment with chemotherapy for advanced breast cancer. A study of the EORTC Early Clinical Trials Group (1994)

  • Toxicity analysis of adjuvant FEMTX or FAMTX for resected gastric cancer. Second International Conference on Biology, Prevention and Treatment of Gastrointestinal Malignancies, Köln, Germany, January 9-12, 1995 (1994)

  • Is cyclosporin neurotoxicity enhanced in the presence of liposomal amphotericin B. J. Infec. 29: 106-107, 1994 (1994)

  • Reduction of fever and streptococcal bacteremia in granulocytopenic patients with cancer (1994)

  • Thromboembolic complications after perioperative chemotherapy in women with early breast cancer : A European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group Study (1994)

  • Perioperative chemotherapy in early breast cancer: Past, present and future (1994)

  • Quality assessment in breast conserving surgery : documentation and analysis of the surgical procedure (1994)

  • Adjuvant therapy with dibromodulcitol and BCNU increases survival of adults with malignant gliomas. Communication at the 1st Neuro-Oncology Conference, Maastricht, The Netherlands, October 1994 (1994)

  • Adjuvant therapy with dibromodulcitol and BCNU increases survival of adults with malignant gliomas. Communication at the European Neurological Society, Barcelona, Spain, June 1994 (1994)

  • Adjuvant therapy with dibromodulcitol and BCNU increases survival of adults with malignant gliomas. Communication at the American Academy of Neurology, Washington, DC, USA, May 1994 (1994)

  • Age effect on the survival of patients with glioblastoma and anaplastic astrocytoma (1994)

  • High dose chemotherapy with ABMT/PBSCT in breast cancer in Europe in 1993 : what is going on ? Communication at the 20th Annual Meeting of the European Group for Bone Marrow Transplantation, Harrogate, UK, 13-17 March 1994 (1994)

  • Non tumoral death after megatherapy for neuroblastoma. The EBMT experience. Communication at the 20th Annual Meeting of the European Group for Bone Marrow Transplantation, Harrogate, UK, 13-17 March 1994 (1994)

  • Current issues on the prophylaxis and the management of fungal infections in leukemic patients (1994)

  • Chemotherapy of soft tissue sarcomas under cover of hemapoietic growth factors. ACO Schwerpunktsymposium "Weichteil sarkome", Vienna, Austria, September 30, 1994 (1994)

  • Phase II study of Lobaplatin in head and neck cancer. Proc. 8th NCI - EORTC Symposium on New Drugs in Cancer Therapy, Amsterdam, The Netherlands, 1994 (abs. 218) (1994)

  • Phase II trial of cystemustine, a new nitrosourea, as second line treatment of malignant glioma. 19th Congress of the European Society for Medical Oncology. November 18-22 1994, Lisbon, Portugal, abs. P62 (1994)

  • Results of a phase II trial with eystemustine in advanced non small cell lung cancer (NSCLC) ( EORTC 04891). 19th Congress of the European Society for Medical Oncology, November 18-22, 1994, Lisbon, Portugal, abs. P928 (1994)

  • Comparison of CA125 kinetics and WHO criteria to evaluate chemotherapy response (R): an EORTC ovarian cancer study with Taxotere. 19th Congress of the European Society for Medical Oncology, November 18-22, 1994, Lisbon, Portugal, abs. P502 (1994)

  • Réponse à la comparaison des variations du taux de CA 125 et les critères OMS pour évaluation de la réponse à la chimiothérapie dans les cancers de I'ovaire : expérience de I'EORTC avec le Docetaxel. 14e Forum de Cancérologie, Paris, France, May 30-June 1, 1994. Bull (1994)

  • Comparison of CA 125 kinetics and WHO Criteria to evaluate chemotherapy response : an EORTC ovarian cancer study with Taxotere (1994)

  • Activity of Taxotere (Docetaxel) in liver metastasis of advanced breast cancer : analysis on 17 patients. Experience of the EORTC Clinical Screening Cooperative Group. 19th Congress of the European Society for Medical Oncology. November 18-22, 1994, Lisbon, Portugal, abs. P159 (1994)

  • Docetaxel en 1ère intention dans les cancers du sein avancés : étude comparative de tolérance sur deux doses sans premedication. 14e Forum de Cancérologie, Paris, France, May 30-June 1, 1994. Bull (1994)

  • Safety evaluation of 2 doses of Taxotere (Docetaxel) without routine premedication as first line in advanced breast cancer : EORTC Clinical Screening Group report (1994)

  • Evaluation of 2 doses of Taxotere (Docetaxel) as first line in advanced breast cancer. EORTC Clinical Screening Group report (1994)

  • Evaluation of 2 doses of Taxotere (Docetaxel) as first line in advanced breast cancer. EORTC Clinical Screening Group report. 19th Congress of the European Society for Medical Oncology. November 18-22 1994, Lisbon, Portugal, abs. 0132 (1994)

  • A phase II trial of Taxotere (Docetaxel) 75 mg/m2 every 3 weeks, as first line chemotherapy in advanced btreast cancer. A second EORTC Clinical Screening Group Study. 19th Congress of the European Society for Medical Oncology. November 18-22, 1994, Lisbon, Portugal, abs. 199 (1994)

  • Immunological results of protocol 58881 from EORTC Children Leukemia Cooperative Group. Leukemia and Lymphoma, 13 (Suppl. 1): 99-100, 1994 (1994)

  • Second EORTC Clinical Screening Group phase II trial of Taxotere ( Docetaxel ) as first line chemotherapy in advanced breast cancer (1994)

  • Results of phase II trials with cystemustine at 90 mg/m2 in advanced malignant melanoma EORTC 04892. 19th Congress of the European Society for Medical Oncology, November 18-22, 1994, Lisbon, Portugal, abs. P927 (1994)

  • Results of two phase II trials with Cystemustine in five different tumoral localizations. Proc. 8th NCI - EORTC Symposium on New Drugs in Cancer Therapy, Amsterdam, The Netherlands, 1994 (abs. 289) (1994)

  • Results of two phase II trials with Cystemustine in advanced malignant melanoma. Proc. 8th NCI - EORTC Symposium on New Drugs in Cancer Therapy, Amsterdam, The Netherlands, 1994 (abs. 290) (1994)

  • Activity of Taxotere (Docetaxel) in liver metastasis of advanced breast cancer : analysis on 17 patients. Experience of the EORTC Clinical Screening Group. 17th Annual San Antonio Breast Cancer Symposium, December 8-10, 1994 (1994)

  • EORTC Clinical Screening Group: Phase II study of Taxotere ( Docetaxel ) in ovarian cancer. Proc. 8th NCI - EORTC Symposium on New Drugs in Cancer Therapy, Amsterdam, The Netherlands, 1994 (abs. 508) (1994)

  • Phase II trial of Cystemustine, a new nitrosourea, as second line treatment of malignant glioma (1994)

  • Prognostic value of clinical and biological factors in the EORTC Children Leukemia Cooperative Group (CLCG) protocols 58831/58832. Does the Riehm/Langermann risk factor (RF) weight hepato-splenomegaly optimally for prognosis ? Medical and Pediatric Oncology, 23 (3): 186, 1994 (abs O-67) (1994)

  • Long-term side effects in the EORTC Children Leukemia Cooperative Group (CLCG) protocol 58831 (CPM vs No CPM) and 58832 (RT vs No RT). Medical and Pediatric Oncology, 23 (3): 250, 1994 (abs P-244) (1994)

  • Is there a particular clinical significance of CD34 expression in childhood lymphoblastic leukemia ? Results of the EORTC CLCG study 58881. British Journal of Haematology, 87 (Suppl. 1): 1994 (abs 58) (1994)

  • Morphological study of 130 childhood myeloid leukemia (AML) and myelodysplastic syndrome (MDS) reviewed as part of the EORTC Children Leukemia Group (CLCG). British Journal of Haematology, 87 (Suppl. 1): 1994 (abs 57) (1994)

  • Treatment of juvenile chronic myelogenous leukemia (JCML): a retrospective study from the EORTC Children's Leukemia Cooperative Group (CLCG). Medical and Pediatric Oncology, 23 (3): 203 1994 (abs P-58) (1994)

  • Docetaxel en première ligne de chimiothérapie dans le cancer du sein métastatique: étude de phase II du CSG/EORTC. 14e Forum de Cancérologie, Paris, France, May 30-June 1, 1994. Bull. Cancer 81: 558, 1994 (1994)

  • Pharmacokinetic determinants of antitumour activity in bladder cancer patients (1994)

  • Recent developments in the treatment of brain tumors with particular reference to the EORTC efforts. 13th Annual ESTRO Meeting, Granada, Spain, September 26-29, 1994. Radioth.Oncol.32. Suppl.1: S70, 1994 (Abs.281) (1994)

  • Validation of a patient's questionnaire testing the functional results after sphincter-sparing surgery for rectal cancer with correlation with the EORTC QLQ-c30. 13th Annual ESTRO Meeting, Granada, Spain, September 26-29, 1994. Radioth.Oncol.32. Suppl.1: S133, 1994 (Abs.544) (1994)

  • Interinstitutional reproducibility of flow cytometric DNA analysis in breast carcinomas. Analytical Cellular Pathology 6: 23-26, 1994 (1994)

  • Y a-t-il lieu d'associer une chimiothérapie à la radiothérapie préopératoire en cas de lésion localement évoluée ? Conférence de Consensus. Le choix des thérapeutiques du cancer du rectum. Paris, France, December 1-2, 1994 (1994)

  • Critères de choix entre radiothérapie pre et postopératoire et de leur association. Chez quels patients les utiliser? Conférence de Consensus. Le choix des thérapeutiques du cancer du rectum. Paris, France, December 1-2, 1994 (1994)

  • Adjuvant radiation therapy for rectal carcinoma. Present and promise. 4th European Congress of Surgery, Berlin, F.R. Germany, October 25-29, 1994 (1994)

  • Radiochimiothérapie préopératoire dans les cancers du bas-rectum (T3-T4): présentation de l'essai randomisé FFCD-EORTC. FFCS-Acquisitions thérapeutiques récentes dans les cancers colorectaux. Les nouveaux protocoles de la FFCD., Marseilles, France, January 21, 1994 (1994)

  • Combined radiochemotherapy as adjuvant treatment in rectal cancer, current status and on-going clinical trials. EORTC Meeting, Oviedo, Spain, April 16, 1994 (1994)

  • Infrastructure of radiotherapy departments in Europe. Meeting of the European National Societies of Radio-oncology. ESTRO, Granada, Spain, September 5, 1994 (1994)

  • Impact of local control on survival in breast carcinomas and head and neck cancer patients. European Commission: Science, research, development. Directorate General XII, BIOMED 1 Meeting, Brussels, Belgium, September 6, 1994 (1994)

  • Human tumors: bag of cells or cousins of normal tissues? C.E.R.R.O. meeting, Les Menuires, France, January 8-13, 1994 (1994)

  • Arcon in head and neck, bladder and non-small cell lung cancers: a phase I-II study of the EORTC. Proceedings 2nd ARCON Workshop, Gray Laboratories, Mount Vernon Hospital, Northwood, U.K., March 3-5, 1994 (1994)

  • POUR LE GROUPE COOPERATEUR DE RADIOTHERAPIE DE L'EORTC. Radiothérapie accélérée avec inhalation de carbogène et prise de nicotinamide (ARCON) dans le glioblastome, une étude de phase I-II (présentation de l'étude EORTC 22933). Proc. Soc.Française de Radio-Oncologie (SFRO) Paris, France, November 1994, (1994)

  • Accelerated radiotherapy with carbogen and nicotinamide (ARCON) for glioblastoma, a phase I-II study: a presentation of EORTC 22933. Proc. ARCON 2nd Workshop, Northwood, U.K., March 1994 (1994)

  • Adjuvant Cyvadic chemotherapy for adult soft tissue sarcoma - Reduced local recurrence but no improvement in survival: A study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group (1994)

  • Treatment and prevention of invasive mycoses in neutropenics and in BMT transplant patients (1994)

  • Bone marrow transplantation or intensive consolidation chemotherapy in acute myeloid leukemia. The EORTC-LCG and GIMEMA experience. Conference on Autologous Bone Marrow Transplantation (K. Dicke et al), Dallas, August 1994 (1994)

  • The treatment of secondary myelodysplatic syndromes. International Symposium on Hodgkin's Disease, Milano, Italy, 10-12 March 1994 (1994)

  • Feasibility of an assessment of the quality of life for AML patients in first complete remission (CR): intensive chemotherapy vs bone marrow transplantation (autologous or allogeneic). An EORTC-GIMEMA study based on an extended QLQ-30 questionnaire. Meeting of the EORTC Study Group of Data Management. Maastricht, September 16, 1994 (1994)

  • Recombinant human granulocyte-macrophage colony stimulating factor (GM-CSF) during induction treatment of acute myelogenous leukemia (AML). A randomized trial from EORTC-GIMEMA Leukemia Cooperative Groups. Blood, 84 (10, Suppl. 1): 230A (abs. 909) (1994)

  • Adult Ph+ acute lymphoblastic leukemia in ALL-3 EORTC study. Blood, 84 (10, Suppl. 1): 144A, 1994 (abs. 562) (1994)

  • Evaluation of the role of allogeneic bone marrow transplantation in the prospective randomized study on AML: a study of the Leukemia Cooperative Groups of the EORTC and GIMEMA. European Bone Marrow Transplantation Meeting, Harrogate, Yorkshire, UK, 13-17 March, 1994 (abs. 369) (1994)

  • Interleukin-3 (IL-3) plus low-dose Ara-C can induce "true" complete responses in myelodysplastic syndromes (MDS). Onkologie 17 (Supl. 2): 41, 1994, (abs 164) (1994)

  • Interleukin-3 (IL-3) plus low-dose Ara-C can induce "true" complete responses in myelodysplastic syndromes (MDS). Blood, 84 (10, Suppl. 1): 316A, 1994 (abs. 1251) (1994)

  • Randomized phase II study of LD-AraC plus rhGM-CSF in advanced myelodysplasia. Acute Leukemias V, Münster 27 February 2 - March 1994, pp A29 (abs 114) (1994)

  • Immunological data of the EORTC LCG study in adult ALL. British Journal of Haematology, 87 (Suppl. 1): 1994 (abs 9) (1994)

  • EORTC-GIMEMA AML8 protocol. A phase III study on autologous bone-marrow transplantation in acute myelogenous leukemia. Leukemia and Lymphoma 13 (Suppl. 1): 101, 1994 (1994)

  • Treatment of patients with acute promyelocytic leukemia. The EORTC-LCG experience. Leukemia, 8 (suppl. 2): S48-S55, 1994 (1994)

  • Effects of retinoic acid and cytokines on the growth of and the expression of interleukin-8 in human epithelial ovarian cancer cell lines. 8th NCI-EORTC Symposium on New Drugs in Cancer Therapy, Amsterdam, The Netherlands, March 15-18, 1994 (1994)

  • Overview of EORTC activities including management of fungal infections in cancer patients (1994)

  • A randomized study for stages IIIb-IV M.Hodgkin comparing 8 courses of MOPP vs an alteration of 2 courses of MOPP with 2 courses of ABVD (1994)

  • Epidemiology of mycoses in the immunocompromised host: neutropenics (1994)

  • Invasive fungal infections are a challenge for optimal management of cancer patients: the EORTC perspectives (1994)

  • Lipid complexed Amphotericin B: Indications an Clinical Use. Epidemiology of Fungal Infections (1994)

  • Emerging Trends in Fungal Infections in Neutropenic Patients (1994)

  • Emerging mycoses due to uncommon fungal agents in the immunocompromised host (1994)

  • Liposomal amphotericin B: enhanced efficacy, more safety versus costs (1994)

  • Epidemiology of invasive infections in BMT. Communication at the 20th Annual Meeting of the EBMT and 10th Meeting of the Nurses Group. Harrogate, United Kingdom, March 13-17, 1994 (1994)

  • Antifungal prophylaxis in neutropenics (1994)

  • Invasive Fungal infections are a challenge for optimal management of cancer patients: the EORTC perspectives. 13th Annual ESTRO Meeting. Granada, Spain, September 23-26 1994 (abs. 131) (1994)

  • Liposomal amphotericin B: Enhanced efficacy, more safety versus costs. 5th Biennial Conference on Chemotherapy of Infectious Diseases and Malignancies, Salzburg, Austria, March 20-22, 1994 (abs. 165F) (1994)

  • Epidemiology of invasive fungal infections in bone marrow transplantation (1994)

  • Alternative modalities of administrating amphotericin B; Current issues. J. Infec. 28(Suppl 1): 51-56, 1994 (1994)

  • A randomized phase II study of low-dose cytosine arabinoside (LD-AraC) plus granulocyte/macrophage colony-stimulating factor (rhGM-CSF) in myelodysplastic syndromes (MDS) with a high risk of developing leukemia. Leukemia, 8 (1): 16-23, 1994 (1994)

  • Introduction of SGDM training activities to EORTC Cooperative Groups. Children's Leukemia Group meeting, Caen, April 1993 (1993)

  • Introduction of SGDM training activities to EORTC Cooperative Groups. Invasive Fungal Infections Group meeting, Brussels, June 1993 (1993)

  • Introduction of SGDM training activities to EORTC Cooperative Groups. Clinical Screening Group meeting, Paris, October 1993 (1993)

  • Introduction of SGDM training activities to EORTC Cooperative Groups. Lung Cancer Cooperative Group meeting, Brussels, October 1993 (1993)

  • Introduction of SGDM training activities to EORTC Cooperative Groups. Head and Neck Group meeting, Amsterdam, April 1993 (1993)

  • Toxicity grading systems, COSA Annual meeting, Australia, November 1993 (1993)

  • Introduction of SGDM training activities to EORTC Cooperative Groups. Early Clinical Trials Group meeting, Rotterdam, June 1993 (1993)

  • Introduction of SGDM training activities to EORTC Cooperative Groups. Gastrointestinal Tract Cancer Group meeting, Porto, April 1993 (1993)

  • Assessment of estrogenic recruitment before chemotherapy in advanced breast cancer: A double-blind randomized study (1993)

  • Phase I and pharmacokinetic study of taxotere administered as a 24 hour infusion (1993)

  • Randomization, registration and EuroCODE (1993)

  • Short versus long term treatment with CMF in postmenopausal patients with advanced breast cancer : an EORTC Breast cancer co-operative phase III trial (10852) (1993)

  • Reporting results (1993)

  • Interim analyses and early stopping rules (1993)

  • Role of the EORTC Data Center (1993)

  • Design and analysis of prostate cancer trials. State of the Art lecture at the Euregio Urological Symposium on Prostate Cancer, Liège, Belgium, April 2-3, 1993 (1993)

  • The Impact of meta-analysis (1993)

  • The need for meta-analysis (1993)

  • Multicenter trials: The experience of the European Organization for Research and Treatment of Cancer (1993)

  • The need for meta-analysis (1993)

  • Analysis of prognostic factors (1993)

  • Pitfalls in the analysis of bone marrow transplantation (BMT) in acute myelogeneous leukemia (AML) patients in first complete remission (CR): the EORTC-GIMEMA experience. Communication at the Workshop Clinical Trials in Oncology: Improving their Design and Analysis, Toronto, Canada, October 28-30, 1993 (1993)

  • Role of the EORTC Data Center (1993)

  • Data collection and databases. Communication at the Seminar on New Trends in the Treatment of Acute Leukemia, Zagreb, Croatia, June 7-10, 1993 (abs L-28) (1993)

  • A reversal of fortune: Practical problems in the monitoring and interpretation of an EORTC breast cancer trial (1993)

  • Impact of antiemetics in cancer treatment: The EORTC experience. Communication at the Seventh European Conference on Clinical Oncology and Cancer Nursing, Jerusalem, Israel, November 1993 (1993)

  • Exclusion of patients from the analysis of randomized phase II and phase III cancer clinical trials. Clinical trials in oncology: improving their design and analysis. Communication at the Workshop Clinical Trials in Oncology: Improving their Design and Analysis, Toronto, Canada, October 28-30, 1993 (1993)

  • EORTC structure and organization (1993)

  • EORTC strategy (1993)

  • Evaluation of collaboration with EORTC (1993)

  • EORTC: Aims, achievements and future perspectives (1993)

  • Impacts of quality control on clinical trials - EORTC (1993)

  • EORTC protocols and case report forms (1993)

  • Impact of antiemetics in cancer treatment: The EORTC experience (1993)

  • European experience in metastatic prostate cancer : Genitourinary cancer update. Communication at the Roswell Park Cancer Institute, Buffalo, October 1, 1993 (1993)

  • Phase II study with taxotere (RP56976) in advanced soft tissue sarcomas of the adult (1993)

  • Methodology and analysis of leukemia trials. Communication at the Seminar on New Trends in the Treatment of Acute Leukemia, Zagreb, Croatia, June 7-10, 1993 (abs L-27) (1993)

  • Double megatherapy and autologous bone marrow transplantation for advanced neuroblastoma : the LMCE 2 study (1993)

  • Breast conservation - state of the art (1993)

  • Double megatherapy and ABMT for advanced neuroblastoma : the LMCE2 study. Communication at the 19th Annual meeting of the European Bone Marrow Transplantation (EBMT) Garmisch-Partenkirchen, Germany, January 17-21, 1993 (1993)

  • Analysis of risk factors in 472 stage 4 neuroblastoma patients of more than 12 months at diagnosis consolidated by megatherapy and ABMT. A report of the EBMT Solid Tumor Registry. Communication at the 19th Annual meeting of the European Bone Marrow Transplantation (EBMT) Garmisch-Partenkirchen, Germany, January 17-21, 1993 (1993)

  • Randomised adjuvant systemic therapy trials in melanoma and the position of interferon in Europe (2006)

  • Serum S-100B protein evaluation in an EORTC randomized melanoma trial: A first report (2006)

  • Impact of pathology review on stage and margin status of radical prostatectomy specimens (EORTC trial 22911) (2006)

  • An integrated psychological strategy for advanced colorectal cancer patients (2006)

  • Comparing translations of the EORTC QLQ-C30 using differential item functioning analyses (2006)

  • Methodological quality of patient-reported outcome research was low in complementary and alternative medicine in oncology (2006)

  • The European Organization for Research and Treatment of Cancer (EORTC) Quality-of-Life questionnaire cervical cancer module - EORTC QLQ-CX24 (2006)

  • Response to commentary on comparing translations of the EORTC QLQ-C30 using differential item functioning analyses (2006)

  • EORTC QLQ-C15-PAL: The new standard in the assessment of health-related quality of life in advanced cancer? (2006)

  • Predicting survival using patient reported information from pleural mesothelioma patients? (2006)

  • An international EORTC phase III randomized controlled trial on the role of adjuvant chemotherapy in newly diagnosed anaplastic oligodendrogliomas: Health-related quality of life and symptom results (2006)

  • An investigation into the value of symptom and health related quality of life data as prognostic factors in newly diagnosed anaplastic oligodendrogliomas patients (2006)

  • Distinguishing between cultural and linguistic response patterns in The EORTC QLC-C30 using differential item functioning (DIF) analyses (2006)

  • Assessment of patient satisfaction: Relevance, cross-cultural assessment and application in oncology (2006)

  • The European Organisation for Research and Treatment of Cancer (EORTC) translation procedure for quality of life questionnaires: Accomplishment and implications for clinical research (2006)

  • Is there a difference in the methodological quality of health-related quality of life assessment between academic and industry sponsored studies? Evidence from randomized controlled trials in oncology (2006)

  • Investigating model selection stability in predicting survival with health related quality of life data in advanced cancer patients. A multivariate analysis of prognostic factors of EORTC 08975 (2006)

  • Early phase in the development of a bone metastases quality of life module (2006)

  • Patients' and health care professionals' (HCPs) perspectives on the most important quality of life issues in bone metastases (2006)

  • An international field study of psychometrics of the EORTC QLQ-PR25 questionnaire in assessing the health-related quality of life (HRQL) of patients with prostate cancer (2006)

  • Which is the most frequently used health-related quality of life (HRQOL) measure in cancer clinical trials? Psycho (2006)

  • The European Organisation for Research and Treatment of Cancer (EORTC) translation procedure for standardized quality of life questionnaires (2006)

  • Patients' and health care professionals' perspectives on the most important quality of life issues in bone metastases. Supp Care (2006)

  • EL GRUPO DE ONCOLOGIA RADIOTERAPICA DE l'EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER (EORTC). Assoliments i objectius. Annals de Medicina 89: 73-77, 2006 (Catalan) (2006)

  • Impact of the bost dose on local control and survival in patients with early stage breast cancer after a microscopically incomplete lumpectomy : 10 years results of the randomised EORTC boost trial 22881/10882 (2006)

  • Radiation technique per patient compared to the radiation policy per institute and early toxicity in the EORTC trial 22922/10925 investigating the role of internal mammary and medial supraclavicular (IM-MS) lymph node chain irradiation in stage I to III b (2006)

  • Surgery does matter to the outcome of T3-T4 rectal cancer patients: Surgical quality assurance in EORTC trial 22921 (2006)

  • Pooled analysis of five large European randomised clinical trials (n=5158) on rectal cancer to identify surgery related parameters affecting outcome. Oral presentation at the 13th Congress of the European Society of Surgical Oncology, Venice, Italy. November 30-December 2, 2006 (2006)

  • The Emmanuel van der Schueren Fellowship for quality assurance in radiotherapy. The final report for 2002-2004 (2006)

  • The Emmanuel van der Schueren Fellowship for quality assurance in radiotherapy. The final report for 2002-2004 (2006)

  • Changing paradigms-an update on the multidisciplinary management of malignant glioma (2006)

  • Correlative studies in neuro-oncolgy trials: should they influence treatment ? (2006)

  • Recent development in the use of chemotherapy in brain tumours (2006)

  • Determinant of patient satisfaction in oncology settings from European and Asian countries: Preliminary results based on the EORTC IN-PATSAT32 questionnaire (2007)

  • The EORTC QLQ-HDC29: A supplementary module assessing the quality of life during and after high-dose chemotherapy and stem cell transplantation (2007)

  • Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer: A randomised phase III trial of the EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER BREAST GROUP (2007)

  • EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update (2007)

  • Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-22973) (2007)

  • Quality assurance in breast cancer: EORTC experiences in the phase III trial on irradiation of the internal mammary nodes (2007)

  • Has the quality of health-related quality of life reporting in cancer clinical trials improved over time? Towards bridging the gap with clinical decision making (2007)

  • The use of differential item functioning analyses to identify cultural differences in responses to the EORTC QLQ-C30 (2007)

  • Concomitant and adjuvant androgen deprivation (ADT) with external beam irradiation (RT) for locally advanced prostate cancer: 6 months versus 3 years ADT, results of the randomized EORTC Phase III trial 22961 (2007)

  • Concomitant and adjuvant androgen deprivation (ADT) with external beam irradiation (RT) for locally advanced prostate cancer: 6 months versus 3 years ADT, results of the randomized EORTC Phase III trial 22961. Oral presentation at the 43rd Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, June 1-5, 2007 (2007)

  • Panel review of anaplastic oligodendroglioma from European Organization for Research and Treatment of Cancer trial 26951: Assessment of consensus in diagnosis, influence of 1p/19q loss, and correlations with outcome. J Neuropathol Exp (2007)

  • Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumors (2006)

  • Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study) (2005)

  • A phase II study of paclitaxel in advanced bronchioloalveolar carcinoma (EORTC trial 08956). Lung (2005)

  • Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: An intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada (2005)

  • Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg (2005)

  • Patients at high risk of progression after radical prostatectomy: Do they all benefit from immediate post-operative irradiation? (EORTC trial 22911) (2005)

  • Reporting recommendations for tumour marker prognostic studies (REMARK) (2005)

  • Initial and late resistance to imatinib in advanced gastrointestinal stroma tumors are predicted by different prognostic factors: A European Organisation for Research and Treatment of Cancer - Italian Sarcoma Group - Australian Gastointestinal trials Group Study (2005)

  • The quality assurance programme of the Radiotherapy Group of the European Organisation for Research and Treatment of Cancer: Past, present and future (2005)

  • Randomised trial of two regimens of chemotherapy in operable osteosarcoma: A study of the European Osteosarcoma Intergroup (2005)

  • An EORTC phase II trial of C-BOP/BEP intensive induction chemotherapy for intermediate and poor risk metastatic germ cell tumours (2005)

  • An international prospective study of the EORTC cancer in-patient satisfaction with care measure (EORTC IN-PATSAT32) (2005)

  • Health-related quality of life in patients with glioblastoma: A randomised controlled trial (2005)

  • Does a patient's self-reported health-related quality of life predict survival beyond key biomedical data in advanced colorectal cancer? (2006)

  • Health-related quality of life and symptom research in glioblastoma multiforme patients (2005)

  • Short-term treatment related quality of life: Results from an international randomized phase iii study of Cisplatin with or without Raltitrexed in patients with malignant pleural mesothelioma: An EORTC Lung-Cancer Group and National Cancer Institute, Canada, Intergroup Study. Lung Cancer 49 (2): 219, 2005 (abs) (2005)

  • Quality of life (QOL) in patients with malignant pleural mesothelioma (MPM) treated with chemotherapy (2005)

  • Establishing symptom and patient reported outcomes reference data for malignant pleural mesothelioma (MPM) patients (2005)

  • A bootstrap model averaging technique to investigate the prognostic value for survival of quality of life information (2005)

  • Non-small cell lung cancer and health-related quality of life (HRQOL): Is baseline HRQOL of prognostic value for survival? (2005)

  • Predicting survival using health-related quality of life scores in glioblastoma cancer: Findings from an international phase III randomized controlled trial. Journal of Clinical Oncology Supplements 23 (16): 861, 2005 (abs 9601) (2005)

  • Establishing baseline quality of life reference data for the EORTC QLQ-C30 in locally advanced breast cancer patients (2005)

  • The value of patient-reported symptoms as prognostic factors for survival in advanced colorectal cancer (2005)

  • The prognostic value of health related quality of life in colorectal cancer patients: A multivariate analysis using a bootstrap model-averaging approach (2005)

  • Health related quality of life outcomes in EORTC cancer clinical trials: What's been the impact? (2005)

  • An international prospective study of the psychometric properties of the EORTC satisfaction with care measure (EORTC QLQ SAT-32) (2005)

  • An international prospective study of the EORTC cancer in-patient satisfaction with care measure (EORTC IN-PATSAT32) (2005)

  • Factors related to patient satisfaction in oncology settings: Findings from an international study (2005)

  • Preliminary results of the design and development of an EORTC Information questionnaire: The EORTC QLQ-INFO 26 (2005)

  • Development of an EORTC module for the assessment of cancer related fatigue (EORTC FA25; FAR15) (2005)

  • Variability and sample size requirements for health-related quality-of-life measures: Understanding the challenges facing investigators (2005)

  • Toward a clearer understanding of the prognostic value of health-related quality of life (HRQOL) parameters in breast cancer (2005)

  • The development of the EORTC QLQ-C15-PAL: A shortened questionnaire for cancer patients in palliative care (2006)

  • Preoperative radiotherapy in rectal cancer: Role and place of fluorouracil-based chemotherapy. Final results of the EORTC 22921 phase III trial. Proceedings of the ASCO symposium on Gastrointestinal Cancer, Miami, Florida, U.S.A., 2005 (2005)

  • A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: Results of the 40955 EORTC trial (2005)

  • The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: The QLQ-CIPN20 (2005)

  • Phase II study of E7070 in patients with metastatic melanoma (2005)

  • EAU guidelines on the diagnosis and treatment of urothelial carcinoma in situ (2005)

  • Randomized trial of 30 versus 20 gy in the adjuvant treatment of stage I testicular seminoma: A report on medical research council trial TE18, European Organisation for Research and Treatment of Cancer trial 30942 (ISRCTN18525328) (2005)

  • Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: A randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group (2005)

  • Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: The EORTC 22845 randomised trial (2005)

  • Conservative local treatment versus mastectomy after induction chemotherapy in locally advanced breast cancer: A randomised phase III study (EORTC 10974/22002, LAMANOMA) - Why did this study fail? (2005)

  • Rectal cancer: Preoperative chemoradiation, a new standard (in French). Cancer Radiothérapie 9: 137-139, 2005 (2005)

  • Health-related quality of life in a randomized controlled trial in glioblastoma patients: A joint study of the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor Group/Radiotherapy Group and National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) (2005)

  • Is CDKN2A +/- CDKN2B and MTAP Inactivation of prognostic significance in B-precursor childhood acute lymphoblastic leukemia? Results of EORTC studies 58881 and 58951 (2004)

  • Monosomy 7 and deletion 7q in childhood AML. A collaborative study of 20 study groups (2004)

  • A new prognostic disease specific model to predict survival after intensive antileukemic treatment for young patients with poor-risk MDS and AML: Results of the CRIANT and AML-10 studies conducted by the EORTC/GIMEMA/SAKK/HOVON/EBMT Groups (2004)

  • Up-front window trial of gemtuzumab ozogamicin (GO) in previously untreated elderly patients with AML: An EORTC Leukemia Group Study (2004)

  • BCG versus chemotherapy in the intravesical treatment of patients with carcinoma in situ of the bladder: A meta-analysis of the published results of randomized clinical trials. Presentation at the Meeting of the North West Urological Oncology Group, Manchester, United Kingdom, December 2, 2004 (2004)

  • Biostatistics and clinical trials (2004)

  • Bladder cancer epidemiology, diagnosis and imaging endoscopy. Presentation at the WHO/ICUD/SIU Consultation on Bladder Cancer, Honolulu, Hawaii, October 3-7, 2004 (2004)

  • EORTC Quality of Life Group. Measurement of quality of life in carcinoid/neuroendocrine tumours. Endocr Relat (2003)

  • Quality of life of lung cancer patients: Validation of the Taiwan Chinese version of the EORTC QLQ-C30 and QLQ-LC13. Quality of Life Research 13: 257-262, 2004 (2004)

  • Use of item response theory to develop a shortened version of the EORTC QLQ-C30 emotional function scale. Quality of Life Research 13: 1683-1697, 2004 (2004)

  • Use of differential item functioning analysis to assess the equivalence of translations of a questionnaire. European Organisation for Research and Treatment of Cancer Quality of Life Group (2003)

  • Development of a questionnaire to evaluate the information needs of cancer patients: The EORTC questionnaire (2004)

  • The EORTC ophthalmic oncology quality of life questionnaire module (EORTC QLQ-OPT30). Development and pre-testing (Phase I-III). EORTC Ophthalmic Oncology Task Force; EORTC Quality of Life Group. Eye 18: 283-289, 2004 (2004)

  • First results of a randomized trial comparing versus observation post operatively in patients with uterine sarcomas. An EORTC GCG study. Journal of Gynecological (2003)

  • Surgery after induction chemotherapy: Morbidity and mortality in the surgery arm of EORTC 08941 trial. Proc. 9th Central European Lung Cancer Conference, Gdañsk, Poland, September 23–25, 2004 (abs. S52) (2004)

  • Radiologic findings in patients treated with Boron Neutron Capture Therapy for glioblastoma multiforme within EORTC trial 11961 (2005)

  • EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer (2004)

  • Early versus delayed endocrine treatment of pN1-3 M0 prostate cancer without local treatment of the primary tumor: Results of EUROPEAN ORGANISATION FOR THE RESEARCH AND TREATMENT OF CANCER 30846 - a phase III study (2004)

  • Doxorubicin and cisplatin chemotherapy in high-grade spindle cell sarcomas of the bone, other than osteosarcoma or malignant fibrous histiocytoma: A European Osteosarcoma Intergroup Study (2005)

  • Phase III trial of satraplatin, an oral platinum plus Prednisone vs. Prednisone alone in patients with hormone-refractory prostate cancer (2005)

  • Medical fellowship programme within the Gynaecological Cancer Group of the European Organisation for Research and Treatment of Cancer (EORTC/GCG) (2004)

  • First line treatment of ovarian/tubal/peritoneal cancer FIGO stage IIb-IV with paclitaxel/carboplatin with or without epirubicin (TEC vs TC). A Gynecologic Cancer Intergroup study of the NSGO, EORTC GCG study 55981 and NCIC CTG. Results on progression free survival. Proc. 40th American Society of Clinical Oncology (ASCO), Annual meeting, New Orleans, Louisiana, U.S.A., June 5-8, 2004 (abs. 5003) (2004)

  • Gemcitabine/carboplatin (GC) vs. carboplatin (C) in platinum sensitive recurrent ovarian cancer (OVCA). Results of a Gynecologic Cancer Intergroup randomized phase III trial of the AGO OVAR, the NCIC CTG and the EORTC-GCG study 55005. Proc. 40th American Society of Clinical Oncology (ASCO), Annual meeting, New Orleans, Louisiana, U.S.A., June 5-8, 2004 (abs. 5005) (2004)

  • After 10 years follow-up interval debulking surgery remains a significant prognostic factor for survival in advanced ovarian cancer. An EORTC-GCG study 55865. Communication at the 10th Biennial Meeting of the International Gynecologic Cancer Society, Edinburgh, United Kingdom, October 3-8, 2004 (2004)

  • Prognostic value of serum CA125 and marker half-life (T1/2) for long-term progression free and overall survival and optimal interval debulking surgery in advanced ovarian carcinoma. An EORTC-GCG study 55865. Communication at the 10th Biennial Meeting of the International Gynecologic Cancer Society, Edinburgh, United Kingdom, October 3-8, 2004 (2004)

  • Drains versus no drains after radical hysterectomy and node dissection (RHND). An EORTC-GCG randomized trial study 55962 (2003)

  • Alterations in the p53 pathway and prognosis in advanced ovarian cancer: A multivariate analysis. Communication at the 10th Biennial Meeting of the International Gynecologic Cancer Society, Edinburgh, United Kingdom, October 3-8, 2004 (abs.122) (2004)

  • Multi-center external validation study of the Amsterdam 70-gene prognostic signature in node negative untreated breast cancer: Are the results still outperforming the clinical-pathological criteria? Communication at San Antonio Breast Cancer Symposium, San Antonio, U.S.A., December 8-11, 2004 (2004)

  • Clinical trial designs for predictive marker validation in cancer treatment trials (2005)

  • Standard cisplatin/infusional 5-fluorouracil (PF) vs docetaxel (T) plus PF (TPF) as neoadjuvant chemotherapy for nonresectable locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN): A phase III trial of the EORTC Head and Neck Cancer Group (EORTC 24971) (2004)

  • MGMT Gene silencing and benefit from Temozolomide in glioblastoma (2005)

  • Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma (2005)

  • Chemotherapy for Brain Tumors - A new beginning (2005)

  • Patients with asymptomatic prostate cancer T0-4 N0-2 not suitable for local definitive treatment: Do they need immediate androgen deprivation? (2005)

  • Immediate versus deferred androgen deprivation in patients with asymptomatic prostate cancer T0-4 N0-2 not suitable for local definitive treatment (2005)

  • Patients with asymptomatic prostate cancer T0-4 N0-2 not suitable for local definitive treatment: do they need immediate androgen deprivation? European Urology Supplements 4 (3): 78, 2005 (abs. 307) (2005)

  • Immediate versus deferred androgen deprivation in patients with asymptomatic prostate cancer T0-4 N0-2 not suitable for local definitive treatment (2005)

  • Health-related quality of life in survivors of locally advanced breast cancer: An international randomized controlled phase III trial (2005)

  • Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3 weeks in solid tumours: An ECSG/EORTC study (2005)

  • Seven year update of an EORTC phase III trial of high dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumors (2005)

  • Seven year update of an EORTC phase III trial of high dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumors (2005)

  • Does post-operative radiotherapy (P-RXT) after radical prostatectomy (Px) improve progression-free survival (PFS) in pT3N0 prostate cancer (PC)? (EORTC 22911) (2004)

  • PSA as surrogate for survival in hormone naïve metastatic prostate cancer. Oral presentation at the FDA Workshop on Endpoints in Prostate Cancer, Bethesda, Maryland, U.S.A., June 20-21, 2004 (2004)

  • Does post-operative radiotherapy (P-RXT) after radical prostatectomy (Px) improve progression-free survival (PFS) in pT3N0 prostate cancer (PC)? (EORTC 22911). Oral Presentation at the 40th ASCO meeting, New Orleans, Louisiana, U.S.A., June 5-8, 2004 (2004)

  • Is prostate-specific antigen a surrogate for survival in advanced prostate cancer? (2004)

  • Is prostate-specific antigen a surrogate for survival in advanced prostate cancer? (2004)

  • Cytoreductive nephrectomy in patients with metastatic renal cancer: A combined analysis (2004)

  • Docetaxel and cisplatin as induction chemotherapy in stage IIIA N2 non-small cell lung cancer (NSCLC): An EORTC phase II trial (08984) (2004)

  • An open multicentre comparative study of the efficacy, safety and tolerance of fluconazole and itraconazole in the treatment of cancer patients with oropharyngeal candidiasis (2004)

  • RFS2000 (9-nitrocamptothecin) in advanced small cell lung cancer, a phase II study of the EORTC New Drug Development Group (2004)

  • A phase II study of ET-743/trabectedin (Yondelis) for patients with advanced gastrointestinal stromal tumours (2004)

  • Phase III study of BEC2/BCG vaccination in limited disease small cell lung cancer (LD-SCLC) patients, following response to chemotherapy and thoracic irradiation (EORTC 08971, the SILVA study). Proc. Amercian Society of Clinical Oncology (ASCO), New Orleans, Louisiana, U.S.A., June 5-8, 2004 (abs. 7020) (2004)

  • A randomized phase III study of cisplatin with or without raltitrexed in patients (pts) with malignant pleural mesothelioma (MPM): An intergroup study of the EORTC Lung Cancer Group and NCIC. Proc. Amercian Society of Clinical Oncology (ASCO), New Orleans, Louisiana, U.S.A., June 5-8, 2004 (abs. 7021) (2004)

  • Phase II study on 9-nitrocamptothecin (RFS 2000) in patients with advanced or metastatic urothelial tract tumors (2004)

  • Predicting survival with health-related quality of life scores in locally advanced breast cancer: Results from an international randomized controlled trial (2004)

  • First line hormonal treatment (HT) for metastatic breast cancer (MBC) with exemestane (E) or tamoxifen (T) in postmenopausal patients (pts) - A randomized phase III trial of the EORTC Breast group (2004)

  • Mastectomy: The preferred treatment in young women? (2004)

  • Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer. First results of a randomized phase III trial EORTC 10901 (2004)

  • Efficacy of adjuvant chemotherapy according to hormone receptor status in young breast cancer patients (2004)

  • EORTC 10981-22023 trial. AMAROS: After mapping of the axilla: Radiotherapy or surgery? Trial update (2004)

  • High quality gene expression microarray data from a multicentre prospective trial: Results of the first microarray analysis in the EORTC 10994/ BIG 00-01 study (2004)

  • Intermittent/alternated therapy with tamoxifen and medroxyprogesterone acetate prolongs time to resistance to tamoxifen without benefit for (progression free) survival in patients with advanced breast cancer. Results of an EORTC phase III study (trial 10863) (2004)

  • First results of a randomized phase III trial comparing exemestane versus tamoxifen as first-line hormone therapy (HT) for postmenopausal women with metastatic breast cancer (MBC) - EORTC 10951 in collaboration with the exemestane working group and NCIC Clinical Trials Group (2004)

  • Conservative local treatment versus mastectomy after induction chemotherapy in locally advanced breast cancer (LAMANOMA, EORTC 10974/22002). Why this study failed? (2004)

  • On behalf of the EORTC RADIOTHERAPY and BREAST CANCER GROUPS. The influence of the boost technique on local control in breast conserving treatment in the EORTC boost versus no boost Trial (2004)

  • Construction and validation of a prognostic model across several studies, with an application in superficial bladder cancer. Statist Med 23: 907-926, 2004 (2004)

  • One immediate postoperative instillation of chemotherapy reduces the risk of recurrence in patients with stage Ta T1 bladder cancer: A meta-analysis of the published results of randomized clinical trials (2004)

  • One immediate postoperative instillation of chemotherapy reduces the risk of recurrence in patients with stage Ta T1 bladder cancer: A meta-analysis of the published results of randomized clinical trials. European Urology Supplements 3 (2): 122, 2004 (abs. 478) (2004)

  • Interim analyses and early stopping rules. Presentation at EORTC course on Clinical Trial Statistics for Non Statisticians, Brussels, Belgium, June 16-18, 2004 (2004)

  • One immediate postoperative instillation of chemotherapy reduces the risk of recurrence in patients with stage Ta T1 bladder cancer: A meta-analysis of the published results of randomized clinical trials (2004)

  • A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: A meta-analysis of published results of randomized clinical trials (2004)

  • Randomized, controlled trial investigating short-term health-related quality of life with doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: European Organization for Research and Treatment of Cancer Breast Cancer Group, Investigational Drug Branch for Breast Cancer and the New Drug Development Group study (2004)

  • EAU guidelines on diagnosis and treatment of upper urinary tract transitional cell carcinoma (2004)

  • Randomized phase II trial assessing estramustine and vinblastine combination chemotherapy vs estramustine alone in patients with progressive hormone-escaped metastatic prostate cancer (2004)

  • Results of the randomized trial comparing radical and partial nephrectomy for small kidney neoplasms: EORTC protocol 30904. European Urology Supplmements 3 (2): 72, 2004 (abs. 280) (2004)

  • One immediate postoperative instillation of chemotherapy reduces the risk of recurrence in patients with stage Ta T1 bladder cancer: A meta-analysis of the published results of randomized clinical trials (2004)

  • One immediate postoperative instillation of chemotherapy reduces the risk of recurrence in patients with stage Ta T1 bladder cancer: A meta-analysis of the published results of randomized clinical trials (2004)

  • Results of the randomized trial comparing radical and partial nephrectomy for small kidney neoplasms: EORTC protocol 30904 (2004)

  • The influence of the boost technique on local control and breast concerning treatment in the EORTC “boost versus no boost” randomized trial. Radiother. Oncol 72 (1): 25-33, 2004 (2004)

  • Concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) for newly diagnosed glioblastoma multiforme (GBM). Conclusive results of a randomized phase III trial by the EORTC Brain and Radiotherapy Groups and NCIC Clinical Trials Group (2004)

  • TheIinternational Bladder Cancer Bank: Proposal for a new study concept (2004)

  • Current and future trials of the EORTC Brain Tumor Group. Onkologie 27 (3): 246-250, 2004 (2004)

  • Quality assurance in the EORTC phase III randomised trial 22922/10925 investigating the role of internal mammary and medial supraclavicular lymph node chain irradiation in stage I-III breast cancer: A report on the dummy run (2000)

  • Optimized technique for irradiation of medial supraclavicular (MS) and internal mammary (IM) lymph nodes in conjunction with breast or thoracic wall. Oral presentation at the ERTED Meeting, Istanbul, Turkey, September 19-23, 2000 (2000)

  • Optimized technique for irradiation of medial supraclavicular (MS) and internal mammary (IM) lymph nodes in conjunction with breast or thoracic wall (2000)

  • Extended field radiotherapy: A geometrical solution for the matching of different fields using asymmetric collimation (2000)

  • Extended field radiotherapy: A geometrical solution for the matching of different fields using asymmetric collimation (2000)

  • Estimation of the influence of the given dose on the endpoint of EORTC trial 22922/10925 concerning Internal Mammary - Medial Supraclavicular (IM-MS) irradiation: A report on behalf of the quality assurance committee after 32 dummy runs (2000)

  • Phase II Trial of chronomodulated infusion of 5-fluorouracil and folinic acid in metastatic colorectal cancer (2000)

  • Do human oligodendroglial and astroglial tumors derive from mature oligodendrocytes and astrocytes, or from precursor glial cells? Proc. at the XIVth International Congress of Neuropathology, Birmingham, United Kingdom, September 3-6, 2000 (2000)

  • Ontwikkeling van een 4-span assay voor tumor necrosis factor. Werkbespreking Algemeen Interne Geneeskunde. Communication at the UMC St Radboud, Nijmegen, The Netherlands, March 20, 2000 (2000)

  • Does plasminogen activator inhibitor-1 (PAI-1) control trophoblast invasion? A study of fetal and maternal tissue in intrauterine, tubal and molar pregnancies. Placenta 21 (8): 754-762, 2000 (2000)

  • QA, RBSG assays (VEGF). Communication at the Annual General Meeting of the EORTC Receptor and Biomarker Study Group. Nyborg, Denmark, June 27-28, 2000 (2000)

  • 20 Years European experience on quality assurance for biochemical assays of tissue biomarkers. Communication at the NCI/EORTC International Conference on the Development of New Diagnostic Tools for Cancer "From Discovery to Clinical Practice: Diagnostics Innovation, Implementation, and Evaluation", Nyborg, Denmark, June 28 - July 1, 2000 (2000)

  • High tumour levels of VEGF predict a poor response to tamoxifen or chemotherapy in advanced breast cancer (2000)

  • Quality control of uPA-PAI-1-protein determination. Communication at the Studies on Adjuvant Chemotherapy In Node-Negative Breast Cancer After Risk Selection By Tumor-Biological Factors, Hamburg, Germany, September, 1, 2000 (2000)

  • High tumor levels of vascular endothelial growth factor (VEGF) predict poor response to systemic therapy in advanced breast cancer. Communication at the American Association for Cancer Researhc Special Conference on "Angiogenesis and Cancer", Traverse City, Michigan, U.S.A., October 11-15, 2000 (2000)

  • Tumor biological prognostic factors uPA and PAI-1 enable risk-adapted therapy decisions in node-negative breast cancer: First interim results of a prospective multicenter therapy trial. Communication at the International Conference (NCI/EORTC) on the Development of New Diagnostic Tools for Cancer "From discovery to clinical practice: Diagnostics innovation, implementation, and evaluation". Nyborg, Denmark, June 28 - July 1, 2000 (2000)

  • Practical guidelines for radiation technologist participating in clinical trials (2000)

  • Strategies for improving patient set-up (2000)

  • Update on EORTC radiation technologist groups activities. Communication at the EORTC Radiotherapy Group Meeting, Zurich, Germany, October 12-13, 2000 (2000)

  • Practical guidelines for radiation technologists participating in clinical trials (2000)

  • Role of radiation technologists participating in clinical trials. A facilitated workshop. Communication at the Fifth ERTED Meeting, Istanbul, Turkey, September 19-23, 2000 (2000)

  • The RTSG clinical trials project of the radiotherapy technologists study group of the EORTC (2000)

  • Clinical trials in breast cancer (2000)

  • Report of the radiotherapy technologists study group (RTSG) of the EORTC (2000)

  • The results of the clinical trial project. Impact on practice (2000)

  • The development of documentation for radiation technologists involved in clinical trials. Proc. Imaging, Oncology, Science (I.O.S.), Birmingham, United Kingdom, May 22-24, 2000 (abs.) (2000)

  • The development of documentation for radiographers involved in EORTC trials (2000)

  • The development of documentation for radiographers involved in EORTC trials (2000)

  • Report of the clinical trials project (2000)

  • Role of taxoids in head and neck cancer (2000)

  • ARCON: Accelerated radiotherapy with carbogen and nicotinamide in head and neck squamous cell carcinomas. The experience of the Co-operative Group of Radiotherapy of the European Organization for Research and Treatment of Cancer (EORTC) (2000)

  • EORTC update of the head and neck cancer altered fractionation phase III trials (2000)

  • Compliance to the prescribed overall treatment time in 5 randomised controlled trials of altered radiotherapy fractionation in patients with squamous cell carcinoma of the head and neck (2000)

  • What do European oncologists know and practise about pain control? (2000)

  • The role of the palliative care team for breast cancer patients. Lecture at the European Breast Cancer Conference (EORTC-Europa Donna-EUSOMA), September 29, 2000 (2000)

  • Irradiation of the eye with a vacuum contact lens immobilisation device. SASRO Meeting, Saint Gall, Switzerland, April 6-7, 2000 (2000)

  • Towards a European standard for best supportive care (2000)

  • The role of taxoids in head and neck cancer. Proc. European Spring Oncology Conference (ESOC) Latest Advances in Anticancer Drug Development, Marbella, Spain, April 28 - May 1, 2000. 1: 93-94, 2000 (2000)

  • Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen ablative therapy: a phase III study of the European organisation for research and treatment of cancer genitourinary group (2001)

  • Equivalence of three or four cycles of bleomycin, etoposide and cisplatin and of a 3- or 5-day schedule in good prognosis germ cell cancer: A randomized study of the European organisation for research and treatment of cancer cooperative group and the medical research council (2001)

  • Predicting the short term and the long term prognosis of patients with TaT1 bladder cancer: Results of EORTC/MRC randomized clinical trials (2001)

  • Is baseline quality of life a prognostic factor for survival in hormone resistant prostate cancer? (2001)

  • Chemotherapy in advanced ovarian cancer. Letter to the Editor (1998)

  • Oxaliplat (1998)

  • A randomized phase II study of taxol or oxaliplatin in platinum-pretreated epithelial ovarian cancer patients (1998)

  • Updated analysis shows a highly significant improved overall survival for cisplatin-paclitaxel as first line treatment of advanced ovarian cancer: Mature results of the EORTC-GCCG, NOCOVA, NCIC CTG and Scottish Intergroup trial (1998)

  • Multiplex PCR Approaches for the Detection of P-53 mutations in microdisected ovarian cancer samples. Proceedings of the 9th P-53 workshop Meeting, Crete, May 9-13, 1998 (1998)

  • Updated analysis shows a highly significant improved overall survival for cisplatin-paclitaxel as first line treatment of advanced ovarian cancer: Mature results of the EORTC-GCCG, NOCOVA, NCIC CTG and Scottish Intergroup trial. ASCO 34th Annual Meeting, May 16-19, 1998, Los Angeles, U.S.A (1998)

  • Variation in the procedure of radical hysterectomy in Europe : an EORTC Gynaecological Cancer Cooperative Group study. Proc. Wertheim-operation Centenary Scientific Meeting 1898 – 1998, Vienna, Austria, September 17-19, 1998 (abs. p3) (1998)

  • Ongoing trials in patients with head and neck cancer. Eur.J. Surg. Oncol. 23: 476-485, 1998 (1998)

  • Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): (2) Larynx preservation using neoadjuvant chemotherapy (CT) in laryngeal and hypopharyngeal carcinoma (1998)

  • Phase I-II study with docetaxel (D), cisplatin® and 5-fluorouracil (5-FU) in patients with locally advanced inoperable squamous cell carcinoma of the head and neck (SCCHN) (1998)

  • For the EORTC Head & Neck Cancer Cooperative Group (HNCCG). Randomized Phase II Trial of Methotrexate (MTX) versus Two Schedules of Paclitaxel (Taxol®) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) (1998)

  • Progress in fighting systemic fungal infections in (1998)

  • Current management of fungal infections in immunocompromised patients and polyene lipid complexes for treatment of invasive fungal infection. J. Inf. Dis. Antimicrob. Agents 15:85-96, 1998 (1998)

  • Impact of Previous Aspergillosis on the Outcome of Bone Marrow Transplantation. Clinical Infectious Diseases 26:1098-1103, 1998 (1998)

  • Evolution of the clinical manifestations of infection during the course of febrile neutropenia in patients with malignancy. Infection 26: 349-54, 1998 (1998)

  • An EORTC multicentre prospective survey of invasive aspergillosis in (1998)

  • An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis (1998)

  • An EORTC IFICG phase III randomized study comparing fluconazole to itraconazole in non neutropenic cancer patients with oropharyngeal candidiasis. oral presentation. 38th Intersc. Conf. Antimicrob. Agents Chemother. San Diego, USA; September 1998 (1998)

  • An EORTC IFICG phase III randomized study comparing fluconazole to itraconazole in non neutropenic cancer patients with oropharyngeal candidiasis. Proc. 38th Intersc. Conf. Antimicrob. Agents Chemother. 1998 (Abs. MN-21, p.594) (1998)

  • Overview of new and developmental antifungal agents. Agents for Change Advisory Board, Madrid, Spain, January 1998 (1998)

  • Chairman session “Fungal Infection in Transplantation”. Transplant Infectious Disease World Congress. Lake Buena Vista, Florida, USA, April 1998 (1998)

  • New antifungal agents in clinical practice. Transplant Infectious Disease World Congress. Lake Buena Vista, Florida, USA, April 1998 (1998)

  • Fungal infections in cancer patients. Proc.4th Congress of the European Confederation of Medical Mycology. Glasgow, U.K. May 1998 (Abs. S4) (1998)

  • Prospects of voriconazole in the treatment of life-threatening Aspergillus infections. Proc. 4th Congress of the European Confederation of Medical Mycology. Glasgow, U.K.May 1998 (Abs. 205) (1998)

  • Further infections after empiric therapy of febrile neutropenia: a predictable sequence? Proc. 8th International Congress of Infectious Diseases. Boston, USA, May 1998 (Abs.26.002, p.108-9) (1998)

  • EORTC Candidemia survey - Indications for an ongoing change in the epidemiology of yeast infections. Proc. 8th International Congress of Infectious Diseases. Boston, USA, May 1998 (Abs.102.002, p.322-3) (1998)

  • Prospects of voriconazole in the treatment of life-threatening Aspergillus infections. 8th International Congress of Infectious Diseases. Boston, USA, May 1998 (1998)

  • Chairman 2nd International Symposium "Therapeutic approaches to new challenges in systemic fungal infections. Antwerp, Belgium, June 1998 (1998)

  • Fungal infections in cancer patients: The EORTC survey and the use of high dose of high dose antifungals. 10th Symp. Intern. Immunocompromised Host Society. Davos, Switzerland, June 1998 (Abs.p.13-4) (1998)

  • Moderator "Management of infections in cancer patients." 10th Symposium of the International Immunocompromised Host Society. Davos, Switzerland, June 1998 (1998)

  • Chairman symposium "Liposomal drug delivery in haematology - recent advances", Joint Meeting of the 3rd Congress of the European Haematology Association (EHA) and the 27th Congress of the International Society of Hematology (ISH). Amsterdam, The Netherlands, July 1998 (1998)

  • Current and evolving strategies for the treatment of invasive fungal infections. Proc. 8th International Mycological Congress. Jerusalem, Israel, August 1998 (Abs. p. 44) (1998)

  • Is profylactisch gebruik van antibiotica bij te verwachten leukopenie dan wel bij leukopenie zinvol? 5th Postgraduate course on Medical Oncology, Veldhoven, The Netherlands, October1998 (1998)

  • Prevention of opportunistic fungal disease in neutropenic patients. Proc. 11th Mediterranean Congress of Chemotherapy. Tel Aviv, Israel, October 1998 (abs.1. p.2) (1998)

  • Treatment of invasive Aspergillus infections. Symposium “Invasive Fungal Disease”. Stockholm, Sweden, October 1998 (abs.6. p.17) (1998)

  • Future developments in the treatment of invasive fungal infections. Symposium “Invasive Fungal Disease”. Stockholm, Sweden, October 1998 (1998)

  • Prevention of opportunistic fungal disease in neutropenic patientsProc. Symposium om Invasiv Svampsjukdom. Stockholm, Sweden 1998, (abs7 p.18) (1998)

  • La diagnosi clinico instrumentale. Covegno Nazionale "Infezioni Fungine in Ematologia". Bergamo, Italy, November 1998 (1998)

  • Prospective evaluation of detection of Aspergillus DNA by PCR with bronchoalveolar lavage fluid of neutropenic patients with fever and pulmonary infiltrates. Proc. 38th Intersc. Conf. Antimicrob. Agents Chemother. 1998 (Abs. J-111, p.483) (1998)

  • J.P. DONNELLY, B.E. DE PAUW, J.F.G.M. MEIS. Cost-effectiveness of liposomal amphotericin B for the treatment of invasive fungal infections in neutropenic patients. Proc. 38th Intersc. Conf. Antimicrob. Agents Chemother. 1998 (Abs. O-14, p.609) (1998)

  • Mitoxantrone versus Daunorubicine in induction-consolidation chemotherapy, the value of low-dose cytarabine for maintenance of remission as well as an assessment of prognostic factors in acute myeloid leukemia in the elderly: Final report of the EORTC-LCG HOVON randomized phase III study AML-9 (1998)

  • The influence of HLA-matched sibling donor availability on treatment outcome for patients with AML: An analysis of the AML 8A study of the EORTC Leukaemia Cooperative Group and GIMEMA. British Journal of Haematology 102: 1344-1353, 1998 (1998)

  • Update of three major Phase III randomized trials from the EORTC Breast and Radiotherapy group. Presentation at the ESTRO International Oncology Forum, London, May 8-12, 2011 (2011)

  • International IMRT credentialing by physical phantom irradiation: The EORTC ROG experience (2011)

  • Irradiation of the internal mammary and medial supraclavicular lymph node chain in stage I to III breast cancer: state of the day of EORTC phase III trial 22922/10925 with 4004 patients (2011)

  • Improved dose homogeneity in the breast using tissue compensators (1991)

  • Improved dose distribution homogeneity in conservative breast cancer irradiation (1991)

  • Should inhomogeneity corrections be applied during treatment planning of tangential breast irradiation? (1991)

  • Breast cancer treatment: which inhomogeneities have to be taken into account? (1991)

  • The impact of surgical and pathological findings on radiotherapy of early breast cancer (1991)

  • Breast irradiation in the lateral decubitus position: technique of the Institute Curie (1991)

  • In vivo dosimetry during tangential breast treatment (1991)

  • Entrance and exit TL-dosimetry in the conservative treatment of breast cancer: a pilot study for the EORTC-Radiotherapy Cooperative Group (1991)

  • In vivo dosimetry for tangential breast irradiation: role of the equipment in the accuracy of dose delivery (1991)

  • Quality assurance of the EORTC trial 22881/10882: "assessment of the role of the booster dose in breast conserving therapy": the Dummy Run (1991)

  • Quality assurance in daily treatment procedure: patient movement during tangential fields treatments (1991)

  • Quality control in the conservative treatment of breast cancer: patient dosimetry using silicon detectors (1991)

  • Tangential breast irradiation: influence of technique of set-up on transfer errors and reproducibility (1991)

  • Early breast irradiation after conservative surgery: quality control by portal localization films (1991)

  • Portal imaging for the verification of breast treatments (1991)

  • Accuracy in tangential breast treatment set-up: a portal imaging study (1991)

  • Quality assurance in conservative treatment of early breast cancer. Report on a consensus meeting of the EORTC radiotherapy and breast cancer cooperative groups and the EUSOMA (European Society of Mastology) (1991)

  • Adjuvant chemotherapy in colorectal Cancer: Mournful, hopeful perpetual motion machine heads to dim light at end of tunnel (1989)

  • EORTC guidelines for Phase I trials with single agents in adults (1985)

  • The European Organization for Research and Treatment of Cancer Genito-urinary tract cancer cooperative group (1980)

  • Cancerologie thérapeutique à l'échelon européen: Principes d'organisation et resultats. Bull Acad Mél Bel 135: 297-308, 1980 (1980)

  • Design of phase II clinical trials in cancer using decision theory. Cancer treatment reports 64 (2-3): 519-524, 1980 (1980)

  • News From E.O.R.T.C. The E.O.R.T.C. Data Center (1977)

  • Health related quality of life and clinical data comprise a valid prognostic tool to aid in survival prediction in a subgroup of metastatic cancer patients (2010)

  • The association between clinical, sociodemographic, and logistic-administrative factors and adherence to completing health-related quality-of-life questionnaires (2010)

  • Final results of the EORTC Intergroup Randomized study 40004 (CLOCC) evaluating the benefit of Radiofrequency Ablation (RFA) combined with chemotherapy for unresectable colorectal liver metastases (CRC LM) (2010)

  • Phase III trial (EORTC 10994/BIG 00-01) assessing the value of p53 using a functional assay to predict sensitivity to a taxane versus nontaxane primary chemotherapy in breast cancer: Final analysis (2010)

  • A double-blind, randomized, placebo-controlled phase III intergroup study of gefitinib (G) in patients (pts) with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021-ILCP 01/03) (2010)

  • Randomized phase II study (EORTC 08062) of amrubicin as single agent or in combination with cisplatin versus etoposide-cisplatin as first-line treatment in patients (pts) with extensive disease small cell lung cancer (ED SCLC) (2010)

  • Randomized phase II/III trial comparing gemcitabine/carboplatin (GC) and methotrexate/carboplatin/vinblastine (M-CAVI) in patients (pts) with advanced urothelial cancer (UC) unfit for cisplatin based chemotherapy (CHT): Phase III results of EORTC study 30986 (2010)

  • Vascular effects of the vascular targeting agent NGR-hTNF in patients (pts) with advanced solid cancer: a dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) EORTC study (2010)

  • Quality-of-life results of an EORTC phase III randomized trial of adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases of solid tumors (2010)

  • Soluble factors (SF) associated with efficacy and toxicity of pazopanib (PZB) in advanced soft tissue sarcoma (STS) patients (pts); An EORTC-STBSG study (2010)

  • Lessons from PETACC 2 - no prognostic impact of KRAS-/BRAF-status in stage III colon cancer treated with adjuvant 5-FU monotherapy (2010)

  • Lapatinib in Combination with ECF/X in EGFR1 or HER2 Overexpressing First-Line Metastatic Gastric Cancer (GC): A Phase II Randomized Placebo Controlled Trial (EORTC 40071) (2010)

  • Outcome of patients (pts) with PDGFRAD842V mutant gastrointestinal stromal tumor (GIST) treated with imatinib (IM) for advanced disease (2010)

  • Activity of eribulin mesylate (E7389) in patients with soft tissue sarcoma (STS): Phase II studies of the European Organization for Research and Treatment of Cancer - Soft Tissue and Bone Sarcoma Group (EORTC 62052) (2010)

  • Brostallicin versus doxorubicin as first line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: An EORTC soft tissue and bone sarcoma group randomized phase II study (2010)

  • LAPATAX: A randomized phase II trial of FEC-docetaxel combined with lapatinib and/or trastuzumab as neoadjuvant therapy of HER2-positive breast cancer; EORTC 10054 trial (2010)

  • Predictive factors for the effect of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC phase III study 40983) (2010)

  • Long-term results from EORTC24971/TAX323: Comparing TPF to PF in patients with unresectable squamous cell carcinoma of the head and neck (SCCHN) (2011)

  • The design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient (1990)

  • Treatment Outcome after Remission Induction Failure in Childhood Acute Lymphoblastic Leukemia. New Engl J Med 366 (15): 1371-1381, 2012 (2012)

  • Systematic review of purine analogue treatment for chronic lymphocytic leukaemia: lessons for future trials (2012)

  • Perspectives in cancer research Tumor markers in non-malignant diseases (1988)

  • Second Neoplasm in Children Treated in EORTC 58881 Trial for Acute Lymphoblastic Malignancies: Low Incidence of CNS Tumours. Pediatr Blood (2011)

  • Nomograms for predicting local recurrence, distant metastases, and overall survival for patients with locally advanced rectal cancer on the basis of European randomized clinical trials (2011)

  • Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial (2012)

  • Nomogram to predict ipsilateral breast relapse based on pathology review from the EORTC 22881-10882 boost versus no boost trial (2011)

  • A hypermethylated phenotype in anaplastic oligodendroglial brain tumors is a better predictor of survival than MGMT methylation in anaplastic oligodendroglioma: a report from EORTC study 26951 (2011)

  • Cardiac safety, efficacy, and correlation of serial serum HER2-extracellular domain shed antigen measurement with the outcome of the combined trastuzumab plus CMF in women with HER2-positive metastatic breast cancer: results from the EORTC 10995 phase II study (2017)

  • Randomized Trials in 2466 Patients With Stage I Seminoma: Patterns of Relapse and Follow-up (2011)

  • Adjuvant radiotherapy after radical prostatectomy in patients with pathologically high risk prostate cancer: 10-Year follow-up result s (2011)

  • Adjuvant radiation for pathologically advanced prostate cancer: A head to head comparison of SWOG and EORTC trials (2011)

  • Adjuvant radiotherapy after radical prostatectomy in patients with pathologically high risk prostate cancer: 10-Year follow-up results. European Urology Supplements 10 (2): 93, 2011(abs 227) (2011)

  • Adjuvant radiation for pathologically advanced prostate cancer: A head to head comparison of SWOG and EORTC trials. European Urology Supplements 10 (2): 90-91, 2011 (abs. 218) (2011)

  • Long term results of immediate post-operative radiotherapy after radical prostatectomy in pT3N0 prostate cancer (EORTC 22911). ASTRO 52nd Annual Meeting, San Diego, California, 31 Nov-4 Dec 2010 (abs 62) (2010)

  • Long term results of immediate post-operative radiotherapy after radical prostatectomy in pT3N0 prostate cancer (EORTC 22911) (2010)

  • PALETTE: A randomized, double-blind phase III trial of pazopanib versus placebo in patients with soft-tissue sarcoma (STS) whose disease has progressed during or following prior chemotherapy. An EORTC STBSG Global Network Study (EORTC 62072). Oral presentation at the Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago, U.S.A., June 3 - 7, 2011 (2011)

  • Oral presentation at ECCO/ESMO, Stockholm, Sweden, September 23-27, 2011 (2011)

  • Quality of life results of an EORTC phase III randomized trial of adjuvant whole-brain radiatiotherapy versus observation after radiosurgery or surgical resection of 1-3 cerebral metastases of solid tumors. Oral Presentation at the 15th Annual Meeting of the Society for Neuro-Oncology (SNO), November 18-21, 2010, Montreal, Quebec, Canada. (Abs QL08) (2010)

  • Clinical neurological outcome and quality of life among patients with limited small-cell cancer treated with two different doses of prophylactic cranial irradiation in the intergroup phase III trial (PCI99-01, EORTC 22003-08004, RTOG 0212 and IFCT 99-01) (2011)

  • Progression-free survival in advanced ovarian cancer: a Canadian review and expert panel perspective. Curr Oncol 18 (Suppl 2): S20 - S27, 2011 (2011)

  • Examining the relationships among health-related quality-of-life indicators in cancer patients participating in clinical trials: a pooled study of baseline EORTC QLQ-C30 data (2011)

  • Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes (2011)

  • Irradiation of the internal mammary and medial supraclavicular lymph node chain in stage I to III breast cancer: state of the day of EORTC phase III trial 22922/10925 with 4004 patients. EBCC 7 2011 (2010)

  • How Well Can You Actually Predict Which Non-Muscle-Invasive Bladder Cancer Patients Will Progress? (2011)

  • EAU Guidelines on Non-Muscle-Invasive Urothelial Carcinoma of the Bladder, the 2011 Update (2011)

  • Time to progression should not be used to infer the ultimate benefit of immediate versus deferred/salvage androgen deprivation therapy for prostate cancer. European Urology Supplements; 10 (2): 253, 2011 (abs. 801) (2011)

  • Immediate or deferred androgen deprivation for patients with prostate cancer and no local treatment of the prostate: long term results of EORTC 30891. European Urology Supplements; 10 (2): 254, 2011 (abs. 804) (2011)

  • Time to progression should not be used to infer the ultimate benefit of immediate versus deferred/salvage androgen deprivation therapy for prostate cancer (2011)

  • Time to disease progression is not an appropriate endpoint in studies of immediate versus deferred/salvage androgen deprivation therapy for prostate cancer (2011)

  • Long term results of iImmediate or deferred androgen deprivation for patients with prostate cancer and no local treatment of the prostate (EORTC 30891) (2011)

  • Long term results of iImmediate or deferred androgen deprivation for patients with prostate cancer and no local treatment of the prostate (EORTC 30891) (2011)

  • Time to disease progression is not an appropriate endpoint in studies of immediate versus deferred/salvage androgen deprivation therapy for prostate cancer (2011)

  • Comparison of 36 Gy, 20 Gy or No Involved Field-Radiotherapy After Six Cycles of EBVP Chemotherapy in Early-Stage Hodgkin's Lymphoma With a Favorable Prognosis: Results of the EORTC-GELA H9-F Intergroup Randomized Trial (2018)

  • Prognosis of sentinel node positive melanoma patients who did not undergo immediate completion lymph node dissection (2012)

  • Randomised phase II study of amrubicin as single agent or in combination with cisplatin versus cisplatin etoposide as first-line treatment in patients with extensive stage small cell lung cancer – EORTC 08062 (2011)

  • The Nordic Melanoma Group and EORTC Melanoma Group. Prognostic and predictive value of YKL-40 in stage IIB-III melanoma (2016)

  • Do results of the EORTC dummy run predict quality of radiotherapy delivered within multicentre clinical trials? (2012)

  • Short-term health-related quality of life and symptom control with docetaxel, cisplatin, 5-fluorouracil and cisplatin (TPF), 5-fluorouracil (PF) for induction in unresectable locoregionally advanced head and neck cancer patients (EORTC 24971/TAX 323) (2011)

  • Expression of (dUTPase) and thymidilate synthase (TS) in stage III colon cancer patients treated with either bolus 5-FU or infusional 5-FU in the adjuvant setting - results of a translational study of the PETACC-2 trial (2011)

  • Radiofrequency Ablation Combined With Systemic Treatment Versus Systemic Treatment Alone in Patients With Non-Resectable Colorectal Liver Metastases: a Randomized EORTC Intergroup Phase II Study (EORTC 40004). Poster discussion session at 2011 ECCO-ESMO-ESTRO Conference, Stockholm, Sweden, September 23-27, 2011 (abstr. 6010) (2011)

  • p53, Ki67 und AMACR-Expression in UICC-Stadium III Kolonkarzinomen: Prognostische Bedeutung nach adjuvanter 5-FU-Therapie (PETACC2-Studie) und klinikopathologische Korrelationen. Der Pathologe S1 (Abs. Fr-060), 2011 (2011)

  • Prognostische Bedeutung und kliniko-pathologische Korrelationen des MSI-Status in Kolonkarzinomen (UICC Stadium III) mit adjuvanter5-FU-Therapie (behandelt im Rahmen der PETACC2-Studie). Der Pathologe S1 (Abs. Fr-061), 2011 (2011)

  • Osteoblastic bone 'flare' in responding patients with extensive stage small cell lung cancer: observations from a prospective randomized phase II trial (EORTC 08062), Mini Oral Presentation at the 14th World Conference on Lung Cancer, Amsterdam, The Netherlands, July 3-7, 2011 (abs. 2290) (2011)

  • Genomic aberrations associated with outcome in anaplastic oligodendroglial tumors treated within the EORTC phase III trial 26951 (2011)

  • Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas (2011)

  • Curr Concepts and Management of Glioblastoma 70 (1): 9-21, 2011 (2011)

  • The EORTC 10041/BIG 03-04 MINDACT trial is feasible: Results of the pilot phase. EurJ (2011)

  • A systemic review of Toxic Death in clinical oncology trials: the Achilles' heel in forensic medicine revisited. Br J Can 107 (1): 1-6, 2012 (2012)

  • Patient Self-Reports of Symptoms and Clinician Ratings as Predictors of Overall Cancer Survival (2011)

  • Premature Ovarian Failure and Fertility in Long-Term Survivors of Hodgkin's Lymphoma: A European Organisation for Research and Treatment of Cancer Lymphoma Group and Groupe d'Etude des Lymphomes de l'Adulte Cohort Study (2012)

  • QA questionnaire in pathology in MINDACT trial. Oral Presentation at 8th European Breast Cancer Conference (EBCC-8), Vienna, Austria, 21-24 March 2012. (abs) (2012)

  • Accès aux échantillons biologiques: la clé pour les recherches cliniques en oncologie. Healthcare Executive 64 (Mai-Juin): 47-50, 2012 (2012)

  • QUALITY OF SURGERY FOR PRIMARY GASTRO-INTESTINAL STROMALTUMORS IN PATIENTS UNDERGOING ADJUVANT IMATINIB. EXPERIENCE OFTHE EORTC STBSG 62024 STUDY. Presentation at the Connective Tissue Oncology Society (CTOS), Paris, France, November 11 - 13, 2010 (2010)

  • Clofarabine in combination with a standard remission induction regimen (AraC and idarubicin) in patients with previously untreated intermediate and bad risk acute myelogenous leukemia (AML) or high risk myelodysplasia (HR-MDS): Phase I results of an ongoing phase I/II study of the leukemia groups of EORTC and GIMEMA (EORTC GIMEMA 06061 / AML-14A trial) (2014)

  • Randomized Phase III Study Comparing Paclitaxel-Bleomycin, Etoposide, and Cisplatin (BEP) to Standard BEP in Intermediate-Prognosis Germ-Cell Cancer: Intergroup Study EORTC 30983 (2012)

  • First-line treatment of advanced ovarian cancer with 5 paclitaxel/carboplatin with or without epirubicin (TEC versus TC)- a gynecologic cancer intergroup study of the NSGO, EORTC GCG and NCIC CTG (2012)

  • BPA uptake does not correlate with LAT1 and Ki67 expressions in tumor samples (results of EORTC trial 11001) (2011)

  • Ulceration and stage are predictive of interferon efficacy in melanoma: Results of the phase III adjuvant trials EORTC 18952 and EORTC 18991 (2012)

  • 50 years of the EORTC and the central role of the EORTC Headquarters (2012)

  • Statistical methodology for personalized medicine: New developments at EORTC Headquarters since the turn of the 21st Century (2012)

  • EORTC topics in neurooncology: The long path from a focus on neurological complications of cancer towards molecularly defined trials and therapies in neurooncology (2012)

  • The EORTC Breast Cancer Group: Major achievements of 50 years of research and future directions (2012)

  • The EORTC Cancer in the Elderly Task Force, a Protostar for EORTC's future (2012)

  • The EORTC Children's Leukemia Group: Preclinical and clinical research and resulting achievements (2012)

  • Major achievements of the EORTC Cutaneous Lymphoma Task Force (CLTF) (2012)

  • Development of clinical trial protocols involving advanced radiation therapy techniques: The European Organisation for Research and Treatment of Cancer Radiation Oncology Group approach (2012)

  • Glufosfamide: can we improve the process of anticancer agent development?. Expert Opin Investig Drugs 21 (5):749-754, 2012 (2012)

  • Exploratory analysis of prognostic factors for patients (pts) with advanced soft tissue sarcoma (ASTS) receiving combination chemotherapy: A joined study of the EORTC Soft Tissue and Bone Sarcoma Group and the French Sarcoma Group (2011)

  • The impact of gender on the outcome of malignant melanoma: Overview of seven EORTC phase III trials (2011)

  • Active immunization toward the MAGE-A3 antigen in patients with metastatic melanoma: Four-year follow-up results from a randomized phase II study (EORTC16032-18031) (2011)

  • A randomized phase III study comparing paclitaxel-BEP (T-BEP) to standard BEP in patients with in intermediate prognosis germ cell cancer (GCC): An intergroup study of EORTC, German TCSG/AUO, MRC, and Spanish GCC group (EORTC 30983) (2011)

  • An analysis of preoperative chemoradiotherapy with 5FU/leucovorin for T3-4 rectal cancer on survival in a pooled analysis of EORTC 22921 and FFCD 9203 trials: Surrogacy in question? (2011)

  • Evaluation of disease-free survival as surrogate endpoint for overall survival using two individual patient data meta-analyses of adjuvant chemotherapy in operable non-small cell lung cancer (2011)

  • EORTC 22071-24071: Randomized, phase III trial of EGFR-antibody combined with adjuvant chemoradiation for patients with head and neck squamous cell carcinoma (HNSCC) at high risk of recurrence (2011)

  • Does disease control rate (DCR) at 9 and 18 weeks predict overall survival (OS) in patients with malignant pleural mesothelioma (MPM)? An individual patient data combined analysis of 10 European Organisation for Research and Treatment of Cancer (EORTC) Lung Cancer Group (LCG) studies (2011)

  • Final results from an EORTC (GU Group)/NCRI randomized phase III trial of adjuvant interleukin-2, interferon alpha, and 5-fluorouracil in patients with a high risk of relapse after nephrectomy for renal cell carcinoma (RCC) (2011)

  • EORTC 18991 phase III trial: Long-term adjuvant pegylated interferon-?2b (PEG-IFN) versus observation in resected stage III melanoma: Long-term results at 7.6-years follow-up (2011)

  • The EORTC Gastrointestinal Tract Cancer Group: 50 years of research contributing to improved gastrointestinal cancer management (2012)

  • The EORTC Genito-Urinary Cancers Group: 35 years of achievements and future strategy (2012)

  • EORTC Gynecological Cancer Group on the frontline of practice-changing clinical trials (2012)

  • From chemoprevention and organ preservation programs to post-operative management: major achievements and strategies of the EORTC Head and Neck Cancer Group (2012)

  • Three major achievements of the Infections Disease Group (2012)

  • EORTC Leukemia Group achievements (2012)

  • Treatment for non-small cell lung cancer, small cell lung cancer and pleural mesothelioma within the EORTC Lung Cancer Group: past, present and future (2012)

  • Clinical achievements of the EORTC Lymphoma Group and aspects of future group strategy (2012)

  • EORTC Melanoma Group achievements (2012)

  • Identification, validation and clinical implementation of cancer biomarkers: Translational strategies of the EORTC PathoBiology Group (2012)

  • EORTC-related new drug discovery and development activities: role of the Pharmacology and Molecular Mechanisms Group (2012)

  • Health-Related Quality of Life in EORTC clinical trials ?30 years of progress from methodological developments to making a real impact on oncology practice (2012)

  • EORTC Radiation Oncology Group: 50 years of continuous Accomplishments (2012)

  • Achievements of the EORTC Soft Tissue and Bone Sarcoma Group (2012)

  • New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: A pooled analysis of EORTC Brain Tumour Group phase I and II clinical trials (2012)

  • Appropriate end-points for right results in the age of antiangiogenic agents: Future options for phase II trials in patients with recurrent glioblastoma (2012)

  • Fifty Years of Progress Against Cancer - The European Organization for Research and Treatment of Cancer Celebrates its Achievements (2012)

  • Breast conserving therapy versus mastectomy for stage I-II breast cancer: 20 year follow-up of the EORTC 10801 phase 3 randomised trial (2012)

  • Clinical predictivity of transplantable tumor systems in the selection of new drugs for solid tumors: reply to a commentary. Cancer Treatment Reports 69 (11), 1985 (1985)

  • Quality of life results of an EORTC phase III randomized trial of adjuvant whole-brain radiatiotherapy versus observation after radiosurgery or surgical resection of 1-3 cerebral metastases of solid tumors. SNO 2010 (2010)

  • Personalised medicine in oncology: Questions for the next 20 years (2012)

  • Local excision with or without radiotherapy in ductal carcinoma in situ: treatment and prognosis after a recurrence (2012)

  • New validated prognostic models and prognostic calculators in patients with low-grade gliomas diagnosed by central pathology review: a pooled analysis of EORTC/RTOG/NCCTG phase III clinical trials (2013)

  • Highlights from the EORTC 50th anniversary conference: 50 years of progress against cancer,15-16 march 2012, Brussels, Belgium: A perspective and focus on progress in quality of life (2012)

  • Predictive Factors for the Benefit of Perioperative FOLFOX for Resectable Liver Metastasis in Colorectal Cancer Patients (EORTC Intergroup Trial 40983). Ann of Surg 255 (3): 534-539, 2012 (2012)

  • Hyperdiploidy with 58-66 chromosomes in childhood B-acute lymphoblastic leukemia is highly curable: 58951 CLG-EORTC results (2013)

  • The components of progression as explanatory variables for overall survival in the RECIST database (2012)

  • Pazopanib for metastatic soft-tissue sarcoma (PALETTE): A randomized, double-blind, placebo-controlled phase 3 trial (2012)

  • PALETTE: Final overall survival (OS) data and predictive factors for OS of EORTC 62072/GSK VEG110727, a randomized double-blind phase III trial of pazopanib versus placebo in advanced soft tissue sarcoma (STS) patients (2012)

  • Final results of an EORTC GU Cancers Group randomized study of maintenance Bacillus Calmette-Guerin in intermediate and high risk Ta, T1 papillary carcinoma of the urinary bladder: One-third dose versus full dose and 1 year versus 3 years of maintenance (2013)

  • Systematic Review and Meta-Analysis of Randomized Trials of Central Nervous System Directed Therapy for Childhood Acute Lymphoblastic Leukemia (2013)

  • Trial design on prophylaxis and treatment of brain metastases: lessons learned from the EORTC Brain Metastases Strategic Meeting 2012 (2012)

  • A prospective international multicentre Phase II trial of intravenous pegylated liposomal doxorubicin (PLD) mono-chemotherapy in patients with advanced Mycosis fungoides stage IIB, IVA and IVB (Final Results from EORTC 21012) (2012)

  • An international study of multitrial data investigating quality of life and symptoms as prognostic factors for survival in different cancer sites. 48th Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago (USA) (2012)

  • Does change in health-related quality of life (HRQoL) score predict survival? Analysis of a lung cancer RCT (2012)

  • Health-related quality of life assessment in EORTC cancer clinical trials (2012)

  • Intermittent (IAD) versus continuous androgen deprivation (CAD) in hormone sensitive metastatic prostate cancer (HSM1PC) patients (pts): Results of S9346 (INT-0162), an international phase III trial (2012)

  • The Clinical Trials Directive: can we get it right second time around. Cancer World, 39: 47 - 49, 2010 (2010)

  • L'avenir de la recherche clinique académique indépendante en Europe. Science Connection 32: 23 - 25, 2010 (2010)

  • Fund, trial, treat. Public Service Review, European Union 19: 228 - 229, 2010 (2010)

  • Funding treatments, finding trials. Public Service Review, European Union 21: 210 - 211, 2011 (2011)

  • Collaborate and conquer Public Service Review, European Science & Technology 11: 348 - 349, 2011 (2011)

  • The health of European medical research. Science & Society 12 (2): 110 - 112, 2011 (2011)

  • Accès aux échantillons biologiques: la clé pour les recherches cliniques en oncologie. Onco hemato 6 (1): 8 - 13, 2012 (2012)

  • Molecular Momentum. Public Service Review, European Science & Technology 14: 176 - 177, 2012 (2012)

  • Célébrer 50 ans de progrès grâce à l'EORTC souvent initiés par des Belges!. L'événement 408: 18, 2012 (2012)

  • La Recherche Clinique, Optimisme et Patience, Une promesse pour demain. Cancerinfo, Ensemble pour la vie 111: 8, 2012 (2012)

  • 50e anniversaire de l'EORTC. Cercle de Lorraine 149: 27, 2012 (2012)

  • L'EORTC, 50 ans d'avancées majeures en cancérologie. L'événtail 2: 78, 2012 (2012)

  • Manager de recherche. Tendances Trends 10: 118 - 119, 2012 (2012)

  • Un demi-siècle de recherche. Juliette & Victor 29: 27, 2012 (2012)

  • On ne va pas éradiquer le cancer. La Libre Belgique, Mercredi 7 mars, pages 54 - 55, 2012 (2012)

  • La force des essais en réseau. Le Soir, Sciences & Santé, Vendredi 16 mars, page 31, 2012 (2012)

  • European Organisation for Research and Treatment of Cancer - EORTC. Belgian Research in Europe, 1st Quarter, Pages 34-35, 2012 (2012)

  • European Organisation for Research and Treatment of Cancer - EORTC (2010)

  • Analysis of the quality of reporting surgical procedures in patients undergoing resection for primary gastrointestinal stromal tumors: A reporting tool derived from the EORTC-STBSG 62024 trial (2012)

  • Global differences in chemotherapeutic regimens of soft tissue sarcoma (STS): Results of PALETTE, an EORTC 62072/GSK VEG110727 global network phase III trial of pazopanib versus placebo (2012)

  • Lapatinib in combination with ECF/x in EGFR1 positive first-line metastatic gastric cancer (GC): A phase II randomized placebo controlled trial (EORTC 40071) (2012)

  • Phase II study of bortezomib with cisplatin as first-line treatment of malignant pleural mesothelioma (MPM): EORTC 08052 (2012)

  • Efficacy and safety of bexarotene combined with psoralen/ultraviolet A light (PUVA) compared to PUVA treatment alone in stage IB-IIa mycosis fungoides (MF): Final results from EORTC cutaneous lymphoma task force (CLTF) phase III clinical trial 21011 (2012)

  • Randomized phase III trial of intravenous (IV) versus hepatic intra-arterial (HIA) fotemustine in patients with liver metastases from uveal melanoma: Final results of the EORTC 18021 study (2012)

  • Superior Outcome of Women With Stage I/II Cutaneous Melanoma: Pooled Analysis of Four European Organisation for Research and Treatment of Cancer Phase III Trials (2012)

  • International collaboration in clinical trials (2010)

  • European Commission Considers Revisions to Clinical Trials Directive. J Nat Can Inst 102 (5): 292-297, 2010 (2010)

  • Analysis of surrogate gene expression markers in peripheral blood of melanoma patients to predict treatment outcome of adjuvant pegylated interferon alpha 2b (EORTC 18991 SIDE STUDY) (2013)

  • Female Gender and Carcinoma In Situ in the Prostatic Urethra Are Prognostic Factors for Recurrence, Progression, and Disease-Specific Mortality in T1G3 Bladder Cancer Patients Treated With Bacillus Calmette-Guerin (2012)

  • Quality assurance of the EORTC 22043-30041 trial in post-operative radiotherapy in prostate cancer: Results of the Dummy Run procedure (2013)

  • Allogeneic, but not autologous, hematopoietic cell transplantation improves survival only among younger adults with acute lymphoblastic leukemia in first remission: an individual patient data meta-analysis (2013)

  • Commentary: Fifty years of the European Organisation for Research and Treatment of Cancer (EORTC) - Making the difference for the European oncology community (2012)

  • THE ADDED CLINICAL VALUE OF HEALTH-RELATED QUALITY OF LIFE RESEARCH: MAJOR OUTCOMES OF THE POOLED ANALYSIS OF PHASE III RANDOMISED CLINICAL TRIALS (2012)

  • A SYSTEMATIC REVIEW IN HEALTH-RELATED QUALITY OF LIFE REPORTING IN SMALL-CELL LUNG CANCER CLINICAL TRIALS: AN EXAMINATION INTO THE ADDED VALUE OF HEALTH-RELATED QUALITY OF LIFE FINDINGS. Oral Presentation at the ISOQOL Annual Conference, Budapest, Hungary, 24-27 October, 2012 (2012)

  • Joint modeling of longitudinal health-related quality of life data and overall survival. Oral Presentation at the ISOQOL Annual Conference, Budapest, Hungary, 24-27 October, 2012 (2012)

  • BOTTOMLEY, on behalf of the Lung Cancer Cooperative Group, Quality of Life Department and Patient Reported Outcome and Behavioral Evidence (PROBE). Does change in health-related quality of life (HRQoL) score predict survival? Sensitivity analysis of a lung cancer RCT (2012)

  • MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status (2012)

  • Adding docetaxel to cisplatin and fluorouracil in patients with unresectable head and neck cancer: a cost-utility analysis (2012)

  • on behalf of the EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER QUALITY OF LIFE GROUP. A review of the existing EORTC quality of life measures in Spanish: response scales evaluation (2012)

  • on behalf of the EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER QUALITY OF LIFE GROUP. Linguistic differences between translations of quality-of-life questionnaires: a comparative study of the English and Polish versions of EORTC QLQ-C30 (2012)

  • Reference values of oesophago-gastric symptoms (EORTC QLQ-OG25) in a population-based setting (2012)

  • Evidence-based guidelines for interpreting change scores for the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (2012)

  • Local recurrence rates after radiofrequency ablation or resection of colorectal liver metastases. Analysis of the CLOCC and EPOC trial (EORTC #40004 and #40983) (2014)

  • Intrinsic molecular subtypes of glioma are prognostic and predict benefit from adjuvant PCV chemotherapy in anaplastic oligodendroglial brain tumors. A report from EORTC study 26951 (2012)

  • EORTC 26083 phase I/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastoma (2012)

  • S. VILLA, F. FAUCHON, B. G. BAUMERT, L. FARISELLI, T. TZUK-SHINA, R. D KORTMANN, C. CARRIE, M. B. HASSELL, M. KOURI, E. VALEINIS, D. VAN DEN BERGE, R. P. MUELLER, G. TRIDELLO, L. COLLETTE, A. BOTTOMLEY. An EORTC Phase III trial of Adjuvant Whole-Brain Radiotherapy Versus Observation in patients with 1 to 3 Brain Metastases From Solid Tumors After Surgical Resection or Radiosurgery: Quality-of-Life Results (2012)

  • An international prospective study establishing minimal clinically important differences in the EORTC QLQ-BM22 and QLQ-C30 in cancer patients with bone metastases (2012)

  • Endorsing high quality standards in developing measures to assess QoL in cancer patients: the Data Repository initiative on behalf of the EORTC QLG (2012)

  • Outcome of congenital acute lymphoblastic leukemia treated on the Interfant-99 protocol (2009)

  • Should Adolescents With Acute Lymphoblastic Leukemia Be Treated as Old Children or Young Adults? Comparison of the French FRALLE-93 and LALA-94 Trials (2003)

  • Intermittent versus Continuous Androgen Deprivation in Metastatic Hormone Sensitive Prostate Cancer Patients: Survival Results of SWOG S9346 (INT-0162) - An International Phase III Trial (2013)

  • Acute lymphoblastic leukaemia (2008)

  • The process of reconciliation in translating quality of life questionnaires: Evaluation of existing translation guidelines and a set of recommendations. Expert Rev Pharmacoeconomics Outcomes Res 12 (2): 189-197, 2012 (2012)

  • Promoting pan-European cancer research for the benefit of all cancer patients. Expert Rev. Pharmacoecon. Outcomes Res 12 (4): 443-445, 2012 (2012)

  • Long-Term Results of the Randomized Phase III Trial EORTC 18991 of Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III Melanoma (2012)

  • Adjuvant Ganglioside GM2-KLH-QS21 Vaccination vs Observation after Resection of the Primary >1.5 mm in Stage II Melanoma Patients: Results of the EORTC 18961 Randomised Phase 3 Trial (2013)

  • Clinical prognostic factors affecting survival in patients with newly diagnosed glioblastoma multiforme (GBM) (2004)

  • Concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) for newly diagnosed glioblastoma multiforme (GBM). Conclusive results of a randomized phase III trial by the EORTC Brain & RT Groups and NCIC Clinical Trials Group (2004)

  • Sequential administration of gemtuzumab ozogamicin and conventional chemotherapy as first line therapy in elderly patients with acute myeloid leukemia: A phase II study (AML-15) of the EORTC and GIMEMA Leukemia Groups (2004)

  • Interferon-alpha-2a with or without 13-cis retinoic acid in patients with progressive, measurable metastatic renal cell carcinoma (2004)

  • Ethnic variations in uterine leiomyoma biology are not caused by differences in myometrial estrogen receptor alpha levels (2003)

  • Combined vascular endothelial growth factor and TP53 status predicts poor response to tamoxifen therapy in estrogen receptor-positive advanced breast cancer (2003)

  • SR31747A inhibits breast and prostate cancer cells growth (2003)

  • Invasiveness of transformed human breast epithelial cell lines is related to cathepsin B and inhibited by cysteine proteinase inhibitors (2003)

  • Fas/FasL expression in tumor biopsies: A prognostic response factor to fluoropyrimidines (2003)

  • Comparison of expression of cathepsins B and L and MMP2 in endothelilacells and in capillary sprouting in collagen gel (2004)

  • Integrating proteomic and functional genomic technologies in discovery-driven translational (2003)

  • Evolution of the brain tumour spheroid model: Transcending current model limitations (2003)

  • Real-time reverse transcriptase polymerase chain reaction analysis of human breast cancer cell lines resistant or sensitive to treatment with antiestrogens. Endocr Relat (2003)

  • Immunofluorometric quantification of human kallikrein 5 expression in ovarian cancer cytosols and its association with unfavorable patient prognosis. Tumor Biol 24: 299-309, 2003 (2003)

  • Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 status (2003)

  • Photochemical internalization of a peptide nucleic acid targheting the catalytic subunit of human telomerase (2003)

  • Expression of adrenomedullin in human ovaries, ovarian cysts and cancers. Correlation with estrogens receptor status (2003)

  • Steroids and adrenomedullin growth patterns in human ovarian cancer cells: Estrogenic-regulation assay (2003)

  • Mutation analysis in the coding sequence of thymidine kinase 1 in breast and colorectal cancers (2003)

  • Transforming growth factor beta-1 and amphiregullin act in synergy to increase the production of urokinase-type plasminogen activator in transformed breast epithelial cells (2003)

  • Clinical relevance of matrix metalloproteinase-13 measured with a new highly specific and sensitive ELISA in ascitic fluid of advanced ovarian carcinoma patients (2003)

  • Comparative evaluation of urokinase-type plasminogen activator receptor expression in primary breast carcinomas and on metastatic tumor cells (2003)

  • Advanced statistical methods for the definition of new staging models. Recent Results in (2003)

  • Human kallikrein 8, a novel biomarker for ovarian carcinoma (2003)

  • Differential effects of vascular endothelial growth factor A isoforms in a mouse brain metastasis model of human melanoma (2003)

  • Proteases in brain tumour progression (2003)

  • Selective suppression of cathepsin L by antisence cDNA impairs human brain tumor cell invasion in vitro and promotes apoptosis (2003)

  • Pooled analysis of prognostic impact of uPA and PAI-1 in breast cancer patients (2003)

  • The prognostic value of the mitotic activity index in patients with primary breast cancer who were not treated with adjuvant systemic therapy (2003)

  • Vascular endothelial growth factor is associated with the efficacy of endocrine therapy in patients with advanced breast carcinoma (2003)

  • F.C.G.J. SWEEP, V.C.G. TJAN-HEIJNEN, A. GEURTS-MOESPOT, D.T.H. VAN TIENOVEN, J.A. FOEKENS. P.N. SPAN, J. BUSSINK and L.V.A.M. BEEX. Vascular endothelial growth factor independently predicts the efficacy of postoperative radiotherapy in node-negative breast cancer patients (2003)

  • A Prognostic index for operable, node-negative breast cancer (2004)

  • Phase III study of letrozol versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: Analysis of survival and update of efficacy from the International Letrozol Breast Cancer Group (2003)

  • Quantitative assessment of HER-2/neu protein concentration in breast cancer by enzyme-linked immunosorbent assay (2003)

  • Ribozyme-mediated inhibition of PKC-alpha sensitizes androgen-independent human prostate cancer cells to cisplatin-induced apoptosis. Prostate 54: 133-143, 2003 (2003)

  • Immunoassays of urokinase (uPA) and of its type-1 inhibitor (PAI-1) in detergent extracts of breast cancer tissue (2003)

  • Radiosensitization of human melanoma cells by ribozyme – mediated inhibition of survivin expression. J Investigative Dermatol 120: 648-654, 2003 (2003)

  • Urokinase-type plasminogen activator (uPA) and its receptor (uPAR): Development of antagonists of uPA/uPAR interaction and their effects in vitro and in vivo (2003)

  • Tumor tissue concentrations of the proteinase inhibitors TIMP-1 and PAI-1 are complementary in determining prognosis in primary breast cancer (2003)

  • Tumor markers: From laboratory to clinical utility (2003)

  • Molecular Beacon reverse transcription-PCR of human chorionic gonadotropin-ß-3, - 5 and -8 mRNAs has prognostic value in breast cancer (2003)

  • Carbonic anhydrase-9 expression levels and prognosis in human breast cancer: Association with treatment outcome. Brit J (2003)

  • Gastrointestinal stromal tumours. Glivec, a wonder drug (2002)

  • Design of phase II trials for sarcomas (2002)

  • The use of tyrosine kinase inhibitors, the present and the future (2002)

  • Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of (2002)

  • The EORTC laboratory research division (2002)

  • EORTC 10968: A phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx®, Doxil®) at a 6-week interval in patients with metastatic breast cancer (2002)

  • Cancer progression and tumor cell motility are associated with the FGFR4 arg(388) allele. Cancer Research 62: 840-847, 2002 (2002)

  • P16INK4A promoter hypermethylation: Improved detection by fluorescent methylation specific-PCR in non-small-cell lung cancers and paired plasmas. Clin (2002)

  • Prognostic value of plasminogen activator inhibitors in breast cancer (2002)

  • Clinical value of components of the plasminogen activation system in ovarian cyst fluid (2002)

  • Evaluation of the efficiency of chemotherapy in in vivo orthotopic models of human glioma cells with and without 1p19q deletions and in C6 rat orthotopic allografts serving for the evaluation of surgery combined with chemotherapy (2002)

  • Prognostic significance of plasminogen activator inhibitor-1 in breast cancer, with special emphasis on locoregional recurrence-free survival (2002)

  • Re: Coexpression of survivin and TERT in soft-tissue sarcoma (2002)

  • Clinical relevance of invasion factors uPA and PAI 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination (2002)

  • Enhanced benefit from adjuvant systemic chemotherapy in breast cancer patients classified high-risk according to uPA and PAI 1 (n=3,424) (2002)

  • Transcription factor YB-1 predicts clinical drug resistance and tumor aggressiveness in human breast cancer independent of tumor biological factors HER2 and uPA / PAI-1 (2002)

  • Lysosomal enzymes, cathepsins in brain tumour invasion. J. Neuro- (2002)

  • Pooled analysis of prognostic impact of uPA and PAI-1 in 8,377 breast cancer patients (2002)

  • Higher expression of human kallikrein 10 in breast cancer tissue predicts tamoxifen resistance (2002)

  • The prognostic value of vascular endothelial growth factor in 574 node-negative breast cancer patients (2002)

  • High tumor tissue concentration of plasminogen activator inhibitor-2 (PAI-2) is an independent marker for shorter progression-free survival in patients with early stage endometrial cancer (2002)

  • Quality control for biomarker determination in oncology: The experience of the Italian Network for Quality assessment of Tumor Biomarkers (INQAT) (2002)

  • Neutralization of adrenomedullin inhibits the growth of human glioblastoma cell lines in vitro and suppresses tumor xenograft growth in vivo. Am. J. Pathol. 160: 1279-1292, 2002 (2002)

  • Levels of plasminogen activators and their inhibitors in maternal and umbilical cord plasma in severe preeclampsia. Am. J. Obstet. Gynecol. 187: 1019-1025, 2002 (2002)

  • Prognostic assessment of PTK activity in T1-T2, N0-N1, M0 breast cancer: a multicentric retrospective study (2002)

  • Inhibition of telomerase activity by a distamycin alkylating derivative: Effects on cell proliferation and induction of apoptosis in human melanoma cells (2002)

  • Prognostic value of the urokinase-type plasminogen activator, and its inhibitors and receptor in breast cancer patients. Clin. Breast Cancer 3 (2): 138-146, 2002 (2002)

  • An ELISA avoiding interference by heterophilic antibodies in the measurement of components of the plasminogen activation system in blood. J. Immunol. Methods 268: 219-231, 2002 (2002)

  • Probing the interaction of urokinase-type plasminogen activator (uPA) with its receptor CD87. Biological Chemistry 383: 207-216, 2002 (2002)

  • Clinical utility of uPA/PAI-1 determination in primary breast cancer tissue for individualized therapy concepts. Clin. Breast Cancer 3 (3): 196-200, 2002 (2002)

  • Flow cytometric S-phase fraction measurement in breast carcinoma: Influence of software and histogram resolution. Cytometry 48 (2): 66-70, 2002 (2002)

  • Comparison of cysteine and serine proteinases and their inhibitors as prognostic factors in invasive ductal breast carcinoma. Cancer Detection and Prevention 26: 42-49, 2002 (2002)

  • Constitutional alterations of the ATM gene in early onset sporadic breast cancer. J. Med. Genet.39 (10): 751-753, 2002 (2002)

  • Ribozyme-mediated attenuation of survivin expression sensitizes human melanoma cells to cisplatin-induced apoptosis. J. Clin. Invest. 109: 285-286, 2002 (2002)

  • Tumorbiologie des Primären Mammakarzinoms und „Minimal Residual Disease“ (MRD). [Biological Factors of Primary Breast Cancer tissue and "Minimal Residual Disease" (MRD)] (2002)

  • The urokinase protease system as a target for breast cancer prognosis and therapy: Technical considerations. Journal of Clinical Ligand Assay 25: 43–52, 2002 (2002)

  • Differential effects of fibroblast growth factors on the plasminogen-activator and insulin-like-growth-factor systems in human breast fibroblasts. Thromb. Haemost. 87: 674-683, 2002 (2002)

  • R.R. BOSCH, L.V.A.M. BEEX AND C.G.J. SWEEP. Expression of the transcription factor Ets-1 is an independent prognostic marker for relapse-free survival in breast cancer (2002)

  • Survivin expression and resistance to anticancer treatments: Perspectives for new therapeutic interventions. Drug Resistance Updates 5: 65-72, 2002 (2002)

  • Transcription and alternative splicing of telomerase reverse transcriptase in benign and malignant breast tumors and in adjacent mammary glandular tissues: Implications for telomerase activity (2002)

  • New approaches to the understanding of tamoxifen action and resistance. Proc. 11th International Congress on Hormonal Steroids (ICHS) and 7th International Congress on Hormones and Cancer (ICHC), Fukuoka, Japan, October 21-25, 2002 (2002)

  • Clinical trials in ovarian carcinoma: Study methodology (2005)

  • Integration of new or experimental treatment options and new approaches to clinical trials (2005)

  • The Gynecologic Cancer Intergroup (GCIG): History and current status (2005)

  • EORTC GYNAECOLOGIC GROUP, NCIC CLIN. TRIALS GROUP. Prognostic value on clinical and molecular markers in advanced ovarian cancer (AOC): Importance of residual (Rs) disease. Translational study using tumor specimens from EORTC 55931/NCIC 0V10 phase III randomized clinical trial (RCT) (2005)

  • The survival benefit of interval debulking surgery (IDS) in advanced ovarian cancer is maintained during ten years; The EORTC GCG 55865 study. 14th International Meeting of the European Society of Gynecological Oncology (ESGO) (2005)

  • Commentary on "Second Surgical Cytoreduction for Advanced Ovarian Carcinoma". Rose P. G., Nerenstone S., Brady M. F., Clarke-Pearson D., Olt G., Rubin S. C., Moore D. H., Small J. M., the Gynecologic Oncology Group (2005)

  • Analytical aspects of biomarker immunoassays in cancer research (2005)

  • Association of DNA methylation of phosphoserine aminotransferase with response to endocrine therapy in patients with recurrent breast cancer (2005)

  • Suppression of rat breast cancer metastasis and reduction of primary tumour growth by the small synthetic urokinase inhibitor WX-UK1 (2005)

  • Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: An EORTC Receptor and Biomarker Group (RBG) collaboration. Oncol Rep 14 (1): 235-239, 2005 (2005)

  • Prognostic relevance of uPAR-del4/5 and TIMP-3 mRNA expression levels in breast cancer (2005)

  • Reporting recommendations for tumour marker prognostic studies (REMARK) (2005)

  • Statistics subcommittee of the NCI-EORTC Working Group on cancer diagnostics. Reporting recommendations for tumor marker prognostic studies (REMARK) (2005)

  • Statistics subcommittee of the NCI-EORTC Working Group on cancer diagnostics. REporting recommendations for tumor MARKer prognostic studies (REMARK). Nat Clin Pract Oncol 2 (8): 416-422, 2005 (2005)

  • Tumor markers in breast cancer- European group on tumor markers recommendations. Tumour Biol 26 (6): 281-293, 2005 (2005)

  • Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in a cohort of Caucasian individuals (2005)

  • Value of intravenous 6-mercaptopurine during continuation treatment in childhood acute lymphoblastic leukemia and non-Hodgkin's lymphoma: Final results of a randomized phase III trial (58881) of the EORTC CLG. Leukemia 19 (5):721-726, 2005 (2005)

  • Results of 58872 and 58921 trials in acute myeloblastic leukemia and relative value of chemotherapy vs allogeneic bone marrow transplantation in first complete remission: The EORTC Children Leukemia Group report. Leukemia 19 (12): 2072-2081, 2005 (2005)

  • Gemtuzumab ozogamicin (Mylotarg) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: Final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell'Adulto Leukemia Groups. Leukemia 19 (10): 1768-1773, 2005 (2005)

  • Low-dose cytosine arabinoside (LD-AraC) vs LD-AraC plus granulocyte/macrophage colony stimulating factor vs LD-AraC plus Interleukin-3 for myelodysplastic syndrome patients with a high risk of developing acute leukemia: Final results of a randomized phase III study (06903) of the EORTC Leukemia Cooperative Group. Leukemia 19 (11): 1929-933, 2005 (2005)

  • Dexamethasone versus methyl-prednisolone in induction therapy for adult acute lymphoblastic (ALL) and non-Hodgkin lymphoma (NHL) Patients 60 yrs old: Final results of the EORTC All-4 phase III trial (2005)

  • Allogeneic (Allo-) or autologous (Auto-) peripheral blood stem cell transplantation (SCT) randomized versus a second intensive consolidation after a common induction and consolidation course in patients with bad prognosis myelodysplastic syndromes and acute myelogenous leukemia following MDS of more than 6 months duration: The final analysis of a joint study (CRIANT) of the EORTC, EBMT, SAKK, HOVON and GIMEMA Leukemia Groups. Blood 106: 11, 2005 (abs. 794) (2005)

  • High dose cytosine arabinoside (HD-AraC) vs standard dose araC (SD-AraC) during Induction, and stem cell transplantation followed by IL-2 or no maintenance in acute myelogenous leukemia (AML): First report on the AML-12 Phase III trial of the EORTC Leukemia Group (LG) and GIMEMA (2005)

  • European Organization for Research and Treatment of Cancer (EORTC) (2005)

  • Indications for BCG and its action on the progression of superficial bladder cancer (2005)

  • Bacillus calmette-guerin versus chemotherapy in the intravesical treatment of carcinoma in situ: A meta-analysis of the published results of randomized clinical trials (2005)

  • Is baseline quality of life a prognostic factor? (2005)

  • Evaluation of treatments: Do statistics lie? (2005)

  • Bacillus calmette-guerin versus chemotherapy in the intravesical treatment of carcinoma in situ: A meta-analysis of the published results of randomized clinical trials. Communication at the 2005 Annual Meeting of the American Urological Association, San Antonio, Texas, U.S.A., May 21-26, 2005 (2005)

  • A meta-analysis of randomized trials investigating TUR plus one immediate instillation of chemotherapy (2005)

  • Bacillus calmette-guerin versus chemotherapy in the intravesical treatment of carcinoma in situ: A meta-analysis of the published results of randomized clinical trials (2005)

  • BCG in the treatment of superficial bladder cancer (2005)

  • Interim analyses and early stopping rules (2005)

  • Common pitfalls in assessing and reporting results (2005)

  • Predicting recurrence and progression in stage Ta T1 bladder cancer patients using EORTC risk tables (2005)

  • Predicting recurrence and progression in stage Ta T1 bladder cancer patients using EORTC risk tables (2005)

  • Predicting recurrence and progression in stage Ta T1 bladder cancer patients using EORTC risk tables (2005)

  • High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder. Urol 66 (6): 90-107, 2005 (2005)

  • A Bayesian approach to jointly estimate centre and treatment by centre heterogeneity in a proportional hazards model. Statist Med 24: 3789-3804, 2005 (2005)

  • Concepts for banking tissue in urologic oncology: The international bladder cancer bank (2005)

  • Outcome measures for clinical research in sepsis: A report of the 2nd Cambridge Colloquium of the International Sepsis Forum (2005)

  • Bacillus calmette-guerin versus chemotherapy in the intravesical treatment of carcinoma in situ: A meta-analysis of the published results of randomized clinical trials. European Urology Supplements 4 (3): 219, 2005 (abs. 866) (2005)

  • Bacillus calmette-guerin versus chemotherapy in the intravesical treatment of carcinoma in situ: A meta-analysis of the published results of randomized clinical trials (2005)

  • La experiencia de la EORTC en el tratamiento endovesical profilactico de los tumors superficiales (2005)

  • Patients with T0-4N0M0 protate cancer not suitable for local treatment with curative intent (EORTC 30891): Which subgroup needs or does not need immediate treatment? (2006)

  • Gleason score and margin status are the strongest predictors for benefit of radiotherapy after radical prostatectomy. Oral presentation at the AUA annual meeting, Atlanta, Georgia, U.S.A., May 20-25, 2006 (2006)

  • Gleason score and margin status are the strongest predictors for benefit of radiotherapy after radical prostatectomy (2006)

  • Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: Long-term results of the European Organisation for Research and Treatment of Cancer H7 Randomized controlled trials (2006)

  • KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours (2006)

  • A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC 10993) (2006)

  • EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome (2006)

  • RECIST revisited: A review of validation studies on tumour assessment (2006)

  • Progression-free survival rate as primary end point for phase II cancer clinical trials: Application to mesothelioma - the EORTC Lung Cancer Group (2006)

  • Does downstaging in patients (pts) with IIIA-N2 non-small cell lung cancer (NSCLC) and a response to induction chemotherapy (ICT) influence outcome with surgery (S) or radiotherapy (RT)? An exploratory analysis of EORTC 08941. Proc. American Society of Clinical Oncology (ASCO), Atlanta, Georgia, U.S.A., June 2-6, 2006 (abs. 7047) (2006)

  • Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: Impact of other therapies on outcome (2005)

  • A European organization for research and treatment of cancer-international antimicrobial therapy group study of secondary infections in febrile, neutropenic patients with cancer (2005)

  • The prognostic significance of CDKN2A, CDKN2B and MTAP inactivation in B-lineage acute lymphoblastic leukemia of childhood. Results of the EORTC studies 58881 and 58951 (2006)

  • Results of a longitudinal survey on quality of life (QoL) in 935 patients with supradiaphragmatic early stage Hodgkin lymphoma (HL) enrolled in the EORTC-GELA H8 trial (# 20931) (2006)

  • Tumour response to preoperative anthracycline-based chemotherapy in operable breast cancer: The predictive role of p53 expression (2006)

  • EORTC randomized phase II study of recombinant interferon alpha and recombinant interferon alpha and gamma in advanced renal cell carcinoma (1991)

  • Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ (DCIS): Ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853 - A study by the EORTC Breast Cancer Group and EORTC Radiotherapy Group (2006)

  • Histopathologic assessment of hot-spot microvessel density and vascular patterns in glioblastoma: Poor observer agreement limits clinical utility as prognostic factors. A translational research project of the European Organization for Research and Treatment of Cancer Brain Tumor Group (2006)

  • Predicting survival in advanced cancer patients: is it possible with patient-reported health status data? (2006)

  • What has been learned from meta-analyses of neoadjuvant and adjuvant chemotherapy in bladder cancer? (2006)

  • Estimation and prediction in a multi-state model for breast cancer. Biom Journ 48 (3): 366-380, 2006 (2006)

  • Hyperfractionated or accelerated radiotherapy in head and neck cancer: A meta-analysis (2006)

  • Clinical trials design and treatment tailoring: General principles applied to (2006)

  • European move affects academic trials research (2006)

  • Chemotherapy with preoperative radiotherapy in rectal cancer (2006)

  • In vitro antimicrobial activity of moxifloxacin against bacterial strains isolated from blood of neutropenic cancer patients (2006)

  • Challenges of cancer research in Europe - the case of translational research. European Oncological Disease 1: 15-18, 2006 (2006)

  • Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouraci, leucovori, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: The European Organisation for Research and Treatment of Cancer Chronotherapy group (2006)

  • Phase III intergroup study of fludarabine phosphate compared with cyclophosphamide, vincristine, and prednisone chemotherapy in newly diagnosed patients with stage III and IV Low-grade malignant Non-Hodgkin's lymphoma. J Clinical Oncol 24 (10): 1590-1596, 2006 (2006)

  • Phase 1 European Organisation for Research and Treatment of Cancer study determining safety of pegylated liposomal doxorubicin (Caelyx®) in combination with ifosfamide in previously untreated adult patients with advanced or metastatic soft tissue sarcomas (2006)

  • Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: A study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC-ISG-AGITG) (2006)

  • Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer (2006)

  • Phase I and pharmacokinetic study of halofuginone, an oral quinazolinone derivative in patients with advanced solid tumours (2006)

  • Guidelines for primary radiotherapy of patients with prostate cancer (2006)

  • Quality assurance in the EORTC randomized trial 22922/10925 investigating the role of irradiation of the internal mammary and medial supraclavicular lymph node chain works (2006)

  • 1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment (2006)

  • Gene signature evaluation as a prognostic tool: Challenges in the design of the MINDACT trial. Nature Clinical Practice (2006)

  • Morbidity from pelvic lymphadenectomy in men undergoing radical prostatectomy (2006)

  • Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: Data from Southwest Oncology Group Trial 9346 (INT-0162) (2006)

  • EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours (2006)

  • Non-infusional vs intravenous consolidation chemotherapy in elderly patients with acute myeloid leukemia: Final results of the EORTC-GIMEMA AML-13 randomized phase III trial (2006)

  • Randomized phase III trials of adjuvant FAMTX or FEMTX compared with surgery alone in resected gastric cancer. A combined analysis of the EORTC GI Group and the ICCG (2006)

  • Selection of immunostimulant AS15 for active immunization with MAGE A3 prote (2013)

  • Predictive gene signature in MAGE A3 antigen-specific cancer immunotherapy (2013)

  • Protocol of the Definition for the Assessment of Time-to-event 3 End-points in CANcer trials study: Formal consensus method 4 for the development of guidelines for standardised time-to-event 5 end-points' definitions in cancer clinical trials (2013)

  • Results of a randomised phase III trial (EORTC 62012) of single agent doxorubicin versus doxorubicin plus ifosfamide as first line chemotherapy for patients with advanced or metastatic soft tissue sarcoma: a survival study by the EORTC Soft Tissue and Bone Sarcoma Group. Proc. 37th European Society for Medical Oncology Congress (ESMO); September 28-October 2, 2012; Vienna, Austria (Abstract LBA7) (2012)

  • Long-term cosmetic changes after breast-conserving treatment of patients with stage I-II breast cancer and included in the EORTC 'boost versus no boost' trial (2012)

  • A European Organisation for Research and Treatment of Cancer Phase III Trial of Adjuvant Whole-Brain Radiotherapy Versus Observation in Patients With One to Three Brain Metastases From Solid Tumors After Surgical Resection or Radiosurgery: Quality-of-Life Results. Jour (2013)

  • Parenthood in Survivors of Hodgkin Lymphoma: An EORTC-GELA General Population Case-Control Study (2012)

  • Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): A multicentre randomised controlled trial (2012)

  • Is adjuvant chemotherapy useful for soft-tissue sarcomas? , (2012)

  • Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma: an EORTC-STBSG study (2012)

  • Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial 21011 (NCT00056056) (2012)

  • Effect of completion-time windows in the analysis of health-related quality of life outcomes in cancerPatients (2013)

  • Randomized Trial Comparing Monthly Low-Dose Leucovorin and Fluorouracil Bolus With Bimonthly High-Dose Leucovorin and Fluorouracil Bolus Plus Continuous Infusion For Advanced Colorectal Cancer:A French Intergroup Study (1997)

  • Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: fifteen-year recurrences and subsequent outcomes from the EORTC randomised phase III trial 10853 (2013)

  • Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer - Differential treatment strategies for subtypes of early gastroesophageal cancer (2012)

  • Sex is an independent prognostic indicator for survival and relapse/progression-free survival in metastasized stage III to IV melanoma: a pooled analysis of five European organisation for research and treatment of cancer randomized controlled trials (2013)

  • Attitudes of young patients with breast cancer toward fertility loss related to adjuvant systemic therapies. EORTC study 10002 BIG 3-98 (2014)

  • The future of clinical research in oncology: where are we heading to? Chinese (2013)

  • Comparison of the Sentinel Node Procedure between Patients with Multifocal and Unifocal Breast Cancer in the EORTC 10981-22023 AMAROS Trial: identification rate and nodal outcome (2013)

  • Normal tissue complication probability (NTCP) parameters for breast fibrosis: pooled results from two randomised trials (2013)

  • Sentinel Node Identification Rate and Further Nodal Involvement in Patients with Multifocal Breast Cancer in the EORTC 10981-22023 AMAROS Trial (2012)

  • Adjuvant Radiotherapy After Breast-conserving Surgery for Ductal Carcinoma in Situ - Fifteen-year Results of the EORTC Randomized Phase III Trial 10853 (2012)

  • Academia-Industry Partnerships: Are we ready for new models of partnership? The point of view of the EORTC, an academic clinical cancer research organization (2013)

  • Moving the boundaries of international collaboration on clinical trials and QoL: experiences in oncology and legislation within the European Parliament (2013)

  • An European Organisation for Research and Treatment of Cancer phase I study of lapatinib and docetaxel as neoadjuvant treatment for Human Epidermal Growth Factor Receptor 2 (HER2) positive locally-advanced/inflammatory or large operable breast cancer (2013)

  • Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary endpoint for mesothelioma clinical trials (EORTC 08052). 2013 (2013)

  • Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia: Results of a randomized phase III trial of the EORTC and GIMEMA consortium (AML-17). 2013 (2013)

  • Randomized Phase III Study of Erlotinib Versus Observation in Patients With No Evidence of Disease Progression After First-Line Platin-Based Chemotherapy for Ovarian Carcinoma: A European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup Study (2014)

  • Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951 (2013)

  • Randomized trial of cisplatin (C), methotrexate (A), bleomycin (B), and vincristine (O) vs ABO in advanced squamous cell carcinoma of the head and neck. Communication at the Annual Meeting of the ESMO, Nice, December 1984 (abs. 54) (1984)

  • Mitoxantrone in advanced renal cancer: A phase II study in previously untreated patients from the EORTC Genito-Urinary Tract Cancer Cooperative Group (1984)

  • N-(phosphonacetyl)-L-aspartate (PALA) in advanced ovarian cancer: A phase II trial of the EORTC Gynecological Cancer Cooperative Group. Proc. ESMO 10, 1984 (abs. 108) (1984)

  • Phase II trial of mitomycin-C/cisplatin in disseminated squamous cell carcinoma of the uterine cervix: An EORTC Gynecological Cancer Cooperative Group study. Proc. ESMO 10, 1984 (abs. 197) (1984)

  • Carboplatin in combination chemotherapy for ovarian cancer, a feasibility study (1984)

  • Vincristine, bleomycin, mitomycin-C, cisplatin as additive treatment to radiotherapy in poor risk patients with squamous cell carcinoma of the uterine cervix. Proc. ESMO 10, 1984 (abs. 264) (1984)

  • Phase II trial of bleomycin in advanced ovarian epithelial cancer: An EORTC Gynecological Cancer Cooperative Group study. Proc. ESMO 10, 1984 (abs. 273) (1984)

  • EORTC Gynecological Cancer Cooperative Group phase II trials in disseminated cancer of the uterine cervix. Communication at the III Congresso Portugues de Ginecologia, Coimbra, Portugal, June 11-14, 1984 (1984)

  • EORTC Genito-Urinary Group protocols for bladder cancer. Communication at the Decimo Corso d'Aggiornamento in Oncologia Medica, Roma, Italy, November 5-9, 1984 (1984)

  • EORTC Gynecological Cancer Cooperative Group (1977-1984). Proc. Decimo Corso di Aggiornamento in Oncologia Medica, Roma, November 5-9, 1984 (1984)

  • Current status of EORTC protocols for disseminated testicular nonseminomatous cancer (1984)

  • Randomized trial of cisplatin (C), methotrexate (A), bleomycin (B), and vincristine (O) vs ABO in squamous cell head and neck cancer. Communication at the Annual Meeting of the Swiss Society of Oncology, Geneva, April 13-14, 1984 (1984)

  • Phase II trial of a combination of low dose cisplatin and bolus 5-fluorouracil in recurrent and metastatic squamous cell carcinoma of the head and neck. Communication at the Annual Meeting of the ESMO, Nice, December 1984 (abs. 56) (1984)

  • Phase II trial of a combination of 5-fluorouracil and mitomycin C in metastatic or locally recurrent head and neck cancer. Communication at the Annual Meeting of the ESMO, Nice, December 1984 (abs. 57) (1984)

  • Combination chemotherapy with cisplatin, methotrexate, bleomycin, and vincristine (CABO) in advanced squamous cell carcinoma of the head and neck (1984)

  • High LET particles in radiation therapy. Journal Européen de Radiothérapie, Oncologie, Radiophysique et Radiobiologie, 5 (3): 115-248, 1984 (1984)

  • Study of effect of androgens and immunotherapy combined to maintenance chemotherapy in acute myeloid (1984)

  • Chemotherapy for adult acute lymphoblastic leukemia. A randomized study. Proc. ESMO 10, 1984 (abs. 197) (1984)

  • Lung cancer trials in the EORTC. Communication at the Decimo Corso d'Aggiornamento in Oncologia Medica, Roma, Italy, November 5-9, 1984 (1984)

  • Phase II study of vindesine in disseminated squamous cell carcinoma of the uterine cervix (1984)

  • Adjuvant chemotherapy of superficial transitional cell bladder carcinoma: Preliminary results of a European Organization for Research on Treatment of Cancer randomized trial comparing doxorubicin hydrochloride, ethoglucid, and transurethral resection alone (1984)

  • Controlled Clinical Trials in Urologic Oncology (EORTC Monograph Series No 13), Raven Press, New York, 1984, 329 pp (1984)

  • Letter to the Editor of the Journal of Urology on behalf of the EORTC Genito-Urinary Tract Cancer Cooperative Group, 1984 (1984)

  • Aims and activities of the EORTC Genito-Urinary Tract Cooperative Group (1984)

  • Cardiovascular toxicity in the EORTC protocols 30761 and 30762. Communication at the American Urological Association, New Orleans, U.S.A., May 6-10, 1984 (1984)

  • EORTC phase II chemotherapy studies in prostatic cancer (1984)

  • Communication at the 8th National Nurses Symposium, Leeds, Great Britain, April 2-4, 1984 (1984)

  • Rationale for intravesical chemotherapy for superficial bladder cancer. Proc. Symposium on Urological Oncology, Lisbon, Portugal, (F. Calais da Silva and L. Denis, eds.), 1984, pp 119-120 (1984)

  • Communication at the European Association of Urology, Copenhagen, Denmark, May 23-26, 1984 (1984)

  • Phase II studies with mitoxantrone in renal cell and bladder cancer (1984)

  • Adjuvante chemotherapie des oberflächlichen blasenkarzinoms Ta/T1: Ergebnisse der EORTC studien (1984)

  • Combination chemotherapy with cisplatin and VM26 in advanced transitional cell carcinoma of the bladder (1984)

  • Adjuvante behandeling van het blaascarcinoom Ta en T1 na TUR met adriamycin of epodyl. Een fase III onderzoek. Proc. Lustrum Nederlandse Vereniging voor Urologie, Rhenen, The Netherlands, May 13-14, 1984 (1984)

  • Do bone scans predict prognosis in prostatic cancer? A report of the EORTC Protocol 30762 (1984)

  • Tryptophan metabolites in superficial bladder cancer: The background to and preliminary report on EORTC trial 30781 (1984)

  • Proc. Lustrum Nederlandse Vereniging voor Urologie, Rhenen, The Netherlands, May 13-14, 1984 (1984)

  • Current status of EORTC GU Group protocols for bladder cancer (1984)

  • EORTC protocols in prostatic cancer (1984)

  • Proc. EORTC Symposium on Urological Oncology, Lisbon, Portugal, March 15-17, 1984 (1984)

  • Etoposide and cisplatin combination for the treatment of non-small cell lung cancer. Experience of the EORTC Lung Cancer Working Party (Belgium). Communication at the Symposium on Vepesid: Recent Progress and Future Prospects, London, United Kingdom, September 1984 (1984)

  • Treatment of superficial bladder carcinoma: Randomized European clinical trials (1984)

  • Doxorubicin versus 4'epidoxorubicin, a preliminary report of a randomized phase II-III study in pretreated breast cancer patients. Communication at the International Symposium "Advances in Anthracycline Chemotherapy: Epirubicin", Milan, Italy, June 10-12, 1984 (1984)

  • Rational basis for the choice of regimens for empirical therapy of sepsis in granulocytopenic patients. Clinics in Haematology 13: 573-586, 1984 (1984)

  • EORTC ANTIMICROBIAL THERAPY PROJECT GROUP. A cooperative trial of a short course versus a regular course of amikacin in combination with ceftazidime as empiric treatment in febrile neutropenic patients. Proc. Third International Symposium on Infections in the Immunocompromised Host, Toronto, Canada, 1984 (abs. 113) (1984)

  • Autologous Bone Marrow Transplants and Solid Tumours (EORTC Monograph Series No 14), Raven Press, New York, 1984, 192 pp (1984)

  • Drug therapy: EORTC Brain Tumour Group studies. Communication at the Second International Symposium on Biology of Brain Tumors, London, United Kingdom, October 24-26, 1984 (1984)

  • Misonidazole in radiotherapy of supratentorial brain gliomas in adult patients. Oncology Digest, 18-19, 1984 (1984)

  • Cisplatin plus vindesine in multitreated advanced breast cancer - A phase II trial of the EORTC Breast Cancer Cooperative Group (1984)

  • Currently active protocols in the EORTC Breast Cancer Cooperative Group (1984)

  • Medical adrenalectomy and cyclic chemotherapy preceded by estrogenic recruitment in advanced breast cancer. A phase II trial of the EORTC Breast Cancer Cooperative Group (1984)

  • Phase I studies with carboplatin (1984)

  • An overview of the EORTC Breast Cancer Cooperative Group's activities. Proc. 10th Course "Aggiornamento in Oncologia Medica", Roma, Italy, November 1984 (1984)

  • Data quality control in cancer clinical trials. Communication at the Workshop on use of Computers in Europe for Collection of Data in Therapeutic Radiology and Oncology, Geneva, Switzerland, March 26-28, 1984 (1984)